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Summary 
The transition to a new technology, market or regulatory regIme can be difficult for any 
organisation to manage. Technological and institutional change has proven to be a big cause for the 
failure of established firms and many examples exist of such failures. The Trade Related 
intellectual property rights agreement (TRIPs), as part of The World Trade Organization (WTO) 
agreement, represents such an institutional change for knowledge based industries from developing 
countries. As a result of the TRIPs agreement all of the WTO member countries will move from no 
or partial patent protection to fully fledged patent protection. This represents a radical break with 
the past in which developing countries typically had only weak levels of patent protection. Against 
this backdrop, the research examines the learning processes involved in the development of 
innovative R&D capabilities within the context of the Indian pharmaceutical industry, in response 
to the strengthening of patent law. 
In the last decade much research has addressed the process of dynamic learning within firms, 
however this has predominantly focused on firms from advanced countries. Previous research on 
developing countries mainly focused on building the minimum knowledge base essential for 
production and innovation activity. In recent years limited research has begun to explore dynamic 
learning in finns from developing countries. However, there still remains a scarcity of research 
which examines firm-level learning processes central to the development of advanced level 
capabilities. This research addresses this deficiency by applying the conceptual understanding 
developed within advanced countries to a developing countries context. This is operationalised 
through a set of research activities which investigate firm-level learning, knowledge creation and 
innovative capability within the context of the Indian pharmaceutical industry. 
The substantive conclusions are that the development of new capabilities involves the removal of 
redundant capabilities, coupled with the acquisition of new knowledge. The findings also indicate 
that Indian firms are hiring Indian scientists educated or working overseas in multinational 
pharmaceutical R&D and collaborating with Indian and overseas research institutes and 
universities to acquire capabilities in innovative R&D. Furthermore, inter-firm differences in 
leanling processes suggest that at a finn level, learning is neither linear nor automatic and requires 
a deliberate strategy. The thesis also provides important insights into knowledge creation 
capabilities that have significant implications with respect to innovative activity for firms from 
other developing countries. 
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Chapter 1 
INTRODUCTION 
1.1 The issues addressed 
The transition to new technology, science, market or regulatory regime is difficult for any 
organisation, public or private to manage. The discontinuities forcing these transitions are 
mostly driven by technology, competitors, regulatory events or significant changes in 
economic and political conditions. Even when established firms recognise the need to 
change in response to shifts in their external environment, they are often unable to respond. 
Technological change and institutional change have proven to be big causes for the failure 
of established firms and history is full of such examples (Tushman and Anderson, 1986; 
Henderson and Clark, 1990; Utterback, 1994; Christensen, 1997). With the advent of 
globalisation the pace of these transformations appears to be accelerating and the resulting 
pressure to change is mounting. Therefore in recent years the ability and efforts of firm, 
enterprise or countries to develop appropriate understanding and response to change by 
transforming capabilities has become one of the central areas of research in management 
SCIence. 
In the globalised era, the ability of firms to renew or reconfigure existing competencies and 
create new knowledge for innovation has emerged as a strategically important capability 
(Dosi, 1988; Pavitt, 1991, Teece et aI., 1997). Several firm level empirical studies of 
renewal or reconfigurations of capabilities involving mechanisms of learning and 
knowledge creation have emerged during the past two decades. Some of these studies have 
drawn on the traditional 'organisationalleaming' literature (e.g. Simon, 1991; Hedberg, 
1981; Levitt and March, 1988). These studies argue that knowledge is the foundation of 
capability and source of performance differences among firms in their industry (see for 
instance, Nonaka and Takeuchi, 1995; Leonard - Barton, 1995; Kogut and Zander, 1992; 
Teece et aI., 1997; Henderson and Clark, 1990). This literature mainly concentrating on 
finns from advanced countries competing at the technology frontiers, addresses the firm's 
capabilities - and knowledge creation in industrialised economies with reference to 
maintaining and renewing strategic innovative capabilities that already exist ( e.g. Cohen 
and Levinthal.1 990; Prahalad and Hamel,1990; Kogut and Zander, 1992; Nonaka and 
Takeuchi,1995; Spender, 1996a). However this body of literature pays little attention to 
how those capabilities or knowledge bases were initially accumulated. 
In the case of firms from developing countries, transformation of capabilities differs in 
complexity compare to firms in advanced countries as in developing countries economic. 
political and social complexities makes the transformation of capabilities a challenging and 
difficult process. 
In the past the literature focused on developing countries has mainly addressed process of 
capability accumulation in firms and industries (see for instance Dahlman and Westphal, 
1982; Bell and Pavitt, 1995; Lall, 1987, 1992; Katz, 1987; Hobday, 1995). Most of these 
studies have been based on long-term descriptions of capability accumulation in industries 
from developing countries. This tradition has concentrated on the learning process 
involved in building essential minimum knowledge base to engage in innovation activity. 
Therefore, these studies have not yet paid enough attention to the capability transformation 
or capability renewal in developing countries firms. Also despite the emergence of more 
comprehensive firm level studies during the mid -1990s (eg. Kim, 1997a; Du~ nit, 2000; 
Figueiredo, 2003) comparative analysis of learning and capability accumulation in firms 
from developing countries or newly industrialising countries has still been absent in this 
research stream. 
This research takes up that task. This research explores the learning processes involved in 
the transformation of capabilities to develop new competencies by firms from developing 
country as a response to change in regularity environment. More specifically this research 
investigates approaches used by the Indian pharmaceutical firms to move from imitative 
R&D competencies to innovative R&D competencies as response to the change in patent 
law. The focus of the research is firm levelleaming processes involved in reconfiguration 
or renewal of capabilities for innovation and inter firm differences in learning processes. It 
also covers the long term process of capability accumulation at industry and firm level. 
The impact of the Trade Related Intellectual Property Rights (TRIPS) agreement as part of 
the World Trade Organisation (W.T.O.) agreements on pharmaceutical industry in 
developing countries forms the genesis of this research. TRIPS is instrumental in setting 
uniform standards of intellectual property all over the world and as a result large part of the 
world is moving from partial or no patent protection to the full fledged patent protection. 
Pharmaceutical industries based in developing countries have built basic capabilities 
through imitative R&D and which will be restricted as a result of strengthening of patent 
law. As a result pharmaceutical firms in developing countries have to undergo 
discontinuous learning for transforming existing capabilities and developing of new 
competencies to survive and grow in emerging con1petitive environment. The extensive 
literature that deals with the change in patent law and its impact on various healthcare 
" 
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Issues has not paid enough attention to the strategic capability transformation by 
phannaceutical finns from developing countries as a response to the changed patent law. 
The empirical evidence for this research comes from a study of the innovative finns in the 
Indian phannaceutical industry. The choice of India provides the ideal setting for this 
research as the Indian phannaceutical industry is one of the success stories of self reliant 
imitation based development in the developing world. 
1.2 Research context and question 
World trade agreements, especially TRIPS agreements, are setting new 'rules of the game ~ 
by hannonising the intellectual property rights (IPRs) all over the world. Now due to 
TRIPS agreements for the first time in international law, all countries are required to 
provide protection to both process and product inventions made in all fields of technology, 
subject to classical parameters of novelty, non-obviousness and usefulness. In the case of 
phannaceuticals and agro chemicals, patents will now be granted both for products and 
processes for the inventions in all fields of technology; the patent tenn will be twenty years 
from the date of application. In the case of a dispute on infringement, the responsibility of 
proving innocence lies with the accused, rather than the patent holder proving infringement 
of the accused. This broad regulatory framework will now guide and control the 
phannaceutical industry in WTO member countries. 
The strength of the patent regime plays an important role in knowledge intensive industries 
and especially in the phannaceutical industry. In the pharmaceutical industry, patents 
provide strong appropriation and profit maximisation by conferring limited monopoly 
rights to inventors. As a result the strength of an IPR regime is a strategically important 
issue for phannaceutical firms but sensitive for countries. The degree of patent protection 
given to phannaceutical products in the past was clearly related to the development of the 
domestic pharmaceutical industry. In some developing countries like India and China the 
absence of product protection allowed the non market mediated mechanisms like reverse 
engineering or imitative R&D and thus played a crucial role in the development of the 
domestic phannaceutical industry. But now due to the strengthening of patent law, these 
activities will be restricted and that will severely affect industrial growth (Watal And 
Mathai, 1995). Thus TRIPs agreement represents a substantial and complex challenge for 
pharmaceutical firms in developing countries. 
NUlnbers of studies have been carried out on the effect of change in patent law on drug 
related healthcare issues in developing countries. These include studies focusing on socio 
economic issues like the pricing of the drugs (see for instance, Lanjouw. 1996; WataL 
2000: N ogues, 1993), technological development of the ,firms (e.g. Sequeria, 1998) and the 
3 
resultant heterogeneity (D'Este, 2002) as well as strategic issues like adaptive strategies of 
finns as a response to change (Madanmohan and Krishnan, 2003; Halemane and Dongen. 
2003). Most of the research on effect of TRIPS agreement has focused on welfare issues 
like prices of drug and strategic issues like its implications for technological development 
foreign direct investment But very few studies have explored how the pharmaceutical 
finns in developing countries are responding to changes in patent law or how these firms 
are overcoming the organisational and managerial challenges associated with 
transfonnation of finn capabilities in their responses to change in patent laws. 
This research examines these questions by studying the innovative finns In Indian 
pharmaceutical industry and so Indian phannaceutical industry is focus of this research. 
Some of the finns from Indian pharmaceutical industry have responded to TRIPS 
challenge by building capabilities for innovation and therefore these finns provides ideal 
set up to explore questions raised by TRIPS. There are two important challenges for Indian 
phannaceutical finns in development of competence for innovative R&D. The first 
important challenge for Indian finns is financial and infrastructure requirements for 
innovative R&D. The innovative research and development is a very costly and risky 
process, it takes up to 8-10 years and 500 -600 US$ million (Appendix I). However the 
bigger and more complex challenge is of knowledge bases and capabilities; the knowledge 
base and capabilities required for innovative R&D and reverse engineering R&D differs a 
lot 
So it raises the question: 
• How are Indian pharmaceutical firms building strategic knowledge creation 
capability for innovation as a response to change in regulations? 
• How relevant is knowledge accumulated through imitation for firms in their 
efforts to create innovative novel products? 
1.3 The case study: The Indian pharmaceutical industry 
The Indian phannaceutical industry has shown remarkable growth in recent years and it is 
now respected in the world as 'wonder of the third world'. The pharmaceutical industry in 
India is comprised of public and private sector units in organised sector and small scale 
units in the unorganised sector. It represents a successful high technology based industry. 
which has witnessed consistent growth over the last three decades. Its total worth in 2003 
was US $ 6.5 billion and in last decade, it has consistently grown at 8-10 % in a year. If s 
fourth largest pharmaceutical industry in terms of volumes and 13th largest in terms of 
market value. The Indian pharmaceutical industry is now counted among top fi\'e 
manufacturers of bulk drugs. 
The weakening of patent law in 1972 played a key role in growth and development of the 
Indian pharmaceutical industry. From 1970 onwards Indian pharmaceutical firms slowly 
started dominating the domestic market reducing the market share and influence of 
Western companies. Today the market share of Indian firms in domestic market is around 
60-70% compared to 10% in 1970 (Ramani, 2002). The Indian pharmaceutical industry has 
developed enough capabilities to make the country self sufficient in its health care needs. 
Of the 550 bulk drugs which are formulated in the country, about 350 drugs are 
manufactured indigenously. 
In recent years it has emerged as one of the major suppliers of cheap drugs to developing 
as well as advanced countries. Now Indian pharmaceutical industry exports generic drugs 
not only to the developing or emerging regions like South East Asia, CIS (Commonwealth 
of Independent States) countries, Africa, but also to the highly regulated US and European 
markets. In 2003 Indian pharmaceutical exports were worth $2billion and have increased 
consistently over the last decade making it a strategic trade sector in the Indian economy. 
During the last three decades, the large private Indian pharmaceutical firms focused their 
efforts on reverse engineering oriented process R&D, and activity was limited to applying 
known knowledge, or to making small adjustments in the contents (Wendt, 2000). A few 
government owned laboratories under the Council of Scientific and Industrial Research 
(CSIR) also operated in pharmaceutical R&D, specifically focusing on the 'indigenisation' 
of technology. The intensive efforts of Indian pharmaceutical firms has resulted in 
extensive expertise regarding production technologies and process R&D and the lag period 
between the launch of a new product in its first market and India was thus reduced, in some 
cases as low as two years (Lanjouw, 1996). As a result Indian pharmaceutical firms have 
accumulated extensive knowledge in process R&D (synthetic and organic chemistry). In 
recent years Indian firms have developed some of the most innovative processes for drug 
production. 
However with the signing of WTO agreements, specifically TRIPS in 1994, the Indian 
industry and market structure is poised to change. In a product patent regime, Indian firms 
will have to look for new sources of growth and in the emerging competitive scenario the 
biggest source will be productive R&D, which can deliver patentable innovations. Some 
Indian pharmaceutical firms have shown early success in innovative R&D and this 
research explores how these firms are transforming existing capabilities to achie\'e success 
in innovative R&D. 
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1.4 Theoretical Framework 
The theoretical framework used for analysis is based on the concepts from organisational 
learning, knowledge based theory of the firm and innovation management literature. In a 
rapidly changing globalising world, the challenge for firms is to find new ways of doing 
things (Teece, 2000). In the management literature there is increasing evidence that 
knowledge allows the creation of the capability and that determines the ability to do things 
(Grant, 1991; Henderson and Cockburn, 1994; Leonard- Barton, 1995). The manner of 
knowing or learning is as important as what should be known (Spender and Grant, 1996). 
Leonard - Barton (1992) points out that the firm nurtures and creates knowledge through 
certain activities and these activities basically involve the sharing of knowledge within the 
organisation, and the transfer and integration of knowledge across organisational 
boundaries. However in the case of technological advances or fundamental regulatory 
reforms firms have to develop new competencies through revolutionary change or 
discontinuous learning (Tushman and O'Reilly III, 1996). The capability of the firm to 
maintain, nurture and renew or reconfigure technological capabilities is based on the 
ability of the firm to develop new competencies by acquiring new knowledge and 
integrating or combining it with existing knowledge bases (Kogut and Zander, 1992, 
Teece, et aI., 1997; Cohen and Levinthal, 1990). In a similar vein Henderson and Clark, 
(1990) suggest that such change and adoption involves not only learning new components 
of knowledge but also the new linkages between the components and so it requires 
reconfiguration of existing systems of linkages in new way. Therefore in such uncertain 
environment firms' ability to change and adopt depends upon the absorptive capacity 
which is defined as ability to evaluate, assimilate and apply outside knowledge (Cohen and 
Levinthal, 1990). Absorptive capacity is viewed as a function of two separate but 
interrelated dimensions: 
a. the firm's ability to acquire the knowledge relevant to the new technological paradigm 
b. firm's ability to integrate external knowledge into existing capabilities. 
The theoretical framework broadly focuses on practices or mechanisms associated with 
these two dimensions of absorptive capacity. Therefore it explores the processes involved 
in acquisition, transfer, assimilation and application of new knowledge. It also explores the 
relevance of prior knowledge in terms of its nature, its usefulness in innovative R&D and 
the processes involved in building the prior knowledge base. 
Large pharmaceutical firms' transformation of capabilities as a response to 
biotechnological challenge helps in activating the framework. The emergence of 
biotechnological change and responses to large pharmaceutical firms provides better 
understanding of mechanisms used by incumbent firms to transform its capabilities in face 
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of an external technological discontinuity. It specifically illustrates the specific 
mechanisms involved in development of new competencies through discontinuous 
learning. In this research these mechanisms used as a guide to explore the transformation 
of capabilities in Indian pharmaceutical firms. 
1.5 Research Methodology 
The empirical part of the thesis will draw from data collected through range of quantitative 
and qualitative methods. This research is focused on exploring processes involved 
development of capabilities in Indian pharmaceutical firms. So qualitative research 
methodology forms the main basis of research strategy and interviews as the principle 
mechanism of data collection. It is quite evident from different researchers ~ approaches to 
studies of capability development that qualitative methodology certainly helps to capture 
the richness and complexities of the issues at hand (Hoskisson et aI., 1999). 
Research was carried in two phases; the first phase involved qualitative interviews with 
pharmaceutical consultants, patent experts and presidents of Indian pharmaceutical 
associations. Along with interviews, an electronic survey was also carried out to explore 
effects of change in patent law on the Indian pharmaceutical industry. The survey was sent 
electronically to scientists/researchers working in Indian pharmaceutical firms, universities 
and supporting research institutions. The interview questions and survey questionnaire 
used for the first phase was mainly focused on industry level issues such as the effect of 
changes in patent law on industry structure, market structure and emerging challenges. 
In the second phase research is focussed on firm level analysis as the micro level analysis 
can provide better understanding of the processes involved in transformation of existing 
capabilities and development of new competencies. According to Pavitt (1991) firms are 
key actors in the process of technology capability development as the technological change 
is basically localised in the firms. Therefore in the second phase a case study methodology 
(Yin, 1994) was chosen to examine the firm level learning processes involved in the 
knowledge accumulation and development of new competencies. The Indian 
pharmaceutical firms who have made transformations from imitative R&D to innovative 
R&D are selected to study in this research. The multiple case study design was used and 
the cases were chosen on the basis of degree of innovativeness and strategies to transform 
themselves. But only those firms were selected for the study which has filed patent for new 
chen1ical entities in India as well as in US. 
The inten'iews were transcribed and analysed by using techniques like pattern matching 
(Yin, 199.+) and systematic building of analytical tables (Miles and Huberman. 1984). The 
" 
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different patterns were identified and categorised using Atlas. Ti data analysis software. 
The interview transcripts were analysed by locating series of narratives around the 
transformation issues in each firm and from these, replicating patterns of acquisition and 
transformation processes were identified. These patterns were supplemented by secondary 
data which was collected from industry journals, industry association publications and 
annual reports of firms. The observed patterns in Indian pharmaceutical firms were then 
compared with the theoretical patterns identified from the framework to find the 
similarities and differences between them. The results of analysis were sent to key 
members of each researched firm and their feedback was included in the final results. 
1.6 Principle findings 
1.6.1 Firm level processes involved in development of knowledge capability for 
innovation 
This research shows that development of new capabilities involved removal of capabilities 
which were redundant in new era, acquisition of new knowledge and combination of new 
knowledge with existing relevant capabilities. The analysis revealed that in case of Indian 
pharmaceutical firms the main rigidities that emerged are a. imitative R&D organisational 
routines, b. in-house nature of R&D and c. organisational mindset shaped by short term 
vision of R&D investments and domestic market approach. 
In the case of Indian pharmaceutical firms networked model of collaborative R&D and 
learning by hiring has emerged as the main mechanisms of knowledge acquisition. These 
firms created linkages with Indian as well as international research institutes to fill the 
knowledge gaps and train its scientific workforce. The Indian pharmaceutical firms hired 
product R&D experienced scientists working overseas in MNC pharmaceutical R&D firms 
or universities to acquire the know-how in innovative product R&D. The hiring of foreign 
educated or experienced scientists helped Indian firms to fill knowledge gaps in areas of 
innovative R&D and acquire crucial tacit knowledge. In the case of Indian pharmaceutical 
firms the presence of diaspora in terms of Indian scientists community in advanced 
countries emerged as an important resource of knowledge in the advanced areas of 
innovative R&D. 
The analysis points out that the Indian pharmaceutical firms set up various organisational 
arrangements like adoption of matrix form of project management to encourage the sharing 
of knowledge among its R&D scientists. These mechanisms helped Indian pharmaceutical 
firnls to create an environment that facilitated the assimilation of new knowledge among 
its scientific workforce. 
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The analysis also shows a strong emphasis on the integration of different knowledge bases 
across all firms. In the case of Indian pharmaceutical firms cross disciplinary teams and 
frequent scheduled as well as ad hoc project meetings played a critical role in achieving the 
integration of different knowledge bases. 
This research points out that learning process adopted by the Indian pharmaceutical finns 
shared similarities with the large multinational firms' approaches to transform their 
technological identity as a response to molecular biology advances. This suggests that as 
far as intra firm learning is concerned learning processes followed by technology frontier 
firms are also applicable to firms from developing countries. However firms in developing 
countries have to modify learning strategies according to their institutional environment. 
1.6.2 Movement from imitators to innovators: neither linear nor automatic 
The inter firm comparative analysis reveals subtle differences in functioning and 
implementation of learning processes in each firm showing that learning at firm level is 
neither automatic nor linear and requires a deliberate learning strategy. For example, in 
case of learning by hiring, the nature of scientists targeted for recruitment as well as 
sourced used by firms for recruiting new scientists differs a lot. Similarly inter firm 
differences emerged in supportive learning mechanisms that encourages interaction among 
distributed knowledge systems. The learning mechanisms like incentive policies, top 
management commitment and emphasis on collaboration and networking differed across 
the firms. This influenced the creation of environment that facilitates the development of 
collective knowledge. Therefore it emerges that movement of a firm from imitative R&D 
to innovative R&D is neither linear nor automatic and requires an intensive effort from 
firms to invest in different mechanisms of learning. 
The inter firm differences in implementation and functioning of learning processes also 
suggest that firm engaged in different modes of learning as they respond to external 
conditions. These differences have profound effects on the movement of firms from 
imitative R&D to innovative R&D and emerged as one of the main reason for differences 
in innovative R&D capabilities among the firms under study. Therefore this finding 
support the observation by Figueiredo (2002) that the way in which intra firm learning 
processes and mechanisms managed over time plays a substantial part in influencing inter 
firm differences in terms of technological capability and, in tum, the competitive 
performance. 
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1.6.3 Technological capability accumulation process in Indian pharmaceutical 
industry and TRIPs 
The Indian pharmaceutical industry's journey from being an import depended industry to 
becoming a global supplier of pharmaceuticals has been long and eventful one. This 
research presents a model of dynamic learning processes involved in technology capability 
development in Indian pharmaceutical industry. It shows that industry has followed the 
trajectory of starting with duplicative imitation followed by creative imitation to rise up the 
value chain of pharmaceutical R&D and finally as a result of change in patent law industry 
is undergoing learning to develop capabilities in innovative R&D. 
The analysis reveals that strengthening of patent laws as a result of TRIPs agreement had a 
positive impact on large Indian pharmaceutical firms and catalysed their movement from 
imitators to innovators. It played an important role in creating 'crisis for their existence' 
and that triggered their movement towards the innovative R&D competencies. However it 
also emerged that imitative R&D in these firms created important essential basic 
capabilities and that acted as a base for innovative R&D. The basic and intermediate 
technological capabilities learnt as a result of imitative learning certainly gave these firms 
a solid base for development of competence in advanced innovative R&D. This certainly 
raises the question about linking patent laws to trade policy as evident in the WTO and not 
to capabilities of domestic pharmaceutical industry. 
This research also shows that strengthening of patent law changed the strategic orientation 
of Indian pharmaceutical industry and forced Indian firms to pursue the alternative 
technological innovative trajectories. These Indian pharmaceutical firms responded to 
strengthening of patent law by adopting ambidextrous technology capability development 
paths in form of innovative process and product R&D. The Indian firms are competing in 
advance countries generic markets and supplying active pharmaceutical ingredients to 
large MNC pharmaceutical firms, and in parallel to that these firms are also developing 
new chemical entities and new drug delivery systems. Therefore these Indian firms 
transformed their capabilities ambidextrously; on one side by incrementally improving the 
basic capabilities by competing in generics market and supplying drugs to MNC, while at 
the same time these firms developed capabilities in innovative R&D which represents a 
radical change. This finding has important implication for pharmaceutical firms in other 
developing countries which will be facing similar challenges due to TRIPS agreement. 
Pharmaceutical firms in other developing countries can adopt similar approach in their 
responses to regularity discontinuities. 
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1. 7 Structure of the thesis 
This section describes the organisation and content of all the chapters in the thesis. Figure 
1.1 depicts the flow of the chapters in our thesis. 
Chapter 2 
Researc Context 
~ 
Chapter 1 Chapter 3 Chapter 5 Chapter 9 
I ntrod uction Literat re ReVi/"" Research Methodology Conclusion 
Chapter 4 
Theoretical Framework Analysis and Discussion 
Figure 1.1 The thesis organisation 
This dissertation consists of nine chapters, including this introductory chapter. The content 
of the subsequent chapters are briefly described below. 
Chapter 2 provides the general overview of the research context. It focuses on the genesis 
of the research; the Trade Related Intellectual Property Rights (TRIPS) agreement and its 
impact on the knowledge based industries in developing countries. It also briefly discuses 
the relevant literature on various patent related issues such as evolution of patent system in 
advanced and developing countries and its impact. In the concluding section this chapter 
introduces the characteristics of Indian pharmaceutical industry which is the main focus of 
this research. 
Chapter 3 reviews the literature on the technology capability development in relation to 
firms from developing countries and advanced countries and concentrates on broader 
aspect of that process. It shows that transformation happening in Indian pharmaceutical 
firms has not been explored by both strands of researchers. 
Chapter 4 presents the theoretical framework used in this research for exploring the firm 
level processe invol ved in discontinuou or dynamic learning for the development of ne'v\ 
knowledge creation capability for innovation in Indian pharmaceutical firm . The 
theoretical framework i ba ed on the absorptive capacity concept and build on earli I 
framework which have focu ed on organisational knowledge creation. It dra\\ on the 
1 I 
strategic management and organisational theory literature focused on knowledge, learning 
and innovation. It shows the role of knowledge in developing capabilities for innovation 
and organisational processes involved in creating knowledge. The approaches used by 
large pharmaceuticals firms to transform their technological capabilities as a response 
biotechnological change guides the theoretical framework. 
Chapter 5 discusses the research methodology. This chapter explains rationale for 
conducting the research in two phases and choosing case study as a research methodology 
in second phase. It explains in detail how the interview questions were framed to make 
theoretical framework operational. This chapter concludes with a discussion on the method 
employed for the data analysis. 
Chapter 6 describes the historical evolution and important characteristics of the Indian 
pharmaceutical industry. It presents the capability creation model and discusses the long 
term technology capability accumulation process in Indian pharmaceutical industry. It also 
illustrates the impact of institutional environment on learning process involved in 
technological capability accumulation process. 
Chapter 7 introduces cases of the six innovative Indian pharmaceutical firms. It describes 
the evolution of organisational capabilities and discusses processes used by these firms' to 
transformed strategies, markets, product portfolio and capabilities as a response to change 
in patent law. 
Chapter 8 focuses on the learning processes involved in development of capability for 
innovation In firms under study. It presents analysis of inter-firm similarities and 
differences In terms of learning processes and its influence on development of the 
innovative capability. This chapter concludes with pointing out the limitations of learning 
hierarchy models. 
The dissertation concludes with Chapter 9. The chapter begins with a research summary 
and follows that with discussion about main contributions that can be drawn from our 
research. This discussion covers relevance of research to practising managers, academic 
literature and policy implementation. Finally the thesis provides an insight into limitation 
of research and direction for future research. 
" 
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Chapter 2 
RESEARCH CONTEXT 
2.1 Introduction 
This chapter provides a general overview of the research context. It focuses on the effect of 
change in patent law on firms from developing countries as a result of World trade 
organisation (WTO) agreements. This forms the genesis of the research presented in this 
thesis. 
The WTO agreements are influential in reducing the tariff and non tariff barriers of 
international trade. These agreements were developed through a series of trade negotiation 
rounds, held under General Agreement on Trade and Tariffs (GATT). The GATT, a trade 
pact and organisation was founded in Geneva in 1948 to pursue the objective of free trade 
in order to provide equal growth and development to all member countries. The first seven 
rounds mainly focussed on tariff reductions but later negotiations included other areas such 
as anti-dumping and non-tariff measures. The culmination of the negotiations in the last 
round - the 1986-94 Uruguay Round - created the WTO on 1 st January, 1995. WTO 
agreements are thus instrumental in setting uniform rules and regulation for trade in goods 
as well as services all over the world and therefore in recent years it has emerged as one of 
the main backbone of globalisation process. According to Govindrajan and Gupta, (2000) 
this reduction of tariff and non tariff barriers along with the advances in information and 
communication technologies is playing a key role in driving a globalisation process by 
facilitating trade among different countries. 
However, the WTO agreements became a very controversial issue with the introduction of 
intellectual property laws as the third leg of the WTO in the form of 'Trade Related 
Intellectual Property Rights (TRIPS). Bhagwati (2002) an advisor to the WTO questions 
the validity of IPR as an instrument of trade and suggests that the WTO now rests on a 
tripod whose third leg, namely TRIPS, is shorter than the other two, goods and services. 
For many decades the intellectual property rights issues were highly contentious and now 
with the passing of TRIPs agreement, they have again became a highly debated and 
controversial issue. Machlup (1958) shows the long history of doubts about the patent 
system expressed by European and American economists. In the TRIPS agreement, the 
contentious requirement of strengthening the patent regime for pharmaceutical and agro-
chemical products brought highly sensitive issue of healthcare and welfare into sharp focus 
" 
13 
especially from the developing countries perspective. This led several developing countries 
questioning the motives of WTO agreements. 
Two - third of the WTO members (around 146 countries) are developing and least 
developed countries and industries from these countries are certainly going to be affected 
by the emerging 'trade' regimes. According to Rodrik (1997) in the emerging new trade 
environment developing countries now have to implement an agenda of refonns that took 
today's advanced countries generations to accomplish. It is clearly evident that this change 
in the 'rules of the game', specifically the strengthening of IPR regimes will exert 
significant pressure upon sectors like pharmaceuticals, chemical and agro chemical that 
have long enjoyed protection and an assured domestic market (Das and Nair, 2000). 
Therefore the changes in patent regulations due to the TRIPS and its impact on learning 
processes in knowledge based industries like phannaceuticals from developing countries 
fonns the genesis of this research. It raises the question: 
How are firms from a developing country building a strategic knowledge creation 
capability for innovation as a response to the forces of globalisation? 
This chapter gives an overview of debate about various issues about intellectual property 
laws and its linkages with current research. 
Section 2.2 discusses the various issues related to the patent system and shows the 
difference between the evolution of patent systems in advanced and developing countries. 
Section 2.3 then concentrates on the Trade Related Intellectual Property Rights agreements 
(TRIPS) and its consequences on patent regulation all over the world. Section 2.4 reviews 
the literature regarding the changes of patent systems and their impact on the domestic 
pharmaceutical industry in different countries. Section 2.5 presents the characteristics of 
the Indian pharmaceutical industry which is the focus of this research. Finally this chapter 
concludes with the research questions. 
2.2 WTO and Patents - Trade Related Aspects of Intellectual Property Rights 
Over the years advanced countries have strengthened their patent system whereas the 
developing countries showing different needs and priorities have set up weak patent laws 
or in some cases these countries have reduced the strength of patent system. But the 
growing role of the US in the late 1970s as a major producer of know-how and the 
catching - up process in newly industrialising countries led to a growth of pressure from 
the US on these countries to strengthen their patent laws. This pressure was triggered by 
significant inroads by newly industrialising countr.ies into US markets and increasing trade 
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deficits (Granstrand, 1999). From the beginning of the 1990s, US industries through 
vanous initiatives started pushing for stronger patent laws domestically as well as 
internationally. This led to the incorporation of intellectual property rights (IPR) laws as a 
trade issue in the Uruguay round of negotiations of GATT and this finally resulted in the 
TRIPS agreements. 
The intellectual property right is a grant intended to allow the holder to prevent others from 
making commercial use of innovation for a limited period of time. The intellectual 
property system comprises a number of legal instruments like patent, designs and 
trademarks along with copyrights. Under the modem patent system there are three main 
requirements which patent applications have to fulfil: novelty - some degree of difference 
to any previous innovation; non-obviousness - the innovation is not apparent to someone 
who is technologically competent in the field; and utility - there is a specified commercial 
purpose to innovation. There was wider agreement about the basic requirement of the 
patent system but the strength or efficacy varied a lot between countries. 
The TRIPS agreement is now instrumental in universalising the standards of intellectual 
property rights all over the world and framing equal 'rules of the game' for advanced as 
well as developing countries of the world. It is the most important instrument to date 
concerning intellectual property protection. It covers the seven IPRs such as copyright and 
related rights, trademarks, geographical indications, industrial designs, patents, layout-
designs of integrated circuits and undisclosed information. Among all these, 'patents' is the 
most important form of IPR for industrial firms operating in the advanced as well as 
developing countries 
The next section summarises the history of the development of the patent system and 
illustrate the different interpretation in advanced and developing countries. 
2.3 Brief History of the Patent System 
The historical evolution of the patent system in the advanced countries is well documented 
by David (1993), Penrose (1973), Machlup (1958) and Granstrand (2003). The first patent 
law is attributed to the Republic of Venice and dates from 1474. The patent code 
incorporated various ideas and inventions shown to be workable and useful; and these 
ideas and inventions received ten years of protection subject to compulsory licensing. 
The Patent laws spread in Germany and England in the 16th and 1 7th century and by the 
early 19th century across the whole Europe while the US congress passed its first law of 
patents in 1793. In Europe, England reyiewed its patent system several times in the period 
1851 to 1872. According to McLeod (1991) presence of patent system played an influential 
role in shaping the industrial revolution. The patent system in the US evolved differently 
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from the Europe. Initially the patent institutions in the US were derived from those of 
Britain's North American colonies but from 1790 to 1836, as a net importer of technology. 
the US restricted the issue of patents to its own citizens and residents. Even in 1836, 
patents fees for foreigners were fixed at ten times the rate for US citizens and residents, 
and only from 1861 foreigners were treated on a non - discriminatory basis (CIPR Report, 
2002). 
The first important landmark in historic evolution of patent system is 'The Paris 
convention of 1883' - proposed and formalised by a select group of industrialised 
countries. It is the first multinational treaty on intellectual property rights which was signed 
and ratified by many countries. This convention specified that national patent system 
should treat domestic and foreign applicants equally and accept patent applications up to a 
year after the first application in another member country. Apart from these regulations, 
the member countries were free to determine the standards, subject matter and period of 
protection. This convention left countries entirely free to establish the criteria for 
patentability and the strength of protection offered to patent holders (Penrose, 1951). The 
basic tenets of the patent law in advanced countries are thus based on the Paris convention 
of 1883. 
In recent years the patent system in advance countries has broadened the scope of domains 
of patents by accommodating the emerging technologies from advances in fundamental 
sciences like patenting of live organisms and in some cases it gave rise to the whole new 
industry like biotechnology. However, as David, (1993) points out by widening areas of 
dispute, the patent system also raised new questions and created many 'awkward 
ambiguities' especially in case of new technological industries like biotechnology and 
information technology. A major source of difficulties is the problem of achieving 
consistency in the application of legal principles, preserving the force of precedent and 
likely costs of entailed litigation and innovation. It has been noted now that with the 
changing nature of technology, the application of patent and copyrights is rather ill suited 
to some of the new technologies (WIPO, 1989) 
The historical evolution of patent laws in the developing countries has differed a lot from 
the advanced countries. Most of the developing countries were colonies till World War II 
and after independence they continued with the same regulations of colonised era. The 
regulations slowly started changing in the 1960s and 1970s as most of the developing 
countries either abolished or weakened their patent laws; for example~ Turkey weakened 
its patent law in 1961, Brazil in 1969 and India in 1971. The main reason behind this was 
the argument that a patent system would not be stimulus to innovative activities in 
developing countries because these countries have little capability to innovate. The market 
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in the developing countries has a huge need but very little purchasing power providing low 
incentive for innovation. Also the developing countries had very few inventions worth 
patenting in advanced countries and so they can not expect the reciprocal advantages from 
granting patents to foreigners (Penrose, 1973). This belief that developing countries will 
suffer the negative consequence of patent monopolies granted to foreign investors created 
the weak patent regimes in these countries. 
However, with emergence of the US industry as an innovative technology producer, the 
US government started pressing for a 'trade based approach' to improve IP protection 
while trading with weak IPR regime countries. It enacted the Trade and Tariff Act (1984 
amendments) which in section 301 specified that countries could be removed from the 
privileged trade status if they did not provide effective minimum safe guards for the 
acquisition and enforcement of the intellectual property rights. Brazil and India were 
penalised through this provision and South Korea was pressured into reforming its patent 
law; Mexico and Chile did the same with effect from 1992, Brazil changed it in 1997 
(Kaplinsky, 1989). 
Different arguments were put forward in regarding the strength of the patent system mostly 
focussing around its role in economic growth, technology transfer and foreign direct 
investment. The next section briefly discusses them. 
2.3.1 Strength of Patent system and its economic implications 
Over the years studies covering the strength of patent system and its role in development of 
technological and innovative capabilities have largely shown sharply conflicting views. 
2.3.1a IPR and economic growth, innovative activity 
The broad argument put forward in support of a strong patent system relates to the issue of 
development and economic growth. Researchers claim that intellectual property rights 
have a significant role as an incentive for spurring innovation (Kanwar and Evenson, 
2003). Arrow (1962) argues that there is a tendency in industry to under invest in R&D and 
patent protection is one of the several alternatives of appropriation that act as an 
encouragement for industry to invest in R&D. 
Mazzoleni and Nelson (1998) summarises four different broad theories that has been put 
forward to explain the purpose of patents: patent protection motiYates inventions, induces 
development and commercial inventions, promotes disclosure of inventions and it enables 
orderly development of broad prospects. 
It is argued that the strong patent system stimulates innoyation by granting the innoyutor a 
limited period of exclusive control of the right t<~ use, manufacture and sell the innoyation. 
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The principle way a patent affects invention and innovation is through its effects on the 
rate of imitation. Thus a delay in imitation through patent protection and the resultant 
period of exclusive rights would be a stimulus for firms to invest in R&D. Based on the 
distinction between invention on one hand and development and commercialisation on 
other had it is argued that patents plays an important role in inducing firms to commits 
resources to the development of inventions as holding of a patent at an early stage provides 
assurance that, if development is technologically successful, its economic rewards can be 
appropriated. However Mazzoleni and Nelson (1998) points out that the effectiveness of 
patent protection varies from industry to industry and in most industries patents were not 
an important part of the incentives firms have for investing in the R&D. Also in many 
industries patents are not needed to induce further development from invention; a head 
start on commercialisation can yield large profits (Mansfield, 1986; Levin et aI, 1987; 
Cohen et aI, 1997). It also argued that a patent system as an incentive to innovation will be 
at the expense of society as the exclusive rights conferred by the patent system enables the 
innovator to charge monopolistic prices during the lifetime of the patent (Arrow, 1962; 
Nordhaus, 1962; Scherer, 1972). 
The other major justification for the patent system is that the patents are incentive for 
innovators to make disclosure of their innovations which they might otherwise keep secret. 
It therefore creates a way of quick and wide diffusion of technical information underlying 
new dimensions. However, critics have raised concerns regarding the quality and quantity 
of the disclosures and utility of the information provided in patent disclosures (Sideri, 
1994). 
Recently another argument for the patent system has emerged that it provides a legal base 
to facilitate the process of technology licensing and research collaboration. This has been 
argued to be particularly important in cases of collaborative research (Scothmer, 1991), 
when the innovator lacks the 'complimentary assets' to successfully commercialise an 
innovation (Teece, 1986). However, Merges and Nelson (1990) show through various 
cases from different industries that across the board strengthening of intellectual property 
rights courts the danger of increasing litigation conflicts and cost of innovation. 
Other complex issue related to patent system as an incentive for innovation include optimal 
breadth or scope of a patent as well as optimal combination of length and breadth (Gilbert 
and Shapiro, 1990; Klemperer, 1990). In the context of the strengthening of patent la\\'s 
around the world, Mazzoleni and Nelson (1998, pp 273) conclude that "there is a reason 
for concern that the present movement towards stronger patent protection may hinder 
rather than stimulate technological and economic progress", 
" 
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2.3.2 IPR and developing countries 
In the context of developing countries arguments about the influence of patent systems 
especially in the context of technological capabilities are focused on foreign direct 
investment, technology transfer and trade. 
It is argued that the stronger patent systems promote technological development by 
encouraging the acquisition of technology by market mediated mechanisms like 
technology licensing and foreign direct investment (F errantino, 1993; Mascus and 
Penubarti, 1995; Smith, 2001). The fear of imitation and reverse engineering will prevent 
the transfer of technology in the case of a weak patent system. Mansfield and Lee (1996) in 
a sample of 14 countries find the perceived weakness of intellectual property protection 
adversely affecting the volume as well as the composition of US FDI inflows to other 
countries. Empirical evidence shows that, other things equal, countries with stronger IPRs 
do attract more imports, though the effect varies across industries, however this 
'favourable' impact of strong IPRs has generally been confirmed by a number of studies 
(for example Ferrantino, 1993; Mascus and Penubarti, 1995; Smith, 2001). These studies 
also argues that the result shows that foreign firms prefer exporting less to countries with 
weak intellectual property rights in order to avoid their products being copied by local 
firms. However researchers point out that the same findings also implies that stronger 
protection may encourage arm's length licensing of knowledge and reduce the need for 
undertaking direct investment (Mascus, 1998; Yang and Mascus, 2001). 
The other important argument put forward in support of strong patent systems is that it 
promotes technology transfer through MNCs establishing R&D subsidiaries (Ferrantino, 
1993; Mansfield, 1994). However Kumar (1996) suggests that availability of abundant 
trained low cost human resources and scale of ongoing R&D in the specialised knowledge 
fields of MNCs appear to be more important considerations for location of R&D than the 
strength of the IPR regime. 
The arguments supporting the weak patents regime argues that the weak protection of IPR 
helps the cheap acquisition of technology through imitation or reverse engineering. Several 
studies of East Asian countries have pointed out the importance of non market mediated 
mechanisms like imitation in facilitating the firm level technological learning (Kim, 1997b; 
Hobday, 1995; Nelson and Pack, 1999; Lall, 2000; Amsden, 1989). It has been argued that 
the learning that is required in imitation or reverse engineering may be absent in market 
mediated acquisitions. Weak patent systems increase the opportunities for firms in 
developing countries to adapt and improve knowledge acquired from foreign sources. The 
basic and intermediate innovative capabilities learnt as a result of the imitative learning can 
give finns a head start for accumulating the advanced innovative capabilities. 
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The TRIPS debate basically centred around the arguments relating to technological 
development, FDI and technology transfer and reduction to barrier of trade by having 
uniform patent systems. The other argument was related to the perception that firms from 
advanced country firms were losing sales due to the weak patent systems in developing 
countries. It was this loss of potential profit which originally motivated advanced countries 
especially the US to bargain hard to bring intellectual property rights within the purview of 
the GATT/WTO. 
Now with the signing of the TRIPS agreement, patent systems all over the world will 
converge with the IPR regulatory systems practised in advance countries. This will have 
enormous implications for the healthcare sector in developing countries as out of the seven 
IPRs cover by TRIPS; three aspects have a direct impact on pharmaceuticals - patents, 
trademarks and the protection of undisclosed information or trade secrets. These are 
discussed in the next section. 
2.3.3 TRIPS agreement and its implications 
The TRIPS agreement is a big and difficult step for firms operating in the knowledge 
intensive sectors from developing countries. It specifies the stronger levels of IPR 
protection, endorsing the perspective that countries should provide strong patent systems to 
benefit from technological licensing, FDI and investment in research and development. 
The TRIPS agreement contains seven parts, Part I contains the general provisions and basic 
principles which govern the agreement; Part II, the substantive, minimum standards on 
seven intellectually property rights (lPRs); Part III, procedures and measures for their 
enforcement; Part IV, arrangements for the prevention and settlement of disputes; Part V, 
maintenance of IPRs and related procedure; Part VI, transitional arrangements and Part 
VII, the other final provisions for the implementation of the agreement. 
In the case of pharmaceuticals and agro chemicals, patents will now be granted both for 
products and processes for inventions in all fields of technology, subject to the classical 
criteria of patentability i.e. novelty, non obviousness (or inventive step) and usefulness (or 
capability in industrial application). There can be no discrimination between imported or 
locally produced products (Article 31). The patent term will be twenty years from the date 
of application, applicable to all members of the WTO (Article 33). 
Compulsory licensing is a very important issue for the developing countries. According 
TRIPS agreement the use of patents without the authorisation of the rights holder should be 
decided on a case by case basis and no across the board licenses will be permitted 
(ArticleJO). Importantly in the case of a dispute on infringement. the responsibility of 
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proving innocence lies with the accused rather than in proving the infringement of the 
accused by the patent holder (Article 34). 
This broad regulatory framework will now guide and control the pharmaceutical industry 
in WTO member countries. The TRIPS agreement became effective on 1 st January, 1995. 
Advanced countries were given 1 year to comply whilst developing countries and 
transition economies were given until 1 st January, 2005. For developing countries that 
required national patent law amendments to introduce patents for pharmaceuticals, such 
action could be delayed up to January 2005. Least developed countries are expected to 
enact TRIPS in 2016 with respect to pharmaceutical products. However Article 70:8 made 
it mandatory for members to accept patent applications for pharmaceutical and agricultural 
chemical products from 1 st January, 1995 itself. Such products were to be granted 
exclusive marketing rights (EMRs) for a period of five years from the date of marketing 
approval in these countries or until the patent is granted or rejected, whichever period is 
less, provided that a patent application has been filed and patent granted after 1 st January, 
1995 and marketing approval obtained there. This means that at the minimum all 
pharmaceutical inventions for which patent applications were sought in any WTO member 
nation from 1994 onward have been covered by TRIPS obligations. In sum, all developing 
countries that did not previously do so, now had to make available patent protection for 
pharmaceutical inventions from 1995 onwards. The economic effects of which could be 
expected to begin at the earliest from 2000 onwards (when new drugs begin to get 
exclusivity under TRIPS provisions) and plateau by 2015 (when newly patented products 
may off set by older products losing their patent protection) (Scherer and Watal, 2001). 
For developing countries these changes in patent regulations are more important due to 
well documented relationship between patent and pharmaceutical products and its 
subsequent influence on a country's health care policy. 
The next section discusses the importance of patents in pharmaceutical industry and 
reflects on the implications of TRIPS for pharmaceutical industry in developing countries. 
2.4 Patents and the pharmaceutical industry 
The pharmaceutical industry is among the most R&D intensive industries, measured by the 
percentage of sales devoted to such activities (PhRMA, 2004). This industry is 
significantly different from other high tech industries in that the R&D process is made of 
different phases which are stringently controlled by regulation and therefore it takes 10-
15years from initial discovery to the commercialisation of the drug. At each stage a firm 
needs to invest a lot which makes pharmaceutical R&D a very costly and risky process. 
EffectiYc IPR protection is seen by the pharmaceutical industry as critical for it to recoup 
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its large R&D expenditures. In pharmaceutical industries patent have the ability to provide 
strong appropriation and profit maximisation by conferring limited monopoly rights to 
inventors. Chemical products are easy to patent because of structure of the molecule of 
each product is different; therefore it is difficult to invent around drug product patents. So 
the strength of the patent regime plays an important role in pharmaceutical firm's strategic 
decision making. 
Many studies have shown the prominent role of patents in the pharmaceutical industry and 
the important link between strength of patent protection and investment in R&D (e.g. 
Mansfield, 1986; Levin et ai., 1987; Taylor and Silberson, 1973). Mansfield (1986) 
showed that around 65% percent of pharmaceutical and 30% percent of chemical 
inventions would not have taken place but for patent protection while in most other 
industries patent protection doesn't play such a critical role. Levin et ai., (1987) confirmed 
the importance of patents in pharmaceutical by showing that product patents were found to 
be highly effective as a means of appropriating returns only in 5 of 130 narrowly defined 
industries. These five included drugs, organic chemicals, and pesticides among others. 
The availability of medicines is an important component in any country's healthcare policy 
and hence the strength of an IPR regime is a sensitive issue for different countries. In the 
case of diseases like AIDs the availability of drugs at affordable prices makes the 
difference between life and death. Due to this reason even different developed countries 
tightened up their patent laws after assessing the capability of their domestic 
pharmaceutical industry. Full patent protection for pharmaceuticals was not introduced 
until: 1949 in UK, 1960 in France, 1968 in Germany, 1977 in Switzerland and 1978 in 
Sweden (Nogues, 1993). Due to the pressure from the European Commission, Italy also 
introduced pharmaceutical patent protection in 1978. Spain and Portugal revised their 
patent laws in 1992 as a requirement for joining the European Union. 
The world pharmaceutical industry is geographically highly concentrated with firms from a 
few developed countries accounting for the bulk of world production. Almost 82% of the 
world production in 1990 was in advanced countries with developing countries accounting 
for only 18%. This imbalance regarding the concentration of industry influenced 
developing countries to reduce the strength of their patent systems. 
2.4.1 Patents and pharmaceutical industry in developing countries 
In the past many developing countries were dependent on imports for vitally needed drug 
supplies, which made the costs of imported drugs and policies to reduce them, a matter of 
national concern. In some developing countries the market share held by foreign firms has 
been higher than 50% and has even reached 80 to 900/0 in some cases (Watal and i\1athai. 
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1995). Therefore the weakening of the patent law in developing countries often targeted 
phannaceutical, chemical and food technologies where protection was either excluded or 
only minimal protection was given. Food and medicine were seen as essential needs of the 
population and the weakening of patent laws was seen as a protection from means by 
which finns can create monopolistic control. 
The learning process involved in development of phannaceutical manufacturing and R&D 
capabilities is much more complex compared to other sectors. The large multinational 
finns that dominate this sector develop a significant proportion of knowledge and through 
patent effectively control the diffusion of knowledge. These firms conduct most of their 
activities at home or in other developed countries and prefer direct investment to licensing 
when producing abroad. Therefore most of the developing countries have built domestic 
phannaceutical industries by adopting weak patent laws which provided protection only to 
the production processes, not products. This allowed the manufacturing of the same 
product albeit with small modifications in production processes. This started the trend of 
reverse engineering in developing countries. On the basis of reverse engineering these 
countries developed the domestic phannaceutical industries and some countries now are 
not only just serving basic domestic needs but also exporting some of their products (see 
Table 2.1). Countries like Argentina, Mexico, Brazil, Egypt, Turkey, Colombia, and 
Indonesia are capable of servicing domestic demands while countries like India, South 
Korea and China even figure amongst the 20 largest phannaceutical exporters. These 
countries have developed enough capability to produce active phannaceutical ingredients 
and are now exporting drugs to other developing countries as well as to the highly 
regulated generic markets in advanced countries. 
However, this entry of phannaceutical finns from developing countries in global generic 
markets along with changes in large phannaceutical finns~ business modelled to increase 
in pressure on developing countries to strengthen their patent laws. In the last two decades 
large phannaceutical firms based in advanced countries have came under heavy regulatory, 
social and economical pressure. The increasing cost of drug discovery due to stringent drug 
regulations, public pressure to reduce healthcare bills and competition from generic 
industries has led to an erosion of profits. In this context, the growing size of developing 
country markets for patented drugs became evident, along with possible opportunities to 
reduce drug discovery cost by outsourcing non critical parts like clinical trials in 
developing countries created new benefits for large pharmaceutical firms to push the 
developing countries for the strengthening of patent laws. Due to these emerging 
opportunities, hannonisation of the patent protection system in industrial economies and 
nlaking developing countries introduce product patent protection became important part of 
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large pharmaceutical firms' strategies in particular US pharmaceutical industry. The US 
pharmaceutical industry played a decisive role in bringing intellectual property into GATT 
agenda in 1986, and in the development of relevant rules, as contained in the TRIPS 
agreement (Ryan, 1998, pp68-69). 
Table2.1: Examples of pharmaceutical industries in developing countries at different stages of 
technological development (Source: adapted from Ballance et al., 1992) 
Stage 1. No production capabilities 
Bahrain Laos Senegal 
Botswana Maldives Swaziland 
Iceland Oman 
Stage 2 Production capabilities for formulations 
Algeria Ecuador Kenya 
Bangladesh Hong Kong Madagascar 
Chile Iran 
Stage 3. Production capabilities for both active ingredients and formulations 
Argentina Cuba Korea 
Australia Egypt Norway 
Bolivia Hungary Poland 
Brazil India Spain 
Bulgaria Indonesia Turkey 
Canada Ireland Russia 
China Mexico 
The degree of patent protection given to pharmaceutical products in the past was clearly 
related to the development of domestic pharmaceutical industries. Now due to the TRIPS 
agreements for the first time in international law, all countries are required to provide 
protection to both process and product inventions. This strengthening of patent law will 
certainly restrict reverse engineering or imitative R&D. In some developing countries like 
India, Argentina and China the absence of product protection played a crucial role in the 
development of the domestic pharmaceutical industry and would be severely affected by 
TRIPS (Watal and Mathai, 1995). 
The next section will review some of the literature on studies covering strengthening of 
patent law and its effect on pharmaceutical industries in deyeloping countries. 
2.4.2 Implications of strengthening the patent law and its effects on pharmaceutical 
industry: 
Pharmaceutical industries in developing countries have been the subject of a number of 
empirical studies about the influence of the strengthening of patent regime focusing on 
socio economic issues like pricing of the drugs and welfare cost (see for instance, 
Lanjouw, 1996; Watal, 2000; Scherer and Watal, 2001; Pangariya, 1999; Nogues, 1993). 
These studies although inconclusive point towards increase of prices in case of the 
patented medicines and significant welfare losses. Some of the researchers have 
a. investigated the link between strengthening of patent system and its effect on the 
technological development (Sequeria, 1998; Kumar, 2003; D'Este, 2002) and 
b. analysed the effects of strong patent system in output and trade performance of the 
industry (Weisburst and Scherer, 1995; Felker et ai., 1997). 
But not enough attention is paid to the impact of changed patent law on the learning 
process involved in building technological capabilities in pharmaceutical firms from 
developing countries and resultant responses from firms to transform their competencies. 
Most of the research examining the effects of changes in patent law on pharmaceutical 
industries has been focused on investigating the link between strengthening the patent 
system and the effect on the technological development of pharmaceutical industries 
(Sequeria, 1998; Kanwar and Evenson, 2003). For instance Sequeria (1998) investigated 
the effect of strengthening the patent regime on technological development in the Spanish 
pharmaceutical industry. He found that in general a strong patent system did not influence 
the development of production capabilities but had a marginal influence on the rate of 
accumulation of innovative capabilities through reorienting the 'culture' of the industry 
towards attaching greater importance to innovation. According to Kumar (2003) the 
strengthening and harmonisation of the IPR regime affect the process of technological 
development of poorer countries in a significant manner by choking an important 
contributor of growth that has been variously described as imitative duplication or reverse 
engineering. Some studies like D'Este (2002) notes that a change in the regulatory rules 
significantly alters the business environment and imposes the adaptation of new 
behaviours. In the Spanish pharmaceutical industry strategies of the firms differed 
markedly between those conducting innovative activities and those specialising in the 
Inarketing of branded generics. 
Some studies have analysed the effects of patent system in output and trade performance of 
the industry. In the case of Italy (Weisburst and Scherer, 1995) and Hungary (Felker at at.. 
1997) the bulk pharmaceutical production g.n)\\'th rate declined after the introduction of a 
strong patent system. In the Italian case the modest trade surplus in pharmaceuticals of 
$40.6 million in 1979 was converted into a trade deficit of $827 million by 1988 (Challu~ 
1995) and within a decade of strengthening the patent regime Italy lost domination over 
drugs export market to other countries. The studies have consistently shown that strong 
patent systems are associated with increasing foreign firm's market shares. In the case of 
Japan and Italy the introduction of strong patent systems has led to an increase in the 
market share of foreign firms. In Italy Weisbrot and Scherer (1995) shows large scale 
foreign acquisitions of small and medium sized domestic firms. 
Felker et aI., (1997:33) states that in the case of Hungarian pharmaceutical industry, prior 
to 1970 most research was aimed at developing processes for copying products, but since 
the 1980s firms have sought to rely on their own R&D for product development to 
complement foreign licensing. Similarly Madanmohan and Krishnan, (2003) suggest that 
in the case of Indian pharmaceutical firms response to changes in patent law, the 
predominant strategy Indian firms is to build capacity to achieve scale economics while the 
other preferred strategy is to stabilise and control the environment through developing 
alternative technology trajectories. 
In the case of Indian pharmaceutical firms the important constituent of alternative 
technological trajectories is innovative process and product R&D. Therefore this research 
focuses on learning processes adopted by Indian pharmaceutical firms to transform from 
imitative R&D to innovative R&D as a response to change in patent law. It explores the 
question of developing knowledge creation capability for innovation by studying the case 
of Indian pharmaceutical industry. 
The next section will provide the rationale for choosing Indian pharmaceutical industry as 
a case study and presents the important characteristics of the industry. 
2.5 The Indian pharmaceutical industry 
The Indian pharmaceutical industry is the 13 th largest in the world in terms of market 
output; accounting for a market of about US$ 2.5 billion (Ramani, 2002). Today it is 
ranked as the most advanced pharmaceutical industry amongst developing countries and 
one of India's best in science based industries. The Indian pharmaceutical industry has 
developed wide ranging capabilities in the complex field of drug process development and 
production technology. It is well ahead of other developing countries in terms of process 
R&D capabilities and the range of technologically complex medicines manufactured. The 
Indian pharmaceutical industry comprises 250 large units which include public sector. 
Indian companies and foreign subsidiaries and 8000 small scale units. These 250 large 
., 
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units have an almost 70% share of pharmaceutical activity and therefore dominate the 
Indian pharmaceutical sector. 
The growth of the Indian pharmaceutical industry was very slow till 1970. The patent act 
of 1970 and government investment in the drug industry infused life into the domestic 
pharmaceutical industry. The increasing opportunities due to weakening of the patent law 
led to the entry of a number of manufacturers who set up production units of different 
sizes. The availability of trained manpower, comparative ease of imitation and a strong 
chemistry base among Indian research institutes supported the manufacturers and gave the 
Indian pharmaceutical industry its current profile. 
This indigenous capability development in the Indian pharmaceutical industry represents 
one of the most successful cases of self reliant development in knowledge based industries 
from developing countries. The pharmaceutical industry is now a net foreign exchange 
earner and chief exporter of cheap generic drugs to the CIS countries, Latin America, 
USA, UK and Africa. The ability to produce cheap generic drugs makes the Indian 
pharmaceutical industry one of the most strategic industries not only for India but for other 
developing countries also. 
The following section will describe the changes in the Indian regulatory regIme 
concentrating on Patent Acts and its influences on technological development of Indian 
pharmaceutical firms. 
2.5.1 The 1911 patent law 
India inherited the Patents and Designs Act, 1911 from its colonial rulers. This patent act 
provided protection for all inventions except those relating to atomic energy. The duration 
of the patent term was 16 years from the date of application. During this era, the Indian 
healthcare sector was dominated by multinational pharmaceutical firms. A few Indian 
domestic pharmaceutical and chemical firms tried to develop their own technology but 
they ran into trouble with foreign patent owners (Kumar, 2003). Desai (1980) presents 
cases where foreign patent owners were neither using their patents for domestic 
manufacturing nor allowing those patents to be used by local firms and this observation is 
also reflected in the report of the second Patent Enquiry Committee (1957-59). This report 
points out that foreign patentees were acquiring patents not in the interests of economy of 
the patent granting country but with the objective of protecting an export market from 
competitors especially from developing countries. Due to such behaviour, drug prices 
remained out of the reach of the large Indian population creating a health care crisis. 
Lanjouw (1996) notes that during the era of strong patent laws drug prices in I ndia were 
ranked amongst the highest in the world.;fhe committee therefore recommended that it 
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will be beneficial for India to adopt a patent system that is focused on ensuring access to 
resources at lower prices to its vast population. Desai (1980) suggests that Indian firms 
were not against patents in principle but wanted greater access to patented know-how 
especially when patent owners were not allowing their patents to be used. 
However this dual pressure, from the needs of a vast population and from domestic firms, 
started building up in late 1960s and finally led to the weakening of the patent laws in the 
beginning of the 1970s. 
2.5.2 The 1970 Patent Act 
The Patents Act 1970 laid the foundations of the modem Indian pharmaceutical industry. It 
has been hailed as an ideal legislation for developing countries and became the model for 
other developing countries like Argentina, Mexico, Egypt, Brazil and Chile 
(Chandiramani, 2002). 
The 1970 Patent Act removed the product patents for pharmaceuticals, food and agro-
chemicals, allowing patents only for production processes. Since virtually any chemical 
compound can be made by a variety of processes, the scope of patent protection was 
greatly reduced. In the case of pharmaceutical, food and chemical patents, the statutory 
term was shortened to five years from grant or seven years from application, which ever 
was shorter and for other products the patent period was allowed up to 14 years. 
Compulsory licenses could be issued after three years. The 1970 Patent Act greatly 
weakened intellectual property protection in India, particularly for pharmaceutical 
innovations. It started the era of reverse engineering where firms developed new products 
by changing their production processes. The entrepreneurial pharmaceutical distributors 
and scientists used the opportunities provided by patent law to establish a profitable 
pharmaceutical business. The absence of a product patent regime gave Indian 
pharmaceutical firms a breathing space and allowed them to learn the basics of 
pharmaceutical R&D. A number of quantitative studies have shown that the abolition of 
product patents in chemicals and pharmaceuticals has facilitated the development of local 
technological capability in the Indian pharmaceutical firms (e.g. Fikkert, 1993; Haskar, 
1995; Kumar and Saquib, 1996). Fikkert (1993) found that the weak patent regime played 
a crucial role in the development of R&D in Indian pharmaceutical enterprises and 
specially in absorbing considerable foreign technology. Two decades after 1970 the Indian 
pharmaceutical industry emerged as the highest R&D spender and among the most 
innovative sectors of the Indian industry (Kumar and Saquib. 1996). Howc\,er, the 
weakening of patent laws had some negative impact in terms of R&D technology transfer 
and Raizada (2002) acknowledges that citing the drop in patent registrations in India. The 
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number of patents granted per year fell by three quarters over the following decade, from 
3923 in 1970-71 (of which 639 were to Indian applicants, 3294 to foreign applicants) dO\\TI 
to 1,019 in 1980-81 (349 Indian, 670 foreign) 
Indian pharmaceutical firms have shown incredible skills in reverse engineering R&D and 
now account for 70% of bulk drugs and 80% of formulations produced in the country 
(Hamied, 1993). By 2000 out of the top ten firms, in terms of market share, six were Indian 
firms unlike the 1970s when the list was dominated by the subsidiaries of foreign 
multinationals (OPPI, 2001). 
From the early 1990s Indian companies were making the international quality products 
with increasing sophistication. This is reflected in the increasing share of Indian firm's 
revenue coming from exports, a sign of increasing maturity as well as a rise up the value 
chain by Indian pharmaceutical manufacturers. However this process of gradual capability 
building was truncated by the signing of WTO agreements and the introduction of full 
fledged patent protection to pharmaceutical products. 
2.5.3 The Indian patent law 1999 - Compliance with TRIPS 
The signing of WTO agreements has put the Indian pharmaceutical industry at the 
threshold of a major transformation. The 1999 Patents Act strengthens the patent 
protection along the lines specified by the TRIPS agreement (Table 2.2). Therefore it 
introduces the recognition of product patents for pharmaceuticals, food products, agro 
chemicals and micro organisms. Among other changes, increased in the life of patent from 
existing seven years to 20 years have important implications for drug related healthcare 
Issue. 
Products that were patented before 1995 and already in the Indian market remain free of 
patent protection. This means that a large amount of existing medicines which are basic in 
nature remain available off-patent. However Indian pharmaceutical firms will not be 
allowed to reverse engineer new technologies or molecules without formal licenses from 
patent holders. This means that a main source of molecules for Indian industry will be 
blocked. Most of MNC pharmaceutical firms who hold the patents for new technologies or 
molecules have already established a presence in the Indian market and those who have not 
are preparing plans to enter Indian market. Therefore as Halemane and Dongen (2003) 
indicate, Indian companies will have to look for new sources of growth in future. Large 
Indian pharmaceutical firms have recognised the change in rule of the game and the 
importance of innovative R&D for long term survival and success. 
" 
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Table2.2: Indian patent act of 1970 and TRIPS 
The Indian Patent Act, 1970 The Indian Patent Act, 1999 
1. No product patents allowed for Both product and process patents for 
phannaceutical, food products and phannaceuticals, food products and agro 
agrochemicals. Only process patents. No chemicals, and micro organisms. 
patents for micro organisms. 
2. Process patents for the above have a All patents have a tenn for at least 20 years 
statutory tenn limit of the shorter of7 years from filling. 
from application or 5 years from granting. 
3. Government retains wide powers to grant No automatic licenses, compulsory licenses 
compulsory licenses. only in cases of national emergency. 
4. Importation does not fulfil working No discrimination between domestic 
requirement production and importation 
5. In all cases, the burden of proof in an In the case of infringement, the burden of 
infringement case falls on the patentee. proof lies with alleged infringer (reversal of 
burden of proof). 
The challenge facing the industry is to make a transition from the era of protectionism to 
an era of global competition. Indian pharmaceutical firms are applying different adaptive 
strategies like vertical integration, capacity additions, brand acquisition strategy, marketing 
channels integration strategy and R&D integration strategies as a response to change in 
patent law (Madanmohan and Krishnan, 2003). Among them the most ambitious and 
challenging strategy is to develop new competencies for innovative R&D. In the 
pharmaceutical industry innovative R&D represents new chemical entities or new drug 
delivery systems. But it also represents an enormous challenge for firms due to the 
infrastructural and financial resources involved in innovative R&D and more importantly 
the difference of knowledge bases involved in innovative and imitative R&D. 
2.5.4 Challenge of knowledge base: 
The Patent act 1970 enabled the Indian pharmaceutical industry to develop skills in reverse 
engineering and to produce the alternate processes for drugs. Reverse engineering or 
imitation was the mechanism of knowledge acquisition used by firms in Indian 
pharmaceutical industry to acquire outside knowledge and develop skills in process R&D. 
This process of reverse engineering involves copying of existing molecules by 
manufacturing them with a different process. As a result the Indian pharmaceutical firms 
had their knowledge base firmly rooted in organic and synthetic chemistry. Indian 
pharmaceutical firms had not made any efforts to acquire other scientific disciplines to 
create or develop innovations or novel products (Ramani, 2002). However innovative 
product creation in pharmaceutical R&D is a very complex process and requires 
integration of different specialised knowledge bases like organic, medicinal chemistry 
along with biology and pharmacology. This difference of knowledge base in imitative 
R&D and innovative R&D is reflected in Bell and Pavitt's (1995) observation that 'across 
a range of industries and technologies, increasing specialisation has widened the gap 
between the kinds of knowledge and skills required to use given technologies and those 
required to create and change technology'. 
Therefore the distinction between the ability to produce a product by imitation or ability to 
copy technology or use the given technology and capability to generate it or create and 
change technology, have profound implications in pharmaceutical R&D. The difference in 
scientific knowledge base along with managerial and organisational issues of managing 
knowledge creation process adds up the complexities. So it raises the questions: 
• How are Indian pharmaceutical firms building knowledge creation capability 
for innovation as a response to change in regulations? 
• How relevant is knowledge accumulated through imitation for firms in their 
efforts to create innovative novel products? 
In the new environment, Indian firms have to under go dynamic learning to develop new 
competencies. The process of technologicalleaming and of progressing from imitation and 
reverse engineering to establishing a genuine indigenous innovative capability must now 
be done differently from the past. 
2.6 Summary 
This chapter presented the genesis of research along with detailed overview of the issues 
related to that. It discussed different issues related with patents. evolution of the TRIPS 
agreement and its impact on pharmaceutical industry especially in the devcloping 
countries. The change in regulation as a result of the TRIPS agreement raised some 
questions for pharmaceutical firms in developing countries. This chapter concluded with a 
presentation of those questions. specially.focusing on the ability of the finn to transfonll its 
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capabilities and develop new competencies as a response to the turbulent external 
environment. 
The next chapter reviews the literature focused on capability accumulation, creation and 
transformation based on firms from advanced as well as developing countries. 
Chapter 3 
LITERA TURE REVIEW 
3.1 Introduction 
This chapter reviews the developing country and strategic management literature within 
the field of technological capability development and concentrates on broader aspect of 
that process. 
The focus of this research is development of knowledge creation capability for innovation 
in firms from developing countries as a response to change in the external environment. It 
analyses processes involved in discontinuous learning for development of new capabilities 
which have received little attention in context of firms from developing countries. 
The literature on firms from developing countries mostly focuses on the issue of long term 
process of technological capabilities accumulation in industries and firms from these 
countries. Researchers studying technological capability development in developing 
countries suggest that in the earlier stages of technological development, firms in 
developing countries mostly acquire technologies which are matured in advanced 
countries. This acquisition is mostly done through formal channels of technology transfer 
like licensing or joint venture or non formal channels like reverse engineering or imitation. 
The acquired technologies are assimilated and improved through indigenous technical 
effort regardless of the source and channel of technology transfer which finally results in 
technological development of firm and country (Bhagawati, 1996). However, changes in 
the world trade environment are limiting formal and non formal modes of technology 
transfer for firms in developing countries. The widening gap between kinds of knowledge 
and skill required to imitate or operate given technology and the kinds of knowledge 
required to create, generate or change technology has reduced the possibilities of acquiring 
the latter largely by experience in the former (Bell and Pavitt, 1993). Therefore in this new 
era the ability of firms in developing countries to create new knowledge for innoyation has 
become a strategically important capability. So the explicit investments in acquiring and 
accumulating knowledge and skill have become the necessary basis for building firm ~ s 
'change generating' or dynamic capabilities. 
The area of rebuilding or reconfiguring of capabilities has been addressed by strategic 
nlanagement literature (SML) however by focusing on innovative firms competing at 
technological frontiers in advanced countries. However such firm level studies of 
capability transformation to develop ne~\' competencies are absent in deyeloping countries 
..,.., 
.'-' 
literature. Also despite the emergence of more comprehensive firm level studies during 
mid -1990s (eg. Kim, 1997b; Dutrenit,2000; Figueirdo,2003) inter firm comparative 
analysis of learning and capability accumulation in firms from developing countries or 
newly industrialising countries has still been a neglected area in this research stream. 
Indian pharmaceutical firms' transformation of capabilities to develop competencies in 
innovative R&D provides that opportunity. 
Section 3.2 reviews the developing countries literature (DeL) regarding building 
technological capabilities and indicates the limitation of it in terms of research on firm 
level processes involved in learning and in rebuilding or renewing of the firm capabilities. 
Section 3.3 reviews the strategic management literature concerned with maintaining and 
renewing core capabilities or competencies in the most innovative firms. It also indicates 
the limited attention given to processes of long term capability accumulation in this 
research tradition. Section 3.4 then locates the topic of this research within the broader 
research areas covered by developing countries firm's literature and strategic management 
literature. 
3.2 Technological capability accumulation in developing countries literature 
This section reviews the developing countries literature about technological capabilities. It 
describes the emergence of technology capability as a concept, taxonomy and its 
application. 
Bell and Pavitt (1993) distinguished capabilities in terms of production capabilities and 
technological capabilities and this research focuses on technological capabilities. The 
review shows that developing countries literature has not paid enough attention to 
organisational and managerial issues associated with management of technological 
knowledge, learning and innovation, albeit with some exceptions like Kim (1997a). 
Dutfenit (2000) and Figueiredo (2003). It also reveals that there has been a complete lack 
of research on technological capabilities on firms in science based industry like 
pharmaceutical from developing countries. 
3.2.1 Technological capability development: concepts 
The processes involved in technological capabilities accumulation in firms and industries 
from developing countries have been the focus of attention for many researchers in the last 
20 years. Over the years developing countries have rapidly accumulated and diversified 
their industrial production and technological capabilities. According to Dosi et aL (2000) 
to be capable of something is to ha\'e a generally reliable capacity to bring that thing as a 
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result of intended action. Capabilities fill the gap between intention and outcome, and they 
fill in such a way that the outcome bears a definite resemblance to what was intended. 
The technological capabilities are defined as "the stock of resources needed to generate 
and manage technical change, including skills, knowledge and experience and institutional 
structures and linkages" (Bell and Pavitt, 1993). The concept of technological capability is 
interchangeable with other concepts that refers to same idea, such as technological effort 
(Dahlman and Westphal, 1982; Lall, 1987) or technological capacity (Bell, 1984a; Katz, 
1987; Scott- Kemmis and Bell, 1985); basically describing technological capabilities as 
"the ability to make effective use of technological knowledge". Production capabilities are 
defined as the "stock of resources used to produce industrial goods at given levels of 
efficiency and given input combinations: equipment (capital enabled technology), labour 
skills (operating and managerial know-how and experience), product and input 
specification and the organisational methods and systems used" (Bell and Pavitt, 1993). 
According to Bell and Pavitt (1993) technological accumulation refers to any process by 
which capabilities for generating and managing technical change are increased or 
strengthened, whereas they associate technological change with any process leading to a 
change in the existing set of production capabilities. 
Technological capabilities refer to both; technical knowledge component which enables 
firms to generate innovations and organisation component which enables firms to manage 
the implementation of their in-house innovations and their linkages with external sources 
of knowledge. Production capabilities involve replicating the tasks while technological 
capabilities involve resources aimed at generating and managing changes in context of 
maintaining competitiveness in a changing environment (Bell and Pavitt, 1993). The 
distinction between technological and production capabilities reflects the increasing 
specialisation and professionalization of the activities involved in generating and managing 
change. 
The processes by which technological capabilities are accumulated have often been 
referred to as learning (Bell and Pavitt, 1993). Firms build technological capabilities 
through learning processes, so technological learning refers to the dynamic process of 
acqulf1ng, assimilating and applying technological knowledge. Technological 
accumulation refers to the process involved in learning over time, development of skills. 
knowledge and institutions that make country's capacity to generate and manage change. 
However building technological capability is not an automatic process; some latecomer 
firms succeed and others fail in catching up with the technological frontier (Dosi. 1988: 
Katz, 1987; LaB. 1992; Hobday. 1995: Bell and Payitt. 1995). 
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3.2.2 Taxonomy of capabilities: 
Lan (1992) based on the mastery and complexity of technological activities and drawing 
on Dahlman and Westphal (1982), Katz (1984), Dahlman, et aI., (1987) and Lall (1987), 
presents taxonomy of firm level technological capabilities. Bell and Pavitt (1995) and 
Arffin and Bell (1997) further developed Lan's taxonomy of technological capabilities. In 
the framework technological capabilities are broadly categorised into three levels: basic~ 
intermediate and advanced. The columns set out the main technological capabilities by 
technical function. Investment capabilities refer to generating change and managing its 
implementation during large investment projects. Largely they include activities related to 
both decision making and control along with preparation and implementation of projects. 
Production capabilities refer to generating and managing technical change in processes and 
production organisation, and in products. The other support function includes linkage 
capabilities; developing linkages and interaction with firms and institutions. 
In this taxonomy, levels of technological activities are based on the distinction between the 
kind of knowledge and skills required to operate given technology and the kind of 
knowledge required to change technology (Bell and Pavitt, 1993). It distinguishes between 
the routine production activities and innovative technological capabilities; routine 
production capabilities are basic capabilities required to be in market. Basic level 
innovative capabilities include the ability to make minor adaptations to production and 
assimilate technology to the firm's environment. Intermediate innovative capabilities 
involve the ability to generate incremental technical change in product design, quality and 
production processes, it also includes ability to search and evaluate external sources of 
technology. Advanced innovative capabilities refer to the ability to generate new products 
and process innovations (table 3.1). 
Basic level capabilities may permit only relatively minor and incremental contributions to 
change, but at the intermediate and advanced levels, technological capabilities may result 
in more substantial, novel and ambitious contributions to change (Bell and Pavit, 1995). 
Lan (1992: 168) points out that this categorisation of capabilities is only indicative as it is 
difficult to judge whether a technical function is simple or complex, nor do the stages show 
a necessary sequence of learning. He further notes that the very nature of technological 
learning (accumulated experience of problem solving aided by external inputs or formal 
research effort) would seem to dictate that mastery would proceed from simpler to more 
difficult activities but different firms and different technologies adopt different sequences 
and the extent of inter firm differences in technological effort and mastery may \'ery by 
industry, by size of firm or market; by le\'el of development or by trade! industrial 
strategies pursued. Different technologies differ greatly in their learning requirements 
36 
Paginated 
blank pages 
are scanned 
as found in 
original thesis 
No information 
• • • IS missing 
" 
involving different costs, risks, duration and linkages. This clearly shows the limitation of 
conceiving technological accumulating on broad stages and the need for more finn level 
research about processes involved in technological capability accumulation (Bell and 
Pavitt, 1995). It also signifies that this framework has limitations for its application to the 
finn level exploration of processes involved in technological capability accumulation as 
complexity of the technical function is subjective to individual task depending on the 
technology, finn, industry and market (Lall, 1987). 
In addition Lall (1987) recognises that the 'classification has dealt strictly technical aspects 
of an enterprise; however organisational capabilities have to accompany technological 
ones'. Even though both the technological and organisational institutional factors are 
recognised as part of the technological capabilities, the interaction between both 
dimensions is a key issue but is hardly treated in developing countries literature. 
3.2.3 Accumulation of technological capabilities in developing countries 
In the last two decades, the literature on accumulation of technological capabilities in 
developing countries has emerged as a widely researched area and the following section 
briefly reviews some of the studies covering different aspects of technological capabilities. 
Earlier research on developing countries mostly covered technological adaptation (a 
movement along the frontier) than technological innovation (a movement of the frontier), 
based on the premise that adaptation of different technologies with which finns are not 
familiar would require same kind of technical effort as developing new techniques of their 
own. The ultimate achievement is to be a technologically mature finn and Bell, et aI., 
(1984b) observes that the majority of infant industries in developing countries never 
achieve maturity because of their failure to build up adequate technological capabilities. 
The impetus for the studies on developing countries lies in two large projects started in 
1980s. In the early 1980s, the World Bank financed the project on 'the acquisition of 
technological capability' under the direction of Carl Dahlman and Larry Westphal. It 
covered four newly industrialised countries namely, India, South Korea, Brazil and 
Mexico. The studies mainly covered the manufacturing based industrial sectors like 
cement, iron and steel, pulp and paper and textiles. Each country was studied by different 
researchers, following a similar methodology and using identical questionnaires. The other 
study on developing countries was the Research programme in Science and Technology of 
IDB (Inter- American Development Bank) / ECLA (UN economic mission for Latin 
America). This included comparative research of metalworking industries from six Latin 
Anlerican countries. 
" 
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The World Bank research project and studies of India by Lall (1987), South Korea by 
Westphal, et aI., (1985) created and enriched the literature focusing on accumulation of 
technological capabilities in the developing countries. The various authors analyse how 
firms move from having the abilities to operate different production functions to being able 
to undertake innovative capabilities. These studies focused on the key issues related to 
capability accumulation like characteristics of learning processes, influence of technology 
transfer, intricacies involved in diffusion of technologies. According to Lan (1987) the 
process of technological change in developing countries is one of acquiring and improving 
on technological capabilities rather than of innovating at frontiers of knowledge. This 
process essentially consists of learning to use and improve production technologies that 
already exist in the advanced industrial countries. He further suggests that the enterprises 
deploying industrial technologies imported from advanced countries requires learning and 
conscious effort in the application of that technology to local needs. 
Technological development is growth in a firm's ability - regardless of whether or not the 
firm is at the world technological frontiers - to innovate, copy or select the correct 
technology, and assimilate that technology. So technological development is achieved 
through growth in general ability to undertake this broad range of tasks or the ability to 
perform different types of technological activities. It illustrates that the process of 
technological change in developing countries is one of acquiring and improving on 
production capabilities rather than innovating at frontiers of knowledge. Dahlman, et aI., 
(1987) suggest that firms in developing countries have accumulated technological 
capabilities in a particular sequence moving through definite stages. According to them 
building technological capabilities follows the sequence which generally starts with 
production capability and proceeds to investment and innovation capability. Therefore the 
learning hierarchy progresses from learning to produce, learning to produce efficiently, 
learning to improve production, learning to improve products and finally culminates in the 
development of new products. However Forbes and Wield (2002) question this learning 
hierarchy model, arguing that moving from imitation to innovation is not simply a case of 
one (process) giving way to another (product). 
Some researchers focused on analysing the characteristics of the national systems of 
innovation (see for instance, Kim, 1993; 2000: Lundvall 1992; Nelson, 1993); the 
influence or features of macro economic trade policies like import substitution or export 
oriented that hamper or stimulate the technology capability accumulation at country and 
firm level (Nelson and Pack, 1999; Katz, 1987. 2000: Kim, 2000; Lall. 1987, 2000) and 
sources of international competitiveness (Haque, 1995; Katz. 1995). This research analyses 
the differences among economics. industries and finns. in which some introduced and 
mastered new technologies while others encountered difficulties in technological 
development and international competitiveness. It also focuses on illustrating that at finn 
level there had been an 'indigenous technological effort' which has resulted in the 
accumulation of technological capabilities. But as Bell and Pavitt (1993) point out, the 
knowledge and institutional bases required for production capability and technological or 
innovative capability have become increasingly differentiated and increasing economies of 
scale have reduced learning opportunities for acquiring technological capabilities through 
production capabilities. As a result, accumulation of innovative technological capabilities 
has become increasingly uncoupled from the accumulation of production capability. This 
was reflected in studies of the industrialisation and catching up of finns in East Asian 
countries and the processes involved in the accumulation of innovative technological 
capabilities. The next section describes some of that literature. 
3.2.3 Building of complex technological capabilities in newly industrialising countries 
The transformation of South Korea and Taiwan into industrialised economies shifted the 
focus of research towards the acquisition of a more complex knowledge base required for 
innovative activity. Research into the process of catching up by the newly industrialising 
countries in South East Asia explains the stages involved in moving from acquiring foreign 
technology to building increasingly more innovative technological capabilities (see for 
instance Hobday ,1995; Kim,1997a; Kim, Lee and Lee, 1987; Amsden, 1989; Enos and 
Pack, 1988; Nakoaka, 1993; Pack and Weshphal,1986). Westphal et ai., (1985) and Enos 
and Pack (1988) have demonstrated the importance of foreign technology collaboration 
agreements for functions such as training engineers and obtaining detailed blueprints in 
case of Korean firms for acquiring innovative capabilities. Hobday (1995) describes the 
rise up the value chain of firms from Taiwan in stages, from being original equipment 
manufacturers, to producing their own designs, and finally creating their own brands. He 
focuses on different learning strategies used by the firms to progressively assimilate 
foreign technology in order to develop design capabilities, to catch up and also leapfrog 
competitors at international level. Nakaoka (1993) describes successful cases of 
technology capability building from capital goods company from Korea, Taiwan and role 
of Japanese cooperation in it. He emphasises the role of domestic market and strategy 
related to international market in the learning process. Enos and Pack (1988) and Amsden 
(1989) focus on the accumulation of technological capabilities based on factor market 
determinants like skilled human resources. Nelson and Pack (1999) point out that South 
Korean or Taiwan success tells a story of cumulati\'e leaming~ of climbing the ladder rung 
by rung, as it were. A high rate of i~vestment in physical and human capital is also a part 
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of these stories, but only as handmaiden to the innovation and learning process within the 
firms. As firms climbed the ladder, and as the economies became increasingly 
sophisticated the need for detailed government diminished. So detailed government 
involvement both fell away, and was pushed away. They argue that the absorption or 
assimilation of increasingly modem technology and change in industrial structure were 
critical components of the transformation. Perez and Soete (1989) present a different 
perspective on technological capability building and suggest late industrialising countries, 
under very specific conditions, can bypass large parts of this cumulative process and leap 
frog to newly emerging complex technologies. 
Lall (2000) based on experience of East Asian economies suggests that in terms of macro 
economic policies, export orientation has been conclusively shown to be a better strategy. 
He further adds that classical import substitution, with hapzard and open ended protection 
for all activities with no regard to efficiency, clearly breeds inefficiency and technological 
sloth. Trade intervention can be effective in stimulating technological learning if mounted 
with certain conditions like those of East Asian economies. The governments in these 
countries intervened both selectively and functionally in promoting technology 
development (Amsden, 1991; Pack and Westphal, 1986; Lall, 1996; Westphal, 2002). The 
presence of certain conditions for interventions like strong leadership commitment to 
competitiveness, flexibility in policy making, close interaction with industry and exposure 
to export competition to discipline both firms and government made the government 
intervention effective and successful (Lall, 1994; Stiglitz, 1996; Westphal,2002). 
In general, researchers studying newly industrialising economies analyses the deliberate 
learning strategy followed by these firms to sequence learning activities, and the role of the 
government interventions, trade policy and factor markets. These authors focuses on the 
accumulation of stocks of technological knowledge, and much less on the process of 
specialisation of knowledge bases and other firm specific issues like the coordination and 
integration mechanisms of knowledge across organisational boundaries. Bell and Pavitt 
(1995) point out that the rate at which a firm should proceed in accumulating capabilities, 
the level of sophistication and sequencing of accumulation among different functional 
areas will differ widely, suggesting the need for more research on strategies for 
accumulating technologies at firm level. 
The next section reviews the studies which have focused on firm level research In 
developing countries. 
" 
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3.3.4 Firm level process in accumulation of technological capabilities 
Few studies have explored the finn level process involved in the accumulation of 
technological capabilities in developing countries or newly industrialising countries. Only 
some of the researchers like Kim and Kim, (1985), Kim (1997a), Dutinit (2000) and 
Figueirdo (2003) have focused on organisational and managerial issues involved in the 
accumulation of technological capabilities and the development of innovative capabilities. 
Kim and Kim (1985) studied the patterns of innovative behaviour in Korean firms and 
showed the key role of infonnal mechanisms in transferring important technology from 
advanced countries to newly industrialising countries. 
Kim (1998, 1997a, 1999) introduced a new framework to analyse the process of building 
innovative and complex capabilities in Korean finns, focusing on role of organisational 
factors in the process of knowledge creation. He explores the process of creation of new 
knowledge at international level instead of the concern for using existing knowledge that 
distinguishes most of the developing countries literature. Using the case study 
methodology, he shows the sequential patterns of learning in two South Korean firms 
namely, Samsung and Hyundai. These studies show that these South Korean firms not only 
followed a deliberate and persistent technology strategy, which gradually changed as the 
finn acquired technological capabilities from creative imitation to innovation. Top 
management in the finn constructed a crisis to expedite the learning processes within the 
finns and implemented an active management of dynamic learning. Firms managed the 
learning process in such a way that different internal components of a knowledge system 
were articulated to strengthen the knowledge building process. However according to Kim 
(1997a) two critical enabling factors that set Korean finns apart are the Korean 
government and the Korean people. He particularly stresses that successful technological 
learning requires an effective national innovation system. The focus on the national system 
of innovation and the Korean worker in research makes the external condition more crucial 
factor for building firm level technological capabilities than internal factors. At the firm 
level Kim focuses on crisis construction as an important mechanism for discontinuous or 
dynamic learning but other supportive mechanisms of managing knowledge which play an 
important and essential role have not brought into focus. The other firm level study 
focused on Vitro, a Mexican finn in glass industry by DutnSnit (2000) concentrates on 
these issues. She analyses the mechanisms of managing knowledge \\'hile studying the 
transition of a Mexican finn from 'early stage of accumulation of minimum knowledge 
levels of innovative capability to the management of knowledge as a strategic assef. She 
builds on Kim's (1999) theoretical framework and focuses on processes involved in the 
conversion of individual into oliganisational learning, the coordination of learning. 
41 
knowledge integration and knowledge creation. Research develops the three different 
stages of building technological capabilities. In the first stage, the minimum essential 
knowledge base is built, while in the second stage the minimum essential knowledge base 
is transformed into strategic capabilities. The third stage firm has been able to build up 
strategic capabilities and is able to nurture and renew them continuously. The study shows 
that transition process in the Mexican firm was truncated because the support and the 
resources were unstable over these stages of different innovation strategies applied by firm. 
She further explains that the firm pursued a pioneer and fast follower strategy in different 
areas at the same time. The knowledge management was not considered in a systematic 
approach and the technological knowledge was not distributed across other organisational 
units of firm pointing out the importance of organisational factors like coordination and 
integration of different knowledge bases and difficulties in managing them. However, 
while analysing the transition of the knowledge management mechanisms in the firm this 
research neglects the influence of constituents of external environment which as Kim -s 
research shows affect the firm's learning mechanism. A nation's capability to foster and 
manage technological change is crucial to its firms' ability to survive and grow in the 
international marketplace (Bell and Pavitt, 1995). 
Even though the research on technological capabilities in firms from developing countries 
covers a broad range of industries, there are no studies concerning highly knowledge 
intensive science based industries like pharmaceuticals. Different technologies involve 
different breadth of skills and knowledge, with some needing a relatively narrow range of 
specialisation and others a wide range. The learning processes by which those resources 
are accumulated are complex and specialised. The process of technological accumulation 
and change in science based sectors like pharmaceuticals is more difficult and demanding 
as it requires highly professionalized and specialised technological activities in R&D 
laboratories and other similar institutions. Also large firms at technological frontiers that 
dominate these sectors develop and control significant proportions of both their product 
and process technology, and are reluctant to give easy access to this major source of 
competitive advantage to firms which are outside the technological perimeters. In these 
sectors large firms conduct most of their technological activities at home or in other 
developed countries, and prefer direct investment to licensing when producing abroad. The 
learning process by technological capabilities are built in science based industries is far 
more complex and specialised and therefore in context of developing countries needs more 
attention. 
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The review of developing countries literature suggests the following important points: 
A. One of the concerns of the DCL was to illustrate at the firm level as well as country 
level that there had been an indigenous technological effort which had resulted in the 
accumulation of technological capabilities. It shows that firms build technological 
capabilities through learning processes - firms learn over time, accumulate technological 
knowledge, and can progressively undertake new activities and acquire new capabilities. 
B. In general the focus of the DCL has been on the learning processes to establish a base 
of technological knowledge that did not previously exist, as opposed to renewing the 
accumulated knowledge base or using that knowledge base in a different way. Bell and 
Pavitt (1993) point out that change generating capabilities have become increasingly 
complex and specialised as they have become increasingly more differentiated from the 
capabilities required to use them and have become increasingly differentiated. 
C. The variability of technological accumulation patterns suggests the need for care and 
clarity in choosing specific strategies for accumulating technologies at the firm level. 
Although there is growing body of knowledge concerning the technological strategies of 
the firms in the industrialised countries that have already accumulated some advanced 
levels of capabilities, there are few guidelines for firms to follow in designing strategies to 
move from more basic levels to these advanced capabilities (Bell and Pavitt, 1995). 
To summarise, the firm level research of technological capability renewal and development 
in developing countries needs more attention as technological change is mostly localised at 
the firm level. Therefore understanding of the dynamic process of technological learning at 
firm level is most essential as formal education and training in institutions outside industry 
can only provide essential bases of skill. This has to be augmented by learning within 
firms, and of which 'learning by doing' provides only part of what is needed (Bell and 
Pavitt, 1993). 
The next section reviews the strategic management literature focused on the processes 
involved in capabilities transformation and creation in firms from advanced countries. 
3.3 Renewing capabilities in the strategic management Literature 
This section reviews the strategic management literature concerned with maintaining, 
nurturing and renewing core capabilities/ competencies by most inno\'ati\'e fimls 
conlpeting at the technological fr.ontiers in advanced countries. It presents the different 
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concepts in strategic management literature used to analyse the rebuilding or renewal of 
distinctive capabilities. It points out that the research concerned with firm level studies of 
learning and capability building is focused on the most innovative firms competing at the 
technological frontier. However this review of strategic management literature also shows 
the limited insights into processes involved in building the basic core or distinctive 
capabilities. This literature fails to answer the questions of how do successful firms get to 
the point where they have superior resources and knowledge? (Helfat and Raubitschek, 
2000). 
3.3.1 Firm capabilities and strategic management 
Strategic management literature is mainly concerned with the patterns of actions and 
resource deployments that a firm undertake to achieve its objectives while simultaneously 
adapting to changing environmental conditions. This adaptation occurs through the process 
of matching internal capabilities with external opportunities and threats. Grant (1991) 
defines capabilities as what firm can do as a result of teams working together, although he 
further adds capabilities is not simply a matter of assembling a team of resource. 
According to Grant (1991) capabilities involve complex patterns of coordination between 
people and between people and other resources. 
However in recent decades accelerating changes in markets, competition and technology 
are giving rise to more challenging questions for firms and as a result a large amount of 
research has been focused on examining how firms can align or adapt themselves to those 
changes and maintain competitive advantage. The strategy management literature points 
out that in an environment of increasing change and uncertainty, accumulated distinctive 
competencies or capabilities gives firms the competitive advantage (Grant, 1991; Leonard 
- Barton, 1995; Pavitt, 1991; Teece et aI, 1997; Henderson and Cockburn, 1994; Nelson 
and Winter, 1982). In the case of a rapidly changing environment, a firm's capability to 
adapt to new circumstances and innovate rather than innovation per se, improves the 
chances of its long term success (Harris and Mowery, 2001). Central to this perspective has 
been the prescribed role for the firm as the developer of distinctive competencies - that is. 
firms are encouraged to innovate by searching out new resources, or new ways of using 
existing resources, as the basis for future organisational rents (Galunic and Rodan, 1998). 
This research suggests that firms compete on the basis of distinctive competencies or 
capabilities that are accumulated over time (Leonard - Barton, 1992; Prahalad and HameL 
1990; Teece et at., 1997; Nelson and Winter, 1982, Pavitt. 1991). Distinctive competencies 
refer to the unique capabilities possessed by the firm which enable it to do some things 
'better' than its competitor. 
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The unit of analysis in this research is firm, and insights are based on firm level research 
into sources of sustainable competitive advantage. It is built up on the idea of Penrose 
(1959) that the profitability and growth of a finn should be understood in terms of its 
possession and development of unique resources and Polanyi's (1966) work about tacit 
knowledge. This literature share the idea that knowledge allows the creation of capabilities 
and those capabilities detennine the ability to do things (Leonard - Barton, 1992; Prahalad 
and Hamel, 1990; Teece, et aI., 1997). 
According to Dosi et aI., (2000) capabilities involve organising activity and the exercise of 
capability is typically repetitious in substantial part, and routines represent the chunks of 
organised activity with a repetitive character. Organisational routines are regular 
predictable patterns of activity which are made up of a sequence of coordinated actions by 
individuals. Therefore, a capability is, in essence, a routine, or a number of interacting 
routines (Grant, 1991). This concept of routines as the basis of capabilities is based on the 
evolutionary economic perspective developed by Nelson and Winter (1982). They defined 
the finn as a repository of knowledge, dependent on its past history and the firm stores the 
knowledge generated by learning in organisational routines. However routines are not only 
building blocks of capabilities; knowing the job involves knowing things that are 
relational, involving other participants and organisation specific factors (Nelson and 
Winter, 1982). The major function of organisational routines is coordinating the skills of 
organisation, that is, of turning that collectivity of skills to useful effect (Dosi et aI., 2000). 
The knowledge embedded in routines cannot be fully captured in codified form, it has a 
tacit dimension; some of the knowledge required to do ajob is skill-like and can be learned 
only through experience in the specific organisation. Therefore several routines are seen as 
the source of distinctiveness and therefore competitiveness of the firm. 
Building on the tacit knowledge component from evolutionary economics perspective but 
rooted in resource and capability view, Prahalad and Hamel (1990) introduced the notion 
of core competencies as the source of a firm's advantage in a changing environment. 
According to them core competencies are the collective learning in the organisation, 
especially how to coordinate diverse production skills and integrate multiple streams of 
technologies. Comparing large corporations to a tree, Prahalad and Hamel, (1990) suggest 
that core competence is the root system that provides nourishment sustenance and 
stability. The pattern of internal coordination and learning is difficult for competitors to 
inlitate, as it has a tacit component and this tacit component of core competencies creates 
competitive advantage for firms. They further point out that in the long run the finn' s 
competitiveness derives from its ability to build core competencies at lower cost and faster 
than competitors. And so the finn's long term success lies in its ability to consolidate 
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corporation wide technologies and production skills into competencies that empower 
individuals businesses to adapt quickly to changing opportunities. 
Prahalad and Hamel (1990) explain that at organisational level core competence involyes 
communication and deep commitment of many people working at different levels across 
organisational boundaries. At technological levels core competencies exists, as a set of 
technological field (e.g. Optic media in Philips) or as a capacity to do something with 
technology or to apply capacity to other fields (e.g. capacity to miniaturise in Sony or 
3 M' s capacity to substrate, coatings and adhesives and various ways to combine them to 
develop different products). This explanation implies that core competence cover both, 
technological and organisational dimension, however the empirical definition of core 
competencies suggests that it is conceptually more focused on the technological 
dimensions. 
Focusing on core competency perspective Leonard - Barton (1992: 114) suggests that a 
core capability is an 'interrelated, interdependent knowledge system'. This knowledge 
system comprises four interdependent dimensions: 
1. employee knowledge and skills, 
2. technical systems, 
3. managerial systems, and 
4. values and norms associated with the process of knowledge creation and control. 
All four dimensions of core capabilities reflect accumulated behaviours and beliefs based 
on early corporate successes. It is not possible to copy a system and copying an isolated 
mechanisms and fitting them into other knowledge systems does not necessary generate 
same results. The main advantage of core capabilities lies in this unique system or 
linkages, which is not easily imitated by other competitors. Therefore Leonard - Barton 
(1992) points out that as bodies of knowledge, core capabilities cannot be managed in the 
same way as the tangible assets of the firm. However Patel and Pavitt (1994, 2000) based 
on a patent data study of large firms suggest that it is difficult to define a firm's 
technological competencies in terms of a few fields of excellence. According to them. 
firms operating in sectors like automobiles or aircraft which involve making and improving 
complex production systems, require a broad range of technological competencies that 
enable them to stimulate and integrate technological improvements by their suppliers of 
materials, components, subsystems and production equipment. This technical 
interdependence means that the notion of 'focus' and 'make or buy', applied in production 
and marketing activities does not work in relation to technological competencies. They 
argue that finns are typically actiye in many technical fields and haye substantial 
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technological competencies outside their core areas and conventional analysis neglects 
these important background competencies in its focus on distinctive or core competencies. 
Leonard - Barton (1995) in similar vein suggests that the successful large organisations 
derives competitive strength from its excellence in a small number of capabilities clusters 
where it can sustain leadership position over time through effective management of those 
clustered capabilities. She defines three types of technological capabilities that contribute 
to creating a sustainable advantage: core, enabling and supplemental technological 
capabilities. Core technological capabilities are those capabilities that distinguish firm 
competitively, and built up over time and can not be imitated. Enabling capabilities are 
those capabilities which do not give a particular competitive advantage but are necessary to 
a firm as minimum basis for meeting the competition, such as world - class manufacturing 
and supplemental capabilities only add value to core capabilities but could be imitated like 
particular distribution channels or strong but not unique packaging design skills. 
Henderson and Clark (1990) illustrate the cluster of capabilities at product level by 
distinguishing between types of knowledge or capabilities involved in product 
development. They suggest that an individual product consists of multiple components, 
each of which has separate 'component knowledge' consisting of basic knowledge 
underlying the component representing the knowledge of specialist elements in an 
organisation. In addition to that product system requires architectural knowledge or 
knowledge about the ways in which the components of the system are integrated and 
linked together into coherent whole and which is embedded in organisational structure, 
problem solving strategies and information processing procedures of the established firms. 
In the case of technological change the management of organisational renewal should to a 
large extent be aimed at creating new architectural knowledge, which is a matter of 
reconfiguring existing component knowledge (Henderson and Clark, 1990; DeBoer et aI., 
1999). Bogner and Thomas (1994) suggest that researchers have often perceived core 
competence as a static concept implying that core competency approach does not 
adequately explain how and why certain firms have competitive advantage in situations of 
rapid and unpredictable change. In defining a core competence or in describing a 
competitor's competence at any point in time, a description is often used which implies a 
stable condition or relationship. 
In markets where the competitive landscape is continuously shifting, dynamic capabilities 
become the source of competitive advantage (Teece et aI., 1997) \\·here dynamic 
capabilities' refer to the 'firm ~ s ability to integrate, build and reconfigure internal and 
external competencies to address rapidly changing environments'. Building upon the 
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resourced based approach, this perspective has stressed both the dynamic dimension of the 
capability building process and the role of organisational capabilities in that process. 
Dynamic capabilities are defined as 'the subset of competence/ capabilities which allow 
the firm to create new products and processes and respond to changing market 
circumstances (Teece et aI., 1997). These capabilities are rooted in high performance 
routines operating inside in the firm, embedded in firm's processes, and conditioned by its 
history. According to Teece and Pisano (1994) the term 'dynamic' represents the capacity 
of firm to renew competencies so as to achieve congruence with changing business 
environments and the term 'capabilities' emphasises the role of strategic management in 
appropriately adapting, integrating, and reconfiguring internal and external organisational 
skills, resources, and functional competences to match the requirements of a changing 
environment. The firm specific processes that use resources - specifically the processes to 
integrate, reconfigure, gain and release resources - which are key in gaining and sustaining 
competitive advantage in industries facing rapid technological and market changes, forms 
base of dynamic capabilities (Einsenhardt and Martin, 2000). Therefore firm's dynamic 
capabilities are determined by three classes of factors: 
a. processes - managerial and organisational routines; way things are done in the firm 
b. positions - current endowments of technology, customer base, and suppliers 
c. paths - available strategic alternatives. 
Dynamic capabilities thus are the organisational and strategic routines by which finns 
achieve new resource configurations as markets emerge, collide, spilt, evolve or die 
(Eisenhardt and Martin, 2000). The dynamic focus of this perspective is based on stressing 
the importance of continually developing new capabilities as well as exploiting old ones in 
the context of a shifting environment. 
Extending on the Eisenhardt and Martin's (2000) work on dynamic capabilities, Zahra and 
Gorge (2002) shows that the absorptive capacity could be a primary source of creating and 
sustaining a competitive advantage for firms in a dynamic market. 
Dosi et aI., (2000) point out that the concepts of core competence and dynamic capabilities 
point in the same direction broadly concerned with the firm's ability to carry off the 
balancing act between the continuity and change in its capabilities and to do so in a 
competitively effective fashion. The discussion of dynamic capabilities. has however both 
in broader scope and more explicit in its treatment of the details of the capabilities and 
change than the core competence discussion. Teece and Pisano (1994) develop the 
foundation of dynamic capabilities which was further elaborated by other researchers like 
Eisenhardt and Martin, 2000~ Henderson and Cockburn. 1994; Rosenbloom, 2000. Iansiti 
and Clark, 1994~ Helfat and Raubitschek. 2000,). 
Rosenbloom (2000) studied the issue of dynamic capabilities by focusing on NCR' s 
(National Cash Register Company) efforts in adapting to revolutionary technological 
change in its major line of business. He traces the efforts of NCR to adapt to the 
introduction of electronics and 'waves of change' in the business equipment industry. After 
a long unsuccessful period of evolutionary change, NCR regained its market leadership 
and Rosenbloom identified prominent role of top management within NCR, among several 
factors that led to NCR's resurgence. As Rosenbloom (2000) states: 'individual 
leadership ... may well be a central element of dynamic capability'. 
Eisenhardt and Martin (2000) suggest that extensive empirical research has identified 
specific routines which create dynamic capabilities. They suggest that some researchers 
identified the capability for integration as dynamic organisational capability, while others 
focused on reconfiguration of resources within firms as the basis of dynamic capabilities. 
Still other researchers focused on knowledge creation routines as whereby managers and 
others build new thinking in the firm, a particularly crucial dynamic capability and 
essential one for effective strategy and performance. Eisenhardt and Martin (2000) provide 
evidence that dynamic capabilities consists of less structured and less complex routines in 
high velocity markets. 
Many researchers have focused on the concept of knowledge integration as base of firm's 
dynamic capability (see for instance Clark and Fujimoto, 1990; Iansiti and Clark, 1994; 
Henderson, 1994). Based on Dosi and Marengo's (1993) argument that problem solving 
activities, are essence of competence building processes and the basic unit of knowledge 
creation, Iansiti and Clark (1994) suggest that the capacity to integrate diverse knowledge 
bases through problem solving is the basic foundation of knowledge building in an 
organisation and is therefore a critical driver of dynamic performance. Therefore they 
considered the capability for integration as basis for the process of capability building and 
renewal. Similarly, Clark and Fujimoto (1990) points out that in a competitive 
environment, integration is the underlying source of superior performance and in such 
cases integration is seen as specifically organisation specific capability. Clark and 
Wheelwright (1995) suggest that effective product and process development requires the 
integration of specialised capabilities and it is specially challenging in large firms with 
strong functional groups, extensive specialisation, large numbers of people, and multiple, 
ongoing operating pressure. 
Iansiti and Clark (1994) analysed the internal integration across internal boundaries of the 
firms and the external integration across firm boundaries. They define internal integration 
as the capacity for extensive coordination between different specialised subunits within the 
organisation while external, integration is dh"ided into sub dimensions: customer 
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integration and technology integration. Henderson and Cockburn (1994) use same 
approach, but they analyse integration in terms of internal and external organisational 
boundaries as well as technological boundaries focusing on the organisational 
arrangements that allow the integration of different knowledge bases and creation of new 
technological competence. 
Henderson and Cockburn (1994) distinguish firm's capabilities to transform its resources 
on two dimensions: component capabilities and integrative capabilities, where integrative 
capabilities refer to the ability of a firm to use resources and component capabilities in new 
or flexible ways to support organisational renewal. They point out that the ability to 
integrate knowledge both across the boundaries of firm and across disciplines and product 
areas within the firm is an important source of strategic advantage. 
One other important idea in this area is referred to as combinative capabilities by Kogut 
and Zander (1992), concerned with the firm's capabilities of combining new knowledge 
with deeply accumulated knowledge. In combinative capabilities the emphasis is on the 
firm's ability to handle change by transforming old capabilities to produce new 
competencies by recombining existing capabilities and other knowledge. Two points about 
the nature of this transformation are emphasised: 
1) that the firms produces new capabilities by recombining existing capabilities and other 
knowledge 
2) that the ability of the firm to do this is affected by the organising principles guiding its 
operations - principals that include matters of formal structure but, more importantly 
internal social relations shaped in part by difference in the knowledge bases of individual 
and groups within the firm. 
Different researchers in strategic management literature have used a number of concepts, 
however many of them share a basic principle. Henderson and Cockburn (1994) suggests 
that their concept of architectural competence, representing the firm's integrative 
capability is similar to the notions of combinative capabilities (Kogut and ZandeL 1992), 
managerial systems and values and norms (Leonard - Barton, 1992), dynamic capabilities ( 
Teece et aI., 1997). For instance Teece et aI., (1997) suggests that 'core competencies, as 
raised by Prahalad and Hamel, are identical to our concept of capabilities and resources.' 
Therefore as Dodgson (1993) suggests that theoretically different concepts like firm 
specific competences (Pavitt, 1991); dynamic capabilities (Teece and Pisano, 1994) and 
core competencies (Prahlad and Hamel, 1990) share similarity between them. They all 
define organisational uniqueness by knowledge bases and the processes of acquisition, 
articulation and enhancement of the knowledge embedded in firms historically developed 
contexts over which it has control. 
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They use different approaches to express common idea: the uniqueness of firm's 
knowledge and learning, which has difficult to imitate strong tacit component. 
To sum up, this review of strategic management literature shows that despite the 
differences between the concepts of capabilities, there is some consensus that the process 
of maintaining, nurturing and renewing core capabilities or competencies requires 
continual reconfiguration of a bundle of resources through learning processes. Knowledge 
is foundation of the capability and therefore management of knowledge has become a key 
organisational issue in nurturing and renewing or reconfiguring of capabilities. Knowledge 
creating activities like sharing knowledge within the organisation and integration of 
knowledge across organisational boundaries is seen as the basis on which firm create, 
sustain and rebuild technological capabilities (Leonard - Barton, 1992; Dosi and Marengo, 
1993; Prahalad and Hamel, 1990; Teece, et aI., 1997). Specifically as Leonard - Barton 
(1995) points out, it is through systematic decision making and actions, both routine and 
strategic, core and technological capabilities can be built and changed, therefore as firms 
compete on the basis of their ability to create and utilise knowledge, the management of 
knowledge has becomes a central issue. This focus of competence based theories of the 
firm on knowledge and learning highlights the dynamic and evolutionary characteristics of 
firm. 
However some researchers have criticised the treatment of knowledge in competence 
based approaches as 'too objective and too linear'. These researchers suggest that 
competence based approach tends to objectify knowledge within organisations, abstracting 
it from its situated and socially constructed origins. Its managerialist interpretation 
produces too linear a view of the causal relationships between organisational knowledge 
and competitive performance (Scarbrough, 1998; Tsoukas, 1996). Scarbrough (1998) 
suggests that the competencies approach fails to follow the logic of its own argument as far 
as organisational appropriation of knowledge is concerned. He argues that the 
competencies based approaches neglects socially embedded qualities of organisational 
knowledge. Contrasting it with the organisational theorist approach to knowledge. 
Scarbrough (1998) argues that organisational theorist has developed an appreciation of 
organisational knowledge that reflects processes of social construction and the social 
relations in which knowledge is embedded, ranging from inter organisational networks and 
occupational communities. Therefore the treatment of organisational knowledge in 
competence based view of firm neglects the importance of wider institutional context of 
firm's strategic development and which ha\'e critical implication for formation and 
deploynlcnt of knowledge in organisations. 
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3.4 Renewal of capabilities to create knowledge for innovation in Indian 
pharmaceutical firms 
The descriptions of the main issues of both bodies of literature while complementing each 
other, points out some differences in the approach to technological capabilities. 
A. SML has focused on technological as well as organisational dimensions of capability 
creation. It is perhaps more concerned about organisational issues involved in the creation 
of knowledge to maintain and renew the core capabilities. As Pavitt, (1998) points out the 
lack of technological knowledge is rarely cause of innovation failure in large firms based 
in advanced countries and problems are more organisational. However for firms in 
developing countries availability and access to technological knowledge is an equally 
bigger issue and it is reflected in literature on the developing countries which is mostly 
focused technical knowledge dimension of the building up of technological capabilities. 
B. DeL focuses on long term process of technological capability accumulation in firms 
from developing countries and SML focuses on the maintaining and renewing of 
knowledge. Most of the firm level research regarding learning and capability building 
concerned with sustaining, deepening and renewing their existing innovative capabilities is 
focused on most innovative firms competing at the technological frontier in advanced 
countries. Therefore there is a flourishing literature available on the firm specific factors 
that affect the success and failure of innovation in advanced countries, but there is no 
literature of equivalent scope and depth for developing countries (Bell and Pavitt, 1995). 
With the advent of globalisation firms in the developing countries are going through their 
battles of survival and reinvention. Although the uniformation of trade laws due to world 
trade agreements means that a firm that is a new entrant into a US market or other 
advanced country experiences challenges not unlike those of newcomer located in a newly 
industrialising country. In rapidly changing globalise world the challenge for firms is to 
find new ways of doing things (Teece, 2000). However the main difference is in the object 
of analysis, the firm in a developing country and its external environment as opposed to a 
global world player. In a developing country, knowledge of traditional, stable and simple 
technologies may not be a good base from which to learn how to master modem 
technologies. Firms may not know how to build up the necessary capabilities - learning 
itself has to be learned (Stiglitz, 1987). In developing countries firms compete on the basis 
of production capabilities, largely acquired from elsewhere and reinforced hy basic to 
intennediate technological c3pabilities related to a simple knowledge base. The transition 
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from intermediate innovative capabilities to advanced innovative capabilities represents 
movement from simple knowledge base to complex knowledge base. It represents the 
movement towards competing with the technological frontier firms on the basis of 
knowledge bases and capabilities. This transition process and the specific firm level 
processes involved in such transformation, is the focus of this research. 
Therefore, as the review points out, neither developing countries literature nor strategic 
management literature has paid adequate attention to this particular issue. However as 
Teece (2000) suggests, the institutional contexts may be different in developing or newly 
industrialised countries compare to advanced countries but the basic process of learning 
and advancement as a response to change are applicable to them as well. Therefore these 
two literatures provide some ideas that are drawn on to develop the theoretical framework 
that is used in this research. 
3.5 Summary 
This chapter discussed the literature focused on capability creation in firms from advanced 
and developing countries. This review shows that the transformation happening in Indian 
pharmaceutical firms has not been explored by both strands of literature so far and this 
research aims to fill that gap. This research analyses the long term historical process of 
building technological capabilities in the Indian pharmaceutical industry. But it specifically 
focuses on the firm level processes involved in discontinuous learning in the Indian 
pharmaceutical industry as a response to change in external environment and the firm level 
differences in learning process. 
The next chapter reviews some of the literature examining the emergence of knowledge as 
strategic resource and its role in creating innovative capabilities. It also presents the 
theoretical framework used of exploring the capabilities transformation. 
" 
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Chapter 4 
THEORETICAL FRAMEWORK 
4.1 Introduction 
This chapter presents the theoretical framework used in this research for exploring the 
'firm level processes' involved in the development of knowledge creation capability for 
innovation as a response to change in the external environment. It is based on the 
absorptive capability concept and builds on earlier frameworks which have focused on 
organisational knowledge creation. It draws on the strategic management and 
organisational theory literature focused on knowledge, learning and innovation. 
The review of strategic management literature suggests that knowledge is the foundation of 
capability and so management of knowledge facilitates the renewal of existing capabilities 
and helps to develop new competencies. Therefore in last decade knowledge based theory 
of the firm has emerged highlighting 'managing knowledge' as a key organisational issue 
in the nurturing and renewing or reconfiguring of core competencies (Grant, 1996a; 
Nonaka, 1994; Kogut and Zander, 1992). Spender and Grant (1996) point out that there is 
growing belief among managers that understanding the issues related to organisational 
knowledge and learning has a central role in firms' responses to change. Kim (l997a) 
showing the key role of learning in creating and managing knowledge defines 
organisational learning as a dynamic process of acquiring, assimilating and applying new 
knowledge. Other researchers like Tsoukas and Mylonopolous (2004) focusing on the 
interdependencies between knowledge, capability and learning, suggest that organisational 
knowledge, learning and capabilities form a triangle: the ongoing development of 
organisational knowledge is or can be a dynamic capability that leads to continuous 
organisational learning and further development of innovative knowledge assets. Zollo 
and Winter (2002) argue that dynamic capabilities are shaped by the co-evolution of 
learning mechanisms involved in knowledge accumulation, knowledge articulation and 
knowledge codification. Tsoukas and Mylonopolous (2004) summarising the relationship 
between capability, knowledge and learning suggest that a 'learning firm' is a firm that has 
developed the capability to integrate. communicate and create knowledge on an ongoing 
basis. Tidd (2000) presents a framework to link these different but interdependent concepts 
of knowledge, learning and innovation with core or strategic competencies of firms. 
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However in the case of technological advances or fundamental regulatory reforms~ firms 
have to develop new competencies through revolutionary change or discontinuous learning 
(Tushman and O'Reilly III, 1996). The capability of the firm to maintain, nurture and 
renew or reconfigure technological capabilities is based on the ability of the firm to 
develop new competencies by acquiring new knowledge and integrating or combining it 
with existing knowledge bases (Kogut and Zander, 1992, Teece, et aI., 1997; Cohen and 
Levinthal, 1990). In a similar vein Henderson and Clark, (1990) suggest that such change 
and adoption involves not only learning new components of knowledge but also the new 
linkages between the components and so it requires reconfiguration of existing systems of 
linkages in a new way. Therefore in an uncertain environment, the ability of the firm to 
develop new competencies depends upon the firm's absorptive capacity; the firm's ability 
to evaluate, assimilate and apply outside knowledge (Cohen and Levinthal, 1990) and 
which is viewed as function of two separate but interrelated dimensions: 
a. the firm's ability to acquire the knowledge relevant to the new technological paradigm 
and 
b. firm's ability to integrate external knowledge into existing capabilities. 
But the organisational learning literature (Levitt and March, 1988; Cohen and Levinthal, 
1990) and the evolutionary economics perspective on innovation (Nelson and Winter. 
1982; Pavitt, 2002) suggest that a firm's absorptive capacity or learning capability tends to 
be cumulative and path dependent. The prior knowledge base provides the base on which 
firms develop the capabilities to cope with new technological change or new external 
environment. It provides firms an ability to exploit external knowledge and therefore forms 
the critical component of innovative capabilities. So the absorption of new knowledge will 
depend on the accumulated stock of past capabilities or knowledge and mechanisms of 
knowledge transfer (Cohen and Levinthal, 1990). 
The theoretical framework is thus based on the combination of these different conceptual 
perspectives. To summarise briefly, it explores the social processes or mechanisms used 
for knowledge acquisition, transfer, assimilation, and application in innovative Indian 
phannaceutical finns. It also explores the relevance of prior knowledge base in terms of its 
usefulness in a new environment and how firms have built it. 
This chapter presents the theoretical framework based on absorptive capacity concept and 
explain its rationale with the review of literature focused on knowledge. learning and 
innovation. Section 4.2 reviews the literature on knowledge. learning and innovation. It 
shows the role of knowledge in developing capabilities for innoyation and processes 
involved in creating knowledge like organisational learning. communicating and 
remembering. Section 4.3 ·.looks at transfornlation in large pharmaceutical firms as a 
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response to biotechnological change. The processes used by large pharmaceutical firms for 
discontinuous learning guides in operationalising the theoretical framework. Section 4.4 
presents the theoretical framework used for exploring the discontinuous learning in Indian 
pharmaceutical firms. Section 4.5 concludes the chapter. 
4.2 Knowledge, Learning and innovation 
4.2.1 Managing knowledge within the organisation 
The emergent theme in the strategy literature is the idea that the most distinctive role of the 
business system is the way it brings knowledge to bear on superior firm performance and is 
discussed under the heading of knowledge based theory of the firm. 
The knowledge based view argues that firms exist as they provide ideal platform for 
creation, transfer and application of knowledge (Grant, 1996a, Nonaka, 1994, Spender, 
1996a; Tsoukas, 1996). It sees firm as a knowledge system or bundle of knowledge assets 
and effective management of which affords firms competitive advantage (Grant 1996a; 
Spender, 1998). There is increasing understanding that knowledge allows the creation of 
the capability and that determines the ability to do things (Grant, 1996a; Henderson and 
Cockburn, 1994; Leonard- Barton, 1995) and so the manner of knowing or learning is as 
important as what should be known (Spender and Grant, 1996). Knowledge or knowledge 
assets are conceived as know-how embedded in the organisation's activities and these 
knowledge assets are deeply rooted into firms historically developed context. Therefore 
these assets are idiosyncratically complex and dynamic and so unique in nature (Grant 
1996b; Spender, 1996a). According to Tsouskas and Mylonopoulos (2004) the knowledge 
based perspective on organisation links two traditionally different domains: the skills that 
sustain organisational learning and a firm's competitive advantage through idiosyncratic 
capabilities. 
One of the key contributions towards the emergence of focus on knowledge and its 
strategic role is studies of organisational knowledge creation in Japan by Nonaka and 
Takeuichi. Building on the distinction between tacit and explicit knowledge proposed by 
Polanyi (1966) and linking the resource and capability view of the firm with organisational 
learning literature, Nonaka and Takeuichi (1995) developed the model of the various ways 
in which organisations create knowledge. Based on the idea that knowledge is product of 
the learning, they focused on knowledge. The organisational knowledge creation is seen as 
a capability of the organisation. The knowledge creation model relates the tacit and e:\:plicit 
knowledge with individual and organisational knowledge and suggests a style of 
Inanagement and organisational structure for best managing the knowledge creation 
process. Nonaka and Takeuchi (1995) postulate that the organisation creates new 
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knowledge through interactions between tacit 
. and explicit knowledge, and through a 
dynamIc process of conversion of knowledge between these 1'.\ 0 dimensions of knovv ledge. 
Through this 'social conversion' process tacit and explicit knowledge expand in term of 
~ot~ ~uality and quantity. Knowledge is transferred from individuals to a larger group of 
IndIvIduals in a spiralling I £ 11 fi .. process. t 0 ows rom the proposItIOn that, although tacit 
knowledge is initially locked up in the heads of the individuals, shared experiences allow 
individuals to project themselves into each other's thinking processes. 
Socialisation Externalisation 
Internalisation combination 
Fig 4.1: SECI spiral 
According to Nonaka et al.,(2000b) knowledge is created through the SECI spiral which 
goes through four modes of conversion between tacit and explicit knowledge (Fig 4.1): 
1. Socialisation (from tacit knowledge to tacit knowledge); 
2. Externalisation (from tacit knowledge to explicit knowledge); 
3. Combination (from explicit knowledge to explicit knowledge) and 
4. Internallsation (from explicit knowledge to tacit knowledge). 
Socialisation involves transfer from tacit to tacit and is a process of sharing experience 
and thereby creating tacit know ledge such as shared mental models and technical ki 11 . A 
key to acquiring tacit knowledge is experience and without some form of shared 
experience, it is extremely difficult for one person to transfer knowledge to another per on. 
Externalisation is a process of articulating tacit knowledge into explicit concept. It i a 
quintessential knowledge creation process in that tacit knovdedge become explicit taking 
the shapes of metaphors, analogies, concepts, hypotheses or model. Combination i a 
process of y temizing concept into a knowledge sy tern and in olve combining different 
bodie of explicit knowledge. In bu ine context the comhination mode of kn v.ledgc 
conver ion i rno t often seen when middle managers bn.:ak down and opt:rationait 
corporate visions, business concepts, or product concepts. Internalisation is a process of 
embodying explicit knowledge into tacit knowledge. It is closely related to 'learning by 
doing'. When experiences through socialisation, externalisation, and combination are 
internalised into individuals' tacit knowledge bases in the fonn of shared mental models or 
technical know-how, they become valuable assets. 
Central to the Nonaka and Takeuchi's knowledge conversion model and in other works 
related to managing knowledge is Michael Polayni's distinction between tacit and explicit 
knowledge. Tacit knowledge is subjective and experimental and hard to fonnalise. Belief. 
perspective, mental models, ideas and ideals are some of the examples of tacit knowledge. 
Explicit knowledge is objective, rational knowledge and can be expressed in fonns such as 
data, scientific fonnulas, specific actions and manuals. This classic distinction is then used 
to elaborate additional knowledge dichotomies, for example canonical vs. non canonical, 
procedural vs. declarative, and know-how vs know what. The different typologies of 
knowledge advanced the understanding of organisational knowledge by showing its 
multifaceted nature. This distinction between different types of knowledge is the reason 
often cited for distinguishing knowledge from other resources (Kogut and Zander 1992; 
Zander and Kogut, 1995). 
Nonaka et aI., (2000a) also points out that other important feature of knowledge; context 
specificity; without context, knowledge is just infonnation. Therefore knowledge creating 
processes are necessarily context specific, in tenns of who participates and how they 
participate in the process. 
This 'SECI' model perspective suggests that organisational knowledge creation takes place 
between three levels: individual, team and organisation. The spiral represents the dynamic 
process, starting at the individual level and expanding as it moves through communities of 
interaction that transcend sectional, departmental, divisional and even organisational 
boundaries (Nonaka and Konno, 1998). 
Cook and Brown (1999) present the different model for organisational knowledge creation 
albeit based on different types of knowledge (fig 4.2). They point out that tacit and explicit 
knowledge are two different types of knowledge which complement each other but do not 
convert into each other. They further argue that there is fundamental discontinuity between 
individual and group knowledge. They propose that individuals and groups can each 
possess explicit knowledge and tacit knowledge and thereby gi\'ing four different 
categories of knowledge. However all four knowledge types can be mutually enabling in 
the pursuit of purposeful activity or 'active process of knowing'. New kno\\'\edge IS 
generated as different knowledge types 'dance~ together in course of doing something. 
" 
59 
Individual Group 
~ Concepts stories ~ 
"'C 
-
.... 
~ 
.... 
.... 
~ Skills Genres 
~ 
~ 
.... 
.... 
Fig 4.2: Four forms of knowledge (Cook and Brown, 1999) 
Continuing with different types of knowledge and ways of knowing, Spender (l996b: 74) 
sketches a theory of the firm as a system processing different kinds of knowledge and 
generating common knowledge (Fig 4.3). He suggests that knowledge, learning and 
memory form the interdependent parts of organisational system and are influenced by 
particular types of knowledge. The firm comprises of four distinct types of knowledge: 
conscious (explicit knowledge held by the individual), objectified (explicit knowledge held 
by the organisation), automatic (preconscious individual knowledge) and collective (highly 
context dependent knowledge which is manifested in the practice of an organisation) and 
each imply different learning and memory processes. These different types of knowledge 
interact dialectically to form an organic system with knowledge both at the level of system 
and at the level of individuals it embraces. 
Explicit 
Implicit 
Individual 
Conscious 
Automatic 
Social 
Objectified 
Collective 
Fig.4.3: Different types of knowledge (Source: Spender, 1996b) 
These perspectives propose that organisations have different types of knowledge and that 
identifying and examining these will lead to more effective means for generating, sharing 
and managing knowledge in organisations. However, Tsouskas (1996) characterised such 
perspectives as 'taxonomic' and argues that typologies of knowledge are marked by 
'fonnistic' type of thinking as typologies are based on the assumption that observerahle 
systematic sin1ilarities and differences exists between objects of study. The conceptual 
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categories along which phenomenon are classified must be separate, discrete and stable 
and the problem, he claims, is that they hardly ever are. He further explains that as tacit 
and explicit knowledge are mutually constituted - they should not be viewed as two 
separate types of knowledge. Tacit knowledge is the necessary component of all 
knowledge; it is not made up of discrete means which may be ground, lost or reconstituted 
- tacit and explicit knowledge are inseparably related. According to Tsoukas and 
Vladimirou (2001 :976) organisational knowledge is the capability members of 
organisation have developed to draw distinctions in the process of carrying out their work, 
in particular in concrete contexts, by enacting sets of generalisations whose applications 
depend on historically evolved collective understandings. Based on this perspective 
Orlikowski, (2002) suggests that organisational knowledge is observer dependent and 
action based; it is an outcome of the process of knowing where organisational knowing 
refers to ongoing and situated actions of organisational members as they engage the world. 
Continuing with this perspective, Tsoukas and Mylonpoulos, (2004) suggest the 
'constructivist' view of organisational knowledge emphasising that the content of 
organisational activities or the social processes/ practices surrounding the organisational 
activities construct and creates organisational knowledge. Supporting Leonard - Barton' s 
(1995) observation that a firm nurtures and creates knowledge through certain activities 
and these activities basically involve the sharing of knowledge within the organisation and 
transfer and integration of knowledge across the organisational boundaries. She further 
argues that firms create 'the whole system of knowledge management' through different 
activities and which is seen as integral element in gaining competitive advantage. 
According to Tsoukas (1996) firms are distributed knowledge systems which means that 
they are composed of knowledge embodied individuals and their social interactions. The 
creation of knowledge in such system requires promotion of interaction among the 
individuals situated in various parts. Spender (1996b) refers to knowledge emerging from 
such interactions as collective knowledge. He suggest that firm's most strategically 
important feature is its body of collective knowledge and the key to management impact on 
a firm is its influence over the growth and shaping of this collective knowledge. And which 
is based upon the different 'organisational practises', and activities supporting those 
'different practises or ways of doing things'. This viev; is also shared by Nonaka et a1.. 
(2000a) as they suggest that knowledge creation is a dynamic human process; knowledge 
is created through the dynamic interactions among individuals and/or between individuals 
and their environnlent rather than by an individual who operates alone in a vacuum. 
To summarise. the literature covering organisational knowledge creation points out that the 
three notable principles. of knowledge include tacitness (Polayni. 1966: Nonaka and 
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Takeiuchi, 1995), context specificity (the extent to which knowledge is highly 
contextualised and co-dependent on unidentified aspects of local environment) (e.g. Nelson 
and Winter, 1982; Nonaka at aI, 2000a) and dispersion/distribution (spread of knowledge 
among organisational members). The insights from various perspectives on organisational 
knowledge creation suggests a central role of activities or practices that facilitates 
interactions among distributed knowledge systems within firms for creating, sustaining or 
renewing organisational knowledge. Many researchers like Nonaka et aI., (2000b), Cook 
and Brown (1999), Spender (1996b), Tsoukas (1996), Leanoard- Barton (1995) suggest 
organisational knowledge is located in a complex web of social practices and which have 
implication for capability transformation and development of new competencies. 
The next section focuses on the critical process of organisational learning which facilitative 
the creation of new knowledge and development of capability. 
4.2.2 Organisational learning 
Learning is a key process by which firms accumulate knowledge in order to compete; the 
process through which firms create knowledge and develop technological capabilities. 
Dodgson (1993) defined organisational learning as the ways firms build, supplement and 
organise knowledge and routines around their activities and within their cultures, and adapt 
and develop organisational efficiency by improving the use of the broad skills of their 
workforces. He stresses that the importance lies in not only what a firm knows or what 
skills it posses, but how it uses them (Dodgson, 1993: 383). In same way Marengo (1992) 
argued that organisational learning is the process of generating new competencies and 
improving old capabilities. According to Dodgson (1993) the concept of learning provides 
a model for understanding the changes that individuals and organisations face. 
There is increasing interest in organisational learning from different theoretical 
perspectives and disciplines (see for instance Hedberg, 1981; Levitt and March, 1988; 
Dodgson, 1993; Cohen and Levinthal, 1990; Nonaka and Takeuichi, 1995). Dodgson 
(1993) suggests growing interest in organisational learning is a result of increasing rate of 
technological change. Firms have to acquire and use the new emerging technological tools 
to compete efficiently. There are shorter product life cycles which necessitate learning how 
to do things differently. Organisations have to learn faster to become more adaptable and 
change themselves quickly as a response to these technological discontinuities. Firms deal 
with uncertainty in their markets and technologies through organisational learning which 
occurs through all activities of the fim1. Thus learning is a dynamic and integrath'e concept 
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that can unify various levels of analysis: individual, group, and organisation and its use in 
theory emphasises the continually changing nature of organisations (Dodgson, 1993). 
Researchers have used the metaphor of individual learning to explore processes involved in 
organisational learning. These researchers suggest that organisations learn through 
individuals as Simon (1991 :76) points out that 'all learning takes place at individual level, 
inside individual heads; an organisation learns only in two ways :a. by the learning of its 
members or b. by ingesting new members who have knowledge the organisation did not 
have previously. In similar vein Dodgson (1993) argues that individuals are the primary 
learning entity in firms and it is individuals which create organisational forms that enable 
learning in ways which facilitate organisational transformation. However, researchers like 
Hedberg (1981 :6) points out that although organisational learning occurs through 
individuals, it would be a mistake to conclude that organisational learning is nothing but 
the cumulative result of their members' learning. Organisations do not have brains, but 
they have cognitive systems and memories ... organisational memories preserve certain 
behaviours, mental maps, norms and values over time. Therefore individual learning is an 
indispensable condition for organisational learning but can not be sufficient condition 
(Kim, 1998). Cohen and Levinthal' s (1990) concept of absorptive capability can be seen as 
a measure of organisational learning, considering it is a set of collective abilities developed 
through learning activities. As they point out these activities collectively constitute what 
we call a firm's "absorptive capacity". Spender (1996b) points out that learning at 
collective level is the outcome of the interplay between conscious and automatic types of 
knowledge, and between individual and collective types of knowledge as they interact 
through collective social processes such as teamwork. 
Therefore organisational learning is a social process that creates organisational knowledge 
through various activities involving interactions between different knowledge bases, and it 
is not a sum of individual knowledge bases. 
Huber (1991) putting forward the behavioural perspective asserts that 'an entity learns if, 
through its processing of information, the range of its potential behaviours is changed ~. He 
argued that there are four basic learning related processes that determine organisational 
learning. He lists those processes as knowledge acquisition, information distribution. 
information interpretation and organisational memory. Knowledge acquisition is the 
learning related process by which knowledge is obtained. Information distribution is the 
process by which information from different sources is shared and therehy leads to ne\\ 
inforn1ation or understanding. Information interpretation is the process by which 
distributed information is given one or more commonly understood interpretations. 
Organisational memory is the means by which knowledge is stored for future use (Huber. 
1991: 90). This framework emphasising the focus on detailed activities within the 
organisations contributes to clarify the processes related to organisational learning. 
Based on the observations from behavioural studies of organisations, Levitt and March 
(1988) point out the path dependent and cumulative nature of organisational learning. They 
suggest that organisations learn by encoding inferences from history into routines that 
guide behaviour. As Pavitt (1991 :42) argues 'the range of possible choices about both 
product and process technologies open to the firm depends on its accumulated 
competence ... the improvement of these competencies requires continuous and collective 
learning'. Therefore collective or organisational learning is dynamic, but the way it 
develops is constrained by existing ways of doing things, know- how and routines (Dosi, 
1988); prior knowledge permits the assimilation and exploitation of new knowledge 
(Cohen and Levinthal, 1990). 
According to Huber (1998) learning makes available the knowledge which facilitates 
creativity. The 'creative ideas' generated as a result of learning and knowledge in 
organisations are often the origin of the organisation's innovations. Cohen and Levinthal 
(1989) showed the dual role of R&D - as a source of innovation and as a process of 
learning. They argue that while R&D obliviously generates innovations, it also develops 
the firm's ability to identify, assimilate and exploit knowledge from the environment ... a 
firm's "learning" or absorptive capacity and these two roles of the R&D contribute to the 
firm's competitiveness (Cohen and Levinthal, 1989: 569). They argue that organisational 
learning is a function of an organisation's absorptive capacity and it is internal mechanisms 
within the firm that influence its absorptive capacity or ability to learn. 
To summarise review of organisational learning literature shows that learning is viewed as 
a complex , history dependent and target oriented process and suggests an empirical focus 
on the detailed activities within organisations as a way to understanding complexities 
involved in organisational learning. 
The next section focuses on innovation management and identifies varIOUS processes 
involved in application of diverse knowledge bases in creating innovations. 
4.2.3 Product innovation management: Integration and coordination of different 
knowledge bases 
The research on innovation management explains some factors that facilitate the learning 
and knowledge creation. The innovation management literature deals with knowledge 
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creation, by focusing on the product innovations, and offers some explanation for 
management practises that facilitate the achievement of innovations. Coombs and Hull 
(1998) suggests that the perspectives in innovation management literature links knowledge 
to innovation by focusing on finn specific routines and processes, which 'stabilises certain 
bodies of knowledge, embed them in shared understanding in the finn, and provide 
templates for deploying that knowledge to produce innovations which have distinctive 
organisational signature'. 
The different types of knowledge and their role in innovation have also dominated the 
innovation management literature. For example, in the case of the development of a 
particular product, an individual might initiate an idea. But in order for this idea to become 
a product innovation that generates value for the firm, it has to be combined with other 
types of knowledge, such as research & development, manufacturing, marketing and 
customer service while at the R&D project team level it involves different specialised 
disciplinary knowledge bases. This simple description of innovation creation process 
shows involvement of various types of knowledge. A variety of studies have developed 
categorisation of knowledge used in innovation, which go beyond a simple distinction of 
tacit and explicit knowledge. Faulkner, (1994) presents a 'composite typology' of 15 
categories of knowledge used in industrial innovation. Therefore the complexity of the 
task, such as 'product innovation fulfilling demands of external markets', requires diverse 
knowledge sets (Leonard - Barton, 1995; Nonaka - Takeuichi, 1995) and in such cases 
successful management of knowledge for innovation requires the organisational capacity to 
orchestrate and integrate functional and specialist groups (Pavitt, 2002). 
Although it is well understood that firms integrate knowledge all the time at different 
levels, they do it even without calling this activity as integration, without any clear 
objective of doing it and without setting specific mechanisms to facilitate the process. 
However as Tidd et ai., (1997) observed, 'internal structures and processes must 
continuously balance potentially conflicting requirements: 
1. to identify and develop specialised knowledge within technological fields, business-
functions and product divisions, 
2. to exploit this knowledge through integration across technological fields, business 
functions and product divisions'. 
The process of knowledge specialisation and the need to integrate knowledge across 
organisational boundaries refer to different aspects of the firm's activities. Due to this 
conflict Pavitt (2003) suggests that it is necessary for firms to strategically manage 
integration of different specialised knowledge across the organisational boundaries of the 
firm. The investment in organisational level integrative management practices facilitate 
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interactions to create knowledge among individuals situated in different parts of a system 
independently (Un and Cuervo- Cazurra, 2004). 
In strategic management literature, integration is analysed in the context of problem 
solving activities, which are considered to be basic units of knowledge creation. Henderson 
and Cockburn (1994) point out that the externally focused integration: ability of firm to 
access knowledge from outside boundaries of organisation and internally focused 
integration, that is, ability to integrate flexibly across disciplinary and therapeutic class 
boundaries within organisation is very important. External integration refers to problem 
solving activities that span the boundary between the firm and its external environment. It 
is related to generations of options using external sources of information and to the ability 
to evaluate those options according to existing knowledge base (Iansiti and Clark, 
1994:565). 
The other important aspect of managing knowledge for innovation is the coordination of 
learning activities as these mechanisms plays a central role in shaping organisational 
learning process and determining its outcome (Marengo, 1992). In complex organisations 
many different learning processes can proceed at the same time in different directions and 
at different speeds (Dodgson, 1993). Managers have different perceptions about the world 
and understanding about innovation activity and organisational units have to play different 
roles in overall innovation activity of the organisation. For these and other reasons the 
organisational units follow different paths of learning and build different knowledge bases. 
Hence coordination of learning within different units is required to be able to integrate 
knowledge and build strategic capabilities. 
To sum up, the product innovation management literature shows that the integration of 
different specialised knowledge bases and coordination of learning are crucial processes in 
building knowledge creation capabilities for innovation 
The literature based on organisational knowledge creation, learning and innovation points 
out the broader aspect of activities involved in managing knowledge, learning and creating 
innovation. 
A. Researchers from different theoretical perspectives have emphasised that organisational 
knowledge or capabilities or learning is not the sum of indiyidual lcyel knowledge. 
capability or learning. This is quite e\'ident in concepts such as collecti\'c knowledge 
(Spender. 1996a). absorpti"c capacity (Cohen and LeyinthaL 1990). architectural 
knowledge (Henderson and Clark, 1990) \\'hich are highly firm specific capabilitics fed 
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by the learning processes or capabilities or knowledge bases of individual members but can 
not be reduced to their sum. In particular, activities and processes facilitating the relations 
and interactions among different parts of the organisation play a fundamental role III 
driving and shaping the organisational knowledge (Tsoukas, 1996, Spender, 1996a). 
B. The brief review of product innovation management literature suggests that 
organisational level integrative practices reinforce each other and promote knowledge 
creation by establishing interactions and interdependencies among individuals with 
different knowledge sets (Un and Cuervo - Cazurra, 2004). Therefore in firms from 
advanced countries it emerges that success in innovation management depends on the 
effective integration of specialists (discipline, function, division) within the firm and on 
effective outside linkages with sources of expertise, and with needs of eventual customers 
(Bell and Pavitt, 1993). 
These insights provide the outline of the theoretical framework while the large 
pharmaceutical firms' approaches to advances in molecular biology help in 
operationalising the theoretical framework which is discussed in the next section. 
The molecular biology advances had a profound impact on drug discovery and 
development technology. These advances emerged from academia and research institutes 
and shifted the scientific knowledge base of the industry, more precisely it shifted drug 
discovery process from one being chemistry dominated to being molecular biology 
dominated. This created discontinuous innovation for large pharmaceutical firms which 
had little control over these technological developments. As a result the large 
pharmaceutical firms' were forced to develop new competencies in biotechnology. This 
represents a good example of discontinuous learning or dynamic learning as a response to 
technological change and aids in operationalising the framework. In the case of Indian 
pharmaceutical firms the challenge of innovative R&D similarly represents the challenge 
of different knowledge base. Therefore knowledge processes involved in the large 
pharmaceutical firms discontinuous learning emerges as an effective guide in exploring 
Indian pharmaceutical firms approaches. 
4.3 Large pharmaceutical firms and the 'biotechnological' change 
The last 25 years have seen a revolution in the life sciences that has had several dramatic 
effects on the global phamlaceutical industry. Biotechnology and its impact provide an 
intriguing window into how the basic scientific advances affect the established 
67 
competencies of the firm and how firms can adopt and change in the face of such 
challenges. 
The advances in molecular biology and related technologies originated from academic 
research in biological sciences, and its practitioners designed drugs based on scientific 
hypotheses. The drug discovery technology dominant in the 1970s and into the 1980s in , 
pre- biotechnology era, was based on the chemistry and heavily involved the use of 
medicinal chemistry and pharmacology to discover effective molecules. This was reflected 
in large pharmaceutical firms building up comprehensive research strengths in chemistry 
rather than biology. Therefore emergence of advances in genetic and genetic engineering 
popularly known as biotechnology profoundly affected the scientific and technological 
basis of pharmaceutical industry (Galimberti, 1993; Sharp, 1995) and represented a 
dramatic shift in the 'scientific' knowledge base of an industry (Zucker and Darby, 1997; 
Henderson et aI., 1999). Zucker and Darby (1997) refer to these advances as 'archetypical 
example of externally generated, incumbent skill obsoleting, discontinuous innovation' 
which the literature predicts leads to the replacement of incumbents (pharmaceutical firms) 
by entrants (new biotechnology firms). However despite the sweeping natures of molecular 
revolution, incumbent pharmaceutical firms have not been swept away by new entrants but 
on the contrary a substantial number of incumbent firms have flourished at the same time. 
Incumbent firms successfully responded to technological challenge by transforming 
existing capabilities and developing new competencies. 
Zuber and Darby (1996a) report extensive transformation of most of the world's top 
twenty drug discovery firms by the early 1990s as evidenced by discovery of new 
biological entities, genetic sequence patents and co publishing with top academic biotech 
scientists. They suggest that drug discovery pharmaceutical industry appears to present the 
case in which numerous firms have pursued a strategy of transformation of technological 
identity - adopting the new technological trajectory rather than pursuing the 
'underinvestment and incompetence as responses to radical innovation. According to 
Henderson et aI., (1999) the case of the molecular biology revolution and the response 
from firms provides the detailed mechanisms of industrial transformation at the firm and 
industry levels. with the co-evolution of scientific knowledge on one side and 
organisational capabilities, industry structure and institutional context on the other side. 
The next section presents the overview of biotechnology challenge and follows it with 
mechanisnls used by large pharmaceutical firms to change their technological identity and 
capabilities. 
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4.3.1 Overview of Biotechnology change 
The revolution in genetics and molecular biology that began more than 40 years ago with 
Watson and Crick's discovery of the double helix structure of deoxyribonucleic acid 
(DNA) and that continued with Cohen and Boyer's discovery of the techniques of genetic 
engineering. This discovery had an enormous impact on the nature of pharmaceutical 
research and development and on the organisational capabilities required to introduce new 
drugs (Henderson et at, 1999: 283). Initially application of these advances followed two 
relatively distinct technical trajectories. One trajectory was rooted in the use of genetic 
engineering as process technology to manufacture proteins while second trajectory was 
concerned with using advances in genetics and molecular biology as tools to enhance the 
productivity of the discovery of conventional 'small molecule' synthetic chemical drugs. In 
recent years these two trajectories have converged and now efforts in biotechnology are 
largely focused on the search for large molecular weight drugs like proteins that must be 
produced using tools of genetic engineering but whose therapeutic value, as yet, not fully 
understood. 
4.3.1a Biotechnology as a process technology 
Traditionally, most drugs have been derived from natural sources or synthesised through 
organic chemical methods. These traditional methods were not suitable for the production 
of molecules with a large molecular weight like proteins. Proteins are simply too large and 
complex to synthesize feasibly through traditional synthetic chemical methods. In this 
regard Cohen and Boyer's key contribution was the invention of a method for 
manipulating the genetic characteristics of a cell so that it could induce to produce a 
specific protein. This invention made it possible for the fITst time to produce a wide range 
of proteins synthetically and thus opened up entirely new domain of search for new drugs. 
So, for firms choosing to exploit this route the key organisational capabilities have been 
those of manufacturing and process development: learning to use the new rDNA 
techniques as a process to produce natural or modified human proteins. The development 
of this competence created significant challenges for nearly all of the established 
pharmaceutical firms since it required both the creation of an enormous body of new 
knowledge and a fundamental shift in the ways in which manufacturing process 
development was managed inside the firm. The characteristics of knowledge base 
underlying successful biotechnology process development are quite different. Therefore an 
organisation developing a process for protein molecule needs not only new technological 
or scientific capabilities, but also different organisational capabilities than those required 
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for the development of a manufacturing process for a new small molecular weight 
compound. 
4.3.1 b Biotechnology as a research tool 
The new techniques of genetic engineering through their impact on the competencies 
required to discover 'conventional' small molecular weights affected the organisational 
competencies required to be a successful player in the pharmaceutical industry. The tools 
of genetic engineering initially employed as a source of screens with which to search for 
new drugs. In later years, new strategies emerged regarding usage of biotechnology, in first 
the therapeutic properties of a known protein were explored for curing disease state while 
in second strategy the focus was on the specific disease or condition and to attempt to find 
a protein that might have the therapeutic effects. More recently the pursuit of 
biotechnology has come to require new competencies in drug research because it has 
fundamentally shifted both the domain and the methods of search for new therapeutic 
agents. In the traditional synthetic chemical world researchers' searches among the entire 
universe of small molecules, however biotechnology researchers search focuses on more 
than 500,000 proteins present in the human body. This search requires quite different 
technical and organisational capabilities since it calls for firms to develop a deep 
understanding of the role of particular proteins in causing disease. Firms choosing to use 
biotechnology- based research tools thus had to strengthen their scientific capabilities 
especially in biological sciences. 
This way the techniques of molecular biology had dramatic implications both of the 
discovery of new drugs, on one hand and for the ways in which they were manufactured on 
other hand. An extensive literature has documented some of the consequences that the 
advent of molecular biology has produced on the organisation of innovative activities both 
at the firm and industry level (Orsenigo et aI., 1998; Henderson et aI., 1999; Gamberdella, 
1995; Galambos et aI., 1998) and it is briefly discussed in next section. 
4.3.2 Transformation of the identity at large pharmaceutical firms 
Managing the transition into the biotechnology era was not straightforward n1atter and the 
following section covers activities involved in transformation of technological identity by 
large pharmaceutical firms. The large pharmaceutical firms responded to technological 
advances by acquiring the component knowledge bases and reconfiguring the linkages 
between them. 
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4.3.2a Acquisition of new knowledge and internal transformation 
The revolution in life sciences changed the organisational and managerial aspects of the 
drug research; drug research became more knowledge intensive and complex. As a result it 
brought changes in the internal structure of commercial R&D; drug companies began to 
look and behave more like universities with increasing emphasis on collaborations, 
publication and willingness to exploit external sources of technology (Cockburn, 2004). 
According to Henderson (1994) in pre biotechnology era, drug discovery drew on three 
disciplines: analytical chemistry, basic pharmacology and ability to screen thousand of 
compounds through multiple screens. Many firms were organised functionally, with 
medicinal chemists at heart of the process and pharmacologist working down stream in a 
fundamentally reactive mode. This method of drug discovery required little 
communication of knowledge either across the boundaries of the firm or across disciplines 
of or therapeutic areas within the firm. But due to advances in molecular biology, this 
functional organisation of R&D became redundant. In post biotechnology era, modem 
drug discovery requires the input of scientists skilled in wide range of disciplines and as a 
consequence large research oriented pharmaceutical firm now employ molecular 
biologists, physiologists, and biochemists as well as specialists in the traditional disciplines 
of synthetic chemistry and pharmacology. This change in the dominant mode of drug 
discovery greatly increased the need for the exchange of knowledge across the boundaries 
of the firm and across disciplinary and therapeutic class boundaries within the firm. Thus 
the ability to take advantage of biotechnological techniques in drug research required a 
very substantial extension of the range of scientific skills employed by the firm; a scientific 
work force that was tightly connected the larger scientific community and an 
organisational structure that supported a rich and rapid exchange of scientific knowledge 
across the firm (Henderson at aI., 1999). 
Zucker and Darby (1996b) indicate that the large pharmaceutical firms focused on the 
internal R&D transformation primarily by hiring new personnel embodying the new 
technology and incorporating them into the existing structure. In post biotech era the 'star 
scientists' combining genius and knowledge of emergent technologies became the gold 
deposits around which firms and their success was built. Henderson, (1994) suggests that 
the extent of the adoption of new techniques also involved the successful adoption of 
particular, academic like, forms of organisation of research within company. According to 
Galambos et aL (1998) large pharmaceutical firms adopted two approaches for acquiring 
biotechnology capabilities. The more common strategy was to start by developing 
specialised expertise in biotech application and then attempting to generalise it across a 
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range of different therapeutic categories. It involved the building biotechnology capability 
through the process of internal group building. This represented the incremental approach 
and involved increasing investment in in-house biotech R&D to develop competences in 
new techniques. 
The second strategic alternative pursued by large pharmaceutical firms involved 
acquisition of biotech capabilities by establishing licensing, research and equity 
relationships with biotech enterprises. Cockburn (2004) pointed out that internal 
transformation was accompanied by increased willingness to exploit external sources of 
knowledge through in-licensing or strategic partnerships. Supporting this observation 
Nicholls- Nixon (1993) shows that large pharmaceutical firms developed new capabilities 
by investing in biotechnology related R&D activities and accessing new external 
technological linkages. The in-house scientific research raises the ability of firms to take 
advantage of public sciences (Cohen and Levinthal, 1989; Gamberdella, 1992). Therefore 
internal R&D is an important pre-requisite to use strategic alliances as means of acquiring 
knowledge. In the case of large pharmaceutical firms, these strategic alliances, 
collaborations transformed organisation of R&D and played a critical role in development 
of biotechnology competence. 
4.3.2h Mechanisms of knowledge transfer and inter firm networks: 
Most of the major firms invested in biotechnology R&D through collaborative R&D 
arrangements, R&D contracts and joint ventures with new biotechnology start ups (Arora 
and Gamberdella, 1990; Pisano, 1990). The collaborations and joint ventures with 
university scientists and new biotechnology firm were primarily used to augment internal 
expertise (Zucker and Darby, 1997). In general major incumbent firms began to acquire the 
technology through processes of collaboration - both with small biotechnology firms and 
directly with university laboratories - and then moved gradually through a process of 
outright acquisitions of small firms. Zucker and Darby (1997) found that research 
collaborations between firm scientists and university or research institutes scientists 
working in biotechnology area had positive effect on firms' effort to develop 
biotechnology capabilities. Cockburn et aI., (2000) suggest that the rate at which large 
pharmaceutical firms adapted to biotechnology was largely determined by the degree to 
which they were active participants in public science. 
Supporting this observation, Gamberdella (1995) explained that large pharmaceuticals used 
different forms of linkages with universities, research institutes as mechanisms of 
knowledge transfer to complement internal capabilities in biotechnology. He identified 
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four types of linkages like research and lor joint development agreements with other finns, 
research agreements with universities, investments in the capital stock of biotechnology 
firms and acquisitions of biotech firms. Focusing on the biotechnology industry he reason 
that agreements signed by large pharmaceutical firms with new biotechnology fmns (NBF) 
tend to be product specific and aimed at developing and commercialising discoveries made 
by new biotechnology firms. Alternatively agreements with universities usually focused 
more on basic research and are undertaken as a means of obtaining basic knowledge in a 
field and securing the first option to license discoveries resulting from research. Minority 
equity positions in new biotechnology firms are used to monitor the internal research 
activities of the NBF and to establish preferential links. Finally acquisitions are initiated 
for two reasons: either to complement the large firm's internal capabilities in specialised 
areas of technology, or to supplement the firms existing capabilities; as means of catching 
up. Powell (1998) elaborates on the extensive efforts taken by biotechnology and 
pharmaceutical firms in developing capability to collaborate and learn. 
These observations suggests that with the emergence of biotechnology established 
incumbent firms in the pharmaceutical industry were forced to form new relationships with 
universities and new biotechnology firms in order to access the knowledge needed to build 
their own capabilities in biotechnology. Thus in order to remain competitive in 
biotechnology era, incumbent firms extensively used external relationships as a vehicle for 
adjusting their internal technological capabilities. 
This provides the additional evidence of the use of network strategies by large 
pharmaceutical firms and new biotechnology firms. These changes led to transformation of 
new drug discovery and development in large pharmaceutical firms from a totally in-house 
activity to a networked collaborative activity. Therefore in recent years, a dense network of 
collaborative relationships among different types of firms and other research institutions 
has emerged as a major feature of the transformation of large pharmaceutical firms' 
technological capabilities as a response to biotechnological change. 
To sum up, the case of biotechnology or advances in biological science made several of the 
core competencies of existing pharmaceutical firms ~ obsolete (Henderson et aI., 1999). As 
a response to these challenges. large global pharmaceutical firms acquired biotech 
capability by hiring the star scientist, restructuring internal mechanisms of managing 
research, accessing in new external sources of knowledge and investing in the internal 
biotech R&D. These firms collaborated, and in some cases acquired the new biotech firms 
and changed the in-house nature of their R&D to the network model of the R&D. As 
Zucker and Darby (1997) suggests the transformation of technological identity as a 
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response to radical innovation by large pharmaceutical firms provide us better 
understanding of mechanisms used by incumbent firms to transform in face of an external 
technological discontinuity. In case of Indian pharmaceutical firms these mechanisms 
helps in focusing on the areas of investigation. 
The next section presents the detailed theoretical framework which is based on the insights 
from review of literature on knowledge based theory of the firm, organisational learning 
and product innovation management along with mechanisms used by large pharmaceutical 
firms to transform its capabilities and identity. 
4.4 Theoretical Framework for analysing the firm level processes involved in 
development of competency for innovation 
This chapter has reviewed literature about the role of the different processes involved in 
mechanisms of managing knowledge, learning and innovation and its role in development 
of capabilities for firms in changing environments. The experience of today's developed 
and developing countries shows that the differentiated and path dependent processes of 
learning are the basis for changing capabilities as they develop and so both historical and 
contemporary analysis needs to be undertaken in order to understand the dynamics of these 
processes fully (Nelson and Winter, 1982; Bell and Pavitt, 1993). Therefore the theoretical 
framework focuses on both historical and contemporary analysis of processes involved in 
learning and change in Indian pharmaceutical firm. 
In the case of some events, such as fundamental regulatory reforms or radical technological 
advances, firms have to go through revolutionary change or discontinuous learning to 
develop new competencies to adapt and change. This ability of the firm to learn, change 
and develop new competencies is termed by Teece et aI., (1997) as dynamic capability. 
According to Teece and Pisano (1994) dynamic capability of the firm refers to the capacity 
of firm to renew competencies so as to achieve congruence with changing business 
environments. It refers to firm's ability to make effective use of knowledge in efforts to 
assimilate, use, adapt and change existing technologies. Therefore it enables firms to create 
new technologies and to develop new products and processes in response to changing 
economic environment. 
Discontinuous learning normally involves a crisis and a strategy to turn the situation 
around whereas cumulative or incremental learning is learning that can take place along 
current trajectory under normal circumstances (Tushman and O'reilly, 1996; Kim, 1998). 
The example of large pharmaceutical firms' development of biotechnology capability as 
response to advances in molecular biology represents one such example of discontinuous 
leaming. In catching up countries, particularly where the state plays an orchestral role in 
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industrialisation, the change in government policy or new regulation could impose a crisis 
in particular industry. This creates greater challenge for firms in developing countries to 
become more adoptable and respond to change more quickly requiring rapid and greater 
learning. The review of strategic management literature suggests that the capability of the 
firm to renew or reconfigure technological capabilities is based on the ability of the firm to 
develop new competencies by acquiring new knowledge and integrating or combining it 
with existing knowledge bases (Kogut and Zander, 1992, Teece, et aI., 1997; Cohen and 
Levinthal, 1990; Pavitt, 2002). In similar vein Henderson and Clark, (1990) show that in 
order to adapt and change as a response to such challenges, firms must learn not only new 
components of knowledge but also the new linkages between the components and so 
requires the reconfiguration of existing system of managing and creating knowledge in 
new way. In the case of pharmaceutical R&D, the biotechnological change - more 
specifically the pursuit of large molecular weight compounds such as drugs - required new 
competencies in both research and process development, and subsequently it altered the 
relationship between different components of knowledge involved in pharmaceutical R&D. 
Therefore as different researchers have shown as a response to biotechnological change 
large pharmaceutical firms not only developed new competencies through discontinuous 
learning but also reconfigured existing system of managing and creating knowledge in new 
way. 
The firm's ability to develop new competencies depends upon its learning capacity, that is, 
on its ability to acquire, create and disseminate new knowledge. Cohen and Levinthal 
(1990) refer to this organisational capacity to generate new knowledge as absorptive 
capacity and define it as an ability of firm to identify, assimilate and apply external 
knowledge. However they suggest that absorptive capacity tends to be cumulative and path 
dependent as it builds on prior knowledge base and experience which is firm specific. The 
prior knowledge base is an essential component in firm's learning ability or absorptive 
capacity as existing knowledge increases ability to make sense of, assimilate and apply 
new knowledge. Firms tend to move along particular trajectories in which past learning (by 
doing and by other mechanisms) contributes to particular directions of technical change, 
and in which the experience derived from those paths of change reinforces the existing 
stock of knowledge and expertise (Bell and Pavitt, 1993). The stock of past capabilities, 
routines provides the base on which firms develop the capabilities to cope with new 
technological change or new external environment: change is certainly possible. but it is 
conditioned by past. Patel and Pa\'itt (1994, 2000) showed that firms are in fact heavily 
constrained by their prior competencies in the extent to which they are capable of 
accumulating conlpetencies in new emerging fields. 
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The transformation of drug discovery and development in large pharmaceutical firms from 
totally in-house activity to a networked collaborative activity suggests that firms need to 
use external relationships to access relevant knowledge outside the boundaries of the firm. 
as support to efforts in internal capability development but not as substitute to internal 
investment. Technical change is generated out of complex interactions between firms. 
These interactions involve a wide range of technology collaborations arrangements 
between competing as well as complementary firms, while others involves linkages with 
public sector research activities. Thus an important part of the process of accumulating 
industrial technological capabilities involves various kinds of institutional structures within 
which firms can interact in creating and improving the technology they use. However just 
establishing the collaborative arrangements for interactions is not enough to facilitate the 
transfer of knowledge. Bell and Pavitt (1993) focusing on knowledge transfer, suggest that 
the transfer of technological knowledge cannot be wholly embodied in equipment or 
instructions, patents, designs or blueprints. Transfer necessarily requires learning because 
technologies are tacit and their underlying principles are not always understood and 
therefore successful knowledge transfer requires careful management of communication 
between involved entities. 
Absorptive capacity also refers to the organisation's ability to exploit externally acquired 
or assimilated knowledge. Therefore an organisation's absorptive capacity does not simply 
depend on the organisation's direct interface with the external environment but it also 
depends on the transfers of knowledge across and within subunits that may be quite 
removed from original point of entry. The structure of communication between the 
external environment and organisation as well as among sub units of the organisation is an 
important determinant of absorptive capacity (Cohen and Levinthal, 1990: 132). 
Own R&D 
Learning or 
Absorptive capacity 
External knowledge 
Technological knowledge 
F · 44 Model of sources of firm's technological knowledge (Source: Cohen and Levinthal, t 990) Ig .. 
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Thus an organisation's absorptive capacity or capability to learn depends on: prior 
knowledge base, that is, the sum of the abilities of all the individuals in organisation to 
recognise what they know and the way(s) in which they know; and mechanisms of 
knowledge transfer; the effectiveness with which information or knowledge is transferred 
externally between firm and external source as well as internally from one unit to another 
(Fig. 4.4). Zahra and Gorge (2002) re-conceptualised absorptive capacity as a dynamic 
capability and distinguish it in two sub sets of potential and realised absorptive capacities. 
Potential capabilities comprises of knowledge acquisition and assimilation while realised 
capabilities centres on knowledge transformation and exploitation. 
Absorptive capacity is thus a function of two separate but interrelated dimensions: a. the 
firm's ability to acquire the knowledge relevant to the new technological paradigm, and b. 
firm's ability to integrate external knowledge into existing capabilities. 
The theoretical framework broadly focuses on practices or mechanisms associated with 
these two dimensions of absorptive capacity. So its focus is on the transformation of what 
happens in 'practise' as a response to change in external environment. It covers 
accumulation mechanisms which govern the content and location of stocks of knowledge 
in the firm; the transfer mechanisms which govern the balance between, internal and 
external sources of knowledge; it includes assimilation mechanisms which governs the 
way in which firms internalises the newly accessed knowledge and is also focuses on 
application or deployment mechanisms like coordination and integration practises which 
govern the ways in which the stocks of knowledge or specialised knowledge bases are 
brought to bear within decision making. 
The review of relevant literature suggests that these mechanisms play an important role in 
creating, constructing and defining collective knowledge in organisations (Tsoukas, 2000). 
The other approaches or frameworks focusing on the firm level studies in developing 
countries mostly concentrated on the differences in tacit and explicit knowledge or 
between individual, group and organisational knowledge and conversion of different 
knowledge types knowledge to create organisational knowledge (see for instance Kim, 
1997a; Dutfenit, 2000). However varieties of innovation studies have shown limitation of 
such approach as categorisation of knowledge for innovation reflects a fair degree of 
overlap. The knowledge used in innovation does not come in watertight boxes but is 
mutable and multidimensional, precisely because of complex social processes by which it 
is generated and utilised (Faulkner, 1994). The review of organisational knowledge 
creation literature also suggests that the social processes that facilitate interactions among 
distributed knowledge systems within as well as across firms enable the creation of 
knowledge and in this research those social processes are explored. Therefore the focus of 
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theoretical framework is practices or processes involved in managing and creating 
knowledge in contrast to other approaches used for exploring firm based I . 
. earmng processes 
In developing countries. 
Therefore based on insights from discussion, the theoretical framework (Fig 4.5) focuses 
on the social processes or mechanisms used for knowledge acquisition, transfer. 
assimilation, and application. It also explores the relevance of prior knowledge base in 
terms of its usefulness in new environment and how firms have built it. The areas of 
investigation are, 
Integration of different knowledge bases 
I 
I 
Assimilation of knowledge 
I 
Acquisition of knowledge 
I 
Inter firm 
Mechanisms of knowledge Intra firm 
Knowledge 
transfer I-- Knowledge 
base 
base 
Prior knowledge base 
Fig.4.5 Theoretical Framework 
4.4.1 Prior knowledge base 
In the case of the Indian pharmaceutical industry this research explores the nature of the 
existing knowledge base, how Indian firms developed that knowledge base and its 
relevance in innovative R&D. 
In case of large pharmaceutical firms' response to technological change, organisations 
which had indulged in fundamental science under the random screening period regime or 
pre-biotechnology era were at a considerable advantage in adopting the new techniques. 
This investment in fundamental research helped these firms in creating prior knowledge 
base and establishing links with the outside sources of knowledge like academia and 
research institutes which were the originators of the new technology (Gamberdella, 1995: 
" 
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Zucker and Darby, 1997). This observation supports the Cohen and Levinthars stress on 
prior knowledge base and its role in learning. 
4.4.2 Acquisition of knowledge 
Knowledge acquisition is a learning related process by which knowledge is identified, 
accessed and obtained. The large phannaceutical finns' approaches to biotechnological 
change show that investment in internal R&D played crucial role in transfonnation of 
technological identity. It not only generated new knowledge but also created finn's ability 
to exploit external knowledge (Nichols- Nixon, 1993). Other mechanisms adapted by large 
pharmaceutical finns include learning by hiring, acquisitions of new biotechnological 
finns, training and collaborative R&D. 
So in the case of Indian phannaceutical finns this research explores how finns are 
acquiring knowledge to develop competency in innovative R&D. 
4.4.3 Mechanisms of Knowledge transfer: Inter firm and intra firm linkages 
The mechanisms of knowledge transfer here refer to the mechanisms of communication 
between the external environment and the organisation but also among subunits of the 
organisation as the organisation's absorptive capacity does not simply depend on its direct 
interface with the external environment but it also depends on transfer of knowledge across 
and within subunits. Knowledge transfer here is based on Appleyard's (1996) definition of 
knowledge transfer; 'transfer of useful know-how and infonnation across and within finn 
boundaries' . 
External linkages or alliances enable large pharmaceutical finns to develop basic 
knowledge in a number of technological areas, (Arora and Gamberdella, 1990). Cockburn 
and Henderson (1998) suggest that in the pharmaceutical industry it is important for finns 
to be actively connected to the wider scientific community. As a result of biotechnological 
change, large phannaceutical finns' transfonned the integrated in-house nature of 
pharmaceutical R&D to a networked model of collaborative R&D. 
So in case of the Indian phannaceutical finns this research explores the inter-firm 
relationships and mechanisms of knowledge transfer involved in development of 
con1petence for innovative R&D. 
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4.4.4 Mechanisms involved in knowledge assimilation 
The assimilation of knowledge involves the creation of an environment which facilitates 
the process of sharing experiences as without a shared language and a shared way of 
'" discussing, it is difficult to create uniform purpose, construct cohesive meaning, and learn 
in ways which support innovation across the organisation. Organisational routines are one 
way in which knowledge generated by individuals becomes assimilated or embedded in 
organisations. Hedberg (1981 :3) suggests that organisations have cognitive systems and 
memories; members come and go and leadership changes, but organisations' memories 
preserve certain behaviours, mental maps, norms and values over time and this represents 
the assimilation of knowledge. 
So only bringing in some knowledge (by hiring individuals or making acquisitions) is not 
enough; it must be also assimilated and made useful. Therefore in the case of learning by 
hiring; brining in key individuals is not enough but it is also important to analyse where, 
when and how the knowledge possessed by these hired individuals is socialised at the 
organisational level. 
In the case of large pharmaceutical firms' response to technological change, Henderson, 
(1994) suggests that the extent of the adoption of new techniques in incumbent firms 
involved the successful adoption of a particular, academic like, form of research 
organisation. This led to building an environment which encouraged sharing or transferring 
of knowledge within firm. 
Therefore in the case of Indian pharmaceutical firms, this research explores how firms built 
an environment in which individuals create and share knowledge and facilitate 
development organisational competency in innovative R&D. 
4.4.5 Mechanisms involved in knowledge application - Integration of different 
knowledge bases 
According to Cohen and Levinthal (1990: 134) complimentary functions within the 
organisations ought to be tightly intermeshed to create cross functional absorpti\'e 
capacities and superior innovative performance. Some of the integrative mechanisms 
mentioned in the innovation management literature includes teamwork based on cross 
functional and cross disciplinary teams (lansiti and Clark, 1994; Henderson and Cockburn. 
1994), overlapping problem solving, redundancy of knowledge or shared knowledge and 
expertise, strategic rotation of personnel (Nonaka and Takeuichi. 1995). boundary 
spanning or integrators: individuals who stand at the interface between different 
specialised units, knowledge bases or internal and external knowledge (Allen, 1977 ); 
project focuserd organisational structure and processes (Henderson. 1994): small teams 
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with broad task assignments and a 'heavy-weight' product manager (Clark and 
Fujimoto,1990). In case of pharmaceuticals Henderson (1994) suggest that successful 
pharmaceutical firms maintained high level of information flow across the boundaries of 
scientific disciplines and therapeutic areas within firm by organising research by 
therapeutic area or by using cross disciplinary teams, by making world wide research 
through single organisation and by allocating resources through committee rather than 
using single individuals to make key decisions. 
In the case of the Indian pharmaceutical industry, this research explores how firms are 
integrating different disciplinary knowledge to develop competence in innovative R&D. 
4.5 Conclusion 
This chapter presented the theoretical framework used for exploring the firm level process 
involved in redevelopment of knowledge creation capability for innovation in Indian 
pharmaceutical firms as a response to change in external environment. The concepts from 
organisational knowledge, learning and innovation management literature provide an 
outline for the theoretical framework. Large pharmaceutical firms ~ response to 
technological change directs the focus of the theoretical framework, which is the 
'organisational processes or activities involved in creation or construction of knowledge~ 
for innovation. 
" 
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Chapter 5 
RESEARCH METHODOLOGY 
5.1 Introduction 
This chapter presents the research methodology adopted in this research. It discusses the 
various methodological issues concerned with research design like different stages 
associated with research process, rationale behind the selected research strategy, sources of 
managerial and technical data and techniques employed for analysing the data. 
This research explores the effect of change in patent law on strategic orientation and 
learning processes in the Indian pharmaceutical industry. However, the main focus of this 
research is studying the processes involved in the transformation of existing capabilities 
and development of new technological competencies for innovation as a response to 
strengthening of patent law in Indian pharmaceutical firms. Thus this research covers these 
two issues and as a result designing a piece of research within this challenging field 
became very problematic. 
Chapter two discussed various issues concerned with IPR laws and provides background to 
the whole study. It basically focused on the genesis of the research which is 'implications 
of strengthening of patent laws for pharmaceutical firms in developing countries'. This 
chapter shows the various approaches and issues employed by different researchers to 
study the impact of change in patent law. This discussion clearly indicates the complexity 
involved in researching impact of changes in patent law on pharmaceutical firms and their 
strategic responses to such change. Therefore progressive or phased based research 
methodology was adopted, with each piece building on the findings of the earlier phase. 
The first phase of this research focused on understanding the implications of change in 
patent law for the Indian pharmaceutical industry and strategic responses of Indian firms to 
this change while the second phase investigated learning processes adopted by these firms 
to develop strategic knowledge creation capability for innovation. 
The first phase helped in improving knowledge about the real impact of change in patent 
law on the Indian pharmaceutical industry, different strategic approaches adopted hy 
Indian firms and rationale of Indian pharmaceutical firms for selecting innovative R&D as 
one of the important source of survival and growth in strong patent era. 
The findings from the first phase suggested some of the firms in the Indian pharmaceutical 
industry are responding to changes in patent law by developing competencies for 
" 
innovative R&D. The innovaf R&D' h '" Ive In t e pharmaceutIcal mdustry IS represented by 
new chemical entity or new dru d l' . .. . g e Ivery research and whIch IS qUIte complex In nature. 
making the whole process hi hI . k d I .. . g y ns y an cost y. Considenng the resources avaIlable to 
Indian pharmaceutical firms, the movement of Indian firms towards development of 
competencies in innovative R&D raises some important questions. 
It may be useful at this point to reiterate the main research objectives which were presented 
in chapter one and two as research questions: 
• 
• 
How are Indian pharmaceutical firms building strategic knowledge creation 
capability for innovation as a response to change in regulations? 
How relevant is knowledge accumulated through imitation for firms in their 
efforts to create innovative novel products? 
Chapter three reviewed the literature focused on capability development and showed the 
inadequate treatment given to "transformation or renewal of capabilities in firms from 
developing countries" in the developing countries literature as well as in strategic 
management literature. The transformation of capabilities by Indian pharmaceutical firms 
provided the ideal opportunity to study "dynamic learning processes involved III 
development of new competencies for innovation in firms from developing countries". 
A qualitative multi method approach was chosen as the best way to arrive at an 
encompassing process view of transformation of capabilities and development of new 
competencies. The theoretical framework developed in chapter four helped in clarifying 
the area under investigation. It also guided the development of priori constructs and 
directed the collection of data. 
The next section explains in detail the 'progressive or phase-based methodology and issues 
concerned with its implementation. 
5.2 Research process, design and methodology strategy 
Generally the genesis of research in disciplines like social sciences lies in 'new event" or 
'dilemma' which can not fully be explained or comprehended by present or existing 
knowledge. In management science~ it gives rise to the management question, which is 
then framed as a research question. The Research Process model (Fig.S.l) shows different 
steps in the research process that need careful consideration from the point, when (new) 
events or dilemmas' are identified and converted into "problems", when research questions 
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Fig. 5.1 Research Process (Source: Author's modification of original model from BID (2002» 
are posed and when research strategies are chosen. The re carch process can be broadly 
classified in three stages: 
a. research planning stage, 
b. data gathering stage 
c. analysis and interpretation stage. 
The re earch planning stage involve identifying the management que~ tion from One\"~ 
event' or 'dilemma', framing it into re earchable que tlon and preparati n of re. carch 
design. The re earch que tion can be an analytical aid prq arcd to handle c mplc an 
comprehensive problems, arise due to the emergence of new events or dilemma. The data 
gathering stage basically involve the exploration of various sources of information' in the 
, 
earlier part of research it involves a review of existing literature while in later stages it 
involves using a research in t t t 11 .. s rumen 0 co ect necessary InformatIOn from selected 
sample. The analysis, interpretation and resulting stages cover preparation of instrument 
design, selecting the sample, analysing and interpreting the data and finding out the answer 
to the management question. 
The Research Process Model (fig 5.1) can be viewed as an ideal picture of the research 
process but the different steps in real life situations can take a different sequence and 
therefore can occur simultaneously or in some cases change the sequence of the model 
showed here. 
In the field of management research, the selection of research design raises an inevitable 
dilemma for researchers to choose between an interpretive approach covering different 
methodologies like ethnography, phenomenology and case studies or a positivist approach 
associated with inferential statistics, hypothesis testing, mathematical analysis using 
experimental and quasi experimental design. Spender (1996b: 72) suggests that the two 
methods have different objectives and to overlook the incommensurability of these 
approaches is to overlook the irrevocable uncertainties of the human condition and thereby 
everything that makes our knowing, learning and memorising processes interesting, 
"The objective of positivist research is the development of a coherent abstract 
representation of the world out there, the presumed independent and seamless but 
knowledge reality in which we are embedded. The focus of interpretive research is on the 
ways in which attach meaning to our experience" (Spender, 1996b:72). 
Therefore while a positivist approaches treats actors as objects whose behaviour can be 
observed by outsiders searching for general laws, interpretive methods focus on the 
subjective meaning attached to these behaviours. Lee (1991) argues a different viewpoint 
and presents a framework integrating the two approaches, demonstrating 'a particular 
common ground between the two of them' , and 'how these two approaches to organisation 
research can be mutually supportive, rather mutually exclusive'. 
However as Spender (l996b:71) suggests the development of knowledge can not be 
understood in terms of explicit or scientific method of analysis and hypothesis testing 
alone. The attachment of meaning, and the explication and codification of what is learned 
through practise and experience or learning by doing, must also be considered. Thus the 
strength of the qualitative approach is the ability to study participants as people and 
opening a window into the respondent's point of view. Such an approach is more likely to 
provide a better understanding of everyday experiences of managers and scientists within 
X:' 
large organisations. Therefore in recent years it is clearly evident that In studies of 
competencies or knowledge development the interpretive approach has been gaining 
attention as an alternative to the more traditional positivist approach (Hoskisson et al., 
1999). 
5.2.1. Research Design 
There are clearly strengths and weaknesses with both approaches and the decision 
regarding research strategy must depend on the particular requirement of the research. The 
conditions under which research has to be conducted and the type of research question 
raised will furthermore influence the research strategy. The relationship between research 
strategies and the different parameters is drawn up in Table 5.1 
The design of research methodology in this research is influenced by a number of criteria 
including some discussed above. According to Yin (1994), three conditions which direct 
the strategy of the research are, 
a. type of research question posed, 
b. the extent of control an investigator has over actual behavioural events and 
c. the degree of focus on contemporary as opposed to historical events. 
Table 5.1 Relevant situations for different research strategies (Source: Yin, 1994) 
Strategy Form of research Requires control over Focuses on 
question behavioural events contemporary events 
Experimental How, why Yes Yes 
Survey Who, what, where, how No Yes 
much, how many 
Archival analysis Who, what, where, how No Yes/no 
many, how much 
History How, why No No 
Case study How,why No Yes 
Yin (1994) suggests that case studies are an ideal research strategy when a "how" or "why 
. . b . ked about a contemporary set of events over which the investigator has questIon IS elng as 
little or no control. So case studies are empirical inquiries investigating contemporary 
phenomenon or set-off events where the boundaries between phenomenon and context are 
not clearly evident. This makes case study research an excellent research strategy when 
one wants to cover contextual conditions or when the problems inyestigated are emhodied 
" 
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in the surrounding society, implying that the interaction between phenomenon and its 
context is best understood through case study method. 
The questions explored in this research are influenced by contemporary sets of events 
embedded into various contextual elements lying inside as well as outside of firms and 
interplay between those elements. This research is focused on the processes adopted by 
Indian pharmaceutical firms to develop competencies in innovative R&D as a response to 
change in patent law. The Indian specific contextual elements (like existing patent 
regulation, resources available to Indian pharmaceutical firms, institutional environment 
and capabilities of research institutions) need to be considered in exploring the competence 
development in Indian pharmaceutical firms. In this 'context' a research strategy must be 
selected which will allow all contextual conditions to enter into analysis and which 
indicates that the case study research methodology is an ideal research strategy for this 
research. Therefore based on the nature of the research questions, a case study 
methodology is used to find answers for questions raised in this research. 
The multiple case study research design was adopted instead of a single case study and the 
cases were chosen on the basis of degree of innovativeness and their size of operation. Yin 
(1994:45) suggests that multiple case study designs have distinct advantages and 
disadvantages in comparison to single case study designs. The ideal setting for single case 
studies is studying the unusual or rare case or researching a critical or revelatory case. 
Research into all these situations is likely to involve only single case studies as that will 
allow the researcher to analyse phenomenon in depth. Moreover, the conduct of multiple 
case studies requires extensive resources and time putting a lot of stress on a single 
researcher. However, the evidence from multiple cases often is more compelling and over 
all study becomes more robust. Yin (1994) further suggests that in multiple case research 
design each case should serve a specific purpose within the overall scope of inquiry and 
multiple cases should be considered as multiple experiments - that is, to follow replication 
logic and not as sampling logic. In this research six Indian innovative firms are selected as 
cases following the replication logic. 
The fact that a certain method is considered appropriate is not enough to qualify it as 
scientific research. Different researchers have pointed out weaknesses in case study 
research methodology like biased reporting of evidence or just descriptions of events. 
Weick (1979:38) delivers similar criticism and argues that in case study research. "many 
pseudo observers seem bent on describing everything, and as a result describe nothing". 
His suggestion for solving this problem is to ·"invest in theory to keep some control over 
burgeoning set of case descriptions". Therefore in this research theoretical framework 
provides the boundary to the contextual elements and helps in covering weaknesses of case 
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study research. Yin (1994) suggests that systematic use of a theoretical framework early in 
the research process will not only help selecting and designing the chosen research strategy 
but it is also crucial later in generalising results of the study. The theoretical framework in 
this research directs the selection of cases, development of priori constructs and search for 
empirical data. 
5.2.2 Methodology strategy 
In the beginning, the research did not follow a rigid design as at that stage, the focus was 
on acquiring an understanding or a "feel" for the subject and this inevitably put in place 
some restrictions, like fonnation of rigid hypothesis. However after the first phase of data 
collection and with increasing understanding of the area, the research design was firmed up 
for the second phase of case study research. 
In the first phase the focus of the research was to explore the effect of the change in patent 
law on the Indian phannaceutical industry. Therefore it focused on understanding specific 
changes in patent law, its implication for strategic orientation of the Indian pharmaceutical 
industry and the responses of Indian industry to these changes. In this phase an effort is 
also made to understand the institutional environment like regulatory bodies, capabilities of 
research institutes and evolution of the capabilities in the Indian pharmaceutical industry. 
Table.S.2 Patent and licensing data on innovative firms (Source: Annual reports, 2003) 
No. of patents filed for Licensed to MNC 
New chemical entities New drug delivery pha rmaceutical 
Firms systems firms 
DRL 8 3 
Ranbaxy 6 4 1 
Wockhardt 3 
Torrent 4 1 
Lupin 2 1 
Glenmark 2 
Orchid 2 I 
I 
Kopran 3 
NPIL 1 
Sun 3 
h d h the focus of the research was the firm leyel learning processes In t e secon p ase 
involved in the development of new competencies in innoYatiyc R&D. which implies that 
finlls sele.~ted for the study should be innovatiye in R&D. In the case of Indian 
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pharmaceutical industry, only a handful of firms have started moving towards developing 
capabilities in innovative R&D (Table 5.2). This puts a restriction on the number and 
nature of firms chosen for the study. 
In this study patents are used as indicators of firms' capabilities in innovative R&D and 
firms were selected on the basis of patent data. Patents have been associated with 
innovation and performance at many levels: region, country and company and have been 
used as indicators of inventing activity in several empirical studies (Hall et aI., 2000; 
DeCarolis and Deeds, 1999; Ashton and Sen, 1988; Pakes, 1985). Further patents are 
widely accepted measures by policy makers and analysts (Vander Eerden and Saelens, 
1991) in terms of technology strategy and competitive analysis. 
Over the last decade many researchers have used patent and publication data to track the 
knowledge flows into the firms as well as a measure of stock of organisational knowledge 
(Jaffe et aI., 1993; Almeida, 1996; Song et aI., 2003; DeCarolis and Deeds, 1999). Patent 
data have received so much attention because they are systematically compiled, have 
detailed information, and are available continuously across time. A patent document 
contains a host of information like name of scientists, description of the invention, and 
citation to other patents and which facilitates the exploration of knowledge flows and 
stocks. 
However there is some concern with using patent count as a measure of the stock of a 
firm's knowledge or use of patent citations as indicators of domestic or international 
knowledge transfer. First, a patent mainly represents the explicit component of the 
knowledge rather than tacit knowledge and therefore fails to illustrate or explain the 
processes underlying the transfer of knowledge or knowledge flows. Hence patent citations 
data can only indicate the beginning and end points of knowledge transfer. 
Second, firms tend to differ in their policies towards patents. Patent literature shows that 
various strategic uses of patents are made by firms operating in knowledge intensive 
sectors like information technology and pharmaceuticals (Somaya, 2003). Much of 
knowledge building within the firm does not result in patenting, at the same time, not all 
patenting within firms represents knowledge building or knowledge flows. In the case of 
patenting an invention, some citations may be introduced to distinguish the invention from 
dissimilar ones or protect it from litigation. This implies that patents are satisfactory 
indicators of knowledge creation in terms of being documented kno\vledge but only a 
partial measure in case of analysing flows or stocks of organisational knowledge. \"hile 
the preceding discussion suggests that there are problems inherent in the use of patents as 
" 
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output measures of innovative capabilities, it also suggests that they are widely accepted 
objective measures of innovation. 
In the case of the Indian pharmaceutical industry patent data have more limitations as 
publication and patents were not the priority area till 1995 due to the lack of trust in the 
case of the fonner and the lack of value in the case of the later. However it is still a 
creditable source of finn's innovative capabilities as well as its commitment towards 
innovative R&D. The estimated minimum costs of an issued patent is $12,000, which may 
be a fairly insignificant sum to an established phannaceutical finn like Pfizer but to the 
resources limited finns in the Indian phannaceutical industry, this expenditure would be a 
significant investment. For these reasons patent counts adequately capture the capabilities 
in innovative R&D and therefore patent data is used as an indicator of Indian 
phannaceutical finns' capabilities in innovative R&D. 
In the Indian phannaceutical industry, there are a number of finns (10 to 12) who have 
invested in innovative R&D and have products in clinical phases (Table 5.2). However for 
exploring the development of competencies in innovative R&D, only those finns were 
selected for this study, who have filed patents in USA and India for new drug delivery 
systems or new chemical entities (Table 5.3). Some of the finns selected as case studies 
have also licensed their molecules to the multinational pharmaceutical finns proving 
superior capability in innovative R&D. 
Table 5.3 Firms selected for the study 
No. Name of firm Number of Patents filed for Licensed to MNC firm 
NCE NDDS 
1 Ranbaxy 6 4 1 
Laboratories ltd 
2 Dr. Reddy's 8 3 
Laboratories ltd 
~ 
I 3 Wockhardt 3 i 
pharmaceuticals ltd 
-
4 Lupin 2 1 
Pharmaceuticals ltd 
- ----
~~ 
- - -~--------< 
5 Nicholas - Piramal 1 
, 
ltd 
I 
--~~ ~ -~ --- -
---- -------
6 Glenmark 2 
I 
I 
pharmaceuticals ltd I 
-
------
___ ----.J 
---"- --
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Apart from analysing patents as innovative input as well as output measure, the innovation 
literature has also employed two other quantitative measures for studying the innovati,-e 
capabilities. The other measures of innovative input include a. R&D expenditures and b. 
number of scientific personnel. Cohen and Levinthal, (1990) developed the concept of 
absorptive capacity and operationalised it in terms of an input measure, R&D intensity. 
However the application of these measures in this research is limited as they fail to capture 
the productivity of the inputs. The technological learning process is highly idiosyncratic, as 
technologies differ greatly in their learning requirements. The technologies have different 
degrees of dependence on internal knowledge generation and interaction with outside 
sources of knowledge or information such as other firms, consultants, capital goods 
suppliers or technology institutions. This affects the application of quantitative measures in 
analysing technological learning, specially selecting the right measures that will capture 
the actual learning processes or mechanisms. However at the present time, the innovative 
input quantitative measures identified by the innovation literature offer the best 
opportunity for reflecting on abilities of firms' to evaluate, assimilate and apply outside 
knowledge to commercial ends, i.e. absorptive capacity or capability to learn. Therefore in 
this research measures like R&D investment, number of scientific personnel are used as 
supportive tools to the main qualitative evidence. 
In the case study research selection of cases and the definition of specific measures are 
important steps in design and data collection process. The next section discusses the 
various sources of data used for collecting information used in this research. 
5.3 Sources of the data 
The finding or conclusion in a case study is likely to be much more convincing and 
accurate if it is based on several different sources of information following corroborative 
mode. In this study, the data upon which the empirical results rest was drawn from various 
public and private sources. According to Yin (1994) the use of multiple data sources 
allows the investigator to address a broader range of historical, attitudinal, and behavioural 
issues and aids in achieving the triangulation of evidence in the research. Triangulation 
made possible by multiple data collection methods, helps in combining various sources of 
evidence and development of converging lines of enquiry. It provides stronger 
substantiation of constructs/ hypotheses and develops a robust validation to research 
findings (Eisenhardt, 1989). Therefore in this research, the main source of information, 
interviews is con1bined with other sources of information like observation. archival 
records, and reports in trade journals. For example. the two trade journals name!\'. 
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'Pharmabiz' and 'Expresspharmapulse' cover issues concerning the Indian pharmaceutical 
industry extensively and report regularly on the activities of various Indian pharmaceutical 
firms. These sources of information provided very important insights into debates 
surrounding various issues related to strengthening of patent law. In the case of the firms, 
several types of sources of data were used to collect documentary information on each 
firm. For instance, firm specific information was collected from annual reports, analyst 
presentations, conference proceedings, internal firm magazine, and if present, studies of 
firms by other researchers. These documents served to corroborate and enrich the evidence 
obtained from the main source of data collection. 
The primary source of data collection used in this research is interview as it has a number 
of strengths as a method of data collection. Probably the most important strength is that it 
allows both parties to explore the meaning of the questions and answers involved. Thus 
any misunderstanding on the part of the interviewer or interviewee can be checked 
immediately. However interview technique also demands a variety of skills on the part of 
the researcher, often defined under the umbrella of "interpersonal skills". A considerable 
amount of time is also required to design the interview schedule and it is often extremely 
difficult to conduct interviews with key decision makers such as middle or senior managers 
because of their busy schedules. 
5.3.1 The first phase 
In the first phase of the field study, the primary information was collected by carrying out 
interviews with scientists working in research institutes, pharmaceutical consultants, patent 
experts and the president of the Indian pharmaceutical industry association. The second 
phase involved interviews with senior managers associated with selected firms (Appendix 
III). 
In the first phase informal email communications with the individuals associated with the 
Indian pharmaceutical industry emerged as one of the most important sources of 
information (Appendix III). This informal communication included interactions with 
clinical trial researchers, academics, consultants, patent attorneys, journalists and scientists 
working in Indian pharmaceutical firms and it provided interesting insights into the 
"general current opinion" in the industry. This proved to be a very important source of 
precise information, although subjective in nature and generated very helpful insights into 
challenges of change in patent law. regulatory set up established to implement patent laws 
and emerging strategies of firms as a response to these changes. 
Building on these informal communications, a survey questionnaire was prepared to make 
these elactronic interactions more constructiYe and useful in research. Due to the 
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difficulties involved in sending questionnaires to India and in getting them back it was 
decided to send the qu t' . I . I . . es lOnnane e ectromca ly. The survey questlOnnmre was put on a 
website (http://elsa.open.ac.ukJadmin.asp?areaid=oubs_rs) and the link was sent 
electronically to the participants. However sending the survey electronically to various 
scientists raised the problem of getting access to email IDs. The 'Indian Pharmaceutical 
Journal' proved the important source of the email IDs as the published papers have 
author's email ID. It mainly publishes papers from Indian scientists working in the 
pharmaceutical industry and various Indian research institutes. Therefore this proved an 
important and authentic source of information about scientists associated with the Indian 
pharmaceutical industry. The other source used for collecting the email IDs was 
pharmaceutical mailing lists and personal contacts. In the end the survey was sent 
electronically to 300 scientists working in Indian pharmaceutical firms, premier research 
institutes and universities focused on pharmaceutical R&D. It was also sent to the Indian 
scientists working in MNC pharmaceutical R&D based in US. 
In the first phase, focus of the data collection was on the industry level while in second 
phase the focus of the collection of information was on the internal organisational practises 
or firm level processes involved in development of competencies in innovative R&D. In 
the second phase the multiple case study methodology is used and that influenced the 
sources and nature of data collected. 
5.3.2 The second phase 
The data collection in the second phase mainly involved interviews with R&D presidents, 
senior pharmaceutical scientists working in the six innovative Indian pharmaceutical firms. 
Out of six companies selected for the study three have manufacturing units along with 
sales and marketing operations in Europe. In all three firms, the senior manager, in-charge 
of Europe region is based in UK. The interviews with these managers were conducted 
before the field visits in India. These interviews gave glimpses into firm's future growth 
strategies in the generic market and aided in establishing preliminary contacts within firms. 
During the field visits in India, effort was made to interview at least two individuals from 
every firm selected for study. The first phase of field study helped in choosing the initial 
select group of individuals to interview in the second phase. As far as possible. in each 
finn the interview was conducted with senior R&D scientists or R&D vice president or 
director of innovative R&D project. Apart from the select group of individuals, the choice 
of other individuals evolved organically. Researcher began with few selected individuals 
and then extended list as everyone researcher spoke with recommended others who 
researcher should nleet. Arranging the intervie\\"s in the second phase with selected 
individuals proved ve h 11 . ry c a engIng as the whole exercise of initiating the contacts and 
coordinat' . t . lng In ervIew appointments was managed from the UK. 
The majority of the it' n ervIews were conducted by using a semi structured interview 
question bank and lasted btl h . . a ou our. In the beginrung of the interview, researcher briefly 
spoke about the focus f h d . .. o researc an then asked the IndIVIdual to talk about his or her 
perceptions of the ef£ t fl' ec s 0 patent aw changes on the IndIan pharmaceutical industry. 
Each interview was reco d d d 'b d . r e an transcn e for analysIs; however in some cases 
individuals did not allow th d' f h" . e recor lng 0 t e IntervIew. So In such cases researcher took 
notes and then typed up a formal interview report. 
In total 33 interviews were conducted, out of that 10 were conducted in the first phase and 
the other 23 in the second phase. 
5.4 Interview and survey questionnaire 
The process of framing interview questions and the survey questionnaire proved quite 
challenging as the nature, content and focus of the interview questions differed in both the 
phases. 
The questionnaire used in the first phase basically focused on the implications of change in 
patent laws for the Indian pharmaceutical industry and strategic responses of Indian 
phannaceutical finns to this change. It also covered the macro economic issues such as 
effect of change in patent law on industry structure, market structure and emerging 
challenges. 
In the second phase of the field study the focus of the data collection was firm level 
learning processes involved in development of competencies in innovative R&D. In this 
phase, the theoretical framework directs the areas of investigation and guides preparation 
of the priori specification of constructs. Due to the inherent difficulties in studying 
'processes', a question bank was prepared using concepts from the theoretical framework 
(Appendix IV). The interviews generally focused on different organisational learning 
processes or activities involved in acquisition, assimilation, transfer and integration of 
knowledge. Interviews also covered the questions regarding how the firms have built the 
prior knowledge and its relevance in innovative R&D. It referred to the nature of the firm's 
existing base of technical and organisational knowledge, processes involved in creation of 
the existing knowledge base and relevance of the existing knowledge base to innovative 
R&D. The interview questionnaires from other researchers like Madanmohan and 
Krishnan (2003) and Dutrenit (2000) who have explored similar issues of adaptation and 
change associated with capability development also proved helpful in structuring the 
nature af interview questions. In the interview individuals were asked about learning 
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mechanisms and organisational arrangements promoted and established to develop 
~apabilities in innovative R&D. It referred to the different organisational practises involved 
In management of innovative pharmaceutical R&D identified by Henderson and Cockburn 
(1994) as measures of competencies. These measures include organisational processes 
involved in the organisation and management of R&D like project management structure, 
review of research, resource allocation, incentives system, nature of research teams and 
assignment of personnel to research teams. Other areas of focus in interviews were the use 
of collaborations with universities, research institutes by firms, nature of those 
collaborations and mechanisms of the interaction. This list of learning mechanisms and 
organisational arrangements was added to question bank and from which a set of questions 
formed the semi structured questionnaire used in each interview. 
Although the theoretical framework guided the data collection and provided the contextual 
boundaries, the care has be taken to include and explore any critical issues which are 
outside the boundaries of theoretical framework but have implications for answers to 
research questions 
Survey questionnaire used in the first phase of the research was based on the other 
questionnaires used by different researchers like Birkinshaw (2001), Ingelgard et 
a1.,(2002), Thombke and Kuemmerle (2002), Visalakshi and Sandhya, (2000) to study 
various issues related to R&D in the pharmaceutical industry. Major parts of the survey 
questionnaire also evolved in the informal communication with experts and scientists 
working in the Indian pharmaceutical industry. Survey questionnaire focused on exploring 
opinions of the individuals regarding effect of change in patent law on reverse engineering 
R&D, major constraints in moving towards innovative R&D, relevance of knowledge 
accumulated in reverse engineering R&D to innovative R&D, capabilities of Indian 
research institutes and universities and strategic responses of Indian pharmaceutical firms 
to changes in patent law (Appendix V). Using an approach similar to Birkinshaw (2001), it 
explored the opinion of individuals regarding difficulties associated with learning in 
pharmaceutical R&D. The survey helped in understanding the complexities involved in 
developing innovative R&D capabilities in the pharmaceutical industry. Based on the 
Thombke and Kuemmerle (2002) questionnaire, it asked the degree and direction of 
change in value / importance of the various pharmaceutical R&D issues for the Indian 
pharmaceutical industry from 1995-2003. This provided insights into transformation or 
changes into R&D strategies in the Indian pharmaceutical industry. Finally questionnaires 
explored technical competencies in terms of in-house capability of Indian phamlaceutical 
fim1s to perform various scientific processes in innovative R&D like basic genome 
researCH, identification of target molecule and clinical research. The last section of the 
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questionnaire asked particl'pants 'd 
to 1 entify innovative firms III Indian phannaceutical 
industry. 
A five point Lik rt I' 
e sca e IS used in the survey questionnaire and collected data was 
analysed by using non Pt' . . . 
arame nc tests. It IS summansed by usmg a mode and bar charts 
were used for displaying the distribution of observations. 
5.5 Analysing the data 
The interviews along with other sources of information contributed to this story of learning 
processes involved in developing competencies for innovative R&D in Indian 
pharmaceutical firms. In this research the qualitative analysis software, Atlas. Ti is used as 
a tool for data organization and standardisation to facilitate its analysis. Data was 
standardised and transformed into workable units by using techniques like common codes 
and preparing displays of commonly coded data segments which Miles and Huberman 
(1984) refer to as key data reductive techniques for transforming data into workable units. 
In management research, analysis of data forms the pivotal bridge from the information to 
the final insights of the research and so, represents the 'heart' of building theory from case 
studies (Eisnehardt, 1989). Therefore in this research a systematic approach to data capture 
and analysis was taken to ensure a clear 'audit trail' between the data and the conclusions 
that were distilled. 
Eisenhardt (1989) suggests 'within case analysis' as the key step in multiple case study 
data analysis, as the individual case analysis helps in identifying patterns of idiosyncratic 
interaction of factors specific to respective firm before looking for patterns across cases. 
Cross case analysis helps investigators to go beyond initial impressions and improves the 
likelihood of accurate and reliable theory, that is, a theory with close fit with data. 
Therefore in this research, each firm was examined as an entity in its own right before case 
cross analysis was undertaken. The 'within' as well as 'cross case' analysis of the 
empirical evidence was carried out by using various analytical techniques like pattern 
matching (Yin, 1994) and by building of analytical tables (Miles and Huberman, 1984). 
Yin (1994) suggests that for case study analysis, one of the most desirable strategies is to 
use pattern matching logic. In this research, strategy of pattern coding is used to identify 
the processes involved in transformation of capabilities within and across the firms. In 
analysis first level coding is used as a deyice for summarising segments of data while 
pattern coding is carried out by grouping those codes into a smaller number of overarching 
themes or constructs. The transcripts were analysed by coding the different internal 
organisational processes around the transformation issues within each firm. lbe theoretical 
framework provided broad categories for classification of the data and various pattern 
codes are classified under those broad categories. Then the replicating patterns of internal 
organisation process representing the learning mechanisms and organisational 
arrangements adapted by firms' to facilitate the development of competencies in 
innovative R&D were identified. Miles and Huberman (1984: 67) suggest pattern codes are 
explanatory codes, ones that identify an emergent theme, pattern or explanation that the 
site suggests to the analyst. They act to pull a lot of material together into more meaningful 
and parsimonious units of analysis. The replicating patterns were supplemented by 
secondary data which was collected from industry journals, industry association 
publications and annual reports of firms. The observed patterns in Indian pharmaceutical 
firms were then compared with the theoretical patterns identified from the framework to 
find the similarities and differences between them. Yin (1994) suggests that if the patterns 
coincide with empirical patterns, the results can help a case study strengthen its internal 
validity. Although he also argues that at this point in the state of the art, the actual pattern 
matching procedure involves no precise comparisons and this lack of precision allows for 
some interpretive discretion on the part of the investigator. 
Table 5.4 Cross case analysis 
Learning process and Criterion RAN DRL NPIL WOCK LUP GLE 
mechanisms 
Acquisition of knowledge Present 
Assimilation of knowledge Or absent 
Mechanisms of knowledge 
transfer Nature of 
Integration of knowledge presence: 
Strong or 
Moderate 
or Weak 
1 · h firm the cross case analysis of learning mechanisms and After ana ySlng eac , 
organisational arrangements is carried out to explore the inter-firm differences in processes 
involved in development of competencies in innovative R&D. According to Esinehardt 
(1989) one of the tactics is to select categories or dimensions. and then look ~or with~n 
group similarities coupled with inter-group difference. In this research an extenSIOn of thIS 
tactic is used by preparing analytical tables (Miles and Huberman, 1984) of all codes at 
d I 'f' h firm on those criteria (Table 5.4). So in this research different once an c aSSl ylng eac 
. d' c: ur categories like mechanisms of knowledge acquisition. codes were orgamse In 10 
1 d t c: r knowledge integration and knowledge assimilation. The firms were knowe ge ranSle, 
'fi d' terms of presence/absence of particular learning mechanism I process and classl te In 
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intensity of support for these learning processes. Therefore firms were classified, first on 
the basis of whether that mechanism is present or absent in that firm and then each firm 
was classified on the basis of intensity of support using criteria of strong, weak and 
moderate. This was identified through perceptions, comments, and assessments expressed 
by different interviewees, by doing a systematic search about firms' records in information 
collected from secondary sources, top management support to learning process identified 
from annual reports, and how the learning process operated (e.g. incentive systems for 
scientist, nature of research collaborations). Thus inter-firm differences in learning 
processes and its impact on capability development are examined. 
A case study report with key findings was sent to a key informant in each firm for a 
review. This key informant provided additional details and corrected inaccuracies. 
5.6 Writing the case study 
The case study is written by following a linear analytic structure. The evidence is presented 
in two ways focusing at industry and firm level: 
1. Chapter 6 and Chapter 7 present the case of the Indian pharmaceutical industry. Chapter 
6 describes the institutional environment and impact of change in patent law on the 
strategic orientation of the Indian pharmaceutical industry. It discusses the learning 
processes associated with evolution of capabilities in the Indian pharmaceutical industry by 
presenting the capability creation model. 
2. Chapter 7 discusses a historical evolution in sample firms' technological capabilities and 
presents learning processes involved in development of innovative R&D capabilities as a 
response to strengthening of patent law in each firm. The narrative is supported by 
including the description of innovative input measures like R&D investment, number of 
personnel working in R&D. 
3. Chapter 8 analyses, interprets and discusses the learning processes associated with 
development of innovative R&D capabilities within each firm by linking it with various 
mechanisms identified in the theoretical framework. This chapter also presents inter firm 
differences and difficulties involved in development of innovative R&D capabilities. 
5.7 Summary 
This chapter discussed the methodology adopted in this research. It explained the rationale 
h . pl1ase based or progressive methodology and using case studies as the main for c oosIng a . 
" 
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research methodology. It explained in detail use of different sources of infonnat 
different techniques used to collect necessary data. This chapter concluded 
discussion on the method employed for the data analysis. 
The next chapter describes the important characteristics of various learning mechanisms 
prevalent in the Indian pharmaceutical industry. Then it discusses the results of the first 
phase of data collection, covering the impact of TRIPS agreement and subsequent 
transformation strategies in the Indian pharmaceutical industry. 
" 
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Chapter 6 
THE INDIAN PHARMACEUTICAL INDUSTRY 
This chapter describes the broad characteristics of the Indian governmenf s industrial and 
technology policies and reviews its role in shaping the Indian pharmaceutical industry. It 
also presents the impact of the TRIPS agreement on R&D capability development process 
in Indian pharmaceutical firms and discusses its implications for the existing industrial and 
market structure. Finally by using the 'capability creation model' this chapter discusses the 
learning processes and stages involved in accumulation of technological capability in the 
Indian pharmaceutical industry. 
6.1 Introduction 
National technological capability is a complex mix of skills, experience and effort that 
enables a country's enterprises to efficiently buy, use, adapt, improve and create 
technologies (Lall, 2000). According to Forbes and Wield, (2002) much of the difference 
between countries that developed rapidly and those that have developed more slowly is a 
difference in indigenous technology capability and how that technology capability is 
developed and used. While the firm remains the fundamental unit of technological activity, 
the non market system of inter firm linkages, ways of doing business, and the web of 
supporting institutions affect significantly how firms interact with each other and the 
efficacy with which they exchange the information needed to coordinate collective 
learning and indigenous technology capability development. The main incentives that 
affect the investments in technological capabilities arise from micro economic 
environmental issues like trade policy, domestic industrial policies and domestic demand 
along with factor markets like availability of skills, finance and the nature of the supportive 
institutional base (Lall, 2000). In this context, India presents an interesting example of a 
country with an immense economic potential, cultural diversity and income inequality 
among its population. Over the years the Indian economic policy framework has moved 
from a centrally planned economy to a market dominated export oriented economy and in 
the process, impacting on industrial growth, human resource skills building and institution 
development. It now ranks among the ten largest industrial economies and amongst the 
five largest agricultural economies. 
In the post independent era, Indian economic and industrial policy was dominated hy an 
import substitution ideology where state interventions and regulations played a key role in 
" 
too 
directing firm and national level indigenous technology capability development. It was 
considered essential that the public sectors occupied the economy's 'commanding heights' 
and the state focused on building the 'temples of sciences' in the form of universities and 
higher education institutes. However, in 1990 the balance of payments crisis triggered 
major changes in the Indian government's industrial and economic policy orientation. 
From a relatively inward looking set of policies that was in place till the end of 1980s, the 
policy regime adopted in 1991, sought to break down the walls of protection within which 
the Indian industry had developed in the past (Bhagwati,1993). The existing 
pharmaceutical industry in India is in many ways a product of micro economic 
environment shaped by state regulations and interventions. The Indian pharmaceutical 
industry has come a long way from importing bulk drugs to exporting formulations to 
highly regulated markets in the developed world. This movement of the Indian industry 
involved different learning processes and stages and which are discussed by constructing 
the 'capability creation model (Fig.6.2). This model maps these processes and stages 
involved in technological capability accumulation on a pharmaceutical value chain. It also 
provides a historical background to the current industry situation and presents the nature of 
existing knowledge bases and capabilities in the Indian pharmaceutical industry. 
Section 6.2 presents the changing contours of Indian industrial and technology policy and 
discusses its role shaping the Indian pharmaceutical industry through Indian drug policy. 
Section 6.3 analyses the impact of TRIPS on Indian drug policy and the strategic 
orientation of the industry. Section 6.4 presents the capability creation model in the Indian 
phannaceutical industry and discusses the learning processes involved in technological 
capability accumulation at the industry level. Section 6.5 concludes the chapter. 
6.2 The changing contours of Indian industrial and technology policy 
This section presents the characteristics of India"s industrial policies and their role in the 
growth of the pharmaceutical industry. It also discusses Indian drug policy, R&D 
. . t' d market structure and their influence in shaping the Indian pharmaceutical 1nstltu Ions an 
industry. 
6.2.1 The Indian Industrial Polic)' 
. ddt India~s industrial growth was shaped by industrial policies based In post In epen en era . . . . 
. b t't t' n model and which to a larger extent focused on mdlgemsatlon. 
on the Import -su s 1 U 10 
d· nt shaped and directed objectives of self reliance through various The In Ian govemme 
. . d t . tlv regulating and restricting imports of the technology to protect pOhcles focuse on s rIC • . ' _ 
h · I f~ rt bv Indian fimls. Forbes (1999) pomts out that from 19)6 onwards the local tec mca e 10 • 
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Indian industrial policy had two basic tenets: industrial targeting and licensing, and foreign 
exchange control over all the transactions. This resulted in the direct control of imports of 
capital, intermediate and consumer goods. The main elements of industrial policy 
contained, 
a. protection from import competition, 
b. over valued exchange rates, 
c. restrictions on the inflow of technology and foreign direct investment and 
d. industrial licensing. 
The Indian government introduced a quota system for the import of goods and levied 
custom duties on imported products, in some cases as high as 150 to 250%. This restricted 
the effective inward transfer of imported technology and by that affecting an important 
source of technological learning for Indian industry. Lall (1987) suggests that imported 
technology provides the most important input into technological learning in developing 
countries. However, the effectiveness of modes of technology transfer depends upon the 
policy setting. For example, even for accessible technologies, extemalised modes can be 
wasteful if used in a protected setting to achieve technological self reliance rather than as 
in the case of Japan or Korea, to supplement strong local design and development efforts. 
Desai (1989) points out that the India's policies of regulating the transfer of technology led 
to less technology coming in than should have and less use made of technology that did 
come in than should have. Thus Indian industrial policies certainly limited the import of 
technology. This led to the development of local industries that focused on indigenisation 
to produce everything locally and as a result, the Indian industrial firms developed similar 
technological capabilities and products. 
Indian industrial policies were also characterised by a significant growth of public sector 
investments in areas outside core infrastructure sectors and strict regulation of the inflow 
of private capital and technology into economy (Forbes, 1999). The Indian public sector 
comprised more than 5000 factories, absorbing two thirds of fixed capital investment in the 
factory sector. Except very few, most public sector units generated large losses each year. 
The Indian government controlled the inflow of private investments into the economy 
through the Foreign Exchange Regulation Act (FERA). In 1973 the Indian government 
adopted the FERA to reduce the share of foreign equity in enterprise registered in India. 
FERA allowed a foreign equity holding up to 40% in any enterprise registered in India. 
other than those of strategic importance. This regulation forced MNC firms to reduce 
equity holdings to 40% and which resulted in the departure of leading MNC firms like 
IBM frolll India. The measure like import tariffs and industrial licensing. discouraged 
market competition and several Indian industrial sectors became cro\\'ded hy a huge 
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number of small firms, each doing the same thing. Even in the sectors which were 
characterised by a few larger firms there was little incentive to innovate. The expansion 
beyond licensed capacity was forbidden and therefore there was little drive for 
manufacturing efficiency and process innovations. 
However, the Indian government's industrial policies also forced industrial firms to 
conduct much technical effort through in-house learning, which led to the development of 
firm level technological capabilities. The Indian industry built substantial technical 
abilities by learning to make everything locally and resulted in the development of a range 
of intermediate components of some sophistication. The indigenisation activity forced the 
occurrence of much technical effort in firms and this resulted in the development of a wide 
ranging production base. Thus some firms used the protection policies to build useful 
technological capabilities, however much of the Indian industry was characterised by 
widespread inefficiency and product obsolescence. LaB (1984) summarises the 
technological capability development in pre 1991 era by pointing out that India's industrial 
performance signifies that it had developed the "broadest and best developed technological 
capabilities in the third world", whereas on other hand, India had performed poorly in 
terms of "industrial growth, the expansion of manufacturing exports, the absorption of 
industrial labour and introduction of innovative products in foreign or domestic markets". 
The liberalisation of the Indian economy started in the early 1980s with the Indian 
government adopting policies which substantially eased the import of industrial 
technology. The balance of payments crisis in 1990 gave momentum to economIC 
liberalisation and led to changes in the Indian governmenfs industrial policy. From 1991 
there has been shift away from import substitution and other closed economy approaches 
of industrialisation towards the industrialisation with an open-economy and export 
promotion approach. In the decade of 1990s, the Indian government abolished industrial 
licensing, removed import quotas on non consumer goods and took various measures to 
attract foreign direct investment. The import tariffs on industrial goods were gradually 
reduced every year from 1992; 125% in 1992,85% in 1993,65% in 1994,50% in 1995 
and 40% in 1996. By 2004 the average industrial tariff was reduced to 25%. The change in 
policy led to the entry of products of international quality and every major international 
player now competes alongside Indian firms, thereby dramatically increasing competition 
in Indian markets. After the liberalisation, Indian economy has consistently shown a GOP 
growth rate of about 6 % per annum during 1992-2004. The Indian corporate sector has 
responded proactively to the gro\\1h opportunities afforded by liberalisation. Lots of Indian 
finns have improved their operational performances either by a. increasing their efficiency. 
h. focusing on technology licensing or c. substantially increasing their R&D investments 
103 
(F orbes, 1999). Many Indian finns realised that they had no choice but to improve 
efficiency in order to be able to operate in an open domestic market. Several industrialists 
now perceive exports as being both necessary and attractive. Some finns have moved into 
the overseas markets while others have internationalised their operations by starting or 
acquiring manufacturing units in various countries. 
The next section discusses the Indian government's science and technology policies and 
their impact on technology capability development. 
6.2.2 The Indian science and technological policy 
In the post independent era, Indian policy makers viewed scientific research as an 
imperative activity for technological progress and put an extensive effort into creating a 
scientific workforce and institutions. The objective of self reliance also dominated the 
Indian government's science and technology policy and leading to the establishment of a 
number of state owned research institutes all over the India. 
Forbes and Wield (2002) point out that based on the belief that technology and industrial 
development will automatically follow the scientific research, the Indian government 
invested in building research institutes. Since 1950s the Indian government has set up a 
vast and diversified network of R&D institutions under the umbrella of the Council of 
Scientific and Industrial Research (CSIR). CSIR consists of 43 national laboratories 
employing about 10,000 highly qualified scientific and technical personnel. The Indian 
government funded and conducted over 80% of fonnal R&D through this network of state 
owned R&D institutions. The laboratories of CSIR conducts research into diverse socio-
economic sectors and covers a wide canvass of scientific disciplines ranging from 
microbiology, chemistry and genomics to areas such as oceanography, microelectronics, 
and geophysics. 
The literature on technology capability development stresses the significance of research 
institutions for supporting enterprise efforts to develop their knowledge and capabilities. 
According to Bell and Pavit (1993) public or quasi public institutions (universities, 
government, research laboratories etc) in developed countries complement industrial finns; 
their out put of knowledge are inputs for these firms. However. in India this complement 
between industry and institutes never evolved due to the differences in their research focus. 
The major objective of the work done in the Indian R&D institutes was indigenisation: so 
if some thing is imported, then find the process or mechanism to develop it locally. These 
laboratories never benchmarked their activities to global players, as it was not necessary or 
required to do so (Bowonder and Richardson, 2000). The activities in these labs marginally 
fo~us on the commercialisation as the research orientation and activities in these 
to-l 
laboratories differed from the needs of local industry. As the National Chemical 
Laboratory's business development manager explains, 
"In the past, industry and research institutes operated in the protected environment; a 
kind of monopolist environment. It was seller's market and when you are in seller's 
market, you have no incentive to innovate. Research institutes like us who are working on 
cutting edge science had no takers for what we were doing. There was mismatch between 
our output and what industry wanted". 
In India even a science based industry like pharmaceuticals which is globally characterised 
by strong industry-academia linkage, lacked the web of such linkages. A pharmaceutical 
consultant comments on the experience of pharmaceutical industry'S linkages with 
research institutes, 
"In reality while the institutes outside the industrial sector have excellent scientists, they 
lack two important traits a. sense of what to develop which could be commercially 
interesting and b. the ability to evaluate the economic viability of the processes developed. 
Industry until recently have also been wary of the public institutes since they were afraid 
that confidentially will not be maintained under the structure prevailing in the institutes". 
Thus the crucial link of technological progress; industry-academia linkages didn't evolve 
in India and therefore the investment by Indian government in R&D did not help these 
institutes to emerge as a source of technology. 
According to Forbes (1999) for most firms in India, the major source of technology was 
the informal transfer of technology either through market mediated modes (subcontractors) 
or non market mediated modes (reverse engineering or duplication). The R&D in Indian 
industrial firms had a shorter horizon compared to industrial countries and activities were 
largely involved trouble shooting and technical services (Desai, 1985). The content of 
R&D in the industry became primarily the development of local raw materials, component 
suppliers and substituting an item where the exact item was unavailable by developing a 
local manufacturing process. Desai (1985) points out that out of thousands of industrial 
producers, less than 4000 got permission to import technology; the rest bought borrowed 
or reverse engineered technology within the country. Indigenisation as a main objective 
also led to the neglect of crucial factors associated with the product development such as 
quality and cost involved in developing the product indigenously. Forbes (1999) suggests 
that whether the product compared with what was internationally happening in tenns of 
technology, or was sold at a price that reflected international competitiveness was of no 
concern at all. To a larger extent, the job of R&D in private and public sector units was 
confined to the indigenisation of the next product and not to the improvement of the 
ex.isting product or its nlanufacturing process. 
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However, the liberalisation of the Indian economy in 1991 and signing of the TRIPS 
agreement brought changes in the Indian government's science and technology policies 
and forced CSIR labs to become customer oriented and market responsive. In India the 
traditional measure of R&D funding; the public support mechanisms like grants and 
subsidiaries, were changed to private- public support mechanisms. 
According to Sikka (1998) now national laboratories of the CSIR as well as prestigious 
technical institutes have been instructed by the Indian government to earn at least 30-50 % 
of their R&D expenditure by commercialising the indigenously developed technologies 
and by the generation and utilisation of patents, instead of pursuing R&D just as an 
academic exercise. As a response to new challenges, CSIR introduced two major policy 
thrusts: 
a. to promote the quest for patenting in Europe and US as a mean of engendering a 
strong desire to undertake R&D and to innovate; 
b. to increase the commercial orientation of industrial research, thereby making the 
CSIR less dependent on budgetary support. 
The new policy thrusts have resulted in increasing the collaborative ventures between 
CSIR institutes and Indian industrial firms. NCL's business development manager 
suggests, 
"look at automobile sector, even Indica, Victor are the products of Indian R&D. They 
survived in the competitive market. They obviously (companies) interact with the Indian 
research institutes; they do not have all the capabilities in-house. They will go to lIT 
(Indian Institute of Technology), work with professor on design and all that goes on ". 
In the post 1990 economic environment, the share of private sector spending in R&D has 
also increased and by 2000, the in-house share reached 35% with almost all growth taking 
place in the private sector (Forbes and Wield, 2001). Desai (1980) points out that in 1958 
virtually all industrial research was being done in CSIR laboratories. 
In the post 1990 era, the research institutes are contributing towards increasing Indian 
firms' competitiveness by helping these firms to improve existing products or to develop 
new products. According to the NCL's business development manager, 
"research institutes role will increase because all the firms in industry have to do R&D 
and they can not afford to have all the capabilities in-house. They may keep some core 
competencies but rest of them they have to acquire from outside ", 
The CSIR's current global orientation is also evidenced by the substantial rise in the 
number of patents filed and granted in the US. Over the 1995-99 period, the number of 
patents filed by CSIR rose by 900/0 to 112 in 1998 (Sikka, 1998). 
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6.2.3 The role of industrial and technology policy in growth of Indian pharmaceutical 
industry 
The movement of Indian industrial policies from inwardly oriented measures to breaking 
down walls of protection had enormous effects on the evolution of the Indian 
pharmaceutical industry. Since independence the pharmaceutical industry in India has 
mainly evolved through three phases, each characterised by different policy regimes and 
industry's response to those policies. The first period was prior to 1970, when the industry 
was relatively small in terms of its production capabilities. The second period is the decade 
and a half phase spanning from the 1970s to the beginning of the 1990s, a period during 
which the output of the industry grew remarkably. In the third phase of expansion, from 
1990s onwards, the pharmaceutical industry grew more than three times faster than it did 
during the 1980s. 
The decade of the 1970s was the turning point in the development of the Indian 
pharmaceutical industry. In the pre 1970 era foreign firms had a disproportionately high 
share in the total Indian domestic pharmaceutical production. These firms together 
produced 42% of bulk drugs and formulations and produced about 38 % of all bulk drugs 
produced by the Indian industry (Indian Drug Policy, 1978). To encourage the growth of 
the domestic industry and reduce dependence on foreign pharmaceutical firms, the Indian 
government took forward three key policy initiatives in the 1970's. The first policy 
initiative was the Drug Price Control Order (DPCO) by which the Indian government 
sought to control the prices of drugs. The second was the adoption of a new weak patent 
act which Indian parliament passed in the 1970 but became effective in 1972. The Indian 
Patent Act, 1970 was the most conscious attempt by the Indian policy makers to improve 
the terms of accessing international intellectual property. The third initiative was the 
adoption of a drug policy in 1978 which proposed an elaborate use of the industrial 
licensing system to organise capacities in keeping with the broad objective of capability 
creation in domestic pharmaceutical firms. The Foreign Exchange Related Act (FERA) 
also influenced the working of MNC pharmaceutical firms in India as these firms had to 
bring down their foreign holdings to 40%. 
6.2.3a Drug Price Control Order 
Strict price control regulation was introduced with the 1970 Drug Price Control Order to 
make drugs accessible and affordable to the poor population. The Drug Price Control 
Order was introduced at the beginning of the 1970s with the aim of fulfilling two 
objectiyes. The most obyious objective was to ensure equitable distribution of drugs and 
lll1ake them available at a reasonable price. The second objective \Y3S to create an incentive 
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structure for domestic producers so as to encourage them to produce new formulations at 
cheap prices through efficient process development. Besides covering all formulations, 
DPCO also gave the Indian government power to fix the minimum price of essential bulk 
drugs. Therefore, the price control became applicable to all the bulk drugs and 
formulations available in the Indian domestic market. 
In 1979 a modified DPCO was adopted in which the number of drugs under the price 
control was brought down from 347 to 163. The DPCO, 79 also introduced three categories 
to classify the drugs for price control; 
a. Category I - life saving formulations, 
b. Category II - highly essential formulations 
c. Category III - drugs excluded from price control. 
The important change introduced by the DPCO, 1979 was that all producers belonging to 
the small scale sector, whose annual turnover was less than Rs.l 0 million, were explicitly 
exempted from price control. This exemption was adopted to protect the small scale sector 
in the pharmaceutical industry and proved to be one of the key reasons for the presence of 
a large small scale sector in the Indian pharmaceutical industry. 
6.2.3b The Patent Act 1970 
The weakening of patent laws, through the Patent Act 1970 helped Indian policy makers in 
designing the patent system that ideally served India's development and healthcare needs. 
The historical account of the pharmaceutical industries in Europe, Japan and US suggest 
that before shifting to the strong patent regime these countries used the weak IPR regime to 
encourage and protect the domestic industry. Evidence also suggests that the strong patent 
regime is an important incentive for innovators but it is not enough to promote innovative 
culture especially where the market for innovation is small and capabilities for innovations 
are low or absent. The Indian government adopted the process patent regime in keeping 
with the argument that such a regime would encourage innovations and development of 
local technological capabilities. The other key issues that determined the adoption of the 
weak patent system were the high prices of drugs and abuse of the patent monopoly by 
foreign patent holders. The provisions of the Patent Act 1970 restricted the right of patent 
holders in the area of pharmaceuticals and allowed firms to produce drugs with alternative 
processes. 
6.2.3c Drug Policy 
The first step towards evolving a comprehensive policy regIme for the Indian 
. phamlaceutical industry was taken through the setting up of the Hathi Committee in 1974. 
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The recommendations made by the Hathi Committee in its final report presented in 1975 
formed the basis of the drug policy announced by Indian government in 1978. This policy 
had five broad objectives. The first objective was to develop a strong Indian sector in 
pharmaceutical industry with the public sector playing a leading role. The second was to 
channel the activities of foreign firms in accordance with national priorities and objectives. 
The third was to deepen the production base of the domestic industry by ensuring that the 
production of drugs took place at the most basic stage possible. The fourth objective of the 
drug policy was to encourage indigenous R&D and finally, drugs should accessible to all at 
reasonable prices. 
The 1978 Drug Policy provided incentives to the Indian drug manufacturers by making a 
number of relaxations in the provisions of the Indian industrial policy. These firms were 
granted licenses, which allowed them to produce formulations (drug in tablet or dosage 
form) up to 10 times the value of bulk drugs. Foreign firms faced a relatively strict regime 
as regards to the production of formulation. To ensure that the production of drugs in India 
took place from very basic stage, the drug policy imposed three conditions on the foreign 
drug firms intending to operate in India. The conditions were: 
a. the ratio between production of bulk drugs and formulations that these firms could 
maintain in their final output was 1: 5, as against 1: 1 0 allowed to the Indian firms, 
b. licenses to the foreign firms were provided only if the firms agreed to supply 50% of 
their production of bulk drugs to non-associated formulators and 
c. foreign firms producing formulation based on imported bulk drugs and intermediates 
had to start manufacturing from a basic stage within two years. 
The policies applied to foreign firms were thus aimed at utilising strengths of these firms 
for creating linkages within the industry and increasing industry's downstream capabilities. 
While the DPCO affected the growth of the Indian pharmaceutical industry in negative 
way, the Patent Act of 1970 provided the initial impetus for the industry to take firm roots 
in India. These policy initiatives reduced the entry barriers for small scale entrepreneurs 
and provided these entrepreneurs special incentives such as exemption from price controls. 
These initiatives encouraged entrepreneurial activity among Indian managers and 
scientists, who set up small scale manufacturing units. This led to emergence of an industry 
populated by a large number of small firms. The Indian pharmaceutical industry thus 
consists of large sized Indian private/public sector, MNC pharmaceutical firms and lots of 
small scale private sector firms. The second half of the 1980s shows a remarkable increase 
in the output of the industry in terms of bulk drugs and formulation production 
performance. The latter half of the 1980s was clearly the one in which Indian 
. ,phannaceutical firms consolidated their position in the domestic market. 
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Table 6.1 Growth in Indian pharmaceutical industry during the 1980s (Source: OPPI,2001) 
Year Bulk drugs Formulations Total 
Rs. Million Rs. Million 
1 1980-81 2400 12000 14400 
2 1981-82 2890 14340 17230 
3 1982-83 3450 16600 20050 
4 1983-84 3550 17600 21150 
5 1984-85 3770 18270 22040 
6 1985-86 4160 19450 23610 
7 1986-87 4580 21400 25980 
8 1987-88 4800 23500 28300 
9 1988-89 5500 31500 37000 
10 1989-90 6400 34200 40600 
This era of protected environment, intensive competition among domestic firms and strong 
emphasis on reverse engineering, on one hand created strong capabilities in reverse 
engineering R&D, however it also generated some negative characteristics, which 
dominated 'ways of working' in Indian pharmaceutical firms. The extensive focus on 
reverse engineering R&D allowed Indian pharmaceutical firms to build a strong 
knowledge base in process R&D but this also has resulted in the development of an insular 
technical knowledge base. Reverse engineering does not require specialised investment in 
R&D since firms cannot and are not required to generate new knowledge. Due to the 
intense focus on reverse engineering R&D, Indian firms built strong capabilities in organic 
and synthetic chemistry, but other areas of innovative pharmaceutical R&D like medicinal 
chemistry and biology remained neglected. This led to the development of an insular 
knowledge base in these firms. 
The reverse engineering focused R&D also prevented the development of communication 
channels like publication and conferences, which help in creating links with a larger 
scientific community. NPIL R&D director points out, 
"when you are doing reverse engineering there are very few things which can be put in 
the publication. Indian pharmaceutical companies were working on the processes so there 
was no need as most R&D work was imitative in nature ". 
The weak patent law also affected the Indian pharmaceutical industry's regulatory 
management capability. a key capability required to operate in advance markets. Due to 
., weak patents laws. patents could neither protect any information nor create any value for 
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Indian pharmaceutical firms. This is reflected in the negligible publication and patenting 
activity by Indian pharmaceutical firms in this era, preventing development of basic IPR 
management capability. 
The other major impact of the protective environment was the lack of any innovative 
activity in Indian pharmaceutical firms. Protectionism provided the Indian pharmaceutical 
industry with a domestic market free of competition and as a result there was no need to be 
innovative or seek foreign markets. The weakening of the patent act and the drug price 
control order of the 1970s forced MNC pharmaceutical firms to reduce their operations in 
India, thus providing a space for Indian domestic firms to expand in the local market. This 
provided Indian firms with a domestic market which was large in volume but small in 
value. The lack of enough value in the Indian market proved detrimental to the emergence 
of innovative R&D in Indian pharmaceutical firms. Lall (2000) points out that the nature of 
domestic demand plays an important role in influencing national capabilities as the size of 
the domestic market influences the kind of activities that can be undertaken. In the case of 
India, the income level of the large population is low with less than 4% of the population 
covered by medical insurance and therefore drug expenditure is directly paid by consumers 
(Redwood, 1995). As a result, Indian consumers are more price-sensitive compared to 
consumers in developed countries and quicker to switch to cheaper alternative therapies 
(Lanjouw, 1996). NCL's head of new drug delivery research points out, 
"In India people will say alright I am fine taking 4 tablets a day because I am spending 
only Rs. 8. I don't have to spend Rs. 12 (for superior product). So market does not develop 
for technologically innovative products ". 
The attitude among the Indian population and entrepreneurs that imported technology is 
better and can not be improved locally, was also one of the factors that prevented 
innovative activity in Indian pharmaceutical firms. Forbes and Wield (2002) suggest that 
there are many variables that go into the crucial issue of building an innovative national 
culture and points out a most important barrier is a subtle combination of "not invented 
here" and "foreign is better". The combination of these two syndromes results in attitudes 
and practices against fiddling with the imported technology; a feeling that imported 
technology can not be improved on locally. According to Managing Director of Cipla 
scepticism among Indian doctors about the ability of Indian pharmaceutical firms to 
improve technology is one of reasons for lack of innovative orientation in Indian 
pharmaceutical industry. He elaborates, 
"Essentially. what Indian doctors say is that ijthis product is as good as you say ;1 is. then 
why haren't companies like Pfi~e,. and Glaxo brought it out before you? II's a mindsel, 11 
" lakes more than 50 years 10 get out (~rthat" (Hamied. 2002). 
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Thus the nature of domestic demand provided little incentive for Indian pharmaceutical 
firms to invest in innovative activity and affected the development of innovative culture in 
these firms. 
During 1986-87 the policy regime for the pharmaceutical industry in India was revised. 
The new DPCO was introduced which further reduced the drugs under price control to 
145. In case of formulations two categories of drugs were kept under the price control 
regIme; 
a. Category I - drugs used in the National Health Programme monitored by Ministry of 
Health and 
b. Category II - essential drugs identified by a group of experts. 
The aggressive transformation of the Indian industrial policy orientation in 1990 also 
influenced the Indian government's pharmaceutical industry regulation policy. In 1994 the 
government introduced modifications to the existing drug policy and adopted the new 
DPCO; both measures were aimed at freeing the industry from the limitations imposed by 
government regulations. 
The Drug Policy 1995 abolished licensing policy for all drugs except drugs under the three 
categories 
a. identified bulk drugs which were to be the exclusive preserve of the public sector units, 
b. bulk drugs produced by using recombinant DNA technology and 
c. bulk drugs requiring in-vivo use of nucleic acids. 
The drug policy also removed conditions which stipulated mandatory supply of a 
percentage of bulk drug production to non-associated formulators. The new drugs 
developed through indigenous R&D were put outside of price control for a period of 10 
years from the date of their commercial production. DPCO 1995 reduced the number of 
drugs under price control to 74 while the scope of price control was shortened to only two 
categories: 
a. those in which there were at least 5 bulk drug producers and 10 formulation producers, 
with none having market share exceeding 40 %, and 
b. genetically engineered drugs produced by recombinant DNA technology. 
In 1999, the reservation of 5 drugs for manufacture by the public sector only was 
abolished, thus opening them up for manufacture by the private sector also. Foreign 
investment through the automatic route was raised from 51 % to 740/0 in March, 2000 and 
the same has been raised to 1000/0 in 2002. Automatic approval for' Foreign Technology 
Agreements' is being given in the case of all bulk drugs, their intermediates and 
formulations except those produced by the use of recombinant DNA technology, for which 
. I the procedure prescribed by the government has to be followed. The Indian government 
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introduced some incentives in form of tax exemptions for firms which are in\'esting in 
R&D. The expenditure on filing patents, obtaining regulatory approvals and clinical trials 
besides R&D in biotechnology now includes in the R&D expenditure. 
The changed policy regime in the decade of 90s transformed the Indian pharmaceutical 
industry'S 'ways of working' and saw the strongest performance of the industry on several 
fronts. The important feature of this performance was that it came at a time when the 
industry faced serious challenges due to changes in Indian industrial policies. The 
production of bulk drugs increased from Rs.7300 million in 1990-91 to Rs.37770 million 
in 1999-00 while production of formulation went up from Rs. 38400 million to Rs. 159600 
million during the same period (Table6.2). The share of bulk drugs in the total drug 
production went up from 16.0 % in 1990-91 to 19.1 % in 1999-00. 
Table 6.2 Growth in Indian pharmaceutical industry during the 1990s (Source: OPPI, 2001) 
No. Year Bulk Drugs Formulations 
Rs. Million Rs. Million Total 
1 1990-91 7300 38400 45700 
2 1991-92 9000 48000 57000 
3 1992-93 11500 60000 71500 
4 1993-94 13200 69000 82200 
5 1994-95 15180 79350 94530 
6 1995-96 18220 91250 109470 
7 1996-97 21860 104940 126800 
8 1997-98 26230 120680 146910 
9 1998-99 31480 138780 170260 
10 1999-00 37770 159600 197370 
The industry turned into a net foreign exchange earner during the 1990s and throughout the 
1990s this surplus had been increasing. Total exports have gone up from RS.7848 million 
in 1990-91 to Rs.68520 million in 1999-00 (Table 6.3). The increasing share of 
formulation drugs in export suggests the shift in technological capabilities, specifically the 
transformation of manufacturing facilities to international standards. 
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Table 6.3 Indian pharmaceutical exports (Source: OPPI, 2001) 
No. Year Formulations 0/0 of Total Bulk % of total Total 
Rs. million drugs Rs. 
Rs. million million 
1 1980-81 351 (76) 112.8 (24) 463.8 
2 1981-82 693.4 82 154.5 18 847.9 
3 1982-83 546.0 83 113.4 17 659.4 
4 1983-84 614.6 77 184.6 23 799.2 
5 1984-85 995.0 77 292.5 23 1287.5 
6 1985-86 1065.9 76 333.6 24 1399.5 
7 1986-87 1021.2 54 871.6 46 1892.8 
8 1987-88 882.5 39 1397.1 61 2279.6 
9 1988-89 1572.9 39 2428.7 61 4001.6 
10 1989-90 3142.0 47 3505.0 53 6647 
11 1990-91 3714.0 47 4134.0 53 7848 
12 1991-92 5585.0 44 7226.0 56 12811 
13 1992-93 9655.0 70 4095.0 30 13750 
14 1993-94 13108.0 71 5308.0 29 18416 
15 1994-95 15055.0 66 7601.0 34 22656 
16 1995-96 2,0448.0 64 11329.0 36 31777 
17 1996-97 24148.0 59 16645.0 41 40793 
18 1997-98 29268.0 57 22148.0 43 51418 
19 1998-99 31014.0 52 28704.0 48 59718 
20 1999-00 37520.0 55 31000.0 45 68520 
The export of bulk drugs went up from Rs. 3714.0 million 1990-91 to Rs. 37520.0 million 
in 1999-00 while export of formulations went up from Rs. 4134.0 million to Rs. 31000.0 
million during same period (Table 6.3). The export performance of Indian pharmaceutical 
industry is particularly significant as it reflects the shift of the focus from the domestic 
market towards the global market. 
Over the years the Indian government's policy regIme used for regulating the 
pharmaceutical industry, has moved from strict government control in the 1970s to freeing 
it almost completely to allow market forces to guide it in the 1990s. The relatiye 
performance of the pharmaceutical industry in the industrial sector suggests the favourable 
impact of a mix of policies for the industry. However the signing of WTO agreements 
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especially TRIPS agreement will be affecting an important pillar of the Indian 
pharmaceutical industry's growth; The Patent Act, 1970. 
The next section discusses the impact of the TRIPS on the Indian pharmaceutical industry 
structure and its strategic implications. 
6.3 TRIPS and Indian pharmaceutical industry 
The Indian Government signed the WTO trade agreements in 1995 and thus accepting to 
implement the TRIPS agreement as a framework to regulate the IPR management in the 
country. In 1999, the Government of India made its first amendment to the Patent Act as 
per the requirement of TRIPS, facilitating the introduction of a 'Mail Box' system and the 
Exclusive Marketing Rights (EMR) for products patented elsewhere. The mail box has 
initiated the process of accepting patent applications from January, 1995, which will be 
processed in 2005. In 2002 the Indian government announced the new Pharmaceutical 
Policy taking into account the new obligations undertaken by India under WTO agreement 
and resultant challenges faced by the Indian pharmaceutical industry. The Pharmaceutical 
Policy reduced the number of drugs under price control to 38 and introduced the Patents 
(Second Amendment) bill in Parliament providing patent protection for both products and 
processes and extending the life of a patent to 20 years. 
During the negotiations on the WTO agreements, developing countries particularly India, 
China and Brazil were the strongest opponents of the TRIPS agreement. Till 1988 India 
and other countries prevented a major role for IPRs in WTO agreements but in 1989 India 
made a surprise move and gave up its opposition to include IPR in WTO negotiations. 
Ramanna (1999) suggests that while trade threats were important in initiating changes in 
global policy, domestic level policy change took place only with the mobilisations of a 
domestic industry and research institutes that favoured change. Trade pressure from the US 
through Special 301 was an important factor that influenced changes in Indian global 
policy. But importantly domestic policy shift also occurred and that enabled India to revise 
its patent laws in 1998-99. The change occurred at various levels. Economic liberalisation 
influenced perceptions of industry groups towards intellectual property laws. In tune with 
the pro-reform policy, important industry bodies in 1990s began to advocate the need for 
greater patent protection. The industry bodies began to support the bill to amend patent 
laws in conformity with the TRIPS agreement. According to an IPR consultant, Indian 
firms have realised that if you are part of trading network then you have to follow rules set 
by those agreements. He comments, 
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"if you are playing foot ball game and if you say I will kick everybody around the place, 
then rules don't allow you to kick around the place. You are allowed to push around within 
certain way, then you push around within certain rules". 
A component of this change within industry bodies arose from some domestic firms who 
prospered under the existing patent structure, but came to visualise significant avenues for 
growth from the new patent regime. The NPIL strategic alliance director comments, 
"I actually think it will be much better. The reason is simple as I think there will be 
greater awareness of IPR, there will be more scientists kind of working towards it and 
then rules also equal. Today we are in cowboy country, anybody copying anything, 
somebody have same product then they differentiate by adding some other combination 
which have no rational value and all kinds of things like that. I think that will stop and 
people who are genuinely have something innovative will be rewarded. So though most 
people think all the MNC have that ability, I don't agree with them, I think Indians also 
have that ability, to innovate and to make something new and to do very nice things". 
This industry outlook was supported by the top Indian research and scientific institutes 
who felt that accumulated capabilities could provide benefit to them in the strong patent 
regime (Ram anna, 1999). 
6.3.1 Impact of TRIPS on strategic orientation of Indian pharmaceutical industry 
The basic tenet of the Indian Patent Act 1970 varies enormously from the framework 
established under the TRIPS agreement. Indian pharmaceutical firms which were 
manufacturing and marketing products without license from the original patented products 
will not be able to follow that course as part of their business strategy. The new patent law 
can not stop reverse engineering of drugs whose patents are expired but will certainly 
restrict its application in case of newly patented drugs. Now firms will need licenses from 
original patent holders to make those products. Even if firms are able to develop a 
patentable process for protected products, that process patent will be still dependent on the 
original product patent. As a result the Indian pharmaceutical industry and research 
institutes are now reviewing their strategies, policies and programmes to survive and 
succeed in the strong patent law regime. NPIL' s head, Regulatory Affairs suggests, 
"The main thing is after 2005, we will have product patent that is going to make main 
impact. It is not vel:" clear how things are going to shape up. D?fferent companies are 
looking at it dtfferent~l'''. 
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Indian phannaceutical finns are adapting multiple strategies like vertical integration, brand 
acquisition and marketing channel mix as a response to change in patent laws 
(Madanmohan and Krishnan, 2003). According to business development manager of 
National Chemical Laboratory, 
"] see three developments; some companies will graduate to the new drug discovery, some 
will not do drug discovery in that sense but they will do drug delivery systems and that 
kind of innovations. There will be other group of firms who will be global scale generic 
producers and at least few of Indian firms will concentrate on supplying intermediate to all 
these firms". 
The adoption of the TRIPs framework has forced Indian firms to focus on R&D and 
develop capabilities in different facets of phannaceutical R&D. NCL's business 
development manager comments, 
"With the globalisation and liberalisation there is focus on R&D today, industries realise 
this; today without R&D they can not survive. There is no option but to do R&D ". 
A few Indian phannaceutical finns such as Ranbaxy and DRL are focusing on innovative 
R&D but at the same time seeking to gamer a share of the global generics market. Some 
finns like Cipla are partnering with generics companies in the US for the supply of API 
and building capabilities for contract research. These firms are doing the contract process 
research and custom synthesis work for the western drug and generic companies. NPIL' s 
R&D president comments, 
"I am aware everybody cannot do NCE research to start with. The small group which 
concentrates on this kind of activity (custom synthesis and contract manufacturing) and get 
some money should be encouraged. This research involves designing of new processes for 
MNC pharmaceutical or generic companies to lower the cost of goods or developing new 
formulations to extend shelf or patent life ". 
The contract research model is similar to the Indian software firms' service model, where 
Indian IT firms are leveraging low costs and high skills to become the world~s back office. 
But downsides of the contract service model like commoditisation of business which 
results in declining margins and an excessive dependence on their customers~ fortunes are 
affecting the business models of Indian IT firms. In the pharmaceutical business, contract 
research and custom synthesis also have similar limitations. The NPIL R&D president 
suggests, 
"Contract research has its own value, but anyone who is giving you a contract lrill 
attempt to save something for themselves. These activities will give you money but they can 
be never matched by NCEs. These activities become commodities vel:" fast and can be 
given to your competitor setting up a shop next 10 you. Some degree q( innovation is 
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involved in it but nothing to match NeE. At the end of the day most of us should focus on 
growth through hard core research and generating molecules ". 
The challenge facing the industry is to make a transition from an era of imitation based 
growth to innovation led growth. Lupin VP R&D comments , 
" we are ready to sign TRIPS, what we need, then obviously innovation becomes the 
platform for growth; moving from the API to generic products and innovation either in 
area of new drug discovery or delivery ". 
R&D therefore has become an area of focus for Indian pharmaceutical firms and most 
Indian firms have increased R&D investments. The total R&D expenditure of the Indian 
pharmaceutical industry in 1965-66 was Rs.30 million but by 2000-01 it has reached 
Rs.37000 million (Table 6.4). Remarkably the average R&D intensity of top Indian 
pharmaceutical firms having a turnover of Rs. 5000 million and over has increased from 
3.71 % in 2000 to 4.4% in 2002 (Pharmabiz, 2002). 
Table 6.4 R&D expenditure of Indian pharmaceutical industry (Source: OPPI, 2001) 
Year Rs. million 
1 1993-94 12500 
2 1994-95 14000 
3 1995-96 16000 
4 1996-97 18500 
5 1997-98 22000 
6 1998-99 26000 
7 1999-00 32000 
8 2000-01 37000 
The transformation in large MNC pharmaceutical firms' R&D strategies has also brought 
new opportunities for Indian pharmaceutical firms. Globally the cost of the entire 
pharmaceutical R&D process has increased and fewer drugs have been discovered, forcing 
big MNC pharmaceutical firms' to re-examine the drug discovery process and strategies. 
Many MNC pharmaceutical firms are now collaborating with biotechnology firms as well 
as with small research intensive pharmaceutical firms as a source of new molecules. This 
collaborative approach is mutually beneficial as small firms get an opportunity to share the 
cost and leverage of technical capabilities. Indian pharmaceutical firms are also using these 
opportunities to compensate cost and capabilities gaps. 
MNC pharmaceutical firms are also focusing on the narrow band of therapeutic life style 
diseases. hence vacating research space for small phannaceutical firms. Some Indian 
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phannaceutical firms are concentrating their innovative R&D efforts in those research 
spaces. According to Ranbaxy R&D president, 
"in other words, today there are lots of disease categories available, say, in US $ 100 -
500 million range, which would be far below the radar of big pharmaceutical firms 
because the potential there isn't so high. But it makes perfect sense for Indian 
pharmaceutical firms to play there" (Business World, 2003). 
Thus the Trade Related Intellectual Property Rights (TRIPS) agreement has forced Indian 
pharmaceutical firms to focus on R&D and develop innovative products to compete in the 
global market. Ranbaxy's corporate affairs VP summarises the change in the strategic 
orientation in Indian pharmaceutical industry, 
"one thing became clear that once TRIPs has signed, you had window in which to have 
your own products. In generic market lifeline of an organisation is new products. In 2005 
you will have product that will be recognised but process will become secondary. So 
therefore companies have to have pipelines and for that companies have to invest into new 
molecules development". 
The next section presents the capability creation model to explain processes and stages 
involved in gradual movement of the Indian pharmaceutical industry from acquisition of 
basic minimum knowledge base towards the creation of new competence for innovation. 
6.4 The capability creation model 
The growth of the Indian pharmaceutical industry reflects the rise of the industry up the 
value chain in terms of activities involved in the pharmaceutical R&D. Lupin's VP R&D 
comments, 
"if you see historically,from marketing to manufacturing, from R&D of API to generics 
and now we will be into drug discovery phase. It's a gradual up-gradation through 
which Indian pharmaceutical industry has gone through". 
The growth of Indian pharmaceutical firms on the pharmaceutical value chain is closely 
aligned with various R&D learning processes. This section presents the capability creation 
model which discusses various learning processes involved in capability development and 
maps the upgrading of capabilities in the Indian pharmaceutical industry on the 
phannaceutical value chain 
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6.4.1 Pharmaceutical R&D value chain 
The pharmaceutical R&D value chain (Fig 6.1) characterises pharmaceutical R&D 
capabilities based on criterion of technological and marketing complexity against the 
margin of profit in market associated with a respective category. The intermediate bulk 
drugs are drugs in powder form and involve the lowest level of technological and 
marketing complexity and correspondingly have low levels of profitability, while new 
chemical entities result from highly technological complex research and require strong 
marketing infrastructure. Due to strong patent protection, the profitability associated with 
new chemical entities is very high as most of the time drugs have monopolist presence in 
markets. 
In the value chain, technological complexities increase at each level with a corresponding 
increase in profit margin. The increasing technological complexity requires an increased 
input of original knowledge as well as stronger marketing and distribution infrastructure. 
High 
TechnologicaVMarketing 
complexity 
Value added 
I & branded 
I • 
: generIcs 
Conventional : 
I dosage forms: 
Commodity: 
I 
generICs 
Intermediates & : 
bulk substance j 
Low 2-120/0 12-20% 20-30% 30-40% 
OTC&New 
drug delivery 
systems 
40-60% 
Gross Margin 
Fig 6.1 Pharmaceutical value chain (Source: Barlett and Ghoshal, 2000) 
New chemical entity 
& drug discovery 
60-100% 
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6.4.2 Processes involved in capability accumulation In Indian pharmaceutical 
industry 
In the capability creation model (fig 6.2) a basic level of capability is taken as the ability to 
make minor adaptations to production and assimilate technology into a firm's environment. 
Intermediate innovative capability is the ability to generate incremental technical change in 
product design, quality and production processes, it also includes ability to search and 
evaluate external sources of technology. Advanced innovative capabilities refer to the 
ability to generate new products and process innovations. A knowledge base is categorised 
as simple and complex, based on the technological challenges involved in developing 
particular products and underlying capabilities. This classification of level of capabilities is 
based on Bell and Pavitt (1993) and Lall (1992). 
Based on classification of capabilities in the pharmaceutical industry, reverse engineering 
R&D capability; ability to develop products by copying the process, is categorised as the 
basic capability. Generics R&D involves incremental change representing intennediate 
capability while new chemical entity research involves creating new drugs and innovative 
therapies representing advance capabilities. 
Ti111970, most Indian phannaceutical finns' initial forays into the phannaceutical business 
involved marketing and distribution of imported phannaceuticals. In 1960, close to 90% of 
market share was with MNCs and 10% with Indian companies. In the pre-independent era 
and up to World War II, Indian domestic production only accounted for a fraction of the 
market for medicine. There were less than 10 registered producers of Western-type 
pharmaceutical products in 1915 and 30 in 1947; many of them were producers of non-
pharmaceutical chemicals. The Indian population was largely dependent on imports from 
foreign finns based in the UK, France and Gennany for supply of medicines. The cost of 
these medicines was largely out of the reach for the majority of the Indian population 
(Felker et aI., 1997). Therefore after independence, the Indian government focused on 
pharmaceuticals as a priority area and both, private and public investments were desired 
under the industry policy resolution. Several foreign multinational finns invested in India 
throughout the 1950s and 60s and until the 1970s these finns dominated the Indian market 
for pharmaceutical products. Some multinational companies only set up marketing and 
distribution facilities and imported bulk drugs from their manufacturing facilities. \\'ben 
the Indian government increased pressure against the import of finished products. MNCs 
set up fonnulation units and restricted imports to bulk drugs only. 
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Fig.6.2 Capability creation model 
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The Indian government set up research institutes in fonn of CSIR laboratories like Central 
Drug Research Institutes and invested in public sector enterprises to establish the domestic 
pharmaceutical industry. The first priority for the government was to become independent 
of imports as India was importing almost 900/0 of its bulk drugs requirement. Therefore in 
1954, the Indian government set up a public sector phannaceutical finn called Hindustan 
Antibiotics Limited (HAL) for the production of penicillin and sulfa drugs and in 1961 
with the Russian cooperation Indian government set up another phannaceutical finn; 
Indian Drugs and Pharmaceuticals Limited (IDPL). The public sector units along with the 
research institutes and MNC firms who started manufacturing in India developed the basic 
knowledge base required for the industry and emerged as main source of industrial 
entrepreneurs a decade later (Chaudhari, 1999: 11). The Phannabiz editor comments on 
capability development in pre 1970 era, 
"basically Indian firms like Sarabhai and Alembic were already here. Some· of the 
scientists were working in these companies. Apart .from that IDP L and HAL were there and 
so scientists were working in these two public sector companies. So scientists acquired 
skills over period of time through experiences ". 
Gradually Indian phannaceutical firms started moving into the area of manufacturing 
formulations and followed it by backward integrating into production of bulk drugs. But 
1970 patent law changed the industry structure and market by reducing entry barriers for 
entrepreneurs to operate in this science based industry. This law legalised reverse 
engineering R&D and paved the way for Indian finns to build basic capabilities in 
pharmaceutical R&D. 
6.4.3 Duplicative imitation and basic R&D capabilities 
In the post 1970 era Indian phannaceutical firms focused on adapting technology to the 
firm and country specificity and efforts in these directions fostered the development of a 
basic knowledge base in firms. Indian phannaceutical finns, taking the benefit of the weak 
patent law used reverse engineering or duplicative imitation as the main mechanism of 
knowledge acquisition and built basic capability in process R&D. National Chemical 
Laboratory's business development manager suggests, 
"In early 1970 main driving force at that time was to make drugs available to Indian 
I · P d ts were known' only thing we have to develop was process either popu atlOn. ro uc ' 
h ngineering or through process innovations. Since patent now protected throug reverse e 
h t ~o ,Aeverse engineering and we developed alternatil'e process. For last process, we ave 0 Ui 
'th A esearch l'nstitute or industrr did that, process development ". 40 years el el r . 
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Managers working in publi t' . . . 
c sec or umts, research InstItutes and other IndIan firms sensed 
the opportunities that emer d ft 19 " ge a er 70 and started creatmg therr own firms on the basis 
of knowledge in reverse '. . 
englneenng. AccordIng to a pharmaceutical consultant 
"the major factor was al I . ' 
so peop e who were expenenced in reverse engineering R&D 
moved from comna t 
r ny 0 company and specially carried know-how with them ". 
Indian firms started dev I . db' . 
e opIng rugs y copymg or uSIng known processes to manufacture 
the product at lower co tId' fi '" 
s s. n Ian Inns and research InstItutes SImply followed the patent 
and reverse engineered th lb" 
e process, a elt WIth some minor modifications. Glenmark's 
strategic planning director comments , 
"Earlier there was no R&D a h't . I " s suc , I was SImp y reverse engineering; whatever patent 
said you would reproduce and optimise it". 
Original product 
A + B a' + C = original molecule 
(Process conditions: temp: X; pressure: Y) 
Reverse engineered product 
A + b + d = Reverse Engineered Molecule where d = a'+c 
(Process conditions: temp: X; pressure: Y) 
Fig 6.3 Reverse Engineering Product Development 
In reverse engineering (Fig 6.3), scientists study the different sequential steps involved in 
the making of the final compound. In some cases, scientists keep all these steps same and 
change the solvent or in some cases scientists change some steps and arrive at some 
product with a different process. In most Indian pharmaceutical firms, scientists developed 
skills in reverse engineering R&D through trial and error experimentation or learning by 
doing. The former R&D president of Ranbaxy explains the early efforts of firms, 
"You have to train people; actually quite a bit of training has gone into this. Nothing like 
training, every body comes fi~om university, and had no experience of reverse engineering. 
When there is no reverse engineering really per se in the universities as a course or 
anything so you have to teach them. Then there were few people already available the)' can 
train the younger one. So we have trained the people on the job. that itself investment for a 
year or so when they really start learning or giving results ". 
Reverse engineering R&D also involves purposive searching of the rele\'ant infonnation. 
effective interactions among technical members within a project team and with marketing 
and production departments within firm, effecti\'e interactions with suppliers. customers 
and trial and error in devel' . c: . .. . OpIng a satIslactory result. Thus these actIvItIes helped IndIan 
finns to develop basic capabilities in pharmaceutical product development and 
management. 
Thus Indian pharmaceutic I fi d··.. " .. . 
a Inns use ImItatIve learrung to develop baSIC capabIlItIes m 
pharmaceutical R&D K' d 
. 1m an Nelson (2000) suggest that the important aspect of 
imitative learning is to h c: hn " . '" 
searc lor tec ologIcal mformatIOn and whIch IS an Important 
component of accumulating basic innovative capabilities. In the case of reverse 
engineering pharmaceutical R&D the publicly available knowledge in the patent is not 
always sufficient on its own to produce a reverse engineered product. Some knowledge is 
not disclosed in patents but importantly firms need to have the tacit knowledge to 
complement and interpret disclosed knowledge. Hence the non market imitative or reverse 
engineering based acquisition of knowledge is likely to require the firm to gain the 
necessary tacit knowledge and unavailable information, for example through trial and 
error. In the case of Indian pharmaceutical firms where new products were not registered 
by original patent holders in India, the Indian firms quickly compiled 'product dossiers' 
based on published data and supplemented them with limited Phase III clinical trials and 
got products approved by the drug regulatory authority. 
The focus of Indian pharmaceutical firms in the context of reverse engineering R&D was 
not based on the number of patents firm has filed but on number of products firm could 
reverse engineer and duration for imitative process development. Indian firms competed in 
the fiercely competitive market; in the Indian domestic market there can be up to 100 
brands for anyone molecule. If an original patent holder has developed the product with 
process A, then other company develops the product with process B, third company tries to 
developed product with process C. In this process 6-10 companies are constantly 
developing new ways of manufacturing the product cheaply. The profitability of a drug in 
the market place was mostly determined by the cost and timing of entry in the market. 
According to a pharmaceutical consultant, pharmaceutical MNC's operate on 95% 
production margins; total cost of manufacturing involved in the development of the drug is 
5%. So the marginal or significant improvement in process development does not have a 
significant effect on profit margins. The Indian pharmaceutical firm operates on an 8% 
production margin; the cost of manufacturing makes up the 92% of total cost of the 
product. Therefore even if a firm does a .5% improvement in process, then firm can 
achieve a significant improvement in margins which finally can result in an effectiyc 
increase in profit. This was the driving force for firms in deyeloping efficient cheap 
processes as .5% on an 8% margin nlakes a big difference. Thus the profits in the market 
were directly related to the efficient production processes used hy firms and so Indian 
pharmaceutical firms put an intensive in house effort to develop cheap processes. This 
resulted in the rapid acquisition and assimilation of reverse engineering expertise across all 
firms. Although, this also resulted in the lack of collaborations between industry and 
academia, as profits were totally linked to the superior production process, firms~ made an 
effort to build these capabilities in-house. Along with that lack of trust due to a weak 
regularity environment, hampered the development of collaborative research networks 
between the industry and academia. 
Kim and Nelson, (2000) point out that a reverse engineering strategy also involves 
activities that senses potential needs in a market, activities that locate knowledge or 
products, which would meet the market needs, and activities that would infuse these two 
elements into a new project. As a result of these activities Indian pharmaceutical firms 
built organisational capabilities required to operate scale intensive manufacturing facilities, 
production as well as created strong marketing and distribution networks domestically. 
By the end of 80s, Indian firms were practically manufacturing every new molecule which 
was commercially viable to manufacture without access to process details from the 
innovator company. 
Table 6.5 Time lag between introduction of new drug in the world market and its introduction in India 
(Source: Keayla, 1996) 
No. Drug World market Indian market Time lag before 
introduction by introduction by introduction in 
inventor domestic firm India (years) 
1 Ibuprofen 1967 1973 6 
2 Salbutamol 1973 1977 4 
3 Mebendazole 1974 1978 4 
4 Rifampicin 1974 1980 6 
5 Cimetidine 1976 1981 5 
6 Naproxen 1978 1982 4 
7 Bromhexin 1976 1982 6 
8 Captopril 1981 1985 4 
9 Ranitidine 1981 1985 4 
'10 Norfloxacin 1984 1988 4 
11 Ciprofloxacin 1986 1989 3 
12 Acyclovix 1985 1988 3 
13 Astemizole 1986 1988 2 
r-14 Larazepam 1977 1978 1 
~ 
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One of the indicators of Indl'an fi ~ ",' b'l'" h h ' f h lrms supenor ImItatIve capa 1 ltIes IS t e s ortemng 0 t e 
time lag between the intr d t' f d ' , o uc lOn 0 a rug m the global market by the mventor and the 
marketing of the same d ' h d' , rug In t e In Ian market. Over the years Indian firms have been 
able to progressively shorten the lag between introduction of a drug by inventor and its 
introduction in the Indl'an k t' d'" , , , mar e In lcatIng supenor process R&D capabIlItIes (Table 6,5), 
6.4.4 Creative imitation and intermediate R&D capabilities 
After the liberalisation of the pharmaceutical market in the mid 1990's~ some Indian 
pharmaceutical firms moved towards export markets and specifically generic markets in 
advanced countries, Indian pharmaceutical firms adopted the strategy of 'creative 
imitation' to manufacture products by developing non-infringement processes, These non-
infringing processes can be converted into a patent, which creates a value for firms in the 
market. According to Kim and Nelson (2000) design copies, creative adaptations~ 
technological leapfrogging and adaptation to another industry are different forms of 
creative imitations, Creative adaptations are innovative in a way that they are inspired by 
existing products but differed from them, Creative imitations are aimed at generating 
facsimile products but with a new performance features, It not only involves activities like 
benchmarking but also notable learning through substantial investment in R&D activities 
to create imitative products, which may have significantly better performance features than 
the original. 
Using reverse engineering R&D, Indian pharmaceutical firms built capabilities in process 
development and by late 1980s these firms could produce several block-buster drugs in 
formulation as well as bulk drug forms at considerably lower costs, In the post 1990 era, 
Indian firms started developing processes which contained some patentable novel element. 
The Ranbaxy Vice President of corporate affairs argues, 
"what happening was more innovative way of producing the drug; if you would look at 
what Pfizer did, what DRL did and what Ranbaxy did for various products. Example, 
Prozak which is Fluoxentine used to be sold in particular dosages and strengths. DRL 
not only developed the new process to make Fluoxentine but also they developed new 
dosage form and therefore they got exclusivity in the US. So that innovation". 
The success in generic R&D involves strong interaction and coordination between IPR, 
marketing and R&D departments and therefore requires presence of organisational 
mechanisn1s to facilitate these interactions, The creative imitation process starts with the 
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top management of company selecting a molecule to be developed based on criteria's like 
patent expiry date, market value and complexity of the molecule. Then regulatory team 
scouts use the patent database to search and study for loopholes in patents related to 
selected drugs and report to the R&D team all key information about existing patents on 
the product, for example, different process patent filed by originator. This is crucial step in 
designing the ._.,::.. 
non-huflnglng and novel process. Then R&D team studies all possible 
patents -for hydrides, polymorphs, isomers, other crystalline forms and metabolites. The 
main task of R&D team is to find the process that don't infringe on any of the originator's 
process patents. The R&D team has to chemically produce a compound in an efficient way 
with the same level of bioequivalence as the original compound. Once the R&D team 
develops the non-infringing process, the regulatory and legal team joins the project again. 
These teams start working on filling the regulatory approval in terms of a drug master file 
(DMF) in case of bulk drugs or abbreviated new drug application (ANDA) in case of 
formulation products for the US and European markets. The product then moves to the 
firm's pilot plant for validation and production of exhibit batches to be submitted to the 
FDA with the drug master file or ANDA application. 
A Drug Master File (DMF) is a submission to the Food and Drug Administration (FDA) 
containing confidential, detailed information about facilities, processes or articles 
employed in the manufacturing, processing, packaging, and storing of one or more drugs 
intended for use in humans or animals, while abbreviated new drug application contains 
data which when submitted to FDA provides for the review and ultimate approval of a 
generic drug product. 
Generic drug applications are termed "abbreviated" because they are generally not required 
to include preclinical (animal) and clinical (human) data to establish safety and 
effectiveness. Instead, generic applicants must scientifically demonstrate that their product 
is bioequivalent (Le., performs in the same manner as the innovator drug). 
Lupin's IPR head explains the subtle difficulties involved in imitating the process 
creatively, 
"suppose you have new molecule and you will like to protect this molecule as far as 
possible and so you would like to surround it with as many patents as possible. Every 
nlajor pharmaceutical firm is doing it. Now if I have to enter generic pllase after the 
patent expiration, I have to ensure tltat I do not fall witltin spaces covered by tile patent 
. t o,·d all t'tat litigation and all tltat things. So I wOllld hal'e to of tltose cOnlpallleS 0 av 'I 
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develop the process of formulation or new product which is beyond tlte boundaries 
whatever covered by the scope of the patent. So I would not infringe upon rights of 
others. This was not done 5-6 years ago, but this is done now. All Indian pharmaceutical 
firms arefocusing on generic markets. Firms want to make sure that it is not going to be 
sued for infringement. That's role of R&D; it ensures whatever product we develop, it 
does not infringe on patent of others". 
The important aspect of imitation in generics R&D is to copy the product with innovative 
processes. Thus Indian firms acquired their generics R&D capabilities by assimilating and 
creatively improving on their reverse engineering R&D capabilities. This creative imitation 
allowed Indian pharmaceutical firms to develop the regulatory capability required to access 
global markets, build organisational structures required to manage original research and 
gain entry into the generic markets of advanced countries. Thus, Indian pharmaceutical 
firms moved up the pharmaceutical R&D value chain by developing products for highly 
regulated generics markets in advanced countries. 
Indian pharmaceutical firms initially exported formulation products to least developed or 
developing countries but after 1990 these firms started exporting formulations products to 
generics markets in advanced countries. An important event in the expansion of a generic 
market in the US was the enactment of the Waxman-Hatch Act in 1984. This abolished the 
requirement of fresh clinical trials in case of generic drugs and replaced them with the 
simpler and less expensive 'bioequivalence' and 'bio-availability tests'. There are two 
ways to approach the US generics market; a. Para III - in which case fillings are mainly 
driven by patent expiry and b. Para IV which signifies the patent challenge route to create 
and tap a block buster opportunity by gaining an exclusive marketing right for a limited 
period of time. Some firms like DRL are aggressively pursuing the Para IV route of patent 
challenge, which is a high risk, high return strategy where firms apply for patent 
challenging validation of existing patents and by that, taking on an original patent holder. 
Others like Sun Pharmaceutical and Ranbaxy have followed the conservative approach of 
Para III filling. Some firms like the Cipla are looking at ways to grow in that space through 
tie ups, alliances, etc. with other generic firms like Watson and Ivax. 
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Table 6.6 Share of bulk drugs and formulations in total exports (Source: OPPI, 2001) 
No. Years Bulk Drugs (%,) Formulations (0/0) 
1 1990-91 47 53 ! i 
2 1991-92 44 56 ! 
3 1992-93 70 30 i 
I 
4 1993-94 71 29 
! 
I 
5 1994-95 66 34 
, 
6 1995-96 64 36 I 
7 1996-97 59 41 
8 1997-98 57 43 
9 1998-99 52 48 
10 1999-00 55 45 
Indian pharmaceutical companies have adopted different kinds of strategies to enter the US 
generic markets. Many Indian pharmaceutical firms have set up their marketing 
infrastructure in the us. Some firms have acquired US based firms to set up an operation 
while other firms are forming alliances with generic firms operating in the US for the 
supply of API or formulation generic products (Table 6.7). 
Table 6.7 Foreign acquisitions by Indian pharmaceutical companies (Source: Annual Report, 1995-2003) 
No. Year Indian firm (acquirer) Name of the Country 
firm acquired 
1 1995 Ranbaxy Ohm Labs USA 
2 1997 Sun Pharmaceuticals Ltd Caraco USA 
3 1998 Wockhardt Wallis UK 
4 2000 Ranbaxy Basics Germany 
5 2000 Ranabxy Veratide Germany 
6 2002 Ranbaxy Signature USA 
7 2002 Unichem Niche Generics UK 
8 2002 Dr. Reddy's Laboratories BMS 
UK I i 
9 2002 Dr. Reddy's Laboratories Meridian 
UK i 
10 2003 Wockhardt CP Pharma 
UK I 
11 2003 Zydus Cadila Alpharma 
France I 
12 2004 Ranbaxy 
REG Ayentis France 
13 2004 Glenmark Lab Killinger 
Brazil 
I 
14 2004 Dr. Reddy's Laboratories Trigenesis 
US J 
15 2004 Jubilant Organos~'s PSI group 
Belgium ~ 
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In the post 1990 era Indian pharmaceutical firms invested heavily in improving production 
facilities and adopted Good Manufacturing Practices (GMP) and now most of the leading 
companies have their manufacturing facilities approved by the USFDA and UK's MeA. 
By 2003 India had highest number of FDA-approved plants outside the us. India's 61 
such plants are closely seconded by Italy's 60 plants (Fig. 6.4). 
USFDA approved plants outside the 
US 
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Fig 6.4 USFDA approved plant outside US (Source: US FDA) 
Indian pharmaceutical firms filed patents for the indigenously developed novel and non-
fringing processes with the regulatory authorities in the Europe and US. In earlier years 
filling patents in different regions, which required the same amount of data as regulators 
from the developed world helped these firms in acquiring the minimum regulatory 
expertise. This proved to be an effective mechanism for gathering the knowledge required 
for the successful filing of patents in the US and Europe. The experience was further 
strengthened by the successful filing of patent applications for generics (ANDA) in the US 
and by 2000 Indian pharmaceutical firms had firmly established generics R&D capabilities 
and associated regulatory capabilities (Table 6.8). There has been a spate of DMF fillings 
from 2000 and now even small firms are getting into the value added ANDA segment. In 
2003 Indian pharmaceutical firms filed 73 ANDA applications with US FDA constituting 
20% of the total fillings. At the end of 2003 Indian firms had a total of 106 ANDAs 
approved by the FDA while 108 more ANDAs are filed but yet to get appro also In 2003 
Indian firms submitted 119 DMFs accounting almost 30% of total submissions DMF 
submissions in USFDA. 
1 J 1 
Table 6.8 Share of Indian firms in ANDA approvals and DMF submissions to USFDA (Source: CS FDA) 
Year AND A DMF 
Total ANDA by Share of Indian Total DMF by Share of Indian 
Indian approvals Indian submissions 
firms firms 
1997 572 10 1.7 371 31 9.7 
1998 484 9 1.9 944 38 4.0 
1999 380 8 2.1 390 44 11.3 
2000 583 21 3.6 355 37 10.4 
2001 436 18 4.1 344 59 17.2 
2002 753 32 4.2 368 79 21.5 
2003 627 56 8.9 426 119 28.2 
The exposure to global markets, realisation of future regulatory changes and creative 
orientation to imitative research, all facilitated the development of the 'research tradition' 
in these firms. Nelson and Winter (1982) reflecting on the imitative learning suggest that 
'an imitator working with an extremely sparse set of clues about the product might well 
adopt the more prestigious title of 'innovator', since most of the problem is really being 
solved independently'. This upward movement of Indian firms represents the intermediate 
capability stage as the products resulting from generic R&D require input of original 
knowledge and can give leverage to firms in global markets. 
In the case of Indian pharmaceutical firms the creative imitation in the form of generics 
R&D accelerated their movement towards the acquisitions of advanced level capabilities 
further up the value chain in pharmaceutical R&D. 
6.4.5 Collaborative R&D and advance R&D capabilities 
The movement from intermediate R&D capabilities to advanced R&D capabilities is very 
challenging due to the difference of knowledge base and organisational capability. 
However, the creative imitation in the form of generics R&D has increased Indian 
pharmaceutical firms' awareness of opportunities in new drug delivery systems (NODS) 
and NeE research. Many skills and activities required in generic R&D are applicablc in the 
innovative process R&D. The managerial experience in generics R&D has given Indian 
firms some understanding of the complexities involved in innovativc research and 
1 ..., '") 
.' .... 
organisational infrastructure associated with it. Due to their generic business, these firms 
have built information channels with scientific community in advanced countries. 
The advance level of technological capabilities in the case of pharmaceutical R&D 
involves new chemical entity research either by using research strategies like analogue 
research or rational drug design and in terms of process R&D, new drug delivery systems. 
Analogue research involves working on predetermined targets for specific diseases to 
develop molecules that alter the target's mechanism in the diseased person while rational 
or structure based drug design involves the determination of a disease causing protein ~ s 
three-dimensional structure. Once the structure is known, novel chemical entities are 
designed to 'lock-in' to the protein with the aim of reversing or arresting a disease~s 
progresSIOn. 
The main focus in drug delivery system research is in improving the effectiveness of an 
existing drug, in terms of dosage, length of treatment and biodegradability. Many Indian 
pharmaceutical firms with a proven track record in process R&D see new drug delivery 
systems as a risk free strategy. The drug delivery improvements do not impinge on the 
product patents and the cost of stage I and II trials for an improved drug cost almost 1110 
of a new drug. An improved version of an existing drug also assures good market success. 
From 1995, the large Indian firms started investing heavily in new drug discovery research 
and new drug delivery system research as a response to emerging post TRIPs scenario. 
Lupin's Vice President of R&D suggests, 
"Firms have decided strategically whether they should go into drug discovery or drug 
delivery systems. Some companies like DRL clearly gone into drug discovery and then 
companies like Ranbaxy who first gone into drug delivery and then drug discovery. It is 
doing both. So you see again over a period of time; innovation being the platform, R&D 
becomes the key". 
In terms of new chemical entity research, Indian pharmaceutical firms' strategy is not to 
compete with multinational giants like Pfizer or Glaxo, instead their strategy is to leverage 
technical skills. These firms have filed patents for innovative products by using an 
analogue research as their main research strategy (table 6.9). Indian pharmaceutical firms 
are working with already validated or known targets where structural acti yity of the 
compound is well known and these firms try to find a compound that possesses a better 
efficacy or fewer side effects. 
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Table 6.9 Indian pharmaceutical firms' new chemical entity pipeline (Source: Annual Report, 2003) 
No. Companies Molecules in clinical trials 
1 Ranbaxy 6 
2 DRL 4 
3 NPIL 1 
4 Lupin 2 
5 Dabur 2 
6 Wockhardt 1 
7 Torrent 2 
8 Glenmark 1 
9 Sun Pharma 2 
10 Orchid 1 
In the beginning, Indian firms faced major constraints such as financial and infrastructural 
resources, an insular knowledge base and lack of scientists trained in innovative R&D. To 
leverage the financial cost, Indian pharmaceutical firms started investing the revenue 
generated from generic business into innovative R&D. The other strategy used by Indian 
pharmaceutical firms to cover the financial cost was to partner with MNC pharmaceutical 
firms through licensing of molecules or drug delivery system technology. These licensing 
agreements usually involve milestone payments and limited marketing rights. An Indian 
pharmaceutical consultant describes the early efforts of these firms, 
"These companies saw the writing on the wall and worked towards developing the 
expertise in new areas of drug discovery and development research, considering the low 
resources available to them in comparison to those of MNCs, they have adopted a strategy 
of collaborative research through a licensing route, by gaining up-front milestone and 
royalty payments for the molecules licensed by them to MNCs for further clinical 
development ". 
For example, Torrent pharmaceutical licensed its anti diabetic molecule to Novartis at a 
preclinical stage. According to the agreement, initially Torrent will receive a payment of 
USD 0.5 million and it will develop the molecule till a predefined stage. At this stage 
Novartis will have the option to acquire rights for further development. If Novartis 
exercises this option then Torrent will receive an initial payment of $3million and 
subsequent milestone payments depending on progress. If the product is commercialised 
Torrent will get royalties and \,"ill also lead the co-promotion of the product in India. 
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The low cost of research in India has also helped Indian pharmaceutical fIrms' to overcome 
fInancial constraints associated with new drug discovery. The cost of drug discovery and 
development in India could be one tenth of the cost involved in the development of a new 
molecule in advanced countries. The NPIL strategic alliance director comments, 
"I think luckily for us infrastructure cost is not that much. You can buy machines made in 
Indian industries; they are very good. Let's say you want to increase your chemical lab 
from 1 to 4 how much you will spend on utilities, how much you will spend on gases or air 
conditioning or chilled water etc. The cost per dollar per scientist is much less here than in 
the us. See you can replicate that, so infrastructure doesn't cost that much here. Therefore 
there for US$ 50 million you will hardly get 2 rooms; here you can get the whole factory, 
its same thing". 
The other major constraint faced by Indian pharmaceutical fIrms was the knowledge gaps 
in the new chemical entity research, especially in various disciplinary areas involved in 
drug discovery. Indian pharmaceutical fIrms fIlled the knowledge gaps by hiring Indian 
scientists experienced in drug discovery R&D and adopting a strategy of collaborative 
research with Indian as well overseas research institutes. In the post 1995 era R&D 
scientists became the focus area in the Indian pharmaceutical industry as Indian fIrms hired 
scientists from India as well as overseas universities, companies and research institutes. 
Ranbaxy's Vice President, corporate affairs explains, 
"Indian firm did three things; first they recruited people who had that experience. So 
you have Dr. Venkatswarlu in DRL and you have Dr. Khanna in Ranbaxy and host of 
other people; it's not just one person. Second it started doing recruitment in university 
campuses overseas, in areas where educational qualifications were not available in India 
and lastly it stared sending scientists to symposia, training programmes, conferences to 
pick up the ideas". 
The new drug discovery research requires knowledge about various disciplinary areas and 
effective knowledge transfer mechanisms to facilitate the flow of knowledge. Indian 
phannaceutical fIrms employed a collaborative R&D approach to tap disciplinary 
knowledge bases in research institutes. The NCL director points out, 
"we have strong group in peptide and nucleotide chentistry and you see lot of interest 
front industry. Although 10 years ago we had same people with same group and nobody 
was interested, now we have lot of work ". 
Indian research institutes have built a strong supporting infrastructure as required in drug 
discovery R&D such as analytical instruments and facilities for research which most firms 
in the industry are still lacking. For example, the National Chemical Laboratory have the 
combinatorial chemistry machine while the Central Drug Research Institute owns a high 
through-put screening machine. According to NPIL's R&D president, 
"Putting up a modern drug discovery structure may not be possible at present since it 
would need an ultra high throughput screening and big combinatorial chemistry, or a big 
genomic research or molecular modelling. It may be nice to get into this, but it is too much 
money for Indian companies ". 
Indian pharmaceutical firms are collaborating with Indian research institutes to use these 
supportive infrastructural facilities. NPIL's head of regulatory affairs comments, 
"nowadays government funding to research institutes has gone up a lot, I would say 
compare to old days these institutes are really very well of In fact they have more modern 
instruments than industry, in old days it was reverse. So may be you can have tie up like 
some of them have facilities for generating combi-chem libraries, high throughput 
screening facilities and all these kinds of things. So in fact CSIR allows a firm to use 
laboratories facilities and share the IP R ". 
Recognising the imperativeness of taking proactive measures to give the necessary fillip to 
R&D, the Government had set up various schemes to encourage collaboration between 
research institutes and industry. In 1995 under the Department of Science and Technology, 
the Indian government launched a programme called the New Millennium Leadership 
Technology Initiative (NMLTI) to bring industry and academia together. The basic 
objective of this initiative is to synergise the facilities and competencies of publicly funded 
R&D institutions, academia and private industry for developing technologies for the Indian 
industry. The NMLTI programme caters to all industries and is not restricted to the 
pharmaceutical research only. With a financial outlay of Rs. 800 million, DST has 
sanctioned 49 pharmaceutical industry/institutions collaborations so far. In this programme 
50% funding comes from the government and 50% from industry. 
The Indian government also took major initiatives to increase the interactions between 
industry and public R&D institutions in areas of innovative pharmaceutical R&D. In 2000, 
the Indian government created a Pharmaceutical Research & Development Support Fund 
(PRDSF) with an allocation of Rs.1500 million to start with as a plan fund for promotion 
of R&D in the pharmaceutical Industry. Recently the Department of Science and 
Technology cleared five industry- institution research proposals to be funded through the 
PRDSF programme. 
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Due to these initiatives many research laboratories have taken up industry sponsored 
research and established strong partnerships with industrial firms on a long term basis for 
product and process development projects. A patent consultant comments, 
"Department of Science and Technology (DST) has come in big ways and supported a lot 
with funds; if you see the allocation they are almost doubling over the years. So the 
scientists which are trained in the CSIR institutes are being given considerable exposure to 
the international R&D. These scientists are sent for internship and for short term research 
in institutions abroad. CSIR labs are also initiating lot of exchange programmes and 
scientists comingfrom abroad". 
In the post TRIPs era CSIR had launched many initiatives as a response to the changing 
needs of the industry and knowledge generation. According to NCL's business 
development manager, 
"in case of national laboratories, we have integrated programme of 90 laboratories and 
we are looking at leads from plants. We also have industry supported programme under 
the department of science and technology, we are working together with the industry ". 
The research institutes redefined their role for a post TRIPS scenario by investing in 
development of expertise in drug discovery research, generics research and building 
different relationships for each expertise. In the past, academic research meant just 
publishing journal papers but not releasing technologies into the market place. But now 
CSIR labs are becoming more market oriented and collaborating with industry to bring the 
inventions into the market place. Lupin's Vice President R&D suggests, 
"academic institution culture is also changing in line with 2005. Today publication is 
not the measure, patent is measure, innovation is measure. So most academic institutes 
are working on innovative research. Most academic institutes are trying to collaborate 
with tlte industry. Industry is also trying to outsource some work to academia. To get to 
see what innovation is there, we collaborate together. So there is a lot of cooperation 
going on between industry and academia and systems, disciplines are in place. 
Pharmaceuticallteads are in monitoring committee. It has to Itave commercial viability; 
it must Itave ownership by industry for whatever academia is doing so that automatical(l' 
set tlte focus. SOllIe accountability Itas to be tit ere, some deliverables, measurable, 
timeframes and cost". 
Thus Indian pharmaceutical firms are developing advanced pharmaceutical R&D 
capabilities by adopting collaborative research strategies. 
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6.4.6 Capability creation model: Summary 
The capability creation model provides a broad sketch of activities, depths of knowledge 
and abilities associated with the Indian pharmaceutical industry's rise up the value chain. 
The capability creation model reveals that the Indian pharmaceutical industry moved from 
basic R&D capabilities to advanced level R&D capabilities by undertaking different types 
of activities involving R&D processes like duplicative imitation, creative imitation and 
collaborative R&D. 
Over the years the Indian pharmaceutical industry has emerged as one of the most 
technologically advanced knowledge based industries in developing countries. Indian 
policy makers used patent law to infuse life into domestic pharmaceutical firms and 
provided these firms with protection from competition. Indian firms developed capabilities 
for producing drugs in bulk and formulation form by using duplicative imitation. In the 
beginning of 1990 the Indian government liberalised the economy and along with that also 
opened the Indian pharmaceutical market to multinational firms. Indian pharmaceutical 
firms responded to this challenge by flooding the generics market in advanced countries 
with drugs developed through creative imitation. The duplicative imitation era gave these 
firms two advantages that facilitated generics R&D capability creation -
a. cheap and scale intensive manufacturing facilities and 
b. world class organic chemistry skills, honed by years of reverse engineering. 
However with the strengthening of patent law, Indian firms focused on creating a business 
around intellectual property (IP) products by conducting drug discovery research. These 
firms used collaborative R&D approaches to develop advanced capabilities in 
pharmaceutical R&D while funding these investments through formulations and bulk 
generics business. 
6.5 Conclusion 
This chapter described Indian industrial and technological policies and reviewed its impact 
on the development of the Indian industrial technological capability. The review suggests 
that the pharmaceutical policies adopted by the Indian government played a key role in 
growth of Indian pharmaceutical firms. The different Indian policy regimes influenced firm 
level learning processes and shaped the technological capability accumulation in the Indian 
pharmaceutical industry. The capability creation model showed different learning 
processes like duplicative imitation. creatiYe imitation and collaborative R&D used by 
Indian pharmaceutical firms to move from basic capabilities to ad"anced capabilities. 
reflecting the ilnpact of different policy regimes. The implementation of the TRIPS 
agreement represents an important change in the Indian governmenf s pharmaceutical 
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policy in terms of IPR management in country. The analysis suggests that TRIPS has 
increased focus on R&D in Indian pharmaceutical firms and accelerated the movement of 
Indian pharmaceutical firms towards the development of innovative R&D capabilities. 
The next chapter presents the case of six innovative Indian pharmaceutical firms and 
discusses the development of capabilities in each firm. 
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Chapter 7 
INNOVATIVE INDIAN PHARMACEUTICAL FIRMS 
7.1 Introduction 
This chapter describes the development of innovative organisational capabilities in six 
Indian pharmaceutical firms; Ranbaxy laboratories, Dr. Reddy's Laboratories, Wockhardt, 
Nicholas - Piramal ltd, Lupin Laboratories and Glenmark pharmaceuticals ltd. The focus 
of the description is on the processes associated with the transformation of capabilities 
from imitative R&D to innovative R&D in each firm. These firms are used as case studies 
in this research and therefore the findings of this research are based on the analysis of these 
SIX cases. 
Ranbaxy and Dr. Reddy's Laboratories started investing in innovative R&D from the early 
90s while Wockhardt and Nicholas Piramal started in the late 1990s. Lupin and Glenmark 
entered the innovative R&D programmes later than the other firms in this study. 
Table: 7.1 Firms under investigation 
No. Name of the Status Year of Year of Focus Turnover 
firm establish starting Area 2003-04 
ment Innovative Rs. Million 
R&D 
1 Ranbaxy Indian MNC Generics 
laboratories Innovative 1962 1992 NODS 45,301 
ltd leader NCE 
2 Dr. Reddy's Innovative Speciality generics 
laboratories leader 1984 1994 NCE 20,081 
ltd 
3 Wockhardt Innovative Biotech drugs 
Follower 1959 1997 NCE 7,671 
4 Nicholas Innovative Contract research 
Piramal (I) Follower 1988 1998 NCE 12,690 
ltd 
5 Lupin Innovative Herbals 
Laboratories Beginner 1968 2001 Generics 12,327 
Ltd NDDSINCE 
6 Glenmark Innovative Generics 
Pharmaceuti Beginner 1977 2000 NCE 3,806 
cals Ltd I 
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7.2 Ranbaxy laboratories 
Ranbaxy Laboratories Limited, India's largest pharmaceutical firm, is ranked amongst the 
top ten generic companies in the world. It manufactures and markets branded generic 
pharmaceuticals, non branded generic pharmaceuticals and active pharmaceutical 
ingredients (API) across the world. 
Ranbaxy traces its roots to 1962, when Bhai Mohan Singh's family entered into a 
collaborative agreement with the Italian pharmaceutical firm Lepetit SpA for the 
manufacture of the typhoid drug 'Chloramphenicol' in India. In 1967 a change in Lepetifs 
strategy prompted the family to buy them out. In 1973, Ranbaxy became a public limited 
company and began a major investment programme that included construction of a large 
manufacturing plant, initially aimed at producing active pharmaceutical ingredient for the 
Hoffman La Roche tranquiliser, Diazepam. Like other Indian pharmaceutical firms, 
Ranbaxy's early focus was chemical synthesis, or reverse engineering, of known 
compounds. Ranbaxy rapidly developed a strong expertise in process R&D and prepared 
several dosage formulations of the drugs with cheap alternative processes. Soon Ranbaxy 
began exporting active pharmaceutical ingredients and dosage forms on the basis of this 
formidable capability in reverse engineering. From the early 1980s Ranbaxy's started 
concentrating on the international markets for active pharmaceutical ingredients and 
gradually secured an entry into these markets. In 1978 Ranbaxy entered its first 
international market, Nigeria, through a joint venture and in 1984 Ranbaxy expanded its 
operation to Malaysia. According to Ranbaxy' MD, operating in the open and very 
competitive Malaysian market tested and shaped Ranbaxy's capabilities for future 
international expansion (Brar, 2004). The Malaysian operation helped Ranbaxy in learning 
to compete in free markets and enabled the company to build competencies in highly 
regulated generic markets in advanced countries. 
Dr. Parvinder Singh, the chairman and CEO of Ranbaxy from 1993 until 1999 played a 
key role in shaping Ranbaxy's long term vision. In 1993 taking note of the possible 
strategic effect of the TRIPS agreement on the Indian regulatory system, he articulated the 
new mission for the company: to become 'a research based international pharmaceutical 
company with $1 billion in sales by 2003'. The mission statement took into account the 
changing dynamics of the domestic pharmaceutical market as a result of the product patent 
regime that will exist by 2005, prompting the company to start investing in R&D to 
develop its own molecules. This prompted Ranbaxi s globalisation strategy with the 
companis top management setting up a mission to move from a turnover of $ 300 million 
in 1993 to US$l billion in 10 years. Ranbaxy employed a range of strategies~ including 
alliances, partnerships and acquisitions to gain the flexibility needed for Yiable and 
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profitable business operations worldwide. Ranbaxy's major focus was on the genenc 
market in advanced countries and to cater to those markets the company began developing 
indigenous innovative production processes for drugs. 
7.2.1 The generics strategy 
Based on the globalisation strategy Ranbaxy entered the US market in 1995. In 1996, 
Ranbaxy acquired a New Jersey based firm called Ohm Labs and started a joint venture 
with Schein pharmaceuticals for marketing Ranitidine in US. Such agreements helped 
Ranbaxy in establishing manufacturing operations in the US and allowed the company an 
entry into US generic markets. More importantly, Ranbaxy started applying for patents all 
over the world for innovative production processes developed indigenously by the 
company's R&D teams. This enabled Ranbaxy to market almost a third of its major 
products internationally and maintain a steady increase in its net foreign exchange earnings 
throughout 1990s. The experienced gain through such practise also developed the 
company's regulatory skills needed to obtain approvals for its products under the 
Abbreviated New Drug Applications (ANDAs) scheme in the US. Since 1995, it has filed 
for 127 ANDA and has received 81 approvals; the highest for an Indian company (see 
Table 7.2) 
In 1998 Ranbaxy established a 100 percent subsidiary in the US called Ranbaxy 
pharmaceuticals Inc and started marketing products under its brand name. Within just four 
years of starting its US operations, Ranbaxy touched the US $ 100 million mark in the US. 
This proved to be an important turning point in company's growth. By 2003, Ranbaxy 
reached a position among the top 10 biggest players in US generic market. 
Table 7.2 Ranbaxy's generic product filings (Source: Annual Report, 2003) 
Year DMF (Drug Master Files) AND A 
Till 1999 16 49 
2000 6 12 
2001 8 15 
2002 7 25 
2003 9 26 
Total 44 127 
Along side the US market, Ranbaxy began spreading its operations in Europe. In 1995 it 
set up a manufacturing plant in Ireland and opened a subsidiary in the UK. This proyed 
instrumental in Ranbaxy's forays into other European markets. In 2004 Ranbaxy acquired 
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RPG A ventis SA, the fifth largest generics company in France. RPG has a market share of 
6% in France which is the fourth largest pharmaceutical market. 
The success of Ranabxy's globalisation strategy is reflected in the expansion of its world 
wide. The company's products are now sold in more than 100 countries, have 
manufacturing operations in 7 countries and a ground presence in 34 countries. In 2003, 
Ranabxy achieved annual turnover ofRs. 45,301 million (US$ 972 million) and registered 
robust growth of 27%. Overseas markets contributed 76% of total turnover, out of which 
advanced markets like USA! Europe accounted for more than 50%. 
Table 7.3 Globalisation of Ranbaxy's business and subsequent transformation in markets, products 
and capabilities (stars indicate importance/direction in the segment) (Source: Brar, 2001) 
Strategy 
India 
Exports 
I nternatio nal 
Market 
Developing 
Emerging 
Advanced 
Products 
Competencies 
1980-89 
* * * 
* * 
* * 
* * * 
API, 
Dosage forms 
Backward 
Integration 
1990-99 
* * * 
* * * 
* * 
* * 
* * * 
* * 
Generics, 
Branded generics 
Developmental 
2000 - beyond 
* * * 
* 
* * * 
* * * 
Proprietary 
technology 
Platforms, 
NDDS, VGS 
Innovative research, 
research, regulatory patents, Legal 
Manufacturing, 
Marketing 
brand marketing 
for Rx products 
The globalisation trategy allowed Ranbaxy an opportunity to learn about competitive 
practice required to ucceed in intermediate markets. Table 7.3 how the tran formation 
in Ranbaxy' trategic orientation in term of strategIc market, product and 
competencie . The globaJi ation of bu ine ha helped Ranba y in denving bcncfih of 
14 
economIes of scope and scale in larger markets, facilitated the expanSIOn and 
diversification of its product portfolio and aided development of competencies in 
innovative research and regularity areas. In 2004 Ranbaxy passed the turnover of US$l 
billion and evolved a new mission till 2012 for sustaining significant growth called 'Vision 
Garuda', which involves the transformation of the company into a $5-billion company by 
2012. By then, Ranbaxy hopes to place its own drugs in the market and have a healthy 
pipeline of new drugs under development. 
7.2.2 Research and Development 
Ranbaxy laboratory's initial forays into research and development activities began in the 
late 1970s. According to its former R&D president, until 1979 there was no research to 
speak of and the R&D division had only eight people. The initial effort in R&D was 
focused on formulating bulk drugs into dosage forms and on developing cheap processes to 
synthesize bulk drugs. 
In the 1980s Ranbaxy began focusing on developing novel production process that would 
let it side step other company's process patents. In 1985 Ranbaxy found a novel way to 
manufacture the anti-ulcerant Ranitidine, the world's best selling drug and the generic 
version of Glaxo's Zantac. However, the real breakthrough in process R&D came with the 
development of an innovative novel process for Cefaclor. The molecule was owned by Eli 
Lily through a patent the firm had obtained in 1979. This antibiotic was one of the best 
selling drugs in the 1980s. Ranbaxy started work on developing a new seven stage process 
for the production of Cefaclor in 1988. Ranbaxy invested lot of resources to develop a new 
process for synthesising Cefaclor despite internal doubts about committing R&D resources 
to a product that was difficult to manufacture. The number of steps involved in synthesis of 
product, their potential for hazardousness and associated cost made the product too 
expensive for the Indian market. Also Eli Lily had filed more than 70 patents for process 
improvements to protect the drug from generic competition. But after spending three years 
and nearly Rs.20 million, Ranbaxy emerged as the only other manufacturer of Cefaclor. 
Dr. Parvinder Singh, former MD commented that, 
"we moved through maze of over 70 process patents around Cefaclor to produce non 
jiAinging version of the molecule "(Annual Report, 1993). 
Not only did Ranbaxy produce the product successfully but it also managed to obtain high 
yields from its process. Subsequently in 1992 Ranbaxy started a joint venture with Eli Lily 
for the manufacture and supply of Cefaclor. The development of a non patent- infringing 
process for the antibiotic Cefaclor in 1992 gave Ranbaxy international recognition and 
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huge profits. This success proved important for the future progress of innovative R&D in 
Ranbaxy. 
R&D strategic direction 
Segment 2004 2007 2012 
Generics * * * * * * * * * 
NDDS * * * * * * 
NDDR * * * 
Global US $ 1 Bn US$2Bn US $5 Bn 
Sales 
Fig 7.1 Ranbaxy's R&D strategic direction (stars indicate importance/direction in the segment) 
(Source: Annual Report, 2003) 
On the heels of its success with Cefaclor and roughly in tandem with the vision 2003 
exercise, Ranbaxy stepped up its R&D expenditures from 2~1 of sales to 5%. Dr. Parvinder 
Singh challenged Ranbaxy's top management team with his dream of transforming 
Ranbaxy into "an international, research based pharmaceutical company". He consistently 
questioned the imitative R&D mindsets in scientists and started establishing state-of-the-art 
multi-disciplinary R&D facilities at Gurgaon (near New Delhi), India. The company's new 
strategic intent was to ascend the research value chain and accordingly it began to establish 
capabilities in the areas of discovery research, delivery systems and clinical research (Fig 
7.1) 
Ranbaxy decided to focus on NDDS (Novel Drug Delivery Systems) and NDDR (Nev. 
Drug Discovery Research) as key anchors of innovative R&D. Ranbaxy critically reviewed 
its R&D competencies and adopted a two stage approach, beginning with development of 
NDDS platform first and then followed by development of NDDR. Thus development of 
capabilitie in NDDS will act as a stepping stone to development of NDDR capabilitie . 
Therefore focus on NDDRINCE (New Chemical Entitie ) i ~ for long term alue building 
and on NDDS for medium term growth. Ranbaxy's new drug delivery y tern foeu i on 
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developing new ways of administering drugs at the diseases site through value added 
dosage forms and new platform technologies. 
Ranbaxy gradually changed focus of R&D from process R&D to new initiatives in NDDR 
and NDDS. Over the years Ranbaxy has consistently increased R&D intensity from 2% of 
sales to 6 %, showing consistent commitment towards innovative R&D. It has emerged as 
one of the largest investors in R&D in the Indian pharmaceutical industry with R&D 
investment of Rs.2761 million in 2003. In earlier years, investment was largely directed 
towards the establishment of R&D facilities. Ranbaxy's has established three R&D 
facilities; two at Gurgaon and one at Noida. 
The increase in R&D expenditure experienced by Ranbaxy can be seen more clearly from 
table 7.4. Ranbaxy's former R&D president summarises R&D investment as, 
"we started R&D 20 years back and with very small investments every year we improved 
continuously. We invested in R&D whatever little we can invest but we increased our 
investments every year. It has not built in one or two years, it took us really a bit of time, 
10-15 years where it is today". 
In last decade Ranbaxy R&D investment gained momentum as company started funding 
basic research involved in finding new chemical entities through the revenues generated 
from generics business. 
Table 7.4 Ranbaxy's R&D intensity and investment (Source: Annual Reports 1999-2003) 
Year R&D intensity R&D investments ( Rs 
million) 
1993-94 5.9 192 
1994-95 5.1 396 
1995-96 5.3 427 
1996-97 4.3 540 
1997-98 3.9 608 
1998-99 3.6 698 
1999-00 3.6 843 
I 
2000-01 4.2 1193 I 
I 
2001-02 3.8 1266 I 
2002-03 5.2 1921 
2003-04 6.1 2761 
Ranbaxy had no pnor expenence In basic R&D and initially building a strong, well 
focused inter disciplinary research team posed a major challenge. Dr. Khanna who was 
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head of Ranbaxy's R&D had some experIence of drug discovery and that helped in 
building the foundations for innovative R&D. Ranbaxy's former R&D president explains, 
"we got some people who have experience, then provided them infrastructure and built on 
that basis. We haven't got anyone who is really perfect for drug delivery but we had some 
semi- peliect kind of people and then we said let's start. So with our own brain storming 
push and whatever is there we built". 
In 1999 Ranbaxy registered its first success in innovative R&D with the development of 
once-a-day dosage for the Ciprofloxacin molecule. This improvement in dose 
administration promised greater patient-compliance compared to multiple dosages offered 
by the patent holder, Bayer and hence was a major step forward. Former R&D president 
explaining the Ciprofloxacin OD project comments, 
"actually origination was when we made Cefaclor, bulk drug for Eli Lily and that I 
think we licensed in 1991-92. The total quantity we suppliedfor 5-7 years and we made 
huge profits. That was essentially a chemistry outcome in manufacturing bulk drugs. We 
always used to debate that we should have something similar in formulation which can 
give us this quantum profit like in Cefaclor". 
The development of once-a-day formulation became Ranbaxy's first major innovative 
R&D product. Ranbaxy licensed the once-a-day technology to Bayer AG for 
US$10million for further development and marketing in select markets. In 2004 Bayer 
successfully launched 500mg and 1 gm once-a-day formulation in US, based on delivery 
technology platforms developed by Ranbaxy, thereby triggering the milestone and revenue 
sharing payments. 
Table 7.5 Ranbaxy's NeE pipeline (Source: Annual Report, 2003) 
Urology (BPH) 
Anti- Malaria 
Respiratory 
diseases 
Bacterial 
Infections 
Preclinical 
NeE pipeline 
Pha.~e I 
RBx 9001 
RBx11160 
RBx003 
RBx7644 
Phase n Phase m 
RBx2258 
RBx7796 
1.f7 
Ranbaxy's new drug discovery R&D focus now includes urology, anti-infecti\'e. 
respiratory, anti-inflammatory and metabolic disorders segments (Table 7.5). 
Ranbaxy's first NCE, RBx 2258, for Benign Prostrate Hyperplasia (BPH), has been 
licensed to Schwarz Pharma AG of Germany and is presently undergoing Phase II clinical 
trials in India. Schwarz Pharma obtained the exclusive rights to develop, market and 
distribute the product in the US, Japan and Europe, while Ranbaxy retains rights for all 
other markets. In 2004 Ranbaxy received US $ 4 million milestone payment from 
Schwartz Pharma in addition to already received upfront payment of US $ 6 million. 
Ranbaxy's other promising drug candidate RBx 7796, anti-asthma molecule, is also 
undergoing Phase II clinical trials. Besides these, the company has other molecules in its 
NCE pipeline, which are at different stages of clinical development. 
Despite having a few molecules in clinical and preclinical trial stages, Ranbaxy reached a 
critical stage by 2002 as bulk of its R&D was in generics. Ranbaxy needed more scientists 
with the experience in state of the art drug discovery technologies, particularly to cut down 
the failure rates. It also needed to take quick and clear decisions on several aspects of drug 
discovery like which diseases to concentrate on, techniques to employ etc. To fill those 
knowledge gaps Ranbaxy started hiring Indian scientists based in USI Europe, working 
with multinational R&D laboratories. Former R&D president explains, 
"we have brought a lot of them; I have brought a lot of them. Almost 20% population is 
from US". 
The size and infrastructure in Ranbaxy's R&D, success of Ciprofloxacin OD and the 
credibility it gained form its global alliance with Eli Lily helped company in its efforts to 
encourage 'reverse brain drain'. In 2003 Ranbaxy hired Dr. Rashmi Barbhaiya, who was 
vice president of drug discovery in Bristol Mayer Squib (BMS) as its R&D director. He 
was closely involved in many contemporary drug discovery technologies in BMS. After 
Dr. Bharbhaiya, Ranbaxy hired Dr. Batra from Schering Plough Research Institute in the 
US, as a new vice president pharmaceutical development to lead the development of new 
chemical entities and new drug delivery research. 
In 2003, under the leadership of Dr. Bharbhaiya Ranbaxy took some key decisions 
regarding future direction of its R&D. It decided to focus the research on a few key 
diseases which involve easy targets and relatively simple and short clinical trials like 
infections. metabolic disorders. urology. inflammations and respiratory diseases. In these 
therapeutic segments there is much less competition because many multinationals ha\'c 
been focusing on other areas of research like cardio\'ascular, anti diabetic or anti obesity. 
Ranbaxv decided to put on hold rational drug design strategy and instead choose analogue 
research as main new R&D strategy. Analogue research in\ohes working on 
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predetennined targets for specific diseases to develop molecules that alter the target's 
mechanism in the diseased person. Therefore company decided against large scale 
investments in biotechnology, systemic biology and other biological areas like genomics or 
proteomics. It also decided not to invest in high throughput screening or to build a large 
library of potential drug molecules. 
In recent years Ranbaxy has massively increased R&D staff to create a critical mass of 
scientists working in R&D. In 2004 Dr. Rajinder Kumar, previously global head of 
Psychiatry - clinical research & development at Glaxo Smithkline (GSK) took charge of 
Ranbaxy's R&D with responsibility of accelerating company's drug discovery effort. 
Ranbaxy's focus is now on recruiting the scientific staff to create critical mass in tenns of 
different scientific disciplines involved in discovery research (see Table 7.6). 
Ranbaxy has institutionalised the research review process in the company by setting up a 
science committee. In 1999 Ranbaxy set up the scientific advisory committee under the 
leadership of Dr. Nityanand, fonner head of Central Drug Research Institute, India. The 
tenns of reference of science committee include R&D organisation structure, monitoring 
the R&D activities in global perspective and laying down the guiding principle for 
attracting, retaining and rewarding high calibre scientists as well as implementing a policy 
framework for collaborative R&D programmes. 
Table 7.6 Ranbaxy's R&D employee strength (Source: Annual Reports, 1999-2003) 
Year Total number of No. of people in Scientists 
people R&D 
1994-95 4703 325 
1995-96 4478 380 
1996-97 6131 456 
1997-98 5655 443 
1998-99 5469 498 330 
1999-00 5347 490 410 
2000-01 5784 512 410 
2001-02 6424 580 474 
2002-03 6297 700 583 
2003-04 6797 919 650 
Ranbaxy has also set up a US R&D facility to focus on three areas: clinical research. 
regularity affairs and to give commercial inputs on diseases, targets and compounds to be 
pursued. 
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7.2.3 Strategic R&D alliances 
The other important feature of Ranbaxy's strategy for building capabilities in innovative 
R&D is collaborative research with national and international research institutes. In 2000 
Ranbaxy put together a dedicated team of young professionals to explore and identify in-
licensing! out- licensing and co-development opportunities in areas of new technologies 
and value added products. Ranbaxy is strengthening its collaborative research initiatives 
through alliances with drug delivery companies, research institutes and international 
universities. According to Ranbaxy's Vice President, Corporate Planning, 
"in case of Ranbaxy, collaborative research is linked with the outsourcing philosophy as 
well as filling up gaps in-house capability. It's linked to the number of factors; it's your 
own scientist's capabilities, their experience and exposure ". 
In case of Ranbaxy's drug delivery system research collaboration with UK universities and 
research institutes played a significant role in technology development. The senior scientist 
who led Ranbaxy's effort in Ciprofloxacin OD project credits collaboration with Dr. John 
Staniforth from University of Bath as one of the reasons behind the success of the project. 
Ranbaxy's patent for once-a-day drug delivery system lists Prof. John Staniforth as one of 
the applicants. Following on the success of Ciprofloxacin OD project, in 2001 Ranbaxy 
started collaboration with Vectura limited, a company founded by Prof. John Staniforth. 
Vectura is known for its expertise in application of particle science for the development of 
novel drug delivery systems to develop a novel cost effective, patent protected, oral 
controlled-release technology with potential application for a broad range of 
pharmaceutical compounds. In 2003 Ranbaxy entered collaboration with Institute of 
Nuclear Medical and Allied Sciences (INMAS) for screening and evaluation of 
formulations and drug delivery systems using Gamma Scintigraphy. 
Following the collaborative R&D success in new drug delivery systems Ranbaxy created 
similar alliances for drug discovery research. In 2003 Ranbaxy entered into alliance with 
Glaxo Smithkline (GSK) to discover and develop novel therapies in Ranbaxy's four focus 
therapeutic areas. In a first of its kind of agreement in India, GSK will provide lead 
molecules that act on drug targets specific to Ranbaxy and GSK. Ranbaxy will deploy its 
chemistry team to optimise its chances of success. Ranbaxy will conduct the early clinical 
work which GSK will complete the development. In some cases Ranbaxy will develop its 
own molecule up to Phase II clinical trials and then GSK will carry out late stage 
development of that molecule. 
Ranbaxy's other important collaboration in drug discovery R&D is with the Medicines for 
Malaria Venture (MMV) Geneva, in the development of anti-malarial drugs. Under this 
collaboration Ranbaxv's team of scientist will work together with Unhcrsity of Nebraska's 
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Medical centre, Monash University and the Swiss Tropical Institute to identify lead 
molecules. The development work from pre clinical to clinical studies will be carried out 
by Ranbaxy. The lead candidate from this programme, molecule Rbx 1160 is currently 
undergoing clinical studies in the UK. 
Ranbaxy's innovative R&D strategy has identified biological disciplinary areas like 
genomics, proteomics and systems biology for collaborative research. Ranbaxy plans to 
make up for its biological deficiencies by building network partnerships with overseas 
companies, research institutes and universities. In 2003 Ranbaxy collaborated with 
University of Queensland and Harvard Medical School, US to undertake research in 
biotechnology. In 2004 Ranbaxy signed a collaborative research agreement with A vestha 
Gengraine Technologies Pvt Ltd, to carry out project relating to construction of 
recombinant cell lines required for screening Ranbaxy's drug candidate. 
Over the years Ranbaxy has established strong relationships with Indian research institutes. 
In 1999 Ranbaxy initiated seven R&D projects in collaboration with CSIR labs in various 
areas of innovative R&D. In 2003 Ranbaxy started a collaborative project with University 
Department of Chemical Technology (UDCT), Mumbai involving work on computer aided 
rational drug design and synthesis of new chemical entities. The cost of the project is 
jointly shared by UDCT, Department of Science and Technology (DST) and Ranbaxy. 
In 2004 Ranbaxy signed an agreement with Anna University, Chennai to collaborate on 
drug discovery. Under this agreement, Centre for Biotechnology (CBT), Anna University 
would screen compounds from natural screens as well as synthetic sources. The leads from 
this programme will be optimised and candidates would be identified for further 
development, Ranbaxy would then conduct further clinical development on discovered 
leads. In the same year Ranbaxy entered into research collaboration with National Institute 
of Pharmaceutical Education and Research (NIPER), Mohali and Department of Science 
and Technology (DST), New Delhi, in the area of drug discovery. 
In 2003 Ranbaxy formed a joint venture with Kasturba medical college to set up the 
clinical trial centre to build development phase capabilities. 
7.2.4 Summary 
Ranbaxy is aiming to achieve significant business presence in proprietary prescription 
products in advanced markets by 2012 and is therefore investing in innovative R&D to 
enable a transition from a generic focused company to a branded/specialty pharmaceutical 
product company. Ranbaxy is aggressively hiring senior scientists from overseas and 
practising collaborative R&D to become a research- based international pharmaceutical 
company. 
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7.3 Dr. Reddy's Laboratories (DRL) 
Dr. Reddy's Laboratory (DRL) has emerged as the first Indian pharmaceutical company to 
discover a new chemical entity and license it to MNC pharmaceutical firm. In the last 
decade it has consistently ranked amongst the top ten pharmaceutical firms in India. Now 
the company has 15 manufacturing plants in India, 2 plants in UK and 1 in China. It has set 
up 23 subsidiaries for distributing and marketing pharmaceutical products in the domestic 
and international markets. DRL which started as a bulk drug manufacturer in the 1980s, 
moved to a formulation-focussed company in early 1990s, upgraded itself as a US focussed 
pharmaceutical company in the mid 1990s, and finally it is transitioning into 'a research 
based international company'. Since the start of its operation DRL has continuously sought 
to move up value chain in terms of pharmaceutical products, markets and capabilities. 
Dr. Reddy's laboratories (DRL), founded by Dr. Anji Reddy in 1984, has grown into a 
fully integrated pharmaceutical company with an annual turnover ofRs. 20,081million (US 
$500 million) in 2003. Dr. Anji Reddy began his career with Indian Drugs and 
pharmaceuticals ltd (IDPL), a public sector company after completing his doctoral research 
from National Chemical Laboratories (NCL) India. At IDPL Dr. Reddy gained the hands 
on experience in the manufacturing and implementation of new technologies in bulk drugs. 
After working for six years, he set up two bulk drug companies called Uniloyds and 
Standard Organics in partnerships with two other colleagues. However, he decided to go 
alone and set up a new company called Dr. Reddy's Laboratories Ltd (DRL) in 1984. Dr. 
Reddy's competence was his focus on organic synthesis and under his leadership DRL 
successfully commercialised a variety of new technologies. After a few years, Dr Reddy 
developed a group of scientists with core skills in process research, which enabled DRL to 
develop processes for a number of molecules in a short span of time. DRL started as a bulk 
drug company and with the effort of Dr. Reddy it moved into the formulations business. In 
1986 it started operations on branded formulations and within a year launched Norilet, 
DRL's first recognised brand in India. But big success came with launching of Omez, 
Omezaprozole which DRL managed to launch at 50% lower prices compared to other 
brands prevalent in Indian market at that time. DRL successfully reverse engineered many 
popular patented drugs to expand its therapeutic presence and within a year of its 
inception, DRL became the first Indian company to export bulk drugs or API to Europe. 
Dr. Reddy attributes entrepreneurial thrust and initial success of DRL to the 1970 patent 
law, 
"11'e are products of that (1970 lal1'). But for that, we wouldn't be here. II l1'aS goodfar the 
people of India. and i111'OS goodfor Ihis company" (Forbes, 2001). 
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In case of DRL the transition from predominantly API focused firm to being a formulation 
company took place in 1994. 
With India's shift from current process patent regime to post 2005 product patent regime, 
the broad strategy of DRL is to develop new molecules for licensing through innovative 
R&D and target advanced market for speciality generics product. Dr. Reddy noted, 
"the Indian pharmaceutical industry benefited in the early years due to lack of a patent 
regime. Now that the party is over, there is likely to be a lot of consolidation towards 2005. 
Indian companies need to focus on opening up new markets and we took a step in that 
direction few years ago" (Industry 2,2003). 
DRL strengthened its Indian operation by acquiring American Remedies limited in 1999 
and merging Cheminor Drug Limited (CDL) with DRL in April 2000. This acquisition and 
merger made DRL the third largest pharmaceutical company in India, after Ranbaxy and 
Glaxo (I) ltd. DRL post merger was a fully integrated pharmaceutical company, covering 
the full spectrum of pharmaceutical products, which included bulk drugs, intermediates, 
finished dosages, chemical synthesis, diagnostics and biotechnology. DRL merged 
Cheminor Drug Limited (CDL) with primary mm of supplying APIs (active 
pharmaceutical ingredient) to the technically demanding markets of North America and 
Europe. Cheminor was part of DRL from 1984 and this merger gave DRL entry into value 
added generics business in the regulated markets of APIs. 
7.3.1 The generics strategy 
DRL began its major international operation by entering Russia through a joint venture 
with Biomed in 1992 and in 2002 DRL converted lV into its 100% subsidiary. DRL started 
targeting US generic market by building state of art manufacturing facility in 1994. In 
three years DRL filed its first ANDA (abbreviated new drug application) in 1997 for 
Ranitidine 75mg tablets, and improving on that, in 1999 it submitted a Para IV application 
for Omeprazole. But the big achievement of DRL generic foray came in 2001. In 2001 
DRL became the first Indian company to launch a generic drug, Fluoxentine with 180 day 
market exclusivity in US. As a result of market exclusivity DRL's international sale of 
Fluoxentine 40mg, a generic version of Eli Lilly's Prozac increased massively. The 
generic turnover touched $23.2 million for the third quarter of 2001, with Fluoxentine 
contributing 87% of these sales. 
In January 2003 DRL launched Ibuprofen tablets 400, 600 and 800 mg in the US under its 
own brand name. Ibuprofen became the first generic product to be marketed under DRL 
brand name and thus represented a significant step in DRL's efforts to build a strong and 
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sustainable US generic business. Direct marketing of Ibuprofen was the first step In 
building DRL's fully fledged commercial organisation in the US market. 
In 2002, DRL started its European operation by acquiring two pharmaceutical firms in UK. 
The acquisition of BMS Laboratories and its wholly owned subsidiary, Meridian UK 
allowed DRL to expand geographically and gave company an opportunity to enter the 
European market. 
Table 7.7 DRL' generic product filings (Source: Annual Report, 2003) 
Year DMF (API) ANDA (Formulation) 
Till 2000 18 
2001 8 8 
2002 14 14 ( Para IV -10) 
2003 16 13 
Total 56 35 ( Para IV - 24) 
By 2003 DRL filed 56 DMFs (drug master file) and 35 ANDAs applications with USFDA, 
showing strong capabilities in innovative process R&D and regulatory management (see 
Table 7.7). Mr. G V Prasad, Managing Director of DRL summarises the company's 
journey towards generics, 
"at DRL our starting value proposition was world class skills in synthetic organic 
chemistry. We started as a bulk, API company. Through our experience in India we 
started tapping export opportunities in less regulated markets and in the early 1990s 
shifted focus to the US and other regulated markets. That's how we used the value 
proposition to evolve into a global provider of bulk actives. We started moving up the 
value chain by building on our chemistry skills through vertical integration into finished 
dosages (formulations). The move into generics business was not an easy decision. 
Leveraging the API advantage, DRL has built an exciting pipeline for generics 
business" (prasad, 2003). 
In 2004 DRL acquired Trigenesis Therapeutics Inc; the US based private dermatology 
company. This acquisition gave DRL access to certain products and proprietary 
technologies in dermatology segment. 
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7.3.2 Research & Development 
Recognising the importance of innovative basic research in the post 2005 Indian scenario~ 
DRL built the Dr. Reddy's Research Foundation (DRF) in 1992. DRF is exclusively 
dedicated to research in area of new drug discovery and became the first organisation in 
the Indian pharmaceutical private sector to take up basic research. 
The main objective of setting up this foundation is to discover and develop new chemical 
entities in selected therapeutic areas. Dr. Anji Reddy said, 
"I made up my mind that we can get into drug discovery and took the plunge on 6th 
November, 1993. We jumped into discovery with a budget of about Rs. 65 millions" 
(Reddy, 2004). 
The companies which are part of DRL group commit sizeable resources to support this 
state of the art 'research foundation'. For two years from 1991 to 1993 DRF invested 
heavily in building the physical infrastructure and from 1993 it started recruiting R&D 
staff. The foundation currently has teams of experts from different disciplines such as: 
medicinal chemistry, organic synthesis, fermentation, biochemistry, pharmacology and 
tissue culture. 
DRF started work on drug discovery under the leadership of Dr. Reddy and a core group of 
senior scientists. There were very few scientists with experience of drug discovery in the 
Indian industry or academia. Therefore DRF build the core team for discovery research 
with 4 scientists who had the experience of drug discovery in multinational R&D. Dr. 
Venkatswarlu, DRF president till 2000, had experience of working in Ciba Geigy, 
Hoechest and SmithKlime Beecham. Dr. Rajgopalan, pharmacologist and current president 
of DRF, whom Dr. Venkatswarlu recruited, previously worked on drug discovery in 
Hoechest. Dr. A K Sadhukam had experience of microbiology in Smith Kline Beecham 
and Dr. G Om Reddy came from Astra - IDL. Out of this core team three were in discovery 
research and had the requisite experience of the complexities involved in drug discovery. 
This core group along with Dr. Reddy were responsible for introducing scientific 
programmes, inducting people and making them productive. 
In the beginning DRF's drug discovery research strategy revolved around analogue 
research and created initial success for the company. Dr. Reddy explains, 
"I began looking at molecular structures and realise to my surprise that many players, 
including some of the global majors, were just tinkering around with the molecular 
structure. Seeing this I realised that (f it takes to discover drugs, then we could also be in 
race" (Business Today. 2001). 
In three years of starting innovative research DRF discoyered one of the most potent 
glitazones. Ragagltizar. A Japanese company Sankyo already discoyered class of 
compounds called glitazones that sensitises the body to insulin. Dr. Reddy got interested in 
the activity of glitazones and pushed his team to come up with better molecules. DRF 
scientists researched the activity of glitazones and came out with two new molecules, 
Ragaglitazar and Balaglitazone (DRF 2593). DRL has licensed the molecule Balaglitazone 
(DRF 2593) to Novo Nordisk. This molecule has shown excellent anti-diabetic activity in 
Phase II clinical trails and now Novo Nordisk is planning to take it to Phase III clinical 
trials. 
Soon DRF began evaluating its R&D capabilities and started hiring scientists to fill 
knowledge gaps (see table7.8). Dr. Anji Reddy explains, 
"in year 2000, we began to reflect on our inadequacies. It is one thing to bring NCEs to 
development by analogue research - but the path breaking developments in science 
including the unravelling of human genome, was paving the way for newer hitherto 
unknown targets in drug discovery. We decided to get into this area and started scouting 
for talent all over the world" (Reddy, 2004). 
DRF focused on hiring fresh scientists to work in discovery R&D and identified Indian 
students studying abroad on doctoral and post doctoral courses as one of the main source 
of talent. DRF's former R&D president elaborates, 
"our target was returning Indian students who have gone abroad to do either PhD or 
post docs. They were returning and were very good. Actually for 90% of DRF's R&D 
workforce, it was their first job, whether a bench chemist or vice president, first job in 
the industry. Since we recruited all fresher, it was easy to mould them. So what we did 
from day one became the practise. No one had experience of reverse engineering and all 
were from universities or NCL or NIH. They were not into reverse engineering and it is 
afact that 'reverse engineering' mindset has not come in way of innovative R&D". 
Table 7.8 DRL's R&D employee strength (Source: Annual Reports, 1998-2003) 
Year Total number of No. of people in R&D 
people 
1998-99 
1999-00 2100 229 
2000-01 
I 
2001-02 5500 500 
-
2002-03 5852 725 
- - -
2003-04 
---- ---
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Over the years DRL has consistently increased the R&D intensity of the finn but it 
gathered momentum in late 1990s as DRL started spending nearly 5% to 8%of its turnover 
on R&D compared to industry average of2-3% (table 7.9). During 2003-04 DRL increased 
its investment in R&D initiatives to about 10% of total revenue against 7.6% spent in 
2002-03. This is highest R&D investment to sales ratio in Indian pharmaceutical industry. 
Table7.9 R&D investment of Dr. Reddy's Laboratories (Source: Annual Report) 
Year R&D intensity R&D investments 
(Rs. Million) 
1998-99 2.15 133 
1999-00 2.69 179 
2000-01 4.22 415 
2001-02 6.29 980 
2002-03 7.7 1338 
2003-04 10 1910 
DRF currently has 8 NCEs in various stages of development. Research thrust at DRL is 
focused towards anticancer, anti diabetes, cardiovascular drugs and anti infective (table 
7.10). In 2003 DRL commenced its first clinical trial programme in Canada on DRF 10945 
for the treatment of dyslipidemia. Now DRL has four molecules in clinical development 
and another four in preclinical stages of the development. DRL is pursuing the clinical 
development of three molecules on its own while fourth DRF 2593; the licensed molecule 
is now developed by Novo Nordisk. This is in line with DRL's strategy of investing in own 
discovery molecule up to Phase II and then pursuing licensing opportunities. Through this 
route DRL is building in-house capabilities for drug development as well as enhancing the 
value of new chemical entities. In the licensing deal with Novo Nordisk, DRL got upfront 
payment and will also be receiving milestone payments after successful completion of 
different phases of the clinical trials. Novo Nordisk will take up clinical trials, the 
packaging and global marketing of drug while DRL will be the sole global manufacturer of 
the drug. 
DRF is planning to take DRF1042, an anti cancer molecules to market on its own. DRF 
1042 is a novel orally active camptothecin analogue and is currently undergoing Phase II 
clinical trials in India. 
Table 7.10 DRL's NCE pipeline (Source: Annual Report, 2003) 
Metabolic 
Disorder 
Cardiovascular 
Disorder 
Cancer 
Bacterial 
Infections 
Preclinical 
DRL 11605 
DRF 5265 
DRF 13792 
NeE pipeline 
Phase I Phase n 
DRF 10945 DRF2593 
RUS3108 
DRF 1644 DRF 1042 
Phase 
DRF has put lot of emphasis on attending and presenting its work in different conferences. 
The company views it as an important constituent of creating stimulating R&D 
environment that encourage creativity and innovative thinking. Scientists in DRF patent 
their inventions globally and are encouraged to publish their research findings in some of 
the foremost peer reviewed scientific periodicals and conferences around the world. In 
2001 DRF announced a new anti diabetic molecule at the American Heart Association's 
conference while in 2002 it showcased its anti bacterial molecule at the ICAAC (Inter-
science Conference on Antimicrobial Agents and Chemotherapy) in US. Former R&D 
president explains, 
"we are publishing; we have nl0re than 100 publications. Last year in international 
conference on chemotherapy and microbiology, we had 10 abstract acceptances. This 
year there was American Diabetic Association conference, we had 4 presentations. The 
thinking behind that is first of all, we need to showcase our science. There is no point in 
keeping it by chest, we need to showcase. It also stimulates scientists thinking. First, it is 
promoting a different set of interactions. If our people have gone and made 
presentations in a conference which 1000 scientists are attending, then its validation of 
our science. People come, ask questions and our people stand up and give answers. All 
this adds, first of all to scientist's personality development, exposition of our sciences, 
showcases our work and also learningfrom other scientists' working". 
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Till 2004 DRL has published more than 110 research papers in various peer reviewed 
international and national scientific journals. Dr. Reddy summarises DRF~ s publishing 
philosophy, 
"] have found that in managing science, especially drug discovery, one need to temper the 
commercial imperative with scientific wisdom. When well meaning friends discouraged my 
forays into drug discovery, ] told to my scientists, if we are not able to discover new drugs, 
at least we will definitely publish research papers in reputed journals "(Business India, 
2001). 
The other significant aspect of DRF's R&D set up is the extensive arrangement for review 
of its innovative research. For external review DRF has set up a scientific advisory board 
with best of international and Indian scientists to generate international level project 
reviews, advice and interactions. Eminent scientists like Dr. Mehta, chemist and molecular 
biophysicist; Dr. Balsubramanyam, ex director of CCMB(Centre for Cellular and 
Molecular Biology) ; Dr. Shyam Parthsarathy, anti-oxidant specialist; Dr. K Janardhan 
Reddy, originator of PPAR concept; Dr. Peter Houton from 8t. Jude's medical hospitals 
and Dr. Ashok Ganguli, makes up the DRF's scientific advisory board. This board meets 
specifically twice a year and works as a forum to which DRF scientists expose their ideas 
to international experts, outside boundaries of the company. 
Internally also, DRF's top scientists regularly conduct review meetings, in some projects 
on a weekly basis. Apart from that, on a monthly basis there is monthly report; monthly 
reviews where each scientists makes the presentation on what they have done, what they 
plan to do. This is critiqued, peer reviewed and action plans are formulated. 
DRF is launching many initiatives to retain, train and develop its manpower. These 
initiatives are driven by a three pronged objectives: technology, entrepreneurship and 
globalisation. Looking outside the pharmaceutical industry DRL adopted the revolutionary 
human resource practices present in Indian IT companies. DRL following the Indian 
software companies' human resource philosophy launched different initiatives like 
performance linked pay, culture building activity and leadership development programmes 
(Business Today, 2003). DRL also established a learning centre in 1998 to conduct various 
on the job learning and development programme for its employees. DRL has signed a 
memorandum of understanding with Birla Institute of Technology and Sciences (BITS) to 
promote educational and research activities in the areas of chemistry, pharmacy and 
biotechnology. BITS operates an off campus centre at DRL and conducts educational 
programmes designed to meet the development needs of DRL's employees. In 2003 DRL 
organised convocation and 61 employees were awarded MSc degrees in pham1aceutical 
operations and management and MSc in pharmaceutical chemistry. 
DRL is continuously organising special programmes to give technical staff intellectual 
property skills and project management skills. 
7.3.3 Globalisation of innovative R&D 
DRF after establishing discovery research in Hyderabad wanted to introduce modern skills 
such as drug discovery based on genomics and proteomics. It wanted to move from 
analogue research towards the target based discovery or rational drug design but struggled 
with this change. Former R&D president described the situation as, 
"we could not recruit the requisite skills because it's not the one scientist, you need whole 
team and we could not do this for the period of three years. rVe located scientist but 1 or 2 
may be willing to come out but they had inhibitions and the.l' needed lot of time and they 
were unable to take decisions. Then we decided there is no point in waiting. We can nOl 
bring people here; we will move our lab there". 
Therefore in 2000, DRF set up a lab in Atlanta, US dedicated to discovery and design of 
novel therapeutics. The lab is called as Reddy US Therapeutics Inc (RUSTI) and primary 
aim is to conduct drug discovery using molecular genomics and proteomics approaches for 
next generation drugs. Dr. Reddy explains, 
"I went to US because it was necessary for my survival. I couldn't get the talent for 
biotech research in India" (Business World, 2002). 
DRL recruited Dr. Uday Saxena as CEO of its Atlanta subsidiary and within two months 
RUSTI built a team of 12 scientists. In few years RUSTI developed a technology platform 
and a discovery approach based on the cell matrix signal1ing (CMS) pathway. A lead 
molecule, RUS31 08 is currently in the late preclinical stage 
Identify 
target 
RUSTI, Atlanta 
Target based approach to drug discovery 
Target and biology platform 
I 
1 
DRF, Hyderabad 
Traditional approach to drug discovery 
Organic chemistry and pharmacology 
J 
Aurigene Discovery Technologies 
Fig. 7.2 Building structural biology and medicinal chemistry skills through structured based drug 
design (Source: Annual Report, 2002) 
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DRF raised the funds for international expansion of R&D through IPQ (initial public 
offering) in us. In 2001 DRL completed its US initial public offering ofUS$132.8 million 
ADS (American depository shares) issue and listed on the New York Stock exchange. The 
funds collected from US IPO were diverted into the international expansion of R&D. 
Aurigene is another research based company promoted by Dr. Reddy's laboratories with an 
investment of Rs 111 million in 2001. It is launched as a contract research company to 
provide discovery services to the pharmaceutical and biotech companies. By setting up the 
Aurigene DRL have direct access to discovery research out of three labs (Fig. 7.2): 
a. Dr. Reddy's Research Foundation (DRF), 
b. Reddy US therapeutics (RUSTI) at Atlanta and, 
c. Auriegene at Bangalore and Boston. 
DRF arranges the visits of scientists working in India to its labs in Atlanta and Boston. 
Former R&D president comments, 
"we created important resource by opening lab in US. We wanted an address in US, in 
many ways it is very useful to us. Second, America is home for doing research and we 
thought it will allow us exchange scientists between here and there; cross fertilisation of 
cultures, ideas and then it will make our R&D truly global. WI,en our scientists go for 
conference in US, they spent few days in the Atlanta and vice versa. Their scientists 
come and we want to have more exchange programmes. A scientist from there can come 
back here and work here for several months". 
In 2003 DRL invested Rs. 251.3 million in equity capital of Bio Sciences ltd. In 2004, 
DRF celebrated its 10 year anniversary by organising an international symposium on drug 
discovery called Pharmacophore 2004, addressing the symposium Dr. Reddy said, 
"analogue research first and target based discovery next - we have forayed into both~~. 
7.3.4 Strategic R&D alliances 
DRF has initiated a variety of R&D alliances and collaborations with Indian as well as 
international research institutes, universities and companies. In the beginning DRF entered 
into alliance with the Centre for Cellular and Molecular Biology for utilising its facilities in 
the pre -molecular stage research. DRF collaborated with other premier Indian research 
institutes like UDCT (University Department of Chemical Technology. Mumbai). National 
Institute of Nutrition and Indian institute of Sciences. Over the years DRF has built R&D 
links with international research institutes, universities especially in the US to support its 
own drug discovery research. In the past DRF had alliance with North \\'estem University 
t 6 t 
medical school in Chicago, National Cancer Institute, and National Institute of Health~ 
which played an important role in DRF's learning about intricacies of particular 
therapeutic segments. These interactions are used to augment DRF's capabilities and fill 
R&D gaps; what DRF couldn't do at home, it got things done from there. Former R&D 
president explains nature of interaction, 
ttactually we have deputed one of our scientists in North West Medical School, to go and 
work with professor who is an inventor of or who originated PPAR concept. He went 
and spent more than two years and he has written two pUblications also and we are very 
happy about it". 
DRF has licensed its molecules to MNC firms like Novo Nordisk, Novartis and these 
licensing agreements have also proved to be effective source of learning. Apart from 
financial gains these partnerships gave DRF an opportunity to learn new capabilities 
through joint working in the project. According to DRF R&D president, 
"whenever we have licensing agreements with MNCs, we not only exchange data but we 
also exchange information. Then we sit down, we participate in some of things of the 
project and then learn things from other companies. It is continuous process and that is 
how we always structured our deals. So it is continuous education ". 
Although DRF progress in innovative R&D is quite remarkable, it also had fair share of 
failures. In 1998 DRF signed the agreement with Novo Nordisk to develop and market 
pharmaceutical products of its first molecule, Ragaglitazar. However in 2002 adverse 
effects appeared during clinical trials and Novo Nordisk abandoned research on the 
molecule and decided to work on another DRL molecule, Balaglitazone. In 2002, DRL 
granted exclusive rights for the development and commercialisations of DRF 4158 to 
Novartis Pharma AG, however in 2003 Novartis opted to replace dual acting insulin 
sensitizer, with other follow up compound. However according Dr. Reddy this proved to 
be an important learning experience and led to a change in company's licensing policies; 
DRF decided to out license the molecule only after completion of Phase II of clinical trials 
DRF's fonner R&D president who led company's R&D effort from the beginning till 2002 
summarises efforts at DRF saying, 
"~I think this is greatest thing - creation of world class resource from scratch in a 
location away from the mainstream of pharmaceutical R&D, in the remote corner where 
we did" 't eve" have patent regime ". 
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7.3.5 Summary 
DRL initially started as a manufacturer of bulk actives and using process development 
skills DRL developed several bulk actives and finished dosage. Then DRL moved into 
generic products targeting the highly regulated but very profitable markets in advanced 
countries. From 1990s DRL started developing capabilities in innovative R&D under the 
leadership of core team of experienced scientists and by hiring teams of fresh scientists to 
work with them. DRL expanded its R&D overseas and formed collaborations with research 
institutes and universities. Former R&D president of DRF comments on company's R&D 
efforts, 
"in fact even before we truly globalise our marketing, we globalise our R&D which 
nobody has done. We are the first and our experience is fantastic ". 
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7.4 Wockhardt Ltd 
Wockhardt is now ranked among the top ten companies in India and has developed 
comprehensive expertise in manufacturing and marketing of pharmaceutical and 
biotechnology products. Wockhardt's product portfolio includes pharmaceuticals (bulk 
drugs and formulations), medical nutrition, Agri-sciences and hospitals. Wockhardt ltd was 
started by Khorakiwala family in 1959 as a small pharmaceutical distribution and selling 
entity. The company set up its first formulation plant in 1977 and soon established a bulk 
drug plant in 1983. Now Wockhardt has 8 manufacturing plants in the Aurngabad - 6 in 
the new biopharmaceuticals complex in addition to 1 each in Chikalthana and Waluj. In 
1998 Wockhardt acquired Merind Pharma and became one of the largest producers of 
Vitamin B 12 in Asia. In 2004 Wockhardt commissioned state of the art production facility 
dedicated to the manufacturing of only biotech products. 
The company went public in the year 1992 and since that it has consistently shown 
impressive growth. The turnover of the Wockhardt in 2003-04 was Rs. 7671 million and 
out of that international sales contributed 57%. In international sales, European market 
contributed 37%, the US market contributed 10% and remaining 10% came from the rest 
of the world. 
Wockhardt's post 2005 strategy is based on three dimensions: a. Research and 
development, b. Domestic business and c. International business. In 2000, Wockhardt's 
split up the pharmaceutical business from the agro-chemical, LV. Fluids and hospital 
business into two divisions: Wockhardt Life Sciences and Wockhardt Ltd. The aim of this 
restructuring exercise is to allow Wockhardt Ltd to concentrate more on building skills and 
capabilities in the pharmaceutical business while Wockhard life sciences will strongly 
focus on managing businesses related to agricultural sciences, parentals and hospitals. The 
company is moving ahead with a business strategy which involves using innovative R&D 
for moving up the value chain in both the generic and biotechnology segments. 
7.4.1 The generics strategy 
W ockhardt started targeting international markets in the late 1990s. It entered UK market 
by acquiring Wallis Laboratory, a UK based company~ in 1998 and in 2003 Wockhardt 
acquired another UK based pharmaceutical company CP pharmaceuticals. In 2004 
Wockhardt streamlined its European operation by selling Wallis's manufacturing plant to 
Bristol Laboratories and shifting some of manufacturing operation of Wallis to CP 
Pharmaceutical's plant in UK and rest to company~s Indian plant. Wockhardt is also 
investing £1 million for up-gradation of CP pharmaceutical plant to make it company's 
largest overseas manufacturing base and would eventually become a manufacturing base 
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for Wockhardt's European operations. Wockhardt is now the largest Indian pharmaceutical 
company in the UK and among the top 10 generic pharmaceutical companies in the UK. 
In 2004 Wockhardt took over the business of German pharmaceutical company 'esparma"" 
GmbH to enter Germany, the largest generic drug market in Europe. Esparma has a 
portfolio of 135 marketing authorisations, of which 67 are in Germany. The company also 
has nine international patents and 94 trademarks. This acquisition gave W ockhardt 
increased depth in product portfolio and helped company to strengthen its presence in the 
European business. 
Table: 7.11 Wockhardt's generic product portfolio (Source: Annual Report, 2003) 
Year ANDA DMF 
2001-02 1 2 
2002-03 6 23 
2003-04 10 7 
Total 17 32 
Wockhardt recently launched its US operation by starting Wockhardt Americas Ltd and 
now has its own marketing and regulatory teams based in US. In 2004 Wockhardt 
relocated key officials handling corporate scientific affairs and intellectual property 
management from Mumbai to newly established subsidiary in the US. Wockhardt's US 
strategy is based on launching formulation products through ANDA route and till 2003 it 
has filed 17 ANDA applications with USFDA (see Table 7.11). So focus is on the ANDA 
rather than to file DMF (drug master files) as it doesn't intend to sell API in US and 
Europe markets. Wockhardt currently sells four products in the US - ranitidine, enalapril, 
bethanecol chloride and captopril. 
Currently 80% of Wockhardt's international business comes from developed markets of 
the US and Europe, while 20% comes from the rest of the world. 
7.4.2 Research & Development 
Biotechnology is Wockhardt's R&D thrust area and with three exclusive products in the 
market, the company has been the front runner in the biotechnology research. From early 
1990s company is spending 20 -30% of its total research budget on biotech R&D. In 1995 
Wockhardt formed the joint venture with the German firm Rhein Biotech for 
manufacturing of hepatitis B vaccine and in 2000 company launched its first biotech 
product, a hepatitis B \'accine called Bio\'ac-B. This joint venture helped company to 
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develop manpower trained in biotechnology R&D and provided access to crucial know-
how. In 2001 Wockhardt indigenously produced a drug called erythroprotein (EPG) for 
severe anaemia. In India, erythroprotein was produced for the first time using genetic 
engineering methods. However for W ockhardt important milestone in biotech R&D came 
with development of human insulin. In 2003, W ockhardt launched human insulin named~ 
W osulin. W osulin become the first Human insulin to be made indigenously by an Indian 
company. The company is fourth in the world - first outside US and Europe - to develop, 
manufacture and market this life saving drug used in diabetes. 
Wockhardt is also developing a generic version of biopharmaceutical Interferon alfa 2b 
and which is currently undergoing Phase III clinical trials. The company plans to make a 
foray into global markets on the strength of its biotechnology product portfolio. Building 
on these biotechnology capabilities Wockhardt is aiming to develop competencies In 
genomics and proteomics to support its ambitious new drug discovery programme. 
Wockhardt set up its R&D centre at Aurangabad in 1994 and entered the field of new drug 
discovery research in 1997. From 1998, Wockhardt has been consistently investing into its 
R&D activities and is one of the top R&D investors in Indian pharmaceutical industry (see 
table7.12). 
7.12 Wockhardt's R&D intensity (Source: Annual Report, 1999-2003) 
Year R&D intensity R&D investments ( Rs. 
Million) 
1998-99 10.9 424 
1999-00 4.6 416 
2000-01 7.2 402 
2001-02 6.2 402 
2002-03 6.2 460 
2003-04 7.9 604 
Although Wockhardt embarked on innovative R&D programme little later than its other 
major Indian competitors like Ranbaxy or DRL, it achieved impressive results in the 
chosen therapeutic research area: anti-infective. 
Like other innovative Indian pharmaceutical firms Wockhardt's inno\'ative R&D strategy 
is based on using techniques of analogue research to find new chemical entities. According 
to Wockhardfs head of pharmacology, 
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"right now it's more of analogue but slowly it would be original because we need to train 
our people to develop absolutely new pharmacore and that takes time. So coming out with 
new pharmacore will take 10 more years. Most companies do analogue research only; 
every second day you don't get a new pharmacore ". 
However, unlike other Indian companies, Wockhardt has decided to focus only on the anti-
infective therapeutic segment, as the main thrust area in new drug discovery R&D. 
Wockhardt's head of anti-infective R&D, explained the rationale, 
"even though possibly we could have handle at least one more therapeutic area, easily 
but very conscious and deliberate decision was taken to stay focus in one therapeutic 
area because we wanted to develop skills of that therapeutic area in greater depth and 
ultimately the plan or the vision is, to leverage those in-depth skill sets in long run. We 
thought let us stay focus in one therapeutic area but go in depth and leverage the depth, 
knowledge depths over a period of time. Which in a very remarkable way it 
demonstrated, where in shortest time after starting the programme, we were able to come 
up with a molecule in the clinical development". 
Wockhardt's drug discovery programme has yielded several lead molecules (table 7.13), 
one of which, WCK-771, a broad spectrum antibacterial, has completed Phase I clinical 
trials and is entering the next phase of trials. The new chemical entity WCK771 will be 
useful in treating Methicillin and Vancomycin resistance life threatening infections and 
sepsis. The other chemical entity WCK -1152 has completed pre-clinical trials and a patent 
has been filed. WCK-1152 has been found effective for treating hospital and community-
acquired respiratory tract infections. In case of WCK- 1457, a new chemical entity with 
potent activity against Vancomycin-resistant enterococci, the toxicity studies in progress. 
Table 7.13 Wockhardt's NCE pipeline (Source: Annual report, 2003-04) 
Anti-infective 
Preclinical 
WCK -1457 
WCK-1152 
NeE pipeline 
Phase T Pha.~e n 
WCK-771 
Pha.~e m 
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Wockhardt's has built in-house clinical research facilities and a sixteen-member team is 
looking after development phase involved in commercialisation of innovation. The team 
successfully undertook Phase III clinical trials for Wosulin as per international guidelines. 
These trials involved monitoring 350 subjects at nine different centres. The clinical 
research team has also successfully completed Phase I clinical trials for Wockhardt's new 
chemical entity, WCK-771 as well as preclinical studies on WCK -1152 and filed an IND 
application. 
Unlike other innovative Indian firms, Wockhardt is planning to develop the molecule into 
later phases of clinical trials rather than license it at earlier stages. According to head, of 
anti-infective R&D, 
"we thought that we will make R&D neither as a business centre enterprise nor as a 
source of immediate revenue, like how some companies are at very early stage starts 
hawking their molecules and they say we have these, and that and anybody has interest 
please contact us. We said we will not do as much as hawking at early stage and rather we 
will take R&D as a serious effort for ultimately developing a new product for Wockhardt 
itself to the market". 
W ockhardt has put together a core team for discovery R&D by hiring scientists from 
universities, research institutes or other Indian companies. Wockhardt started building 
team for innovative R&D by hiring Dr. Noel De Souza, a scientist with extensive 
experience in innovative pharmaceutical R&D. Dr. De Souza was R&D president at 
Hoechst's Indian research centre for more than 10 years. To lead its biotechnology effort 
Wockhardt hired Dr. M K Sahib from Central Drug Research Institute (CDR!) institute. 
Wockhardt's anti-infective research programme accelerated after it hired Dr. Mahesh Patel 
from Ranbaxy Laboratories. Dr. Patel had experience in drug discovery due to his working 
experience in Hoechst Research Centre with Dr. De Souza. In 3 years from 2000 scientific 
staff working in Woclhardt has increased from 220 to 400 (table 7.14). But Wockhardt also 
faced some problems in attracting research talent from overseas. According to 
Wockhardt's head of pharmacology research, 
"(f you pay well, you can attract the people. Now it's not the question of salaries but also 
question of where you are located. Like Aurangabad is not a very great place, so people 
coming from outside or abroad, they don't prefer to stay here ". 
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7.14 Wockhardt's R&D employee strength (Annual Report, 2003) 
Year Total number of No. of people lD 
people R&D 
2000-01 2300 220 
2001-02 2700 300 
2002-03 2805 350 
2003-04 2928 400 
Wockhardt's core team working on innovative R&D thus have roots in Indian research 
institutes or Hoechst Research Centre in India. W ockhardt' s head of anti infective research 
explains that, 
'there are few people like me, I have also been trained from abroad but I don't want to 
attribute to what work I did here to my international training, very little role of that. I 
would rather attribute the success ofprogramme which we had here in Wockhardt to my 
initial training at Hoechst for 21 years rather than so- called training abroad. I was 
earlier part of drug discovery team at Ranbaxy, there I joined from Hoechst. We created 
entire team, a set of people and gain significant amount of understanding. Then when I 
came to Wockhardt from Ranbaxy, many of the colleagues preferred to join me here. So I 
think 7 or 8 people from Ranbaxy also came here, formed core team of researchers and 
around which further sub teams were built". 
Wockhardt's R&D is divided around three research units; basic research, biotechnology 
and formulation. These three research units are headed by different scientists and 
pharmacology department provides support to these three departments. The research 
projects are managed by using matrix structure rather than hierarchy. Wockhardt's head of 
pharmacology explain, 
"how Wockhardt works is a beautiful system. Its more of a matrix system rather 
hierarchy system, hierarchy system is also there because people are there at different 
levels but it's not something that very hard and fast rule that this person will report to 
that person. On paper they do report to each other and everything is fine, but it is all 
open matrix system and anyone can walk into any lab, talk to colleagues, alld get the 
data; nothing is confidential except the structure". 
Wockhardt is putting lot of emphasis on coordinating and integrating knowledge flow 
between chemistry and biology. The company has set up cross-disciplinary teams to lead 
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various research projects. Both chemistry and biology have 4 sub teams and this 4 plus 4 
chemistry and biology sub team handle every project, almost from inception to end of 
preclinical stage (fig 7.3). According to head of pharmacology, 
((we do have monthly meetings for biology group where chemistry group goes, we have 
some meetings with chemistry group, where biology group goes and everything is 
coordinated. We have group leaders at different levels and ),ve have director biology and 
we have director chemistry and it works in very integrated waJ"s ". 
Clinical team is separate but according to W ockhardt' s R&D president this arrangement 
creates a seamless structure for the smooth movement of people from one project to 
another. It also allows many people from each team to act as a linkage between pre clinical 
and clinical. 
MED. CHEM I I PEPTIDE L...-M_I_C_R_o_B_1_o_---'11 PHARMACOLOGY 
/' 
~HEM1ST~ 
/ ~ 
ANALYTICAL II COMBI. CHEM TOXICOLOG\' II ANIMAL HOUSE 
INFORMATICS SUPPORT IN FO RlVI A TIC SUPPORT 
Fig 7.3 Wockhardt's research project structure (Source, Patel, 2003) 
The chairman plays an important role in selection of different R&D projects and 
periodically reviews all the research projects. Innovative R&D projects are reviewed 
informally and formally almost on weekly basis. Wockhardt's head of anti-infective R&D 
explains, 
((a formal review process that is there with chairman but when it comes to the scientist'8 
level, its needs to be and also done in very informal way, so lhat it gets handled as part oj 
natural process. Wockhardt also uses the external cOJ1.\ /lltant but onZv when it is 
necessary". 
Add head of pharmaco logy, 
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"more or less internal (review is done) but we do have (arrangement for external 
expertise) as and when required. If an external expertise is required, then we have contacts 
in place. They either are invited to India or data is sent to them or we meet them at 
common places in Europe somewhere; half the way we travel, half way they travel. In 
Wockhardt whichever way we want to do it, we can do it". 
In terms of conferences publication Wockhardt has been very active, specifically in anti 
infective therapeutic area. Company is encouraging its scientists to attend and present their 
work at prestigious scientific conferences and meeting. It annually participates in the 
International conference on Antimicrobial Agents and Chemotherapy (lCAAC). 
W ockhardt' s R&D president suggest, 
"we make regular presentation into it, scientists participate and we have publication but 
all the publication happens only after the patent are in place, that is one thing we all 
follow". 
W ockhardt has put much less emphasis on R&D collaboration with Indian R&D institutes 
compared to other Indian pharmaceutical firms. Wockhardt's head of pharmacology 
describes the experience as, 
"J tried to send my people there in nephro-physiology and other things but it did not 
work, their bureaucracy doesn't suit industry actually. As J told you, it's a government 
organisation that they work like; they don't work actually so it was frustrating 
experience. So after that we never tried". 
7.4.3 Summary 
Wockhardt is focusing on innovative R&D, international business and biotechnology 
products as pillars of its post 2005 strategy. Over the years Wockhardt has consistently 
invested impressively in R&D and emerged as one of top R&D spenders on Indian R&D 
scene. It has taken different approach compared to other firms by focusing on 
biotechnology R&D, selecting only anti-infective segments as research focus area and 
putting much less emphasis on R&D collaborations for developing capabilities in 
innovati ve R&D. 
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7.5 Nicholas - Piramal India Pvt Ltd ( NPIL) 
In 2003 Nicholas Piramal India Limited (NPIL) emerged as 4th largest Indian 
pharmaceutical firm with sales of Rs. 12690 million and 4.4 % market share. In Indian 
domestic market it is leader in the cardio vascular segment and also has a strong presence 
in respiratory, pain management, neuropsychiatry and anti diabetics segments. NPIL' s aim 
is to be an integrated pharmaceutical company with a commitment to discovery, 
development, manufacture and marketing of indigenous pharmaceutical products. NPIL is 
part of the Piramal Enterprises, one of the India's largest diversified business groups with 
interest in retailing, textiles, auto components and engineering. In 2000, the group 
consisted of 26 companies (including joint ventures), with aggregate revenues of about Rs. 
20 billion, however in recent decade pharmaceutical business has emerged as the fastest 
growing and most profitable of the lot. 
The Piramal enterprise was founded in 1933 and until 1987 most of the group's revenues 
had come from textile business, but with increasing uncertainties in textile sector, the 
Piramal group felt the need to diversify and in 1984 it acquired a small glass company, 
Gujrat Glass which supplied bottles and vials to the pharmaceutical industry. This was the 
first indirect contact group had with pharmaceutical business. But in 1988 group went 
ahead and acquired Nicholas Laboratories, an Indian subsidiary of a UK based 
pharmaceutical firm, renamed it Nicholas Piramal India limited (NPIL) and made it 
profitable in 4 years. In 1991 and 1992, NPIL commissioned two manufacturing plants at 
Pithampur, India. 
The success of this acquisition spurred Piramal group to use acquisitions as a strategy of 
growth and started era of acquisitions at NPIL; company then acquired Roche products 
(India) Ltd in 1993, Sumitra pharmaceuticals and Chemicals in 1995, Boehringer 
Mannheim India Ltd in 1997. In April 1997 these three companies merged with Nicholas 
Piramal and a new management team was set up to manage it. This initial acquisition spree 
was followed by two more acquisitions - Rhone Poulenc (India) in 2000 and ICI (India) 
pharmaceuticals in 2002. In Dec, 2003 NPIL bought the 50% stake in Sarabhai 
pharmaceuticals ltd. Since n10st of the sellers were MNC pharmaceutical firms who 
wanted to quit the Indian market, NPIL acquired these firms at attractive prices and 
quickly synergised skills resulting into the mutual benefits. Managing Director of NPIL 
explain the business strategy in using acquisition as a route to growth, 
"look at it fiAom our side; ),i'e knel1' that with TRIPS rules being introduced sometime in 
future, we should need access nel1' products. Also size matters - we needed critical mass to 
leverage on marketing and distribution as well as to increase t/7e utilisation of Pith am pur 
manl1(acturing plant"" (Annual Report, 2003). 
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These acquisitions also helped NPIL in creating linkages with MNC pharmaceutical firms. 
Over the last sixteen years, NPIL has established a strong track record of working cIo ely 
with global innovating companies and has developed an impressive record in managing 
business partnerships (JVs and alliances). NPIL have good business relationship with a 
number of multinational firms like Roche, Boehringer, Allergan, Boots, Aventis, Novarti . 
As a result NPIL has established a good position to become a partner of choice for any 
MNC looking at the Indian market. Building on these relationships NPIL has developed 2 
stream approach for post 2005 scenario. The first stream includes the inward co-licensing 
deals with foreign firms, custom synthesis and contract manufacturing for MN C 
pharmaceutical firms while the second stream involves the development of the product 
patented molecules to make pharmaceutical drugs. 
7.5.1 The contract research strategy 
Based on this strategy, NPIL has decided not to follow the route of other large Indian 
companies of going into US markets with generics products. NPIL wants to become an ally 
of overseas pharmaceutical companies and therefore its main focus areas are custom 
synthesis and contract manufacturing instead of generic markets in advance countries. 
On Patent On patent 
Pre-laun~h growmg mature 
Partner with innovator companies 
across the life cycle and after 
patent expiry 
Off Patent 
Early to market Late to market 
No early - to market 
support for generics 
Fig7.4 NPIL partnership strategy (Annual Report, 2003-04) 
NPIL trategic alliance director describe , 
"[ think Nicholas i. a velY unu ual company because il has a core philosophy thaI 
partnerships prosper and il has a big track record of parllll'rship wilh companies lik 
Hoffman la Roche, Aventi. , of a whole lot o.lcompanies. So Ihi" is Ollr core philosophy Gnd 
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because of partnership two things happen, we learn a lot and also sometimes we give a lot, 
innovative ideas, ways of working which is different. So it's a sort of lYvo way exchange 
and even in the R&D collaborations we do all the time exactly on same line". 
NPIL strategy involves partnering with innovator companies worldwide across different 
segments of the pharmaceutical value chain (Fig. 7.4). It has developed ability to provide 
end to end solutions in terms of chemical synthesis of APIs through to intermediates 
including dosage formulations. NPIL therefore is seeking partnership with small research 
companies, MNC pharmaceutical firms, and generic companies in areas of manufacturing 
active pharmaceutical ingredient, development cheap production processes and new 
formulations. However, NPIL will not provide support to 'early to market' generic product 
development or contract with generics companies for such work. This way NPIL will be 
able to avoid the generic patent challenge game and maintain good relationships with 
MNC pharmaceutical firms. Therefore NPIL will exclusively concentrate in the 'late-to-
market' generics space, as that does not conflict with NPIL's chosen business model. The 
'early to market' generics involves challenges to existing patent and so patent litigation 
with patent holding firm whereas in case 'late to market' generics, patent is already expired 
and therefore involves no patent litigations. 
In 2003 NPIL set up a subsidiary in the US, NPIL Pharmaceutical Inc., for moving the 
custom manufacturing business development nearer to prospective customers. Recently 
NPIL signed its first custom manufacturing contract with Advanced Medical Optics Inc., 
USA for manufacturing select eye care products for their global markets - including US, 
Japan and Europe. 
The other constituent of post 2005 strategy is development of product patented molecule 
and licensing them to MNC pharmaceutical firms. NPIL' s R&D president explained the 
strategy of embarking in innovative R&D, 
"1 think company's management is clear cut that we will go for research, we can't afford 
to live without the R&D, we can't just go on reverse engineering, survival is at stake and 
only way is that if we have something new, we can go and negotiate better, l1:e can move 
better forward. If we don't have anything what you will do then? Even if you have to 
license-in, somebody will see what you have. So for give and take, you should able to gi"rc 
something, otherwise you will be on loosing side all the time ". 
7.5.2 Research and development 
The innovative R&D forms an important constituent of NPIL post 2005 strategy. It is 
based on the idea of developing of the product patented molecules till Phase II and then 
licensing it to the MNC firms. According to NPIL~s R&D president. 
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"the concept of discovering a drug molecule and developing it to a particular stage and 
licensing out or collaborating with a bigger group is the right way. The strategy is 
perfectly fine as we do not have the strength to do it all by ourselves ". 
With this aim in 1998 NPIL forayed into innovative R&D by acquiring the research centre 
of Hoechst Marion Russell located in Mumbai, India. 
The Hoechst research centre is one of the oldest research centres in India exclusively 
working on drug discovery. It has been in existent from 1972 and from its inception the 
research centre focused on new drug discovery research and herbal research. The scientists 
working at this facility have many years of experience in NCEs and international filing. 
This research centre, now renamed as Quest Institute of Life Sciences (QILS), is guiding 
the NPIL's efforts in innovative R&D. QILS R&D president described activities at the 
research centre from the beginning as, 
"we have this from 1972, we are doing basic research, there was never been reverse 
engineering, no iota has been done here. So for us, this is not something new, may be for 
others. From the day I joined; I joined in 1975 and this was drug discovery research 
centre. So for us discovery area is from beginning and probably may be we are adding 
things, we are expanding thrust, but this is not a new concept to us". 
The Herbal drug research unit at QUILS focused on developing standardised, clinically 
proven and safe herbal products for therapeutic and cosmetic use. The acquired research 
centre continued with new drug discovery programs; the focus has not changed, but has 
only been modified to suit the NPIL. 
Analogues research is NPIL's chosen research strategy in innovative R&D. QUIL's R&D 
president argues, 
'for us, new chemical entities (NCEs) can come through modifying known molecules to 
get newer derivatives and developing them. It is not a sin to improve on an existing drug or 
some newly discovered molecule. Even big MNCs are following this concept. So the 
combination of having more modern type of research, trying to improve on existing 
products and strengthening our traditional medicines may be right strategy for India, 
rather than going all the way on to the ultra modern for whose sustenance we do not hG1'C 
financial strength". 
NPIL's R&D is divided into four strategic business unit's (SBU) - Basic research (focusing 
on drug discovery): Natural products research (focusing on developing safe herbal 
products); clinical research (focusing on providing quality clinical and bio-analytical 
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support) and Genomics Research. These SBUs are run by different cross disciplinary teams 
that enable effective project management and a sharing of skills. 
The focus of the basic research is the development of new chemical entities in select 
therapeutic areas. NPIL has narrowed down four therapeutic areas: Oncology, Diabetes, 
Anti Fungal and Rheumatology for its new drug discovery research (Table 7.15). 
Table 7.15 NPIL's NeE pipeline (Annual Report, 2003) 
NeE pipeline 
Preclinical Phase I Phase II Phase III 
Oncology NPI02 
Diabetes 
Anti Fungal 
Rheumatology 
All the lead molecules in these areas are in the preclinical stage. In 2000 NPIL had filed for 
investigational new drug (IND) application to US FDA as well as Indian patent authorities 
for an anti cancer molecule NPI02 (table 7.15). 
In few years NPIL has built a dedicated team of scientists with expertise in medicinal 
chemistry, biological science, analytics and pharmacology and hired international 
consultant to guide company's effort in drug discovery research. From 2000 NPIL started 
creating a critical mass of scientists with expertise in various areas of pharmaceutical R&D 
(table 7.16). NPIL R&D president explained the process of establishing the innovative 
R&D, 
"you have somebody who is a senior person and who has a good idea about how the 
whole thing is run. Then he fills the gap by hiring the people in these areas and getting the 
instruments or putting the infrastructure together. It is like a good architect who has a 
good idea about what he wants and he knows very clearly which contractor good for 
furniture, what to do, its absolutely same concepts in drug discovery". 
In 2002 NPIL hired Dr. Somesh Sharma as chief scientific officer to lead innovative R&D 
effort. He was the vice president of Monoclonal Antibody and Vaccine Unit at Anosys Inc. 
US. Dr. Sharma was in the USA from 1967 where he obtained a Doctorate in Pathology 
from the University of Maryland's School of Medicine. He has co-founded companies like 
Anergen. Wizard Laboratories, S2 Pharmaceuticals and Calyx Therapeutics. 
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In 2004.NPIL hired Dr. Maneesh Nerurkar from Merck as head of formulations and new 
drug delivery systems to strengthen company's new drug delivery efforts. 
Table 7.16 NPIL R&D strength (Source: Annual report, 2003-04) 
Year Total number of people No. of people in R&D 
2000-01 3600 96 
2001-02 3840 130 
2002-03 4036 183 
2003-04 5880 255 
NPIL's strategic alliance director explained the rationale behind hiring the Indian scientists 
working overseas in areas of innovative R&D, 
"for reasons like one is that they have the ability, they can make the difference to field 
and second is with same amount of money here, you can get much more work done. See 
if you have 'thinker' who is very good and comes back and then 'doers' are all here. So 
you can build the team around that person. And with US $lMN we can get like 50 
scientist and there you can get 10, I mean just equivalent, not exactly. So I am just 
saying that for same amount of money you can get the biggest bag of talent here in 
India". 
Over the years NPIL is gradually increasing the R&D investment and are adding new 
resources for innovative R&D (Table 7.17). However compare to NPIL' s major Indian 
competitor its R&D intensity is much smaller. Realising this NPIL is planning to invest 
Rs. 750 million over the next two years and Rs. 400 million per annum subsequently as a 
part of the expansion for the R&D centre. It is developing a new R&D facility in Gurgaon, 
Mumbai to house the planned R&D expansion. This new facility is three times the size of 
current facility and with that NPIL is looking to increase its scientific base by almost four 
times. The new R&D facility will focus on new chemical entities (NCEs) and new drug 
delivery systems (NDDS) in the areas of Rheumatology and cancer research. NPIL is also 
starting a new research centre in Chennai with initial staff strength of 50 scientists. This 
R&D centre will concentrate on process chemistry and stability testing specially for the 
export business ofNPIL. 
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Table 7.17 NPIL's R&D intensity (Source: Annual Reports, 2000-04) 
Year R&D intensity R&D investments (Rs 
Million) 
2000-01 1.80 102 
2001-02 2.16 204 
2002-03 1.63 168.5 
2003-04 3.9 301.9 
In 2002 NPIL established clinical research organisation (CRO), Wellquest to strengthen its 
clinical trial capabilities. Aligned with NPIL's core philosophy of partnership, the aim of 
Wellquest is to serve the generic pharmaceutical industry by conducting clinical 
pharmacokinetic studies and subsequently, leveraging its skills by partnering with Indian 
as well as MNC pharmaceutical companies. Wellquest has state of art facilities in terms of 
infrastructure and GCP/GLP systems. 
The major area of concern for NPIL is lack of capabilities in biological science. According 
to NPIL' s strategic alliance director Indian pharmaceutical R&D have strong capabilities 
in organic chemistry or synthetic chemistry but capabilities in biology are much less. To 
fill that gap NPIL has established a subsidiary Genequest; a research unit totally dedicated 
to the study and advancement of genomics, pharmaco-genomics and bioinformatics. 
Genequest has been positioned as a gene discovery and database company and its key 
focus is to translate cutting-edge research into innovative applications. NPIL has also 
developed a natural products resource library of over 18,000 strains and 6,000 plants. 
Currently, in natural products research, NPIL has programme in fields of musculoskeletal 
disorders, particularly inflammatory disorders, diabetes, hepatotoxicity and antioxidants. 
The other approach taken by the NPIL to fill the gap of biological capability is to hire 
Indian scientists working overseas in area of biological sciences. NPIL strategic alliance 
director suggests, 
"but you can build it, not very difficUlt to build if there is cross border migration. We are 
hiring all our top molecular biologist from us. so we can build it". 
In QILS almost 20-25% of scientists have experience of working abroad. According NPIL 
R&D president key to attracting best research talent is to have a proper working 
atmosphere. He explained, 
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"1 have a very good experience that if you give a proper working atmosphere to a 
scientific person, there would be quite a few wanting to come back from overseas. But once 
they come back you have to encourage them. Money is not the only attraction. 1 had people 
from the best universities in United States like Harvard and MIT We may not be the best 
paymaster in the country. Yet what people are looking at is a place to put their talents in a 
proper research set up". 
To establish 'proper' research setup, NPIL is involving external consultants as reviewers of 
the projects and which also gives NPIL scientists an opportunity to interact with reputed 
international scientists. It has set up a system of continuous external evaluation as well as 
project specific advice by availing the services of external consultant from abroad. In 2002 
research scientist Dr. William Jenkins joined the board of NPIL. Dr. Jenkins will advise 
the company on ongoing R&D programmes, which will include audit of existing projects, 
the evaluation of new projects, and regulatory matters. NPIL is also taking help of Mehta 
Partners, renowned pharmaceutical consultants to evaluate systems and processes in 
research. In 2003 NPIL invited Sir Ravinder Maini and Prof. Bob Chaudhari to join the 
scientific advisory board. Sir Ravinder Maini, received the Lasker award in 2003 for 
pioneering radically new and better treatments for rheumatoid arthritis while Prof. 
Chaudhari has research interest in molecular basis of cancer and neuro-degenerative 
diseases and have a experience as senior research manager with Novartis. In 2004 NPIL 
appointed Dr. Saran Narang, world's renowned molecular biologists, to its scientific 
advisory board. Dr. Narang has been the principle research officer in Genetic Research 
Programme at the National Research Council of Canada since 1981. At NPIL Dr. Narang 
will work on the current cancer research programme. 
NPIL aims to gain significant insights into new drug discovery technology from these 
scientists' contribution to its innovative R&D programmes. 
NPIL is also encouraging its scientists to present the findings at various conferences 
around the world. Recently NPIL presented findings on novel anti- cancer compound at 
conference on molecular targets and cancer therapeutics in Boston, US. This conference 
was organised by American Association for Cancer Research (AACR) jointly with 
National Cancer Institute (NCI) and the European Organisation for research and treatment 
of Cancer. 
7.5.3 Strategic R&D alliances 
NPIL has been involved in many R&D collaborations with premIer Indian research 
institutes like Centre of Integrated Biology. Central Drug Research Institute of India 
(CDRI). Regional Research Laboratory. NPIL has established new department, Strategic 
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Alliance Unit to scout for the collaborations and alliances in R&D as well as other areas 
like marketing and IT technology. 
The QUIL R&D president explains, 
"The CSIR labs we are collaborating with. We are also looking that any body else have 
any special expertise in academia. There are genuine experts, it's not that; I think there 
are some experts who call themselves expert but there are really genuine experts 
especially in CSIR labs. Some of very bright minds are there, so it just matter of knowing 
how to put the two organisations together and getting things done". 
While collaborating with R&D institutes NPIL is more focused on areas related to 
biological science. According to NPIL R&D president biotechnology area is of vital 
importance for drug discovery and in India the biological talents and prowess in molecular 
biology are mainly concentrated in universities and research institutions rather than 
companies as most Indian companies are traditionally focused on organic and synthetic 
chemistry. To fill knowledge gap in biotechnology, in 2003 NPIL has signed an agreement 
with Centre of Biotechnology (CBT) at Anna University for exclusive R&D collaborations 
in areas of cancer and inflammation. The collaboration mainly focuses on identification 
and development of plant extracts in the repository of CBT for the treatment of rheumatoid 
arthritis and cancer. Dr. Balakrishanan Director CBT is head of the collaboration in close 
association with Dr. Somesh Sharma, Chief Scientific officer at NPIL. 
NPIL's other area of focus in R&D collaboration is the identification and evaluation of 
new chemical entities. NPIL has entered into a contract arrangement with Indian research 
institutes to expedite continuous evaluation of new chemical entities (NCEs). In 2004 
NPIL entered into research collaboration with the Indian Institute of Sciences (IISc) 
Bangalore to identify new targets to treat fungal infections. Dr. Sadhale of department of 
microbiology and cell biology at IISc will head the collaborative effort and NPIL will have 
exclusive rights to commercialise any products coming out of this collaboration. NPIL 
already has vast collection of natural products (over 6000 plant extracts and 18,000 
microbial strains), which will also be evaluated during this period. NPIL strategic alliance 
director describe the working relationship, 
"they (scientists from CSIR labs) come at our centre in Delhi; we have two labs working 
jointly. Some work is done in Delhi and some work is done in Bombay, there is free flow of 
ideas and we also measure productivity of our labs. lre are happily going back and 
forth ". 
180 
Recently NPIL has set up offices in UK and US with an accent on R&D collaboration with 
scientists from UK and Canada. In 2004, NPIL entered into an alliance with Imperial 
College, UK to conduct research in the field of rheumatoid arthritis. 
7.5.4 Summary 
In the past NPIL used inorganic route (acquisitions) for developing capabilities in 
manufacturing and marketing pharmaceutical drugs in India. For post 2005 scenario NPIL 
is focusing on partnerships with MNC firms and innovative R&D as main strategies for 
survival and growth. Using inorganic approach of capability development NPIL acquired 
the Hoechst research centre to start its effort in innovative R&D. However NPIL is also 
investing in building innovative R&D capabilities organically by gradually increasing 
investments in R&D, establishing new R&D centres, hiring Indian scientists from overseas 
and collaborating with Indian R&D institutes. 
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7.6. Lupin Pharmaceuticals ltd (Lupin) 
Lupin is a dominant leader in the anti-TB segment in Indian domestic market and in 2003 
had 42% market share of anti-TB segment in India. Over the years, the company has 
diversified into cephalosporins, cardiovascular, NSAIDs, vitamins and phytomedicine in 
order to boost exports and improve margins. In 2003 Lupin emerged as sixth largest Indian 
pharmaceutical company with a turnover of Rs. 12,327 million. Lupin export to almost 
more than 50 countries and 41 % of Lupin's sales in 2003 came from exports; although 
mainly in the form of bulk drugs or active pharmaceutical ingredients to semi regulated 
markets. 
Dr. D B Gupta started Lupin pharmaceuticals Ltd in 1968 and made Lupin a public limited 
company in 1987. The company had an Initial Public Offering (IPO) of Rs1865.2mn in 
1993. In 2003 promoters of Lupin divested 25.1 % of its stake in favour of other investors 
in order to restructure its debt. 
In 1972 the Lupin set up its first manufacturing unit. Now among all Indian pharmaceutical 
companies Lupin has the largest number of plants approved by the USFDA and UKMCA; 
9 out of its 10 plants have USFDA approval. It has manufacturing plants at 3 locations in 
India, most of which are of global scale. Recently Lupin has set up a new plant for 
manufacturing lovastatin, cholesterol lowering active pharmaceutical ingredient, (API) and 
the company is building a new plant at Goa, India to manufacture non-cephalosporin oral 
finished dosages. 
In the past Lupin derived a considerable portion of its revenues from producing bulk and 
intermediate with cheaper processes for drugs, which were bound by product patents in 
more developed countries. Due its skill and focus Lupin has emerged as the largest 
producer of anti-TB drugs Ethambutol and Rifampician in the world. In India Lupin 
achieved major success in the anti-TB segment with its strategy of bundling four essential 
TB drugs into a single dosage pack as AKT -4 kit. Doctors' preferred the AKT -4 kit as this 
bundling helped in preventing the selective discontinuation of medicine by patients and 
either resultant relapse or drug resistance. On the basis of this marketing strategy Lupin 
gain 60% share of Anti-TB market in India. 
7.6.1 The generics strategy 
For post 2005 era, Lupin's focus is on increasing sales of value added products in high 
margin advanced markets and exploration of new chemical entities (NCE) research 
through inno\'ative R&D. Like other Indian pharmaceutical finns. Lupin has built some 
strengths like process R&D capabilities, internationally approved plants and regulatory 
competence to file ANDA application in US (table 7.18). Lupin's post 2005 strategy 
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involves building on these capabilities to enter generic markets in advanced countries and 
develop innovative product through indigenous R&D as a way to secure survival and 
success in product patent regime. In advance market Lupin's strategy is to build 
manufacturing and marketing alliances with strong international players. Lupin has 
established a wholly owned subsidiary in the US to identify and pursue alliance 
opportunities. In 2003 it signed contract with Apotex for supply of API. Apotex is a one of 
the largest generic focused pharmaceutical fum operating in US and Canadian markets. In 
2003 Lupin received FDA approval to launch cefuroxime axetil tablets in the US generic 
market. Following on that Lupin formed an alliance with Watson Pharmaceuticals, a 
leading US generics company, as a marketing partner in the US for cefuroxime axetil 
tablets. 
Table: 7.18 Lupin's generic product filing (Source: Annual Reports, 2003) 
Year DMF ANDA 
2002-03 
2003-04 12 5 
Total 12 5 
In first quarter of 2004-05, the company entered into an agreement with Baxter Health 
Care Corporation, a global medical products company, for exclusively marketing its 
generic version of ceftriaxone sterile vials in the US. 
7.6.2 Research and Development 
In 2001 Lupin decided to engage in innovative R&D and built a state of the art R&D 
laboratory in Pune, India. Lupin is a new entrant to innovative pharmaceutical research 
which is reflected in small but increasing R&D intensity (Fig. 7 .19). Lupin hired Dr. 
Himadri Sen as executive vice president of pharmaceutical R&D and Dr. Sudershan Arora 
as executive vice president, from Ranbaxy's new drug research team to lead company's 
effort in innovative R&D. In Ranbaxy Dr. Sen was in-charge in NDDS (new drug delivery 
research) while Dr. Arora was in-charge of new chemical entity research. 
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Table 7.19 Lupin' R&D intensity (Source: Annual Report, 2003) 
Year R&D intensity R&D investments ( Rs. 
Million) 
2001-02 2.41 231.4 
2002-03 2.30 256.5 
2003-04 3.09 459.9 
The hiring of these scientists proved instrumental in building the core team with expertise 
in drug discovery as other scientists working with them in Ranbaxy also joined Lupin. 
From 2001 number of scientists working in Lupin is consistently increasing (table 7.20). 
Lupin's vice president, NCE explain 
"since I came to Lupin, things have changed because people know what I demand from 
them, what I am looking for a particular project. Because most people who are in Lupin, 
they camefrom Ranbaxy so they know the culture there and then they are here now". 
Table 7.20 Lupin's R&D employee strength (Source: Annual Report, 2003) 
Year Total number of No. of people in 
people R&D 
2001-02 150 
2002-03 3300 180 
2003-04 3600 220 
Lupin is focusing on herbal research as a source of new molecules. According to Lupin~s 
R&D president the route of herbal medicine with established proof of concept is good one 
as there is still lot of knowledge untapped in these areas and if company can establish the 
mechanisms of action in scientific way then these molecules could be patented and 
tnarketed all over the world. In two years of starting innovative R&D, Lupin has made 
significant advances in its anti-psoriasis and anti-migraine programme, both being herbal 
based research initiatives (table 7.21). The anti-psoriasis compound (LL4218) received an 
INDA (Investigational new drug application) approval in April 2004 and has entered phase 
I clinical trials while the anti-migraine compound is in multi-centric phase II clinical trials. 
In case of anti-psoriatic, the chemical characterisation of the actiye compound. LlA218 
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was completed with promising activity in in-vitro and in-vivo experimental models of 
. . psonasls. 
Table 7.21 Lupin's NeE pipeline 
NeE pipeline 
Preclinical Phase I Phasell Phase 
Anti Migraine LL-3348 
Psoriasis LL4218 
Anti - TB LL-4858 
The company is also working on an anti-TB molecule, LL 4858 and is expecting to file an 
IND application in 2004-05. The molecule LL 4858, a new novel anti-TB combination has 
found to be possessing excellent anti-tuberculosis activity. 
The important part of Lupin's innovative R&D project management is creating interactions 
between various disciplinary teams involved with the project. According to head of NCE 
research, group meetings are used for facilitating the information flow across different 
disciplinary groups. He explained, 
"] think our group meetings take care of that. ] talk to my group leaders on a daily basis 
and then we have group meetings here; once every week for different projects where each 
and every chemist, pharmacologist and toxicologist has to participate there. What they 
have done and what they are planning to do next week so that's what we discuss here. So 
that way culture is changing now, they are busy working now when the system is in place ". 
Lupin has set up extensive mechanisms for internal as well as external reviews. For 
external review the company has appointed a team of senior scientists. These scientists 
visit Lupin R&D laboratory 2-3 times a year and review the progress of each R&D project. 
Lupin is also investing in the scientists by encouraging them to publish and attend various 
international scientific conferences. The company also invites reputed scientists at its R&D 
laboratory and organises workshops for its R&D staff. 
7.6.3 Strategic R&D alliances 
Among all the innovative Indian firms, Lupin has built strongest linkages and 
collaborations with Indian research institutes Lupin is actively pursuing collaborath'e 
research programmes with leading Indian research institutes like Indian Institute of 
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Science, National Chemical Laboratory to obtain the lead molecules. These research 
programmes has received funding from CSIR (Council of Scientific and Industrial 
Research) under the New Millennium India Technology Leadership Programme 
(NMITLI). NMIL TI programme is launched by Indian government's Department of 
Science and Technology to increase the collaboration between Indian industry and 
government research establishments. 
In case of psoriasis and TB research projects CSIR spent Rs. 90 million while Lupin has 
invested Rs. 250 million. The company have two partners in these projects - the Central 
Drug Research Institute (CDR!) and National Institute of Pharmaceutical Education and 
Research (NIPER). These projects involved screening of large libraries of chemical 
compounds available at National Chemical Laboratory (NCL), Indian Institute of Chemical 
Technology (IICT) and CDR!. 
These collaborations are aiding Lupin in bridging the infrastructural and capability gaps in 
its R&D. 
7.6.4 Summary 
Lupin is a new entrant to innovative R&D among Indian pharmaceutical industry. The 
company is moving from presence in developing markets to advanced markets and 
transforming its R&D capabilities from imitative process research to innovative areas of 
pharmaceutical research like generics and new chemical entity research. Lupin is 
developing innovative R&D capabilities by hiring senior scientists working in other Indian 
firms and collaborating with Indian research institutes and universities. 
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7.7 Glemark pharmaceuticals ltd (Glenmark) 
Glenmark is a one of the India's fastest growing pharmaceutical firm, with a major 
presence In dermatology therapeutic segment in Indian domestic market. It was 
incorporated in 1977 with initial investment of Rs.1 million and by 2003 it has grown to 
record a turnover of Rs.3860 million. Glenmark is ranked among the top 25 Indian 
pharmaceutical firms and market its products to over 50 countries across the globe. 
Glenmark set up its operation distribution network first and then started investing In 
manufacturing facility. In 1983, the company established its first manufacturing unit in 
Nashik, for producing formulation products like ointments, lotions, creams and powders. 
In 2003 the company commissioned other formulation production facility in Goa. 
Glenmark also has three plants operating for its active pharmaceutical ingredient (API) 
business. One of them is a manufacturing plant of Glaxo acquired by Glenmark in 2002 to 
start regulated market business. Glenmark made this manufacturing plant USFDA 
compliant in two years. Glenmark is currently developing two more sites at Kurkumbh 
and Solapur to serve Indian and semi regulated bulk drug markets. 
Glenmark's post 2005 strategy revolves around four strategic markets; domestic market, 
potential licensing opportunities emerging from innovative R&D, international API market 
and generic market in advanced countries. The core part of the strategy is developing new 
chemical entities for licensing alliances with MNCs pharmaceutical firms for clinical 
development, partnering with global generic companies as a supplier of active 
pharmaceutical ingredients and establishing a global distribution network for marketing 
generics and patented technologies. In 1999 Glenmark launched maiden public issue to 
fund infrastructure development for its post 2005 strategic objectives. The funds raised 
through public issue were invested in setting up a state of art R&D centre and development 
of US FDA compliant manufacturing facility and supportive distribution and marketing 
infrastructure in the US. 
7.7.1 The generics strategy 
In 2003-04 international business contributed 12.3 % to Glenmark's total revenues and 
showed strong growth in export of API and formulations products to semi regulated 
markets. It has established 6 marketing subsidiaries and expanded its operations to 59 semi 
regulated country markets. However, consistent with post 2005 scenario Glenmark is 
seriously looking at opportunities to enter the generic markets in highly regulated adyanced 
countries like US and Europe. Glenmark's aim is to target Europe and US for generics 
market through ANDA filings for products which are going off-patent. In 2003 company 
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filed 4 DMF with USFDA (table 7.22) and set up a wholly owned subsidiary in US to 
augment its presence in American market. 
Table: 7.22 Glenmark's product portfolio 
Year DMF ANDA 
2002-03 
2003-04 4 
Total 4 
Glenmark's advance market strategy involves conducting the primary process R&D and 
manufacturing activities in India and partnering with US generic companies as a supplier 
of API. In terms of formulation or generics market Glenmark is looking for manufacturing 
and marketing alliances with generic companies operating in US. Glenmark has now tied-
up with three companies in North America - Apotex, Eon Labs and KV Pharmaceuticals 
for the supply of API. Under the agreement with KV Pharmaceuticals, Glenmark will 
develop eight generic products and then license them to KV Pharmaceuticals for regulatory 
approval and marketing in the US generic market. 
7.7.1 Research and Development 
In R&D Glenmark has focused on three areas of pharmaceutical research; 
a. new drug discovery research, 
b. formulation and new drug delivery system research for regulated and semi regulated 
markets and 
c. process research for bulk drugs (APIs). 
Glenmark's strategy in innovative R&D is to develop promising lead candidates up to 
early clinical stage and then licence them to international pharmaceutical companies 
Glenmark's strategic planning director explains, 
"you have to talk about two types of research and development; one which is probably 
generic oriented and other is your drug discovery R&D. In drug discovery R&D even if 
we have capability we don't have money or the resources to go beyond Phase II so you 
will always need a partner. To top of it all we have weakness in biology and in terms of 
being up to date information because most innovation is happening ill the US". 
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Glenmark initiated discovery research in 2000 and choose Asthama, Diabetes and Obesity 
as focused areas for discovery research. To accelerate drug development Glenmark started 
investing in innovative R&D from 2000 (Table 7.23) and established two R&D centres; 
one in Mumbai and other one in Nashik. The R&D centre at Mumbai is dedicated to the 
discovery of new chemical entities and preclinical research while the other R&D centre at 
Nashik focuses on fonnulation development, new drug delivery systems and development 
of different dosage fonns for existing products. In terms of process R&D Glenmark has set 
up a dedicated team of 50 scientists to work on the development of innovative process and 
delivery systems for the regulated/semi regulated generics and API markets. Six chemistry 
research labs are located at process R&D centre focusing on various aspects of innovative 
process development like chiral chemistry, hetero-cyclic chemistry, resolution chemistry 
and carbohydrate chemistry. In 2 years the strength of scientific staff in Glenmark has 
increased from 100 to 250 (table 7.24), reflecting commitment of the company in R&D. 
Table 7.23 Glenmark's R&D intensity and investment (Source: Annual Reports, 2000-03) 
Year R&D intensity R&D investments 
R&D/Sales (Rs million) 
2000-01 1.45 22.0 
2001-02 3.50 78.1 
2002-03 4.41 147.25 
2003-04 6.52 248.07 
The drug discovery R&D is based in Mumbai where Glen Saldhana, Managing Director of 
Glenmark is directly involved in running it. The strategic planning director explains 
working of discovery R&D as, 
"actually here it is done differently. Discovery is handled by Glen himself so he is a 
sitting head, and the remaining team comprises of heads from biology, chemistry, 
analytical, kinetics". 
Glemark has hired Dr. Gopalan as Vice President of chemical research and Dr. Swaroop 
Kumar as Vice President of biological research to boost drug discovery R&D capabilities. 
Dr. Gopalan has over 15 years of drug discovery experience in India and the US while Dr. 
Swaroop Kumar has experience in areas of preclinical drug discovery research with Dr. 
Reddy's laboratories. Glenmark has built a team of scientists with diverse backgrounds and 
189 
almost 200/0 of R&D scientists have post-doctorate degrees from the US. A few of them 
also have experience of working on drug discovery in R&D's of multinational 
pharmaceutical firms. 
Table: 7.24 Glenmark's R&D employee strength (Source: Annual Reports, 2000-03) 
Year Total number of employees No. of R&D employees 
2000-01 1800 100 
2001-02 2000 150 
2002-03 2500 250 
In four years of starting innovative R&D programme Glenmark has come up with a 
number of strong lead candidates (table 7.25). In the asthma segments, Glenmark's drug 
candidate GRC 3886 is now set to enter Phase I clinical trials. This lead has shown 
impressive anti-inflammatory effects in animal models of pulmonary inflammation. In 
2004 Glenmark contracted Quintiles, a leading global Contract Research Organisation 
(CRO), to conduct Phase I of clinical trials of its drug candidate for Asthma, GRC-3886. 
In case of the, anti diabetic GRC 1087, Glenmark has established proof of concept in 
animal studies and is waiting for approval to start clinical trials. 
Table 7.25 Glenmark's NeE pipeline (Source: Annual Report, 2003) 
Asthma 
Obesity 
Diabetes 
Preclinical 
GRC3566 
GRC 3886 
GRC 1087 
GRC 8087 
NCE pipeline 
Phase I Phase II Phase III 
Like other innovative Indian pharmaceutical firms Glenmark has chosen analogue research 
as main research strategy for discovering new chemical entities. Glenmark's VP chemical 
research explained the analogue strategy, 
"l1!e don't have that much capability to go into three dimensional structure of the 
receptor. thal's why 11'e choose projects in such way fhatthree dimensional picture (~( the 
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receptor is already reported. So when we choose therapeutic targets we take into account 
whether the three dimensional structure of the receptor is known". 
Glenmark has also established a full fledged pharmacology department with modern 
instruments to screen new molecules. The analytical department is a central facility; it 
supports all R&D programmes like drug discovery, new drug delivery system research and 
formulation development projects. Glenmark's strategic planning director describes the 
working of the project as, 
"we only do analogue research; we are not doing rational drug design NeE research. So 
actually you need active pharmacore around which everything is modelled and that would 
be analysed by chemists and if all of them agree that there is space and if the biologists say 
that mechanism will do good then we go ahead with the project". 
Glenmark has also set up a scientific advisory board with internationally reputed scientists 
to review and advice on the research projects. The scientific advisory board includes Dr. 
Clive Page, Director of Pulmonary Pharmacology, King's College, UK an authority on 
asthma in the medical field. Dr. Jonathan Arch, Director of Metabolic Research, 
Buckingham University and Dr. Faizulla Kathawala, a scientific consultant are also part of 
Glenmark's scientific advisory board. 
Glenmark is putting extensive emphasis on conference attendance and presentations. 
Scientists working at Glenmark research centre are encouraged to present research findings 
at various national and international seminars and meetings. Glenmark has already 
presented the findings of asthma and diabetic research in various international conferences. 
In 2003 Glenmark presented GRC 3566 at World Inflammatory conference while GRC 
3886 is been presented at four international conferences in 2004. Glenmark is also active in 
publishing the results of in-house research in peer reviewed international journals. 
The company has incorporated a wholly owned subsidiary in Switzerland during 2004 to 
undertake patent registrations in regulated markets and to set-up R&D activities. 
Glenmark's Swiss subsidiary will manage Glenmark's global IP (intellectual property) 
portfolio and coordinate clinical trials on its NCE compounds. 
7.7.2 Strategic R&D alliances 
Glenmark is collaborating with National Chemical Laboratory (NCL), India for research 
on Anti inflammation therapeutic segment. This collaboration is financially supported by 
departn1ent of Science and Technology's research programme; New Millennium 
Technology leadership initiative (NMTLI). 
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7.7.3 Summary 
The case of Glenmark pharmaceutical presents the response by medium size Indian 
pharmaceutical firm to change in patent law. For post 2005 survival Glenmark is building 
on its process R&D capabilities to develop competencies for generic product R&D to 
compete in API and formulation (generic) markets of advanced countries. Importantly 
Glenmark is also investing heavily in R&D to develop capabilities in innovative areas of 
pharmaceutical research like new chemical entities and new drug delivery system. 
7.8 Conclusion 
This chapter presents the cases of six innovative Indian pharmaceutical firms. It described 
the development of organisational capabilities in each firm, specifically focusing on post 
2005 strategies of firms to transform its product portfolios, markets and R&D capabilities. 
The description mainly discussed the processes employed by each firm to develop 
competencies in innovative process and product R&D. 
Next chapter analyses the firm level learning processes involved in development of 
knowledge creation capability for innovation in firms under study. It discusses the inter-
firm similarities and differences in approaches as well as intra firm intricacies involved in 
transformation of capabilities. 
It concludes with insights on firm level process involved in development of innovative 
capabilities pointing out the limitations of learning hierarchy models of developments. 
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Chapter 8 
ANAL YSIS AND DISCUSSION 
This chapter analyses the finn level learning processes involved in development of 
knowledge creation capabilities for innovation in innovative Indian phannaceutical firms. 
It presents an analysis of intra finn difficulties and mechanisms involved in the 
transfonnation of capabilities and points out inter-firm similarities and differences 
involved in the development of innovative R&D competencies. 
8.1 Introduction 
The theoretical framework (Fig 8.1) discussed in chapter 4 guides the analysis of the firm 
level learning processes involved in the development of innovative capability. The 
theoretical framework is based on the absorptive capability concept and draws on the 
strategic management and organisational theory literature which is focused on knowledge, 
learning and innovation. 
Integration of different knowledge bases 
1 
Assimilation of knowledge 
1 
Acquisition of knowledge 
I 
Inter firm Mechanisms of knowledge Intra firm 
Knowledge transfer I-- Knowledge 
base base 
Prior knowledge base 
Fig 8.1 Theoretical Framework 
Based on the theoretical framework the analysis presented in this chapter is focused on the 
transforn1ation of capabilities in terms what happens in 'practice ~ as a response to change 
in the external environment. So the analysis coyers accumulation mechanisms which 
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govern the content and location of stocks of knowledge in the firm; the transfer 
mechanisms which govern the flow between internal and external sources of knowledge. It 
also includes assimilation mechanisms which govern the way in which firms internalise the 
newly accessed knowledge and examines the application or deployment mechanisms like 
coordination and integration which govern the ways in which the stocks of knowledge or 
specialised knowledge bases are brought to bear within decision making. 
To summarise, it explores the social processes or mechanisms used for knowledge 
acquisition, transfer, assimilation, and application in the sample firms. It also analyses the 
emergence and development of a prior knowledge base and its usefulness in new 
environment. This chapter thus focuses on the diverse set of learning processes used by 
Indian pharmaceutical firms and presents an analysis in terms of the differences in 
functioning and implementation of these processes in each firm. 
The analysis will show that as a response to change in patent law innovative Indian 
pharmaceutical firms have moved incrementally by developing competencies in generic 
productR&D and simultaneously these firms have invested to build the competencies in 
innovative product R&D. The analysis will also reveal that at the firm level movement 
from imitative R&D to innovative R&D requires an 'unlearning' of those capabilities 
which served well in imitative R&D but may not be so relevant in innovative R&D. 
Therefore, an important aspect of learning in the development of innovative R&D 
capabilities is an unlearning of the rigidities accumulated in imitative R&D. 
The analysis will suggest that learning at the firm level is neither a linear nor a automatic 
process and requires a deliberate learning strategy. 
Section 8.2 analyses the response of the sample firms to the strengthening of patent law 
and maps the technological paths adopted by firms on a product- process-proprietary grid. 
Section 8.3 discusses the difficulties involved in moving from a imitative pharmaceutical 
R&D to innovative product R&D capabilities. Section 8.4 presents learning processes 
involved in the development of innovative product R&D capabilities in the firms under 
study. Section 8.5 describes the inter-firm differences in learning processes and its 
implication for development of innovative R&D capabilities. Section 8.6 presents the 
conclusions. 
8.2 Technological paths of innovative Indian pharmaceutical firms 
This section reflects on the paths taken by innovative Indian pharmaceutical firms' to 
transform their R&D capabilities in response to a strengthening of patent law. 
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The product/process and proprietary gird (Fig. 8.2) developed by Forbes and Wield (2002) 
is used for analysing the technology paths taken by Indian pharmaceutical firms in 
response to emerging TRIPS regime. The grid is divided into four quadrants based on 
product - process - proprietary dimensions and provides a framework to track the 
movement of firms from imitative R&D to innovative process and product R&D. 
Proprietary capability comes from knowledge that is distinctive to the firm. The test of 
proprietary knowledge is whether or not it permits the firm to add value ahead of its 
competitors. In some cases this proprietary capability takes the form of intellectual 
property formally owned by firm: patents, trademarks, designs, copyright. 
In case of pharmaceuticals a 'patentable' product or process certainly allows value addition 
in a firm's portfolio compared with competitors and therefore in the grid the proprietary 
dimension for pharmaceuticals takes the form of process or product patent formally owned 
by the firm. In the grid capability to manufacture bulk drugs or API (active pharmaceutical 
ingredient) will occupy the process- non proprietary quadrant while branded formulations 
will represent the product non proprietary quadrant. The manufacturing of active 
pharmaceutical ingredient is basic ability to produce the drug in powder or raw form while 
the branded formulation involves preparing the drug in different dosage forms. Generic 
drugs in advanced markets like the US and Europe represents process - proprietary grid 
and new chemical entities or new drug delivery systems will occupy the product 
proprietary quadrant. Generic R&D involves the development of product with non-
infringing and novel 'patentable' process and which allows firm to add value in 
comparison to competitors. The new chemical entity involves the ability of the firm to 
conduct research and develop innovative patentable drugs in form of new therapies or 
improvement in current therapies as a cure for diseases while new drug delivery system 
(NDDS) involves the development of technology to introduce a drug at the diseased site in 
a novel way. 
The innovative Indian pharmaceutical firms began by manufacturing bulk drugs and then 
followed it by developing capabilities to produce and market branded formulations for the 
domestic market (quadrant I and II). In terms of capability development this represents a 
move from process-non proprietary quadrant to product non-proprietary quadrant, 
represented by vector A in fig 8.2. 
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Generic product R&D which occupies process-proprietary quadrant (quadrant III) involve 
creating non infringing processes or in some cases invalidation of an existing patent. The 
non-infringing process provide the product a novel and innovative element and firms could 
apply for a patent for this new process. In case of innovative lndian pharmaceutical firms 
the development of innovative processes to create generic version of existing drugs forms 
the incremental capability development represented by vector B in fig 8.2. The knowledge 
base underlying generic product R&D builds on organic and synthetic chemistry skills 
accumulated in reverse engineering but adds a patentable innovative element, providing 
value for the firm in comparison with its competitors. This represents process - proprietary 
quadrant (III) and shown by examples like Ranbaxy's process for preparing Cefaclor or 
DRL's development of Fluoxentine 40 mg capsules and subsequent 180 day exclusivity for 
in US generic market. Both were the patentable innovative and novel processes for known 
products and created the value for these firms over their competitors. Indian firm 
developed generic product R&D competencies by building on strong synthetic and organic 
chemistry skills and leveraging process R&D capabilities. This innovative proce R&D 
not only helped these firms to build capabilities in different aspect of regulatory 
management such as strategic patenting of innovation and patent litigation but at 0 
developed the capabilities required to compete in highly competitive generic market of the 
US and Europe. Therefore movement towards innovative proce R&D i e ploitative In 
nature and repre ent incremental capabi lity development. 
In parallel to the capability development in innovative process R&D, these Indian fIrms' 
invested in an exploration of risky and costly but highly profItable and innovative area of 
the new chemical entities represented by a product - proprietary quadrant in the grid 
(quadrant IV). However, innovative product R&D requires a different knowledge base and 
organisational capabilities compared to innovative process R&D. This movement towards 
proprietary product R&D (Vector B 1 and Vector C) is explorative in nature and represents 
the movement towards 'radical' capability development. 
Thus the innovative Indian pharmaceutical fIrms responded to strengthening of patent laws 
by adopting what O'Reilly and Tushman, (2004) have called ambidextrous technology 
capability development paths. Generics product R&D is also creating economic resources 
for Indian firms to fund the investment in exploration of radical capabilities. It helped these 
firms to develop what Teece, (1987) have called complimentary assets such as competitive 
manufacturing, marketing and distribution networks and the ability to deal with regularity 
procedures involved in getting new products to the markets in advanced countries. Thus 
the exploitive use of process R&D has helped these fIrms to develop the complimentary 
capabilities required to compete in new product markets. 
8.3 Difficulties involved in moving from imitative R&D to innovative pharmaceutical 
R&D 
This section presents the classifIcation of knowledge base and respective levels of 
capability in process and product pharmaceutical R&D (Fig.8.3). Using this classifIcation 
it reflects on the diffIculties involved in moving from imitative to innovative R&D and 
discusses their implications for innovative R&D capability development. This 
classifIcation also helps in mapping the level of innovative Indian pharmaceutical fIrms in 
terms of innovative product R&D capabilities. 
In the case of pharmaceutical R&D, process and product R&D capabilities can be 
differentiated on the basis of the complexity of knowledge base which can be characterised 
as basic, intermediate and advanced levels. 
Based on Bell and Pavit (1993), a basic level innovative capability is taken here as an 
ability to make minor adaptations to production and assimilate technology. Intermediate 
innovative capability refers to the ability to generate incremental technical change in 
product design, quality and production processes, it also includes the ability to search and 
evaluate external sources of technology. Advanced ilmOYative capability refers to the 
ability to generate new product and process innovations. Knowledge base can he 
categorised as simple and complex based on the nature of technological challenges 
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involved in development of products and the capabilities required to develop those 
products. 
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In the case of process R&D, the capabilities in reverse engineering, generic R&D and new 
drug delivery systems are mapped as basic, intermediate and innovative. Reverse 
engineering involves copying the manufacturing process using indigenous sources of 
technology while generic R&D includes producing the product with non-infringing and 
innovative processes. New drug delivery systems (NDDS) involve the development of 
technology to introduce a drug at diseased site in a novel way. To the larger extent firm 
develop new drug delivery systems to 
a. develop a generic product, 
b. develop an improved product and 
c. extend exclusivity. 
In all these cases, research involves working on formulation part of already patented drug 
rather than research on a novel drug. It involves findin g of newer and better routes of 
administration of proven drugs by application of modem technology for oral, na a l and 
other forms of drug administrations. This provides the new drug deli\ery ~ y tern re carch a 
definitive and well defined boundary of complexities. fhcrefore ne\\ drug dell cr) 
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definitive and well defined boundary of complexities. Therefore new drug deliyerv 
research is a less risky and cost effective strategy, representing an advance level of 
capability in terms of formulation research part of the process R&D. 
In the case of product R&D analogue research, new target or new leads and original NeE 
research can be characterised as basic, intermediate and advanced level capabilities. 
Structure-based or rational drug discovery is characterised as advanced level of capability 
and involves the determination of a disease causing protein's three-dimensional structure. 
Once the structure is known, novel chemical entities are designed to 'lock-in' to the protein 
with the aim of reversing or arresting a disease's progression. This research will involve 
putting up whole new and original hypotheses about the disease and its treatment. It will 
require in-depth knowledge about biological and chemical aspect of the disease as well as 
skills in areas such as target identification, validation and lead identification, optimisation. 
The target identification involves identifying biological targets that have the potential to be 
starting points for successful and commercially viable treatments while target validation 
involves further screening and a step-wise selection process through different functional 
in-vitro assays (tests). The lead identification and involves chemicals that have proven to 
influence the target in a way that gives them the potential to become effective treatments 
while lead optimisation involves further refining of lead molecules by carrying out tests for 
attributes such as absorption, duration of action and delivery to the target. The results of 
these tests determine whether the leads have the potential for testing in humans and have 
the qualities to become a safe and effective drug. 
The intermediate capability in product R&D represented by new target or new leads 
requires higher skills than analogue research. Thus novelties in terms of new lead or new 
target will demand a deep knowledge about areas such as structure-activity relationship 
which involves analysing reactions between molecular structure of new chemical entity 
and three dimensional structure of protein. 
Analogue research involves the modification of existing molecule which can provide better 
efficacy or reduce the side effects and add value to the therapy. This research makes the 
use of already discovered molecules and targets so the requirements of skills in lead 
optimisation or target validation are limited in it. 
The analysis of the sample firms' capabilities in process and product R&D suggests that in 
terms of process R&D. Ranbaxy has acquired advance level capabilities in process R&D 
while other firms are at intermediate level. In terms of product R&D. DRL has acquired 
the capabilities to conduct research involving new leads or new molecules whereas other 
firms are at analogue research stage. This is evident by the fact that Ranbaxy den~loped the 
once- a- day new drug delivery system for Ciprofloxacin and licensed it to Bayer \\hile 
lC)C) 
Reddy US Therapeutics, DRL's R&D subsidiary in US has filed a patent application for 
molecule which was the outcome of structure based drug discovery research approach. 
This classification of process and product R&D capabilities assist in tracking the 
difficulties and mechanisms involved in the transformation of capabilities to move from 
imitative process R&D capability (reverse engineering R&D) to innovative process and 
product capabilities. The different knowledge base, organisational processes and 
capabilities required in imitative R&D and innovative R&D shows that firm having 
advance level competencies in imitative process R&D may start with little or no basic level 
capabilities in innovative product R&D. Innovative Indian pharmaceutical firms have 
developed basic level of process R&D capabilities through imitative R&D and as a 
response to change in patent law, they are moving towards the development of advance 
level process and product R&D capabilities. This movement involve the integration of 
existing capabilities with newly acquired knowledge but crucially it also involves the 
unlearning of non-relevant capabilities or rigidities. The development of product R&D 
capabilities will involve acquisition of new capabilities and combination of those with 
existing relevant capabilities (fig. 8.3 vectors A and Vectors B). It will also involve 
removal of capabilities which were useful in process R&D but redundant in product R&D 
(vector C). 
The next section discusses the capabilities from process R&D which are not relevant to 
innovative product R&D. 
8.3.1 Learning and unlearning 
The analysis of the firms under study reveals that these firms will have to get rid of 
capabilities which are not relevant to new environment. It also suggests that these firms 
will have to acquire new capabilities and combine them with existing relevant capabilities 
to develop capabilities in innovative R&D (Table 8.1). The analysis of innovative 
pharmaceutical firms suggests that R&D infrastructure, complimentary manufacturing and 
marketing assets, linkages with research institutes and understanding about the 
pharmaceutical R&D are relevant capabilities in innovative R&D. In addition to that firms 
will have to add new knowledge in key product R&D disciplines like medicinal chemistry, 
biology, establish product R&D infrastructure to facilitate the development of innovative 
R&D capabilities and create culture of innovation in their R&D to foster the innovative 
R&D. 
The important rigidities that have emerged are a. imitative R&D organisational routines. b. 
in-house nature of R&D and c. organisational mindset and these are discussed in this 
section. 
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8.3.1a Reverse engineering experienced scientists in discovery R&D 
Success in imitative R&D draws on branches of chemistry like synthetic chemistry, 
organic chemistry and basic pharmacology. Indian pharmaceutical firms in their R&D 
laboratories employ organic and synthetic chemists who could reverse engineer any 
molecule or develop efficient and cheap processes for any patent protected molecule. 
However, innovative R&D is about motivating scientists to think 'out of box~ or think 
differently in novel and creative way. For example, if there is existing anti-diabetic 
molecule already on the market, then developing a new molecule or identifying a new 
target site, which will aid in a discovering a different therapy approach to cure a disease. 
Lupin's head of new drug discovery explained, 
''for new drug discovery you can get good chemist here but they don't have expertise of 
how to design molecule, how to look at receptor, how to look at molecular modelling. If 
you are not trained then it's difficult to understand the interactions". 
Table 8.1 Rigidities, relevant capabilities and new capabilities 
IN 
Understanding of the 
pharmaceutical R&D 
Com plimentary 
technological assets: Skills in 
pharmacology, analytical 
chemistry, process R&D (for 
development phase) 
- Sources of knowledge 
created through distribution, 
marketing routes in overseas 
markets 
R&D Infrastructure 
Existing relationships with 
research institutes 
OUT 
Mindset 
a. Short term vision of R&D 
b. Domestic market focused 
thinking 
Reverse engineering 
experienced scientists in 
discovery R&D 
R&D management 
practises 
a. Resource 
allocation 
b. Project review 
In-house nature of R&D 
NEW 
Culture of innovation 
R&D management 
mechanisms 
Research talent 
a. expertise in medicinal 
chemistry and biology ; 
b. scientists with experience 
in product R&D 
c. incentive schemes for 
scientists 
Product R&D infrastructure 
Networking and 
collaboration capabilities 
The research skills required in innovative R&D differs from imitative R&D in terms of 
design and conduct of experiments as Ranbaxy~s former R&D president elaborates, 
"the organic chemist in process development lab works on or run the batches of 10 kg 
or 20 kg whereas in drug discovery laboratories he does the milligram jobs and this 
switch can be difficult". 
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Process R&D is about developing scale intensive manufacturing processes, so experiments 
involve changing solvents temperature, pressures and studying their impact on the output 
safety and cost Due to working on these parameters scientists create their own biases and 
ways of working which are suitable for process R&D but these become irrelevant in 
innovative product R&D. Lupin's head of new drug discovery explains, 
"There is this scientist; he was head of one group of the generic people. So J tried this 
scientist for eight months in new drug discovery, he couldn't able to deliver anything to 
me. Finally J have to ask him to please go back to generics now. This is my personal 
experience, with reverse engineering experienced scientists, it is difficult ". 
Innovative R&D requires scientists skilled in a wide range of disciplines and scientists 
working in the sample firms lacked the knowledge in those of areas. Glenmark's strategic 
planning director explains, 
"what you need is innovative chemistry so which is not same as reverse engineering. So in 
fact we do not prefer the people in discovery chemistry who have the experience of reverse 
engineering. If the scientist has done some non-infringing work or he has done some 
original work then we will take him but not only process development because you just 
can't take a good process chemist and try to make him a good medicinal chemist or a 
chemist who is able to deliver on an innovative chemistry or chemistry which he is not 
done before ". 
Therefore these firms have not employed process development scientists for new 
chemical entity research and have hired product R&D experienced scientists or fresh 
scientists for innovative product R&D. NPIL's R&D president suggests, 
"J mean they have to break the routines, they are aware about that. So that is why they 
have to hire people who are not already mentally set/or the routines". 
8.3.1h Ways of managing R&D projects 
The reverse engineering method of product development required relatively little 
communication of knowledge across the boundaries of the firm or across disciplines or 
therapeutic areas within the firm. Firms were organised R&D functionally with chemist at 
the heart of the process and pharmacologist working down stream. However, according to 
Henderson, (1994) innovative pham1aceutical R&D requires the exchange of knowledge 
across the boundaries of the firm and across disciplinary and therapeutic class of 
boundaries within the firm. Innovative R&D requires the input from various disciplinary 
knowledge bases and success is linked with organisational ahility to integrate kno\\ledgc 
across disciplines. Therefore. innovative R&D requires different mechanisms to manage. 
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design and reVIew research projects than imitative R&D. Lupin's head of new drug 
discovery suggests, 
"your mind is set for reverse engineering and to transform that mind into nell' drug 
discovery you need to know lot of pharmacology, toxicology and pharmacokinetics. If you 
know only chemistry, you can not design the molecule. You have to look at the total 
pharmacology of that particular disease, then bioavailability issue, toxicology issues ". 
This need for integrating different disciplinary knowledge bases shows that the 
organisational practices and routines accumulated in imitative R&D cannot be directly 
applied in innovative R&D. Glenmark's strategic planning director comments, 
''for innovative R&D, you need to form forum in a way that there is interaction between 
different departments where as reverse engineering is a individual job, one fellow sitting 
in the laboratory can do it. Drug discovery is completely team effort so you have to have 
chemist talking to biologist, biologist talking to the kinetist, kinetist and biologist talking 
to analytical fellow and things like that. So you need to form a forum and structure 
where actually these will come together". 
The R&D culture developed in the imitative 'era' also represented a major obstacle in 
development of innovative R&D capabilities. Lupin's head of new drug discovery 
explains, 
"people are not taking the responsibility which they should take. Its normal culture here 
that you tell them to do certain things then you have to after them to get things done where 
as in US once a person gets in project then they don't talk much. They are busy with their 
own work but here you have to push the people ". 
He elaborates further on his experience in other Indian pharmaceutical firm, 
"they go on working on project which doesn't give anything for 5 years; why you want to 
continue with that. You must throw it away don't run over that anymore or change ways of 
working there. So I don't think we had any major issue there except for culture changes 
which we have to implement there ". 
The other important issue is the R&D infrastructure required for innovative R&D. The 
present R&D infrastructure in Indian pharmaceutical firms is adequate for process R&D 
research but will need up-grading for innovative product R&D projects. Innovative R&D 
requires the state of the art instrumentation specifically in key disciplines like chemistry 
and biology. The emergence of drug discovery technologies like combinatorial chemistry 
or high-throughput screening has transformed the drug discovery process. 
head of pharmacology comments, 
'N ockhardt' s 
"'0' .... '
"we don't have right now the facilities which scientists working overseas have seen 10 
years back. Those things they can get there or in US companies or any other research 
institute overseas just by signing certain things, it's not possible to get it here. We do get 
lot of capital budget but there is still gap between us and West". 
8.3.1c Mindset 
The most important issue that has emerged is mindset to shift from copying a product 
towards a creating and generating innovative product. Indian phannaceutical firms have 
over the years gained immediate returns on R&D investment and have mostly competed in 
the domestic market on the basis of cheap, albeit efficient, production processes. The 
reverse engineering new product development requires short duration for completion of 
projects. Firms can get immediate return on R&D investment by introducing the product in 
market as imitative R&D doesn't require time consuming clinical trials. But in case of 
innovative product R&D the life cycle of product development is long and takes 10-15 
years. So firm have to be mentally prepared to commit the resources for 8-10 years without 
immediate returns. The former R&D president of Ranbaxy comments, 
"it is a mind set problem; those making profits don't want to invest in product R&D. 
The costs involved in drug discovery and development are really enormous and returns 
don't come fast. Most of Indian firms have this habit of getting quick returns and so if a 
firm wants quick return on the investment, its not going to be there". 
Although the innovative firms have increased R&D investment from 1995 (Table 8.3) but 
there is wider consensus about need to increase it still further. One R&D vice president 
defends the gradual increase of R&D investment saying that 'every company needs to 
develop its own comfort zone of risk' and links the issue to the mindset problem. He 
accepts the difficulty of convincing people to make investments without any foreseeable 
returns for 8-10 years, and cite this as a reason for the gradual increase in R&D investment. 
In case of innovative Indian pharmaceutical firms, mindsets shaped by practises of getting 
immediate return on R&D investments, inferior technology and domestic market focused 
thinking has emerged as one of the main constraints to move from imitative R&D to 
innovative product R&D. 
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8.3.1d In-house nature of R&D 
In the reverse engineering era Indian phannaceutical finns built process R&D capabilities 
in-house as profits were totally linked to efficient and cheap production processes. The 
intense competition and lack of trust due to a weak regulatory environment shaped the in-
house nature of R&D, resulting in a lack of collaboration between industry and academia. 
However, innovative R&D requires contributions from various disciplinary areas like 
medicinal chemistry, biology and phannacology which are advancing at an extraordinarily 
rapid rate. Scientists working in innovative R&D need to be current with a wide range of 
specialised knowledge. The Indian phannaceutical finns are chemistry based but biological 
knowledge and talent in India is concentrated in research institutes such as Indian Institute 
of Sciences, National Institute of Immunology, Centre for Cellular and Molecular Biology 
and others. Therefore, Indian phannaceutical finns have to change the in-house view of 
R&D to access and acquire disciplinary knowledge bases in innovative R&D. DRF's 
fonner R&D president suggests, 
"what we need to do in next 5-10 years is enhance our interaction with academia and 
research organisation across the world. Allow our scientists to get exposure in fast moving 
science laboratories". 
8.3.2 Summary 
The analysis points out that in the case of Indian pharmaceutical firms under study the 
main rigidities that have emerged are 
a. imitative R&D organisational routines, 
b. in-house nature of R&D and 
c. organisational mindset shaped by short term vision of R&D investments and a domestic 
market focused approach. 
The difference of knowledge base, organisational practises in imitative and innovative 
R&D implies that the processes and capabilities that served firms well in the past are not 
relevant in new regulatory and competitive environment. According to Leonard - Barton 
(1992) core rigidities are flip side of core capabilities and represent the gap between 
current environmental requirements and a finn~s core capabilities. The deeply embedded 
knowledge system sets actively create problems and so the firm has to eliminate or 
minimise the impact of these rigidities. In case of Indian pharmaceutical firms it suggests 
that an important part of learning is 'unlearning' or forgetting past beha\'iours. Hedberg 
(1981) points out that knowledge grows and simultaneously becomes obsolete as reality 
changes. Understanding involves both learning new knowledge and discarding obsolete 
and misleading knowledge. The discarding acti\'ity - unlearning - is as important part of 
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understanding as adding in new knowledge and slow unlearning is a crucial weakness of 
many organisations in development of new capabilities. So, in case of innovative Indian 
pharmaceutical firms getting rid of 'rigidities' accumulated in reverse engineering era 
forms an important part of learning in development of innovative R&D capabilities. 
To sum up, some of the processes and capabilities accumulated through imitative R&D can 
actively create problems in innovative R&D where projects are designed to develop new. 
non traditional products and capabilities. This suggests that as firms move from imitative 
process R&D to innovative product R&D, they will have to get rid of those capabilities 
which are useful in process R&D but can become rigidities in product R&D. Therefore in 
case of Indian pharmaceutical firms unlearning of obsolete abilities formed an important 
constituent in transformation of capabilities from imitative R&D to innovative product 
R&D. 
The next section elaborates on the learning processes involved III development of 
innovative R&D capabilities in firms under study. 
8.4 Processes involved in the development of competencies in innovative R&D 
This section analyses the learning processes used by the sample firms to develop the 
required competencies in innovative R&D. It focuses on the key knowledge creation 
processes such as the mechanisms involved in acquisition of new knowledge, its 
assimilation, transfer and application. It also discusses relevant aspect of prior knowledge 
base in new environment. 
8.4.1 The prior knowledge base and its relevance in innovative R&D 
Prior knowledge provides the base on which firms develop capabilities to cope with 
technological change or a new external environment. According to Cohen and Levinthal 
(1990), the absorption of new knowledge depends on the accumulated stock of past 
capabilities or knowledge and mechanisms of knowledge transfer. The accumulated stock 
and content of knowledge gives firms an ability to exploit external knowledge and IS 
therefore the critical component firms ~ ability to develop new capabilities. 
Over the years Indian pharmaceutical firms have used reverse engineering as a mechanism 
for knowledge acquisition and built strong capabilities in synthetic and organic chemistry. 
New drug discovery research, however. requires expertise in medicinal chemistry 
(synthesis and natural product extraction), toxico-pathology, bio chemistry, biology in 
addition to clinical pharmacology. Therefore according to one pharmaceutical consultant, 
"current expertise Gl'ailable for reverse engineering research is totally inadequate for new 
drug discol'C!1)l research ". 
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However, from the beginning of the 90s these Indian firms started innovating in process 
development by creating cheaper processes. These firms challenged their scientists to 
develop the product with alternative production processes involving less cost or develop 
processes which would give more yield. This created a strong knowledge base in chemistry 
and greatly increased expertise in pharmaceutical technologies building the foundation for 
innovative process and product R&D. For example, Ranbaxy's process development effort 
for Cefaclor involved developing a new process different from Eli Lily's patented 70 
processes. This required in-depth knowledge about the complexities involved in process 
development as well as creative thinking. 
Gradually these firms started targeting the generics market in advanced countries and 
which involved developing product with new non infringing processes. For example when 
DRL developed Pfizer's drug Prozac (Fluxotine), the company not only produced the drug 
with new process but also with new dosage form and as a result DRL got 180 days 
exclusivity in the US generics market for this innovation. Therefore, the innovation was 
part of not just a new process for producing the molecule but it actually renewed the 
product or created a new market for product; the product was same but the methodology 
adopted involved creativity and innovativeness. The generic product R&D showed the way 
of creatively building a knowledge base and gradually built a tradition of creative research 
in these firms. This innovative way of developing processes for production forced 
scientists to think differently, changing the mindset from 'imitative thinking' to 'original 
thinking'. NPIL' s strategic alliance director comments, 
"It's just the target we never focused them on. In old days we taught them chemistry and 
said do it. We never told them find a non-patent infringing process to make a drug which is 
perhaps eco-friendly whose cost is half and you can find an innovation which you can 
patent. We didn't tell them the goal was that so they didn't have that in their mind". 
The generics product development created understanding about innovative pharmaceutical 
R&D and helped firms to learn about practices required to operate in advanced markets. 
This accumulated knowledge bases helped these firms to identify opportunities to move up 
the value chain in terms of product complexities. In case of Ranbaxy the success of 
Cefaclor spurred them to invest in the Ciprofloxacin OD project. Cefaclor process 
development was the innovative outcome of research to manufacture the active 
pharmaceutical ingredient and this success spurred Ranbaxy's scientists to develop 
innovative product in formulation. This started Ranbaxy's ciprofloxacin once-a-day 
dosage technology development project and which proved to be company's first successful 
new drug delivery project. Ranbaxy's Vice President, corporate affairs suggests that. 
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"it's (reverse engineering) the foundation on which innovative R&D is built up. Jrithout 
that, it was not possible to do that. If somebody to say that I would not look at all these 
capabilities but I would hire people and get going, it can happen for short run but it can 
not happen for long run ". 
This supports Pisano's (1994) view that process development is enabler to product 
innovation and can playa supportive role in product development. 
The influence of accumulated knowledge and strong chemistry skill is reflected in the 
R&D strategies employed by all the sample firms in product R&D. All choose analogue 
research to venture into new drug discovery as this research strategy involves a strong 
chemistry base in terms of modifying the molecular structure to produce the drug with 
better efficacy or less side effects. 
The next section analyses the mechanisms of knowledge acquisition used by firms to 
bridge the knowledge gap in innovative R&D research areas. 
8.4.2 Acquisition of new competencies associated with innovative R&D 
Knowledge acquisition is a learning related process by which knowledge is identified, 
accessed and obtained. The MNC pharmaceutical firms' transformed their internal R&D 
by hiring new personnel embodying the new technology to transform their technological 
identity as a response to biotechnological change. In post biotech era the 'star scientists' 
who combine genius and knowledge of emergent technologies became the gold deposits 
around which firms and their success was built (Zucker and Darby, 1996a). 
The analysis of Indian pharmaceutical firms' approaches also show the important role of 
product R&D experienced scientists in acquiring innovative R&D capabilities. Along with 
that it also points out that that investment in internal R&D is played an important role in 
developing internal knowledge about innovative R&D in these firms. The innovative 
Indian pharmaceutical firms spent initial years in building infrastructure, putting together 
teams of scientists and developing organisational practises to manage innovative R&D. 
8.4.2a Hired product R&D experienced as well as fresh scientists 
Innovative Indian pharmaceutical firms started building innovative capabilities by hiring 
innovative R&D experienced scientists who have either worked overseas or in laboratories 
of multinational companies in India. According to NPIL' s R&D president firms' first have 
get out of reverse engineering and start doing real research: hire the scientists \\"ho have the 
experience in product R&D areas. In India only a handful of scientists had experience in 
innovative R&D and these scientists became the 'guides' for the development of 
innovative R&D capabilities. Most of these scientists either had roots in Hoechst Research 
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Centre in India as during its eXl'stenc thi t d d' . 
, e s cen re was e Icated to new drug dIscovery and 
development or overseas working in MNC laboratories. These scientists fonned the core 
teams in charge of designing and conducting of new drug discovery programmes. NPIL' s 
R&D president explains role of senior scientists , 
"you are there to pick the right people, those who know the business and then obl'iously 
they will drive something which is already exist in the company and they will bring 
something new which is required", 
For the sample firms hiring these scientists played a key role in initiation of drug discovery 
research programme. These scientists had experience in drug discovery and they brought 
crucial tacit knowledge about drug discovery in the Indian finns. Due to their working 
experience in MNC R&D these scientists were well trained and had better exposure to new 
drug discovery technologies compare to existing scientific staff in Indian finns. 
Glenmark's strategic planning director suggests, 
"they have got the exposure and the understanding about how the modern drug discol'ery 
works and that is very critical ", 
These scientists provided leadership to the discovery research teams and brought a 
coordinated approach in conducting a research programme. NPIL' s strategic alliance 
director comments, 
"there is lot more cross border transfer of ideas, huge number of Indian scientists 
abroad who are working in foreign pharmaceutical firms are coming back. At a cheaper 
cost they can recruit the groups around their idea and then make a much better 
innovation out of it. That's the first important trend, people coming back, ideas being 
done even in the US and groups being done here so lot more cross border things". 
These core teams of scientists selected the research programmes and hired fresh scientists 
to create critical mass of drug discovery scientists. Research project teams for innovatiyc 
R&D were built by focusing on fresh research talent rather than hiring those scientists 
experienced in reverse engineering. NPIL R&D president suggests, 
"but generally you hire the new ones and you Itave the people wlto are abroad doing 
this sort of thing and pay them and get tlte"" tltat way YOII are much better bet tltall 
trying somebody who has not done any innovative research for years alld years ill tltis 
area ". 
209 
The innovative Indian phannaceutical firms did not transfer the reverse engineering 
scientists into drug discovery research as reverse engineering activity is still going on in 
these firms. 
The main constraint in innovative R&D for Indian firms was the lack of scientists 'with 
expertise in areas of medicinal chemistry and biology. Glenmark's strategic planning 
director suggests 
"there are no people who have the expertise in biology. There are some people who have 
medicinal chemistry experience but very few people who have drug discovery biology 
experience ". 
To over-come this constraint these firms focused on hiring scientists from Indian as well as 
overseas universities and research institutes. Ranbaxy's former head of new drug discovery 
comments, 
"at Ranbaxy I brought some people from US for molecular modelling, for microbiology, 
some for medicinal chemistry but that's the biggest challenge you have ". 
Firms' targeted returning post graduates and post doctorates from overseas universities. 
Currently around 20% of scientists working on innovative research projects have either 
trained at overseas universities, or have working experience abroad in MNC laboratories. 
DRL R&D president explains, 
"Our target was returning post grads who have gone abroad to do either PhD or post 
docs, they were returning and were very good. Actually for 90% of workforce in the 
R&D, it was their first job, we were able to introduce scientific programme, induct 
people, mould them and could bring that culture into organisations. It is something nice 
to start with the clean slate rather than something that is there and erase it and then put 
it, it's a sort of double job. " 
Innovative Indian pharmaceutical firms like DRL used the relationship with academics in 
Indian universities to track fresh scientists for recruitment. DRF's former president 
explains, 
"We rely heal'ily on unirersity professors because most of their students are abroad. So 
we have enlisted support of the faculty here in various unirersities and from them found 
out what their students are, where they are and what they 'want to do and that allowed us 
to interact H'ith those students Ol'erseas ". 
The number of scientists working in Indian firms has grown considerably in the last decade 
(table8.2). These firms are heavily recruiting the scientific statT to create a critical mass of 
innovative R&D experienced scientists and as a result the percentage of stafT working in 
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innovative Indian pharmaceutical firms has consistently grown in last decade. For 
example, in case of DRL in just 1 year the percentage of people working in R&D has 
grown by 3%. 
Table 8.2 Percentage of R&D staff to total staff (Source: Annual Reports, 2000-03) 
Firms Percentage of R&D staff / Total staff 
2000 2001 2002 2003 
Ranbaxy 8.85 9.02 11.11 13.52 
DRL 9.09 12.39 
Wockhardt 9.57 11.11 12.47 13.66 
NPIL 2.66 3.38 4.53 4.33 
Lupin 5.45 6.11 
Glenmark 5.55 6.00 10 
8.4.2h Increased R&D investment 
The most important feature of knowledge creation strategies is the level and direction of 
resources devoted to learning. The R&D departments provide a major source of learning in 
an activity which is central to firms continuing existence and prosperity. Dodgson, (1993) 
suggests the size and focus of R&D budgets are the primary factors encouraging and 
constraining learning. 
Indian pharmaceutical firms began increasing their investment in R&D from 1995 but this 
only really gained momentum in 2000 (see Table 8.3). The focus of R&D investments in 
these firms has gradually shifted towards innovative process and product R&D. This has 
helped firms in creating the innovative R&D oriented knowledge base required for 
understanding the advances happening at the technological front. Cohen and Levinthal, 
(1990) points out that without investment in the creation of knowledge in particular areas, 
it is difficult for a firm to build capabilities required to acquire, absorb and apply external 
knowledge. 
The sample firms set up the new R&D centres dedicated to innovative R&D equipped with 
state of the art instrumentation and at a different location with different practises than 
reverse engineering R&D. Glenmark's strategic planning director comments, 
"those are separate people, it's a different thing altogether. They are set of complete(l' 
different people that are operating it". 
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Table 8.3 R&D intensity of innovative Indian firms (source: Annual Reports, 2000-03) 
Firms No. of R&D R&D intensity (R&D spend % of sales) 
labs 2000 2001 2002 2003 
DRL 5 4.22 6.29 7.70 10 
Ranbaxy 3 4.20 3.80 5.20 6.10 
Wockhardt 2 7.20 6.20 6.20 7.90 
NPIL 3 1.80 2.16 1.63 3.90 
Lupin 1 2.41 2.30 3.09 
Glenmark 2 1.45 3.50 4.41 6.52 
Indian pharmaceutical firms did establish new disciplinary divisions and regulatory 
departments to support innovative R&D programmes. This was important as the ability of 
firms to make use of outside knowledge depends upon their installed knowledge base and 
the in-house scientific research creates the knowledge base which allows firms to take 
advantage of public sciences (Cohen and Levinthal, 1989; Gamberdella, 1992). Nicholl -
Nixon (1993) shows that the establishment of internal R&D is an important pre requisite to 
the use of strategic alliances as a mean of acquiring external knowledge. Therefore internal 
investment in new disciplines allowed Indian firms to identify external sources of 
knowledge as well as nature of knowledge that should be accessed for acquisition. 
Firms like DRL, Ranbaxy and Glenmark have also opened laboratories in US and Europe 
to make use of the knowledge spill-over and to attract research talent which was reluctant 
to shift to India. 
Although over the years Indian pharmaceutical firms have steadily increased the R&D 
intensity, still it is much less compared to the R&D intensity of MNC pharmaceutical 
firms. In 2003 MNC pharmaceutical firms on an average invested 15.3 % of total sales in 
the R&D (PhRMA, 2004), while the average R&D intensity of the sample firms is 6.250/0. 
The important factor determining R&D investments of Indian pharmaceutical firms is the 
cost of development of a drug in India could be a tenth of the international cost. DRF's 
former R&D president suggests, 
"I think India has human resource cost advantage. By rough math JIJUh at MSc level, 
l rd" 
at PhD level it could be J15t , and at upper level the difference could be 113 . 
However, according to a pharmaceutical consultant the innovative Indian pharmaceutical 
firms' actual R&D expenditure spent on innovative R&D has gro\\TI from 20% in 1995 to 
'11"1 
.... -
40% in 2003. According to Forbes and Wield (2002) the focus of the R&D is far more 
critical to the success of industrial innovation than the level of R&D spending. The 
increasing level of scientific staff and R&D investments suggests that in Indian finns the 
focus of research is gradually shifting towards conducting innovative process and product 
R&D. DRF's fonner R&D president argues, 
"1 still maintain as a scientist and as a pharmaceutical research manager, in discovery 
area or phase, size or level of investments are not key factor of success. Success factors in 
innovative R&D are ideas and people with commitment, few people with commitment. So 
all this has been possible not because of the enormous deployment of the resources but it is 
just top level commitment, few dedicated scientists. They had urged to do something and 
demonstrate that we can also perform given the environment and that's what it is ". 
The analysis of finns suggests that these Indian finns built the core team of scientists to 
lead innovative R&D by hiring drug discovery experienced scientists and with the help of 
these scientists created the research teams by recruiting the fresh scientists from Indian as 
well as overseas universities and research institutes. The imitative as well as innovative 
process R&D has created a knowledge base with strong chemistry skills and this 
accumulated knowledge has built strong foundation for new drug discovery research in 
these finns. 
The next section discusses the mechanism used by innovative Indian pharmaceutical firms 
to build culture of innovation in innovative R&D and to create an environment that 
supports the construction of common knowledge among the scientists. 
8.4.3 Assimilation of new knowledge 
The assimilation of knowledge involves the creation of an environment which facilitates 
processes of sharing experiences as without a shared language and a shared understanding, 
it is difficult to create unifonn purpose, construct cohesive meaning, and learn in ways 
which support innovation across the organisation. The support offered by the organisation 
in tenns of instrumentation, existing knowledge base and linkages creates conditions 
conducive for innovative research (Dodgson, 1991). Organisational environment, structure 
and practises can be designed by building supportive arrangements in order to attract 
personnel capable of creative and innovative ideas and research. Organisational routines 
are one way in which knowledge generated by individuals becomes assimilated or 
embedded in organisations (Nelson and Winter, 1982). 
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8.4.3a Culture of innovation 
In terms of building a creative R&D environment NPIL' s R&D presidents lists the 
important supportive arrangements, 
"infrastructure has to be proper, instrumentation proper, growth possibilities should be 
there. So in case of scientist better ways of publication, possibilities of going to different 
conferences; all those things have to be there. The literature facilities, library facilities 
should be up to the mark". 
For Indian firms attracting and retaining good research talent wasn't very easy and firms 
had to convince these scientists of their commitment by investing in the infrastructure 
required for innovative R&D. According to Wockhard's head of pharmacology, 
"scientists who have worked overseas for 15 -20 years do come here but are not able to 
work here. Their expectations are very high about infrastructure and about capital 
equipment that they want". 
Therefore the innovative Indian pharmaceutical firms' initial effort focused on creating 
ideal infrastructure required for innovative R&D and these firms covered the infrastructure 
limitations with various incentives. NPIL's strategic alliance director comments, 
"'we have to have this innovative thinking and in the past it's been very much I decide 
and you do. Now you have to say no you think and let's think together so more team 
based approach, innovative approach ". 
These companIes are building culture of innovation by encouragIng the creativity, 
providing freedom to work and absorbing the mistakes. According to Wockhardt's head of 
anti -infective research, 
"company overcame the infrastructural limitations by creating pla(forms and 
opportunities for its scientists to learn; learn through failures, learn through success. 
allow them to fail so they can succeed later on, and absorb their failures sportingly". 
In product patent era firms have realised innovation is key and therefore they are giving 
scientists freedom to experiment, make mistakes and learn from the mistakes. The freedom 
to work is provided in terms of opportunities to design research projects. Former R&D 
president of Ranbaxy explained, 
"lot of time they come up with new ideas, this and that, we gave them opportunities to 
express whal they want; you can try to see if thaI works. When new person comes, you 
musl try new things and see what his abilities are. {f you don 'I allaH' new people to work 
nell' ideas. then thaI is not Ihe righllhing ". 
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The top level commitment played a crucial part in firms efforts to build innovative R&D 
environment and is reflected by consistent increase of investments in the innovative R&D. 
Firms which are run by leaders who are scientists have been able to balance this 'return on 
R&D investment' paradox well. DRF's R&D president comments, 
"Scientists require good support from the management and that's what is important. 
Fortunately we have a leader who is a technocrat and then he is not a typical business 
man. That makes the big difference because he understands if somebody says chemistry is 
not working; he understands that, because he is himself a scientist". 
8.4.3b Encouraging scientists to upgrade knowledge in areas of drug discovery 
Indian pharmaceutical firms are now providing extensive training support to enhance 
scientists' research skills and scientific knowledge bases. In the case of fresh scientists 
firms give initial training for a period of six months. In some cases these scientists were 
rotated from lab to lab to evaluate their aptitude and skills. Then scientists were given 
independent task to perform by designing a research programme and giving them the 
opportunity to work on it. They were encouraged to read lot of patents and study structure-
activity relationships. The focus is on how the patent holders started, what they did and 
where did they end up and after that scientists are encouraged to design their own 
molecules. This way of patent analysis provides a scientist an understanding of the 
intricacies involved in innovative drug discovery. 
Table 8.4 Innovative Firms and affiliated university (Source: Annual reports, 2000-03) 
No. Firm Affiliated university 
1 Ranbaxy Laboartories ltd Delhi U Diversity 
2 Dr. Reddy's laboratories ltd BITS, PHani 
3 Wockhardt University of Mumbai 
4 Nicholas Piramal ( I) pvt ltd University of Mumbai 
5 Lupin Laboratories ltd University of Pune 
6 Glenmark pharmaceutical ltd University of Mumbai 
These Indian firms are also helping scientists to pursue their academic ambitions while 
working in organisations. The research centres in all these firms have been recognised by 
reputed Indian universities as authorised PhD centres and therefore post graduate scientists 
can commence their doctoral degree while working in these firms (Table 8A). Due to 
these affiliations the researchers working in these firms get an opportunity to use uniyersity 
facilities such as library and laboratories. This has allowed scientists to pursue their 
215 
academic interests and helped firms' efforts in upgrading researching skills of its R&D 
staff. 
Innovative Indian pharmaceutical firms are sending their scientists in India as well as 
overseas to different workshops, seminars and research institutes to undertake training in 
new scientific tools. NPIL' s head of regulatory department comments, 
"whenever there are some seminars outside we try to send our people, so we encourage 
our people to go to seminar outside because we are not so highly trained ourselves that we 
can train other people ". 
8.4.3c Changed R&D project management structure 
Innovative Indian pharmaceutical firms have changed R&D project management structures 
to maintain a seamless flow of information inside the R&D department. DRF's former 
R&D president focuses on change in practise and comments, 
"In the past results of the test used to be with head of department, he was sharing only 
whenever it was necessary. But now it is not like that. Chemist synthesises a compound, 
submits for screening and results will be shared among scientists. That activity stimulates 
a researcher so this type of seamless interaction and fluid flow of iriformation helps in 
innovative R&D". 
These firms started USIng a 'matrix' style of project management for orgamsmg and 
conducting new drug discovery research projects. For each therapeutic area project, there is 
project manager, project leader and team members comprises of both chemist and 
biologist. The project managers are responsible for project budget, planning and control, 
establishing objectives and ensuring they were met. These project managers are also in 
charge of coordinating resources drawn from various scientific departments. The matrix 
project management system has helped firms to create informal mechanisms of interaction; 
a platform for knowledge sharing by providing an opportunity for chemist and biologist to 
interact on a day to day basis. This has enabled firms to maintain high standards of work 
practise and uniform scientific development of the group through better communication 
among the scientists working on different projects. 
Firms have created various forums to increase the interactions among members of different 
specialised groups. DRF's R&D president focuses on this aspect as most crucial for 
success in new drug discovery, 
"we nlade it such a way that both chemistry and biology become seamless departments 
alld the interactions are very informal; as informal as meeting people 011 the corridors of 
the labs', finding out what is going 011 or telling people what exact(l' they should be 
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looking into. These were a few fundamental things responsible and were really 
motivating factors, in addition to senior people like us; we are all telling them what they 
should doing. I would say that was one of the successful approaches". 
Firms like DRL and Ranbaxy have licensed their molecules to MNC pharmaceutical firms 
for further development. These licensing collaborations have led lots of interactions at the 
scientists level between both firms and that has helped the Indian firms in imbibing some 
of skills in drug discovery management. DRF's former R&D president suggests, 
"Scientists are interacting with their counterparts in these companies. We visit their sites, 
we have joint project meetings and all this information is shared. All this is very rich 
experience and we are happy about it. Today we are better project managers than in the 
past. We have formal mechanisms and processes for everything. " 
This analysis suggests that organisational practises like freedom to work, knowledge 
development opportunities along with matrix management structures have played an 
important role in creating cultures of innovation. These practises are shaping the 
development of organisational knowledge in innovative R&D by facilitating the relations 
and interactions among different parts of the organisation. 
The next section focuses on the mechanisms of knowledge transfer used to create 
knowledge flows to access and acquire knowledge situated outside the boundaries of the 
organisation. 
8.4.4 Mechanisms of knowledge transfer 
A firm nurtures and creates knowledge through certain activities and these activities 
basically involve sharing of the knowledge within the organisation and the transfer of 
knowledge across organisational boundaries. Knowledge transfer here refers to transfer of 
useful know-how and information across and within the firm boundaries (Appleyard's, 
1996). Henderson and Cockburn (1994) point out that externally focused integration: 
ability of firm to access knowledge from outside boundaries of organisation plays an 
important role in problem solving activities. In order to remain competitive in the 
biotechnology era, incumbent pharmaceutical firms have extensively used extell1al 
relationships as a vehicle for adjusting their internal technological capabilities 
(Gamberdella, 1995: Nicholls- Nixon, 1993; Zucker and Darby. 1997). These changes led 
to transformation of new drug discovery and development in large pharmaceutical firms 
from a totally in-house activity to a networked collaborative activity. Therefore in recent 
years, a dense network of collaborative relationships among different types of fimls and 
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other research institutions has emerged as a major feature of the transformation of large 
pharmaceutical firms' technological capabilities as a response to biotechno logical change. 
Similarly the analysis of Indian firms shows the emergence of the network model of 
collaborative R&D as an important mechanism of acquiring externally developed 
knowledge to augment internal capabilities. 
8.4.4a Collaborative R&D 
In the case of innovative Indian pharmaceutical firms networking has emerged as one of 
the key mechanisms for accessing and acquiring outside knowledge. These firms didn't 
have the skills, infrastructure or resources in-house to carry out certain functions and 
activities in innovative product R&D. Thus they collaborated and interacted with the 
Indian as well as overseas research institutes, universities to get their work done. DRF's 
R&D president explains the rationale behind the networking, 
"drug discovery is very complicated and you may not have everything in house, we can't 
and we don't have everything in house so you have to. It's a sort of collaborative 
approach, a collaborative process. We have to really shake hands with the people who 
have got knowledge in this area, bring them as partner or bring them as a contract 
research for you, pay finite amount of money required for it and learn in the process". 
This networking approach has changed the nature of the R&D in these firms, from an 
insular in-house R&D to a collaborative R&D model. Indian firms are building research 
networks by involving themselves in lot of joint projects with Indian as well as overseas 
research institutes, and research companies. Most of the innovative Indian pharmaceutical 
firms have set up special departments of strategic alliances and licensing to scout 
opportunities for collaboration. The members of these departments move around in 
different parts of world to find out what is happening and to initiate relationships in the 
specific areas of interest. 
Successful knowledge transfer requires careful management of communication between 
involved entities as transfer of knowledge necessarily requires learning because 
technologies are based on tacit knowledge and their underlying principles are not always 
well understood (Bell and Pavitt, 1993). During such collaborations inno\'ati\'e Indian 
pharmaceutical firms give their scientists an opportunity to learn in areas of innovative 
R&D by sending them to work in collaborators' R&D department. DRF's former president 
elaborates on the approach, 
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"We were actually designing project with Havard Medical School. We are trying to 
organise collaboration with one of the faculty member in Harvard Medical Schoo!. He did 
not have the manpower and he could have hired manpower fresh only for this project but 
as project is exploratory he did not know how long it will go. So he said why you don't 
depute your own scientist and we are prepare to pay. We are happy whether something 
comes out of the collaborations or not, at least our scientist will get exposure. We are very 
progressive thinking along this line". 
In areas of the clinical development of new chemical entities innovative Indian 
pharmaceutical firms are contracting out the development work to clinical research 
organisation. W ockhardt' s head of pharmacology suggests, 
"Only thing is three of crucial studies we need to contract out because those facilities are 
not here in India. People are not trained and it's cheaper to get those studies done from 
eROs than setting up in-house, that's another thing. We contracted out few studies and we 
did cost analysis and we found that if I get myself trained or anyone colleagues trained and 
then set up essay here, that is going to be more expensive ". 
8.4.4b Publication and patenting policies 
Firms are changing their approach towards publication and now view it as an important 
tool to create an environment for creative research. NPIL's R&D president suggests, 
"Publication is incentives there is no doubt about it. Somebody who is genuine scientist he 
would like to see he has a patent, he would like to see his publication. Ninety percent 
scientists, who are good and craved for discovery and if they have came in this business 
then that's exactly that they are looking for". 
In innovative firms scientists' presentation and participation in conferences is strongly 
encouraged and looked as an important part of growth in scientist's research skills and the 
firms R&D knowledge flows. DRF's former R&D president: 
"Publication is certainly an incentive to the scientist, there is no doubt about that and 
we also need to showcase our science, it stimulates scientists to think. If our people have 
gone and made presentations in a conference, then it's a validation of our science, 
showcasing of our science and also learning from others, all this adds to scientist stature 
as well company's reputation. " 
The innovative Indian firms used publication and attendance in conferences as one of the 
way to create flows of knowledge between its scientists and scientific community outside 
the boundaries of the company. Glenn1ark's VP of chemical research explains. 
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"we go to different conferences; all are encouraged to attend major conferences in drug 
discovery to keep up to date and upgrade our knowledge. Attending the conferences is 
important as many things can be learned by reading publications. In our case we have to 
learn number of things and attending different conferences will also help in increasing the 
understanding ". 
However, all the respondents shared the viewpoint that patenting is the priority for all 
firms and a lack of trust is still preventing full-fledged publication from firms. 
Increasing R&D commitment of the sample firms is matched by increasing intent in filing 
patents. DRF's former R&D president comments, 
"Right from the beginning, we have tuned the mindset IP driven. Whatever they do, they 
should see whether it is worth patenting. Therefore people who are doing research work 
always look at whether there is novelty in what they are doing. The fact that they have 
recognised that there is novelty in what they are going to do and if they do it then they 
establish this novelty, that itself is a driving force for them". 
The earlier analysis of knowledge transfer mechanisms suggests that the collaboration with 
research institutes and universities formed an important constituent in innovative Indian 
pharmaceutical firms' efforts to develop innovative capabilities. 
The next section looks at mechanism employed by innovative Indian pharmaceutical firms 
to create cross disciplinary understanding among the scientists working on drug discovery 
research projects. 
8.4.5 Integration of different knowledge bases 
The product innovation management literature shows that the integration of different 
specialised knowledge bases and coordination of learning are crucial processes in building 
knowledge creation capabilities for innovation. The investment in organisational level 
integrative management practices facilitate interactions and creates knowledge among 
individuals situated in different parts of system independently (Un and Cuervo- Cazurra, 
2004). Henderson (1994) suggests that in pharmaceutical R&D, the ability of the firm to 
integrate flexibly across disciplinary and therapeutic class boundaries within organisation 
is very important in success of drug discovery research. 
Innovative Indian pharmaceutical firms strengthen the internal integration of knowledge by 
putting cross disciplinary teams in charge of the projects. Firms also used mechanisms like 
frequent formal and informal team meetings and reviews to create 'common kno\\ledgc' 
among \'arious members of the team. 
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8.4.Sa Cross disciplinary project teams 
Indian pharmaceutical firms realised that it was not enough to just hire the scientists or 
build new R&D centres, the difficult part was to increase the cross disciplinary 
understanding of the scientists. NPIL' s strategic alliance director comments, 
"we are structuring our places of work to build more team spirit, to build more knowledge 
bases, to build more mobility. You should able to do cross disciplinary work much more 
because as I think new drugs are not going to be 'silos', they all are going to be cross 
disciplinary. So you might have pharmacologist, molecular biologist chemist, toxicologist, 
all different fields workingfor one drug". 
In an innovative product R&D project the screerung of molecules generates crucial 
information about the molecule in terms of structure-activity relationship. All the inputs of 
biological tests or results of screening have to be communicated to the medicinal chemist 
or chemistry team in a manner which is meaningful to the chemist. This information needs 
to be communicated on a continuous basis to minimise the development time and cost. 
Firms are using mechanisms like frequent meetings among project team members for 
increasing the interactions and communications between different specialised knowledge 
groups. The sample firms have set up cross-disciplinary teams of scientists from different 
disciplines like biology, pharmacology, medicinal chemistry, regulatory affairs for each 
therapeutic research area. This cross disciplinary team approach is also helping firms to 
achieve integration of different knowledge bases. According to NPIL' s R&D president, 
"scientists have to share the knowledge, it's not so as box that somebody can't talk to any 
other person. If there is particular problem, people would like to discuss among 
themselves. In our case we have discussions, we sit together and discuss. There are some 
mechanisms, as I said monthly meetings, weekly meetings; there are lots of things like 
that ". 
The aim of firms is to create a common knowledge base among the scientists working on 
project and achieve same level of understanding. In some firms such as NPIL, the internal 
formal meetings are held regularly weekly or fortnightly basis while informal meetings are 
held as and when need basis. 
8.4.Sb Review of research and Scientific Advisory Boards (SAB) 
Periodic reviews of projects, departments and other relevant organisational sub units, plays 
an important role in managing knowledge flows across different parts of the R&D. An 
important aspect of review leaming is learning from mistakes and failures (Dodgson. 
1991). Coombs and Hull. (1998) point out that review procedure generates documents and 
shared knowledge which play an important role in contextualising kno\vledge and creating 
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shared categories for identifying , that which is important'. The review mechanisms also 
playa role in locating skills and capabilities gaps in the R&D function and assist strategic 
decision making by highlighting the deficiencies in search, assimilation and 
communication process. 
Indian pharmaceutical firms have put emphasis on review of research and institutionalised 
the process by creating the various forums. NPIL R&D president: 
"we have culmination here, also the majority of the people have that. One is internal, 
internal reviewing is almost on weekly basis and monthly basis. Written down 
presentations and sometimes the external expert group is made. A sort of peer review to 
find out what's being done, have we done the right thing to check the milestone, if there is 
failure what is reason behind failure". 
These review meetings are held quite often and in these meetings each scientist presents 
research work, which is critiqued, peer reviewed and further action plans are formulated. 
Firms are also used these internal review meetings for increasing the cross disciplinary 
understanding of scientists, as DRF former president indicates, 
"when chemistry is being discussed, biologists will be present, when biology is 
discussed, chemists would be present and so a chemist will learn some biology, at least 
will appreciate what there difficulties are and vice versa". 
Firms have also set up scientific advisory boards (SAB) with well known scientists from 
overseas as well as Indian academia and industry. SAB meet on every quarter or half 
yearly to review and provide advice on the research projects. This forum gives an 
opportunity to scientists from these firms to have closer interactions with experts. DRF~s 
former R&D president: 
"These scientists have diverse experience and rich knowledge backgrounds and they can 
critique. After the review meetings some of the members stay for 2-3 days to have closer 
interactions or discussions and all of which generates valuable feedback and build the 
confidence of researchers ". 
8.4.6 Summary 
To sum up the analysis of the sample firms ~ learning processes suggests that the 
knowledge bases accumulated in reverse engineering R&D ha\'e built strong foundation 
for new drug discovery research in these firms. These firms acquired the knowledge in 
innovative R&D by hiring drug discovery experienced scientists and by creating a critical 
mass of inno\'utive R&D scientists hy recruiting the fresh scientists from Indian as well as 
overseas universities and research institutes. Firms have also collaborated with research 
institutes and universities to access the knowledge situated outside boundaries of firms and 
created cultures of innovation by providing freedom to work and promoted cross 
fertilisation of ideas by encouraging scientists to attend and publish their work in the 
conferences. 
The next section looks at the differences in approaches in knowledge processes in each 
firm and analyses the impact of those differences on the development of capability in 
innovative R&D. 
8.5 Inter firm differences in knowledge processes 
Technological learning is a process that permits a firm to accumulate technological 
capability over time. A diverse set of learning processes are necessary to build and 
accumulate knowledge or capabilities required to generate and manage improvements in 
processes and products. Therefore inter firm differences in operational performances are 
interpreted as an implication of different paths used for accumulation of technological 
capabilities (Dosi, 1988). 
The analysis of innovative Indian pharmaceutical firms' learning processes showed the use 
various learning processes by firms to develop the capabilities in innovative R&D. In case 
of Indian firms, the different level of capabilities in product and process R&D suggests 
differences in organisational learning process. Therefore this section analyses the 
differences in learning processes employed to develop capabilities in innovative product 
R&D. The differences in firms' learning processes were analysed by comparing each firm 
on the basis of presence or absence different learning process and manner in which firm 
has organised and implemented particular learning process. It also discusses implication of 
differences in technology capability accumulation paths for innovative R&D capability 
development. 
8.5.1 Firm level differences in mechanisms of knowledge acquisition 
The innovative Indian pharmaceutical firms employed mechanisms or processes like 
learning by hiring scientists, increasing R&D investment and setting up new disco\'ery 
R&D to acquire knowledge in innovative R&D; however an analysis of these mechanisms 
reveals the differences in terms of implementation and nature of knowledge access for 
acquisition. 
In learning by hiring scientists, Ranabxy put more emphasis on hiring senior scientists 
working overseas in MNC labs than fresh post graduates. Ranba:xy"s former R&D 
president con1ments, 
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"we have lot more qualified people, I wanted highly qualified people. Industrial research 
has base in fundamental research; there is no industrial research without fundamental 
research. So if that is case then people who have some fundamental knowledge it pays in 
the understanding". 
Other finn like DRL built a critical mass of scientists by hiring returning post docs and 
doctorates. DRL's innovative R&D effort was led by India based scientists who had 
worked in innovative research areas in MNC R&D and these scientists built the sub teams. 
In case of DRL for 90% of scientists working in innovative R&D it was their first job in 
the industry. Lupin hired the scientists working in other innovative Indian firms like 
Ranbaxy who had the experience of innovative R&D while \Vockhardt recruited scientists 
working in Indian academia and research institutes. NPIL started its innovative R&D 
research by acquiring the R&D facilities of Hoechst research centre in India. Hoechst 
research centre started operations in 1978 and throughout the period of existence this 
centre was involved with drug discovery research. Table 8.5 gives a graphic representation 
of the data. 
Table 8.5 Inter firm differences in knowledge acquisition processes and mechanisms 
No. Knowledge acquisition RAN DRL woe NPIL LUP GLE 
processes and mechanisms 
1 Hiring senior Indian Present Weak Absent Present Absent Absent 
scientists from MNC R&D 
overseas 
2 Hiring fresh Indian post Absent Present Present Present Absent Absent 
graduates, doctorates and 
post doctorates from 
overseas universities 
3 Increasing investment in Present Present Present Present Present Present 
R&D 
4 Setting up new disciplinary Present Present Present Present Present Present 
units and regulatory 
department 
5 Setting up discovery labs Weak Present Absent Absent Absent Weak 
abroad 
6 Acquisition of R&D labs in Absent Absent Absent Present Absent Absent 
India or abroad 
~-
~ -
Differences have also emerged in case of R&D investments and establishing R&D set up 
overseas. It has emerged all the firms are gradually increasingly R&D in\cstment; ho\\ l'\Cr 
the magnitude and focus of the investments are different in cach timl. In 1003 DRL has 
invested 10% of its turnover in R&D whereas NPIL investment was only 4% (see Table: 
8.3) 
In terms of research strategy in innovative R&D all firms except DRL are adopting the 
cautious approach of analogue research. However, DRL is using an aggressive approach 
focused on acquiring skills in scientifically challenging research strategy of using 
structure-based drug design mechanisms. This is reflected in DRL's establishment of a 
R&D subsidiary in US. DRL, Ranbaxy and Glenmark have opened laboratories in US and 
Europe. However the focus and activities carried out at Ranabxy's US R&D laboratory, 
Glenmark's R&D set up in Switzerland and Reddy US Therapeutics (DRL's US R&D 
subsidiary) differs quite markedly. Ranbaxy and Glenmark overseas R&D set up focuses 
on clinical research and regulatory filling while Reddy US Therapeutics is focused on 
developing capabilities in discovering the molecule by using rational drug design strategy. 
8.5.2 Firm level differences in mechanisms of knowledge assimilation 
The analysis of knowledge assimilation processes or mechanisms in innovative Indian 
pharmaceutical firms shows the differences in firms' approaches in creating an R&D 
environment that facilitates sharing of knowledge and encourages innovative thinking. All 
the firms have started new disciplinary and regulatory divisions to foster learning in new 
areas but firms differed in terms of the internal arrangements needed to support learning in 
innovative R&D. Table 8.6 summarises this inter finn differences in knowledge 
assimilation processes and mechanisms. 
Table 8.6 Inter firm differences in knowledge assimilation processes and mechanisms 
No Knowledge assimilation RAN DRL woe NPIL LUP GLE 
processes 
1 Scholarships to upgrade Present Strongly Present Absent Strongly absent 
scientist's skill level present present 
2 Training programmes Strongly Strongly weak Present weak weak 
present present 
3 Scientific advisory Strongly Strongly absent Present weak Present 
boards Present Present 
4 Encouragement for absent Present absent absent absent Absent 
Publication 
5 Encouragement for Present present Present Present Present Present 
Patenting 
I 
" 
----
-
- -- -
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DRL and Ranbaxy have set up supportive arrangements like incentive mechanisms for 
scientists to upgrade knowledge, training programmes and scientific advisory boards. In 
case of scientific advisory boards firm like Wockhardt have not formalised the 
relationships with experts by setting up scientific advisory board and instead are informally 
engaging with these experts on 'as and when needed' basis. NPIL' s R&D president 
comments, 
"scientists on the panel are very important people; some companies have put the people so 
it's not that you can't have it but can you afford to do this. That can be the question to 
begin with, you may not need to do it because you can't afford to start with. It's good to 
have it but it's not so critical that you can't start if you don't have big people sitting on 
your board or on your advisory board". 
All firms are putting strong emphasis on patenting any novel research work coming out of 
the R&D labs. However, the significant differences emerge in firms approaches towards 
publication strategies. DRL has put equal emphasis on publication and patenting activity, 
but other firms don't conform to this philosophy and differs in their perception regarding 
importance of publishing. Therefore except DRL other firms are reluctant to publish the 
research work in scientific journals or conferences. NPIL strategic alliance director argues, 
"I would say no, this is one thing we will not do. Why because today patent is so tricky I 
don't want to publish, full stop. Because I wanted to protect secrecy for the company, this 
is not an academic institution, this is a company; it needs to protect all its secrets and 
intellectual property to best of its ability. So it will publish only that which it sees useful ". 
However, gradually all firms are encouraging their scientists to attend various scientific 
conferences for stronger interaction with scientific community. For example, in 2003 NPIL 
presented findings on novel ant-cancer compound at conference on molecular targets and 
cancer therapeutics in Boston, US. Similarly Glenmark presented GRC 3886 molecule at 
four conferences in 2004 (Annual Reports, 2003-04). 
8.5.3 Firm level differences in mechanisms of knowledge transfer 
Innovative Indian pharmaceutical firms networking and collaboration strategy showed 
differences in terms of its intensity, targeted nature of knov.-Iedge and sources of 
knowledge used for accessing new knowledge. These inter firm differences involved in 
mechanisms or processes involved in transfer of knowledge are summarised in table 8.7. 
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Table 8.7 Inter firm differences in processes and mechanisms involved in transfer of knowledge 
No. Knowledge transfer RAN DRL WOC l\PIL LUP GLE 
processes 
1. R&D collaboration Present Present Absent Present Strongly Absent 
with Indian research Present 
institutes, universities 
2. R&D collaboration Present Strongly Absent Absent Absent Absent 
with overseas research Present 
institutes and 
universities 
3. R&D collaboration Strongly Strongly Absent Absent Absent Absent 
withMNC Present Present 
4 Cross boundary Present Strongly Absent Present Present Absent 
movement of scientist present 
Ranbaxy and DRL have established a strong collaborative relationships with Indian and 
more specifically overseas research institutes and universities. Other firms like Lupin and 
NPIL are involved in collaboration with Indian research institutes in various areas of 
innovative R&D. Some of the collaborations by NPIL and Lupin are also partly financed 
by Indian government under New Millennium Indian Technology and Leadership Initiative 
(NMILTI). However, Wockhardt has chosen not to collaborate with Indian research 
institutes as top R&D management in the firm have different opinions towards such 
collaborations. According to Wockhartd's anti-infective R&D head, 
"I don't think there is great amount of networking with research institutions within 
country. The small amount we do is purely need based, I don't call it real nenvorking. 
Many of the government or CSIR based laboratories have dttJerent approach to research 
programmes; they don't have a focused kind of thing which industrial R&D need. The 
issues of timelines, commitment, and deliverance are V~J)J complicated and han' a 
potential to become bitter. Initially we were a part of one rescorch programme but at some 
stage we have to leave that programme because we felt that it was H'oslc of time. I mean 
our experience ofnetworking with research institutes in India is not V('l~l' good". 
Ranbaxy and DRL are also collaborating with MNC pharmaceutical firms through 
licensing and research deals. In 2003 Ranbaxy entered into alliance with Glaxo Smithkline 
(GSK) to discover and develop novel therapies in its tour focus therapeutic areas 
")..,..., 
__ I 
Ranbaxy's other important collaboration in drug discovery R&D is with Medicines for 
Malaria Venture (MMV) Geneva, for the development of anti-malarial drug. Under this 
collaboration Ranbaxy's team of scientist will work together with University of Nebraska 
Medical centre, Monash University and the Swiss Tropical Institute to identify the lead 
molecule. Also both DRL and Ranbaxy have out licensed molecules to MNC 
phannaceutical finns and which gives their scientists an opportunity to interact with 
scientists from MNC phannaceutical finns. 
These differences in approaches towards collaboration indicate the difficulties for a firm to 
move from an internally focused orientation and create knowledge flows to access 
knowledge situated outside the boundaries of firm. 
8.5.4 Integration of different knowledge bases 
All innovative Indian pharmaceutical firms have set up forums to facilitate the cross 
disciplinary integration of knowledge. Firms have adopted matrix form of R&D structure 
and set up cross disciplinary project teams to organise and manage innovative R&D 
activities. 
Table8.8 Inter firm differences in knowledge integration processes and mechanisms 
No. Knowledge integration RAN DRL woe NPIL LUP GLE 
processes 
l. Organisational structure Matrix Matrix Matrix Matrix Matrix Matrix 
for R&D 
2 Cross disciplinary project Present Present Present present Present present 
teams 
3 Frequent review meetings Present Present Present Present Present Present 
with team members 
4 Review meetings with Absent Present Absent Present Present Present 
external overseas 
scientists as reviewers 
, 
I 
j 
All finns have employed mechanisms like frequent project team meetings and rc\'ic\\ 
meetings to maintain seamless flow of information inside the R&D. The only differences 
emerged in terms of setting up fonnal processes of having overseas external scientists as 
reviewers (table 8.8). This mechanism of the research review is absent in Ranbaxy and 
Wockhardt. Ranbaxy has set up the scientific advisory board headed by reputed Indian 
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scientist from Indian research institute who is involved in its research programme from the 
beginning while Wockhardt has formed internal review team with chairman as its head and 
uses external consultant only when it is necessary. 
8.5.5 Firms' innovative performance and implications of differences in knowledge 
processes 
The analysis of different learning processes shows the some of the processes and 
mechanisms were present and worked continuously in all firms, however their functioning 
and implementation differed in each firm. The difference in firms' approaches in terms of 
implementation and functioning have affected firms' access to external knowledge, 
internal knowledge sharing processes and application of existing knowledge bases. 
Table8.9 R&D performance of innovative Indian pharmaceutical firms (Source: Annual Report, 2003) 
No. Firms Innovative R&D performance 
DMF ANDA NeE patents New drug delivery 
(Drug Master (Abbreviated (New Chemical systems patents 
File) New Drug Entity patents) 
application) 
1 Ranbaxy 44 127 6 4 
2 DRL 56 35 8 
3 Wockhardt 17 32 3 1 
4 NPIL 1 
5 Lupin 12 5 3 1 
6 Glenmark 4 4 
DRL and Ranbaxy clearly show better performance in terms of innovative R&D although 
these two firms also started investing in innovative R&D comparatively earlier than other 
Indian pharmaceutical firms (table 8.9). But comparative analysis between these two firms 
reflects clear difference in their approaches towards the development of innovative R&D 
capabilities. For instance, DRL has chosen an aggressive research strategy and focused on 
acquiring capabilities in rational drug design approach to discover new chemical entities. It 
also adopted a more academic model of pharmaceutical R&D by focusing on publications. 
collaboration with universities and strong emphasis on scientists' skill up-gradation. DRL 
internationalised its R&D by establishing its subsidiary in US to acquire capabilities in 
rational drug design research. Ranbaxy used a different approach to dey clop the 
capabilities in innovative R&D. It built strong complimentary assets in advanced markets 
by internationalising manufacturing, sales and regulatory functions. Ranbaxy also adopted 
cautious strategy of analogue research for discovering new chemical entities and hired the 
senior Indian scientists based overseas working in MNC phannaceutical R&D rather than 
fresh scientists to acquire capabilities in innovative R&D. 
In follower firms like Wockhardt and NPIL innovative R&D effort began in mid 1990s 
while Lupin and Glenmark started investing in innovative R&D by late 1990s. Wockhardt 
started with biotechnology as main research area and building on that finn started 
developing capabilities in innovative R&D. Unlike other Indian phannaceutical finns 
Wockhardt has focused only on one therapeutic area, anti-infective, as its innovative R&D 
focus and filled the capability gaps through contract research with overseas research 
companies compared to R&D collaboration with Indian research institutes and universities. 
Wockhradt created a core team of scientists by hiring scientists from Indian research 
institutes and academia. The other follower finn NPIL, the youngest finn compared to 
other innovative Indian phannaceutical finns, has over the years grown on the basis of 
using acquisition as means for growth. It thus bought the Hoechst Research Centre to 
acquire capabilities in innovative R&D. Also, NPIL is not targeting the generics market in 
advanced countries and has instead chosen the strategy of partnering with MNC and 
generic pharmaceutical finns for contract manufacturing and custom synthesis. 
A late starter like, Lupin hired senior scientists from other innovative Indian 
phannaceutical firms like Ranbaxy and established strong relationships with Indian 
research institutes for collaborative R&D programmes. Lupin is actively promoting joint 
working and transfer of scientists in collaborating research institutes to train its scientific 
workforce in innovative R&D. 
The other late starter, Glenmark is a small firm compared to other Indian phannaceutical 
firms and its innovation R&D learning strategy reflects the limitation of size. Glenmark 
have small team of scientists working on new drug discovery research programmes which 
are directly supervised by finn's managing director. 
The analysis of innovative Indian pharmaceutical approaches and performance shows the 
finn level differences involved in development of capabilities in innovative R&D. Each 
finn has adopted a strategy which differed from each other in terms of functioning and 
implementation of different learning processes. Firms need diverse set of learning 
mechanisms and reliance on a single mechanism is unlikely to yield any effectiye 
organisational learning (Figueiredo~ 2002). The evidence suggests that functioning and 
implementation of diverse set of learning processes plays a crucial role in technology 
capability accumulation and a continuous effort should be made to improye the learning 
processes particularly their functioning and implementation. Therefore. firms needs a 
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consistent and continuous strategy to manage and organise the diverse set of learning 
processes implying learning at firm level is neither linear nor automatic process and 
requires a deliberate learning strategy. 
8.6 Conclusion 
This chapter analysed difficulties and mechanisms involved in movement of innovative 
Indian pharmaceutical firms from imitative R&D capability to innovative process and 
product R&D capability as a response to change in patent law. The analysis suggests that 
based on imitative process R&D, innovative Indian pharmaceutical firms built capabilities 
in innovative process R&D and simultaneously invested in development of innovative 
product R&D capabilities. This ambidextrous capability development (O'Reilly and 
Tushman, 2004) allowed Indian firms to exploit its process R&D capabilities, which these 
firms have accumulated in reverse engineering era and provided an opportunity to explore 
areas in innovative product R&D. The analysis also suggests that as firms move from 
imitative process R&D to innovative product R&D, they will have to jettison some 
capabilities which were useful in process R&D but can become rigidities in product R&D. 
Therefore in case of innovative Indian pharmaceutical firms unlearning of obsolete 
abilities has emerged as an important constituent in development of new capabilities in 
firms. 
This chapter also analysed firm level learning processes involved in development of 
knowledge creation capability for innovation in firms under study. It focused on firm level 
learning processes involved in acquisition, assimilation, transfer and application of new 
knowledge. The evidence shows that innovative Indian pharmaceutical firms 'created a 
research tradition' by developing non-infringing and novel processes for drugs in imitative 
R&D and that led the foundation for the development of competencies required in 
innovative R&D. These firms consistently increased R&D investment and hired the new 
scientists embodying the innovative R&D knowledge to acquire the advance level 
capabilities in pharmaceutical R&D. These scientists carried the crucial tacit knowledge 
with them and played a significant role in changing the mindset of the organisation. These 
firms created an environment that facilitated the sharing of knowledge among its R&D 
scientists by setting up various supportive arrangements like matrix form of project 
management and cross disciplinary project teams. Some also collaborated with research 
institutes, universities to augment and leverage organisational capabilities in innovative 
R&D. The analysis of learning process further revealed that functioning and 
implementation of these learning processes differed in case of each firm. showing that 
231 
learning at finn level is neither automatic nor linear and requires a deliberate learning 
strategy. 
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Chapter 9 
CONCLUSION, CONTRIBUTION AND IMPLICATIONS 
In this final chapter the findings arising from specific research activities are discussed with 
regards to research questions raised at the beginning of the thesis. It presents principle 
findings of the research and discusses managerial, policy and theoretical implication of the 
research findings. The limitations of the research project are discussed with respect to 
possible future research that could be undertaken. 
9.1 Introduction and Summary 
The influence of TRIPS (Trade Related Intellectual Property Rights) as part of WTO 
(World Trade Organisation) agreement on industries from developing countries formed the 
genesis of the research. Now due to TRIPS agreement all the WTO member countries will 
move from no or partial patent protection to fully fledged patent protection. As a result all 
WTO member countries will have uniform strong patent law and restriction on use of 
reverse engineering as a legal mechanism of knowledge acquisition. This represents a 
radical break with the past in which developing countries typically had only weak levels of 
patent protection. In this context this research examined the influence of patent law on the 
strategic orientation and technological capability accumulation process in Indian 
pharmaceutical industry. It specifically focused on the learning processes involved in 
development of innovative R&D capabilities in the Indian pharmaceutical firms as a 
response to strengthening of patent law. 
This research mainly concentrated on the pharmaceutical industry as the access to 
technology is relatively difficult in this sector. New product development in this area 
involves highly professionalized and specialised technological R&D activities. The 
learning process involved in development of pharmaceutical manufacturing and R&D 
capabilities is much more complex compare to other sectors. The large multinational firms 
that dominate this sector develop a significant proportion of knowledge and through patent 
effectively control the diffusion of knowledge. These firms conduct most of their activities 
at home or in other developed countries and prefer direct investment to licensing when 
producing abroad. Therefore most of the developing countries have built domestic 
pharmaceutical industries by adopting weak patent laws which allowed these countries to 
overcome the patent barriers in acquisition of patented knowledge. In a similar way to the 
Indian pharmaceutical industry. the phamlaceutical industries from these countries will be 
severely affected by the TRIPS agreement. Therefore this research on capability 
, ... " 
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development in the Indian phannaceutical industry has important managerial and policy 
implications for firms and industries in other developing countries which are facing the 
TRIPS challenge. 
The research presented in this thesis differed from previous studies of the patent system in 
developing countries. It employed a capabilities approach to the study of industry and 
firms responses to the strengthening of patent law. The Chapter 2 points out that the most 
of the literature on the patent system in developing countries has 
a. focused on socio economic issues like pricing of the drugs and welfare cost 
(Lanjouw,1996;Watal, 2000; Scherer and Watal, 2001; Pangariya,1999:Nogues,1993) 
b. investigated the link between strengthening of patent system and its effect on the 
technological development (Sequeria, 1998; Kumar,2003; DEste,2002) and 
c. analysed the effects of strong patent system in output and trade performance of the 
industry (Weisburst and Scherer, 1995; Felker et aI., 1997). 
This research focused on the impact of the strengthening of patent law on learning 
processes involved in technological capability development and analysed mechanisms used 
by firms to transform their capabilities. 
Technological capability building is an issue that has been widely discussed in the last 20 
years by different theoretical research traditions. Technological capability consists of 
stocks of resources needed to generate and manage technical change including skills, 
knowledge and experience and institutional structures and linkages (Bell and Pavitt, 1993). 
The research on developing countries mainly focused on the issue of long term process of 
technological capabilities accumulation in industries. To a larger extent, this literature 
discussed capability development in developing countries referring to importance and 
difficulties associated with various formal and non formal mechanisms of knowledge 
transfer. It pointed out that the firms in developing countries compete on the basis of 
production capabilities, largely acquired from elsewhere and reinforced by basic to 
intermediate technological capabilities related to a simple knowledge base. 
However the increasing specialisation of knowledge is limiting the existing modes of 
formal and non formal technology transfer. The widening gap between kinds of knowledge 
and skill required to imitate or operate given technology and the kinds of knowledge 
required to create, generate or change technology has reduced the possibilities of acquiring 
the latter largely by experience in the former (Bell and Pavitt, 1993). In addition to that the 
fast pace of change in markets, technology and competition are making existing finn and 
industrial level capabilities redundant. Therefore in this new era the ability of a finn to 
create new knowledge for innovation has become strategically important capability. The 
area of rebuilding or reconfiguring of capabilities has been addressed by the strategic 
management literature (SML), by focusing on innovative firms competing at technological 
frontiers in advanced countries. This research studied learning and capability building 
concerned with sustaining, deepening and renewing of the existing innovative capabilities 
by focusing on most innovative firms competing at the technological frontier in advanced 
countries. Therefore there is a flourishing literature available on the firm specific factors 
that affect the success and failure of innovation in advanced countries, but there is no 
literature of equivalent scope and depth for developing countries (Bell and Pavitt, 1995). 
The main difference is in the object of analysis, the firm in a developing country and its 
external environment as opposed to a firm in the developed world and its environment. In 
the case of firms from developing countries economic, political and social complexities 
makes the transformation of capabilities a challenging and difficult process. The 
availability and access to technical knowledge for firms from developing countries is an 
important issue and so literature on the developing countries is mostly focused on the 
technical knowledge dimension of the building up of technological capabilities. However, 
Bell and Pavitt (1993) points out that the technical as well as organisational dimension of 
managing knowledge is crucial in building capabilities for innovation. The research on 
developing countries has to a larger extent focused on the accumulation of stocks of 
technological knowledge, and much less on the specialisation of knowledge bases and 
other firm level issues like coordination and integration of knowledge across organisational 
boundaries. Thus research focused on capability development in developing countries the 
organisational dimensions of managing technical knowledge needs more attention (Chapter 
3). 
Some of the researchers like Kim (1997a), Durenit (2000) and Figueirdo (2003 ) focused 
on the organisational and managerial issues involved in the development of innovative 
capabilities. These researchers mostly focus on firm level learning processes involved in 
establishing a base of technological knowledge that did not previously exist as opposed to 
the renewing accumulated knowledge base or using that knowledge base in a different 
way. The change generating capabilities have become increasingly more complex and 
specialised as they have differentiated from the capabilities required to use them (Bell and 
Pavitt, 1993). 
This research mainly investigated these change generating capabilities by focusing on 
learning processes used by Indian pharmaceutical firms to transform existing capabilities 
and develop innovative R&D competencies as a response to strengthening of patent la\\". It 
also covered the technological capability accumulation process in the Indian 
pharmaceutical industry and the impact of strengthening of patent law. Thus this research 
contributes to this neglected area of research in the deyeloping countries literature by 
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investigating the transformation of capabilities and development of new capabilities in 
firms from developing country. 
It addressed two key questions through a case study of the Indian pharmaceutical industry 
and six innovative firms. 
• How are firms from a developing country building a strategic knowledge 
creation capability for innovation as a response to the forces of globalisation? 
Specific: 
• 
• 
How are Indian pharmaceutical firms re-building capabilities for innovative 
R&D as a response to TRIPS agreement? 
How relevant is knowledge accumulated through imitation for firms in their 
efforts to create innovative novel products? 
The research took the firm as unit of analysis and the dynamic process of technological 
learning as its focus. This dynamic and complex process of technological learning was 
explored by developing a theoretical framework drawing on the strategic management 
literature and organisational theory literature focused on knowledge, learning and 
innovation. It explored the social processes or mechanisms used for knowledge acquisition, 
transfer, assimilation and application. It also explored the relevance of prior knowledge 
base in a new environment and processes involved in building it. 
Thus this research shows the learning processes or activities involved in the development 
of a knowledge creation capability for innovation in firms from a developing country as a 
response to change in the external environment. 
9.2 Limitations of the research 
This research is limited by several factors. One set of limitations concern the validity of 
indicators such as number of patents, nature of patents, R&D expenditures and staff ratios. 
These kinds of problems are discussed in the research methodology chapter and care has 
been taken in interpreting trends from indicators. For example, no firm conclusions were 
drawn based solely on trends in indicators such as patents or R&D intensity. 
This research explored capability development in firms from developing countries by 
focusing on 6 firms in 1 industry from developing countries at one point in time. The 
theoretical framework linking ditTerent learning processes guide the investigation in firm 
level learning processes involved in capability development. This framework co\crs 
learning processes involved in acquisition, assimilation. transfer and application of 
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knowledge. Therefore other areas which can play an influential role in capability 
development such as nature of firm at birth or role of top management remained outside 
the scope of this research. 
This research focused on the capability aspect of new chemical entity research in the 
pharmaceutical industry. The pharmaceutical industry is known for keeping secrecy on 
NeE research and due to confidentiality reasons some firms denied access, while those 
granted access declined to share information. Managers from sample firms that did give 
interview were generally unwilling to provide data due to confidentially reasons. For 
example, firms declined data on composition of scientific staff and their distribution in 
research projects, which would have helped in analysing division of labour in R&D. 
In regard to case studies the main limitations were the depth of analysis possible due to 
reliance on a few key individuals and the difficulties in accessing historical firm records. 
The selection of cases was restricted by time available and willingness of individuals from 
firms to participate. 
The interview method of data collection had certain limitations. The individuals contacted 
for the interview were high ranking managers of the firm and therefore struggled to 
allocate more than one hour. This also affected the depth of information that could be 
obtained. Due to busy work schedule of these managers and distance problem between UK 
and India, the opportunities for repeat interviews were fairly limited, which affected the 
feedback on case studies. 
In using interview data important care needs to be taken to understand and differentiate 
between managers' or firms' intent and perception of reality, as expressed by managers in 
interviews, from the 'reality' of what is happening in practise. The qualitative research 
methodology literature suggests triangulation of evidence by using multiple sources of data 
as a mechanism to overcome the problem of bias (Yin, 1994). In this research 
triangulation of the responses from case study was intended to come from comparison of 
interview responses, firm's annual reports, analyst presentations, other published matter on 
the firm and coverage in national and business press. During the case studies it became 
apparent that the lack of availability of publication and patenting data on Indian firms as 
well as lack of access to internal firm data hampered the triangulation, giving rise to the 
problem of bias. 
However despite these limitations, the research represents a substantial advance in our 
knowledge and understanding about the learning process involved in the development of 
advanced level of capabilities in firms from developing countries. The rest of the chapter 
outlines the principle findings and their theoretical, managerial and policy implications. 
The discussion suggests that the transfonnation of capabilities in the Indian phannaccutical 
industry has important implications for firms in other developing countries In their 
response to strengthening of patent laws. But direct adoption of the Indian pharmaceutical 
industry's approaches to other developing countries may not be feasible as these countries 
differ a lot in economic characteristics such as institutions and factor markets. 
9.3 Principle findings 
The evidence showed that Indian pharmaceutical firms developed basic capabilities in 
pharmaceutical R&D cumulatively by adopting two forms of imitation; duplicative 
imitation followed by creative imitation. It also reveals that the strengthening of patent law 
accelerated the movement of Indian pharmaceutical firms towards development of 
innovative product R&D capabilities. It points out that the innovative Indian 
pharmaceutical firms developed innovative R&D capabilities by learning beyond their core 
areas; using prior knowledge base and employing mechanisms like collaborative R&D and 
hiring product R&D experienced scientists. 
9.3.1 Firm level processes involved in development of knowledge capability for 
innovation 
The main research question of the thesis concerned processes and activities involved in 
development knowledge creation capability for innovation in Indian pharmaceutical firms. 
The transition from basic capabilities to advanced innovative capabilities represents a 
movement from simple knowledge base to complex knowledge base. This research shows 
that development of new capabilities involved removal of capabilities which were 
redundant in new era, acquisition of new knowledge and combination of new knowledge 
with existing relevant capabilities. 
The analysis revealed that in the case of Indian pharmaceutical firms the main rigidities 
that emerged are 
a. imitative R&D organisational routines, 
b. in-house nature of R&D and 
c. organisational mindset shaped by short term vision of R&D investments and domestic 
market focused approach. 
In the case of Indian pharmaceutical firms getting rid of "rigidities' accumulated in the 
reverse engineering era formed the important part of learning innovative R&D capabilities. 
The Indian pharmaceutical firms used networked model of collaborative R&D and learning 
by hiring as main mechanisms of knowledge acquisition. These firms collaborated with 
MNC firms, research institutes and universities to augment and leverage organisational 
capabilities in innovative R&D. They created linkages with Indian as well as overseas 
research institutes to fill the knowledge gaps and train its scientific workforce. 
The Indian pharmaceutical firms consistently increased the R&D investment and hired the 
Indian scientists embodying the product R&D knowledge to acquire the capabilities in 
innovative R&D. These firms hired product R&D experienced Indian scientists working 
overseas in MNC pharmaceutical R&D firms or universities to acquire the know-how in 
innovative product R&D. These scientists carried the crucial tacit knowledge with them 
and enhanced the absorptive capacity of firms by helping them in identifying and acquiring 
appropriate technologies. They helped Indian pharmaceutical firms to access knowledge in 
areas of innovative pharmaceutical R&D through their linkages among other scientists 
working in this area and thus considerably reduced the time and cost of acquiring 
knowledge in innovative R&D. These returned brain played a significant role in changing 
the mindset of the organisation by adopting 'new ways of doing things' in R&D in Indian 
pharmaceutical firms. Therefore the Indian scientists working in advanced countries like 
US and UK have emerged as an important source of knowledge in areas of innovative 
R&D for Indian pharmaceutical firms. 
The analysis points out that Indian pharmaceutical firms put extensive emphasis on 
creating an environment that facilitated assimilation of new knowledge among its scientific 
work force. These firms set up various supportive arrangements to encourage the sharing 
of knowledge among its R&D scientists. For example, the firms adopted a matrix form of 
project management, started sending scientists to attend the premier scientific conferences 
and institutionalised the process of reviewing research by establishing scientific advisory 
boards with internationally reputed scientists. These organisational mechanisms along with 
increasing R&D investment allowed Indian pharmaceutical firms to create the necessary 
infrastructure for innovative R&D and helped these firms to attract the top research talent. 
The analysis of organisational mechanisms also showed the strong emphasis on integration 
of different knowledge bases in all Indian pharmaceutical firms. These firms adopted 
measures like cross disciplinary teams and frequent scheduled as well as ad hoc project 
meetings to achieve the integration of different knowledge bases. 
This research reveals that the learning process adopted by Indian pharmaceutical firms 
shared similarities with the large multinational pharmaceutical firms' approaches to 
transform their technological identity as a response to molecular biology adyances. Large 
pharmaceutical firms hired star scientists working in academia and adopted a network 
model of collaborative R&D to transform their teclmological identity and capabilities. This 
suggests that as far as intra firm learning is concerned, learning processes follo\\"ed by 
technology frontier firms are also applicable to finns from developing countries. However 
the nature of the institutional environment and socio economic factors differs a lot in 
developing countries compared to advanced countries. Therefore in developing countries 
finns have to modify learning strategies according to the external environment. 
9.3.2 Inter firm differences 
The analysis of Indian pharmaceutical finns revealed inter firm differences in functioning 
and implementation of learning processes, showing that learning at firm level is neither 
automatic nor linear and requires a deliberate learning strategy. 
Inter finn comparative analysis shows the subtle differences in learning processes in each 
firm. For example in the case of hiring the product R&D scientists, the nature of scientists 
targeted for recruitment as well as sources used by firms for recruiting new scientists 
differed a lot. Similarly inter firm differences emerged in supportive learning mechanisms 
which influenced the creation of the environment that encourages interaction among 
distributed knowledge systems and facilitates the development of collective knowledge. 
The learning mechanisms like incentive policies, top management commitment and 
emphasis on collaboration and networking differed across the firms. The rate at which a 
firm moved in accumulating capabilities and the subsequent level of sophistication varied 
as does the potential sequencing of capability development among different functional 
areas. This suggests that the transfonnation from imitative R&D to innovative R&D is 
neither linear nor automatic and needs a deliberate learning strategy. 
The differences in implementation and functioning of learning processes also suggest that 
finn engaged in different modes of learning in their response to external conditions and 
that emerged as one of reasons for inter-firm differences in firms' innovative R&D 
capabilities. This finding support the observation by Figueiredo (2003) that the way in 
which intra finn learning processes and mechanisms are managed over time plays a 
substantial part in influencing inter finn differences in terms of technological capability 
and, in tum, in competitive perfonnance. 
9.3.3 Technological capability accumulation process in Indian pharmaceutical 
industry and TRIPS 
The Indian pharmaceutical industry'S journey from being an import dependent industry to 
a developer of original pharmaceuticals has been a long and eventful one. This research 
presented a model of dynamic learning processes involved in technology capability 
development in the Indian pharmaceutical industry. It illustrates that the industry has built 
its technological capabilities by moving from basic to intermediate innovative 
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technological capabilities and finally, as a result of change in patent law, the industry is 
undergoing learning to develop capabilities in innovative R&D. 
The technological capability accumulation process in the Indian pharmaceutical industry 
followed the trajectory of starting with duplicative imitation followed by creative imitation 
to rise up the value chain of pharmaceutical R&D. The weakening of patent laws in 1970 
played a crucial role in shaping and building the Indian pharmaceutical industry. It reduced 
market entry barriers, legalised reverse engineering and created a competitive domestic 
market. 
The evidence presented in this thesis strongly suggests that the weak patent system was the 
dominant influence on the development of basic and intermediate capabilities in the Indian 
pharmaceutical industry. It legalised reverse engineering, (an important non-market 
mediated mechanisms of knowledge acquisition) whilst allowing the Indian 
pharmaceutical industry to learn and improve its process R&D capabilities and expand 
production and marketing capacities. 
The nature of the domestic market and industrial policies adopted by the Indian 
government also influenced the development of capabilities in the Indian pharmaceutical 
industry. The intensely competitive domestic market fuelled firm based learning and 
assimilation of basic capabilities bringing about industrial transformation and 
development. But the lack of value and protective nature of the market also prevented the 
development of innovative capabilities. 
This research shows that the strengthening of patent law had a positive impact on large 
Indian pharmaceutical firms and catalysed their movement from imitators to innovators. It 
was emphasised in chapter 6 that the strengthening of patent law changed strategic 
orientation of the Indian pharmaceutical industry and forced firms to pursue alternative 
innovative technological trajectories. The Indian pharmaceutical firms responded to the 
strengthening of patent laws by adopting an ambidextrous technology capability 
development path in the form of innovative process and product R&D. The Indian firms 
improved on the basic capabilities incrementally by competing in advanced countries' 
generics market and supplying drugs to MNC. In parallel. these firms developed 
capabilities in innovative product R&D. 
The generics product R&D created economic resources for Indian firms to fund the 
investment in exploration of radical capabilities. It allowed these firms to exploit their 
process R&D capabilities and explore areas in innovative product R&D. This exploitive 
use of process R&D helped Indian firms to develop the complimentary capabilities 
required to compete in product markets and reduced the Indian firms' dislocation from 
international sources of pharmaceutical innovation, technology and research. 
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The imitative R&D in these finns created important essential basic capabilities and that 
acted as a base for innovative R&D. The basic and intennediate inno\'ati ye capabilities 
learnt as a result of imitative learning certainly gave these firms a solid base for the 
development of competence in advanced innovative R&D. 
To summarise the principle findings of this thesis are: 
A. Imitation played a key role in development of basic and intermediate 
capabilities in Indian pharmaceutical industry. 
B. TRIPS acted as a catalyst and accelerated movement of Indian firms towards 
innovative R&D. 
C. The unlearning of rigidities of reverse engineering era like imitative R&D 
mindset, emerged as key aspect of learning. 
D. Indian firms used mechanisms like collaborative R&D and hiring the scientists 
experienced in product R&D to acquire knowledge in innovative product R&D. 
E. The Indian firms built creative R&D environment by adopting mechanisms of 
managing knowledge which facilitated and fostered sharing of knowledge 
among scientists. 
F. The inter firm differences in learning processes and its impact on capability 
development shows that at firm level learning is neither automatic nor linear 
and requires deliberate learning strategy. 
9.4 Implications of the thesis and future research 
This section discusses theoretical, managerial and policy level implications of the research 
findings. This thesis has drawn on an empirical analysis of the Indian pharmaceutical 
industry to investigate the process of innovative capability development in firms from 
developing countries. It focused on the upstream segment of the drug innovation cycle. 
specifically the discovery aspect ofphannaceutical R&D. 
The application of results from this research in other developing countries can pose 
problems due to subtle differences between developing countries' economies and 
institutions. Broadly all the developing countries share some of the features in terms of 
economic parameters but importantly there are some subtle differences which make each 
country unique. Indian pharmaceutical industry ranks as one of the most advanced science 
based industries among developing countries in terms of sophistication and capabilities. 
Some of the factors that helped this industry include ayailability of trained English 
speaking manpower, institutions. and knowledge seeking culture. The influence of these 
factors puts limitation on the extent to which findings of the research can be applicable to 
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other developing countries. Therefore while drawing implications for other developing 
countries, it is important to remember that each country starts from its own unique set of 
advantages and disadvantages. There can not be direct transfer of the Indian 
pharmaceutical industry's growth model to other countries. However the insights identified 
in this research do present important general considerations. 
9.4.1 Theoretical framework for analysing capability development in firms from 
developing countries 
The theoretical framework presented in this thesis for exploring the development of 
innovative R&D competencies in firms from developing countries provides a novel way of 
analysing the complex set of internal organisational factors involved in capability 
development. It integrates both the competence based view of knowledge and 
organisational behaviour view of knowledge by focusing on socially embedded qualities of 
organisational knowledge as a crucial part of the capability development process. 
This theoretical framework shares similarity with the analytical framework developed by 
Kim (1999) in terms of theoretical foundation. Kim (1997a, 1999) proposed an analytical 
framework based on absorptive capacity concept to explore capability development in 
South Korean firms. Similar to that the theoretical framework developed in this research is 
based on absorptive capacity concept; the ability of firm to evaluate, assimilate and apply 
outside knowledge (Cohen and Levinthal, 1990). However this framework differs with 
Kim's (1997a) analytical framework in terms of its treatment of capability development. 
This research views development of innovative R&D capabilities as a complex interactive 
process built on the situated actions of organisational members as they engage in the 
world. The theoretical framework focuses on the activities and processes that play a 
fundamental role in driving and shaping organisational knowledge by facilitating the 
relations and interactions among different parts of the organisation. The absorptive 
capacity is viewed as a function of two separate but interrelated dimensions: 
a. the firm's ability to acquire the knowledge relevant to the new technological paradigm 
and 
b. firm's ability to integrate external knowledge into existing capabilities. 
The absorption of knowledge depends on the accumulated knowledge base and 
mechanisms of knowledge transfer (Cohen and Levinthal, 1990). Based on these concepts, 
the capability development in the theoretical framework is divided into a series of sub-
processes (prior knowledge base and knowledge transfer, acquisition, assimilation, 
integration) and analyses the Indian pharmaceutical firms by focusing on the activities or 
mechanisms involved in these sub processes. 
The theoretical framework and subsequent research activities have uncovered the nature of 
the firm level learning processes and provided insight into how they affect an 
organisation's ability to capture, assimilate and apply knowledge to commercial ends. This 
framework helps firms and researchers to identify and analyse activities that may influence 
the technological capability development process. Although the theoretical framework has 
its limitations in the fact that, whilst it expresses the nature of the internal organisational 
processes, and identifies number of key areas that constitute such processes, it does not 
itself operationalise these processes. It shows the mechanisms adopted by the innovative 
Indian pharmaceutical firms for creating contexts to facilitate the technological learning 
and capability development in innovative R&D. To this extent the framework developed in 
this research functions as a tool or vantage point from which to explore the issues involved. 
The theoretical framework itself is not operational as it does not lend itself to any form of 
prescription. 
9.4.2 Learning processes 
The accumulation of technological knowledge is complex and often a costly process of 
technological and organisational learning. Bell et aI., (1984b) point out that absence of 
sustained efforts to acquire and use the capabilities necessary for continuous technological 
change often results in failure of learning processes in firms from developing countries. 
It is sometimes suggested that firms in developing countries have accumulated 
technological capabilities in particular sequences, moving through definable stages 
(Dhalman, et aI., 1987). The learning hierarchy model suggests that NIC progresses from 
learning to produce, learning to produce efficiently, learning to improve production, 
learning to improve products and finally culminates in learning to develop new products. It 
has even been suggested that these sequences and stages can provide guidelines for both 
firm level strategies and government policies. 
In a very general sense, such sequences do reflect realities. For example firms in different 
industries seeking to improve their technologies generally have to build on what already 
exists. Beyond such guidelines however rigid ideas about sequences and stages may be 
misleading, especially at the firm level. This research shows that the learning processes 
which underlie accumulation and development of knowledge require technical as well as 
organisational knowledge management capabilities. The important aspect of this learning 
involves unlearning the competencies which might have been useful in an earlier era but 
not relevant in new environments. The doing aspect (the link to production experience) 
remains necessary but not sufficient to development of innovative capabilities. Thus this 
research points out that the move from basic to intermediate and to advance level 
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capabilities is neither linear nor automatic. It requires a deliberate effort from firms to 
invest in different mechanisms of learning. This finding supports observations made by 
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researchers like Bell and Pavitt (1995), Forbes and Wield (2002) that technological 
learning is neither automatic nor linear and depends upon the decisions firms make. 
The variability of the technological accumulation patterns suggest that the need for care 
and clarity in choosing specific strategies for accumulating technologies at firm level. 
Knowledge acquisition through practice often happens in social contexts (Lave and 
Wenger, 1991). Much of the knowledge generated through R&D activity is ofa tacit nature 
and located in the specific context in which it was developed (Nelson and Winter, 1982). 
Chataway et aI., (2003) suggest that the challenge faced by social knowledge is that it may 
not be acknowledged by management. Bell and Pavitt (1995) pointed out that there are few 
guidelines for firms to follow in designing strategies to move from the basic level to the 
advanced level of capabilities. 
In this regard the findings of this research provide insights for R&D managers in terms of 
activities involved in creating an environment that facilitate the development of a 
knowledge creation capability for innovation. This research emphasises the importance of 
these organisational mechanisms in innovative new product development and points out 
various organisational mechanisms like cross disciplinary teams and frequent project 
meetings involved in integration of various knowledge bases. It shows the distinct role of 
knowledge management strategies in shaping the learning environment that facilitated 
transformations of technological capabilities in Indian pharmaceutical firms. To a larger 
extent knowledge creation depends on absorptive capacities but as the Indian 
pharmaceutical industry's example shows some things like firm based strategies, policy 
measures, mechanisms of knowledge management and their networks make the difference. 
The Indian pharmaceutical firms' development of innovative R&D capability suggests that 
the firms and networks can become more adept at creating learning environments which 
enhance sense making and sourcing capacities. 
The importance of these internal activities in the capability development process raises an 
important implication for firms in Indian industries as well as other developing countries. 
The limited resources typical in many firms in developing countries hinders their ability to 
provide necessary environments in terms of recruitment of talented personnel, extensive 
knowledge sources, training and organisational mechanisms to facilitate capability 
development. Hence in the future, emphasis of the technology policy should be on 
providing mechanisms that will help firms increase their awareness and access to external 
knowledge. Technology policy should assist firms in creating linkages between their 
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internal capabilities and external knowledge and help in assimilating these associations 
into business opportunities. 
The research on developing countries suggests that technology development patterns vary 
within developing countries. Technology capability developments in East Asian countries 
share similarities with each other in terms of state intervention in some industries designed 
to protect and accelerate achievement of international competitiveness through attainment 
of the requisite technological capabilities. In this context comparative studies between 
these industrialising countries and newly emerging countries like India and China would be 
useful in building more comprehensive models technological development and growth in 
countries that have not yet embarked on a path of sustained modernisation. 
9.4.3 Technological capability accumulation through imitation and TRIPS 
The studies investigating technology development of Korea (Kim, 1997a) and Taiwan 
(Hobday, 1995) showed that firms in these countries began mainly as imitators, although 
Korean industry experience shows that this does not continue indefinitely. This research 
points to a similar pattern of capability development in the Indian pharmaceutical industry. 
The non-formal mode of imitation; reverse engineering, has played a significant role in 
development of basic capabilities in the Indian pharmaceutical industry. 
The weak patent system allowed development of basic and intermediate process R&D 
capabilities and built production capabilities in the Indian pharmaceutical industry. This 
finding supports the observation by Kim and Nelson (2000) who suggest that duplicative 
imitation, if legal, is an astute strategy in the early industrialisation of low-waged, 
catching-up countries, as the technology involved is generally mature and readily available 
and duplicative imitation of mature technology is relatively easy to undertake. 
However the universal adoption of strong patent protection will affect the application of 
imitation and reduce the opportunities for firms in developing countries to use this mode of 
knowledge acquisition. This certainly raises the question about strengthening of patent 
laws all over world, especially in developing countries irrespective of the capabilities of 
domestic industry. The strong patent law will affect the development of basic or 
intermediate capabilities in firms from developing countries. 
Developing countries are not homogenous. Their scientific and technological capabilities 
differ widely. The findings of this research indicate that the interests of developing 
countries are best served by tailoring their intellectual property regimes to their particular 
econonlic and social circumstances. 
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9.4.4 International knowledge transfer and emerging role of diaspora 
This research showed the importance of the diaspora (trans-national community of 
immigrated Indian scientists and engineers) and Indian scientists educated or working in 
advance countries as an important source of knowledge for Indian pharmaceutical firms. 
The crucial role of scientists or engineers studied or worked in advanced countries as a 
carrier of tacit knowledge is not unique to India. In extensive analysis of the "Asian 
miracle", the World Bank (1993) emphasises that the return of foreign educated nationals 
has provided significant transfer of best practises and state of the art knowledge to South 
Korean and Taiwanese semi conductor firms. Recent firm level studies (Kim, 1997; Song 
et aI, 2003) have also provided anecdotal evidence of the importance of human embodied 
technology transfer in the learning processes of Korean and Taiwanese firms in the semi 
conductor industry. Similarly this research also shows that migration of educated Indians 
in the past to advanced countries have opened up a different strategic option for new 
technology sourcing for Indian firms. It provide evidence to the observation by Saxenian 
(2002) that trans-national communities may become as important as more commonly 
recognised actor - states and multiple corporation - in the growth of new centres of 
technology entrepreneurship. 
The hiring of Indian scientists educated or working in advance countries emerged as one of 
the main mechanisms of knowledge acquisition which allowed Indian pharmaceutical 
firms to develop capabilities in innovative pharmaceutical R&D. The presence of the 
diaspora gave Indian firm an entry to advance technical knowledge which could have been 
difficult to access through other formal or informal modes of technology transfer and 
creates advantage for Indian industry which could have been absent. The case of brain 
drain is turning into brain bank and helping development of capabilities through diffusion 
of knowledge by reverse brain transfer. This has an important implication for international 
knowledge transfer as mobility of scientists across national borders and presence of 
diaspora can mitigate the localised nature of knowledge spill-over and can accelerate 
international R&D spill-over. This suggests that learning by hiring offers a mechanism to 
overcome obstacles in the case of technically advanced and organisationally bound 
technologies. It also highlights the importance of human embodied technology transfer and 
its role in developing capabilities of finns. 
This research however strongly points out that this advantage does not overcome the issue 
of developing good organisational processes for delivering innovation or improvements in 
living and educational environments. The reverse brain drain does not take plan~ 
automatically; government and finns have to create infrastructure and opportunities for 
them to utilise their advanced skills at home. The presence of the diaspora or migration of 
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scientists can help entrepreneurial firms in developing countries play a major role in 
technology areas as long as they know how to manage organisational knowledge and 
create conditions that will facilitate development of innovative capabilities. This research 
shows that Indian pharmaceutical firms invested in building R&D infrastructure, set up 
various organisational mechanisms and created international level incentive structures to 
tap this research talent. 
This finding has further implications for research in international technology transfer and 
development of capabilities in developing countries. The transfer of knowledge through 
human mobility is not a straight forward process. For example former R&D president of 
Ranbaxy commented, 
"it takes time for these scientists to adjust and most of them change. (But) as a company 
we don't have to change anything; they adjust themselves because what we have is very 
international structure. So we don't have to change every time a new person is coming, 
what we have is right structure; people have to fit into it ", 
while in the same firm the senior scientist hired from the US suggested that in the 
beginning he invested a lot of time in changing R&D culture in the firm. This clearly 
points out transfer or diffusion of knowledge through hiring scientists is a complex 
process. Therefore more research is needed to understand the firm and country level issues 
involved in diffusion of knowledge through linkages with the diaspora or migration of 
scientists and engineers. 
In conclusion, findings of this research contribute towards capability development in firms 
from the developing countries and highlight the emerging mechanisms of knowledge 
acquisition in form of linkages with diaspora and migration of scientists. This study also 
shows that as far as intra firm learning is concerned, learning processes followed by 
technology frontier firms are also applicable to firms from developing countries. However. 
it also points out that the patterns of evolution of in organisational characteristics such as 
sources of technology and structure differs from the usual findings in advanced countries 
like the u.s. and U.K. The heterogeneous nature of developing countries economic 
resources and industries makes it essential to test findings of the results in different 
industries and countries. The change in trade rules as a result of WTO agreements also 
affecting the 'rules of the game~ in other sectors. For example, in textile industry the 
'removal quota systems' due to WTO agreements is creating turbulent environment for 
firms in textile exporter countries like Pakistan, India and South East Asia. Such cases 
offer an opportunity to test the finding of this research and develop a comprehensive model 
for capability development in firms from developing countries. 
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The emerging new mechanism of knowledge acquisition; linkages with diaspora and 
migration of scientific labour have implications for diffusion of scientific knowledge in 
developing countries. A comparative study between firms and countries needs to be done 
to unravel the firm and country issues involved in diffusion of knowledge through 
migration of scientific labour in developing countries. The brain gain thesis needs a further 
investigation in other contexts as well, for example examination in labour market sectors 
other than science and technology like managerial and professional. The findings of such 
research will certainly provide useful guidance for the practice and policy development in 
developing countries. 
Thus further examination of organisational and policy issues associated with capability 
development in developing countries which are at different levels of development is 
essential in order to generalise the findings of this study and to develop a robust 
development theory. 
9.S Conclusion 
The accumulation of technological capabilities and development of innovative R&D 
competencies in the Indian pharmaceutical industry provides an insight for policy makers 
in other developing countries. It provides the basis for understanding some of the essential 
elements of effective technology strategy and policy that are required for efficacious 
development of countries that have not yet embarked on a path of sustained modernisation. 
This research shows that the Indian government's import substitution industrial policies 
and weak patent laws provided the Indian pharmaceutical industry with a protected 
environment and helped Indian firms to develop basic capabilities in pharmaceutical R&D. 
But these measures also reduced the incentives for innovation and hampered technological 
growth of Indian firms. The liberalisation of industrialised policies in 1990 spurred the 
technological growth in industry. Thus in the case of Indian pharmaceutical industry the 
industrialliberalisation stimulated innovation but state interventions and protection helped 
industry initially when it did not have basic capabilities required to operate. The 
liberalisation of Indian industrial policies and growing of maturity of Indian 
pharmaceutical industry contributed to movement of Indian pharmaceutical firms towards 
innovation. However, the policy change, in the form of strengthening of patent law. created 
a crisis of existence for Indian pharmaceutical firms and that played an important role in 
accelerating movement of these firms towards the innovative R&D competencies. The 
ambidextrous capability development in the Indian pharmaceutical industry as a response 
to change in patent law has an important implication for phannaceutical firn1s in other 
developing countries which \\'ill be facing similar challenges due to the TRIPS agreement. 
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The entry in the generic market of advance countries helped Indian firms to over come two 
sets of extreme disadvantages; dislocation from frontiers of pharmaceutical research and 
innovation and distance from advanced markets. The present study also revealed the 
important role of the diaspora (trans-national communities of Indian scientists and 
engineers) as a source of knowledge for Indian pharmaceutical firms. 
The Indian pharmaceutical industry's development experience shows that the fast changing 
global economic environment is not inimical to efficacious development for firms and 
industries in developing countries. The forces of globalisation like WTO agreements do 
impose some restrictions on developing countries in terms of choice of policy selections. 
However as Westphal (2002) suggests globalisation and changes in technology are also 
removing barriers to international trade and offering new opportunities for developing 
countries to pursue a strategy of export led technological growth and development. For 
example, the development of innovative R&D capabilities in Indian pharmaceutical firms 
is giving rise to the new international division of labour in the pharmaceutical sector. This 
is opening new possibilities and economic opportunities of convergence for global as well 
as Indian pharmaceutical firms on pharmaceutical R&D value chain. The global 
pharmaceutical industry is undergoing turbulent times due to the decrease in research 
productivity, consumer and government pressure on firms to reduce rising healthcare cost 
and the increasing cost of drug discovery and development. The new division of labour and 
uniformation of IPR laws all over the world suggest that there are further new 
opportunities that can emerge in world pharmaceutical markets. The Indian pharmaceutical 
industry's role in reducing the healthcare cost on the basis of superior process R&D and 
manufacturing capabilities is already well documented. The ongoing expansion of 
international markets for technology and intellectual property rights may well come to 
serve as a force for strengthening "licensing ouC rather than "licensing in" for less 
developed economIes. The licensing agreement of molecules between Indian 
pharmaceutical firms and MNC pharmaceutical firms may be early steps in that direction 
and such licensing will strengthen Indian incentives to expand investment in R&D for 
pharmaceutical firms in India as well other developing countries. 
Although the Indian pharmaceutical firms development of competencies III innovative 
product R&D are obviously modest beginnings in context of the immense world 
pharmaceutical industry, they show competence for high-tech R&D in which India may 
learn to playa prominent role, especially given the large pool of qualified scientists who 
are seriously underemployed. This potential convergence between Indian pharmaceutical 
industry and large multinational pharmaceutical firms has wider implications for access to 
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medicines for the large population in developing countries as well as combating rising 
healthcare costs in developed countries. 
The ambidextrous capability development model and licensing strategy in product R&D 
practised by Indian pharmaceutical firms is giving rise to a new pharmaceutical R&D 
business model which has implications for the development of domestic pharmaceutical 
industries in other industrialising countries. Pharmaceutical industries in some countries 
like South Korea and China have also developed basic and intermediate capabilities in 
process R&D and manufacturing. In this context mechanisms adopted by the Indian 
pharmaceutical industry to develop an advance level of process and product capabilities 
can be applicable to further growth and development of pharmaceutical firms in those 
countries. 
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Appendix 1 
NEW DRUG DISCOVERY AND DEVELOPMENT PROCESS 
Discovery Development Marketing 
Scientific r esearcb Medical and Clinical testing 
Cbemistry, Biology, 
Post Marketing 
Pbarma.cology 
Studies 
Preclinical stage Clinical Stage 
Time: A vg. 18 IND Average: 5 years NDA 
Range: 1-3 years 2-6 2-10 years Average: 2years 
Montbs 2 months-7 years 
Phase II Phase II! Phase III 
Initial Synthesis Safety. I Efficacy I Effectiveness Adverse reaction 
! reporting 
Toxicit}I 
Animal Testing Survey sampling! 
testing 
Volunteers 50-200 I 100-10001 500-5000 
Rate of 
I drop out: 99% 70% 20% 5-8% 
Pharmaceutical new product development is divided in the hvo stages: A. Discovery and 
B. Clinical Development. 
A. Discovery stage: compounds are screened for activity and promising lead molecu le~ 
are selected for further developments. 
1. Pre-clinical Stage 
The pre-clinical stage consists of the laboratory screening of molecule to e aluate their 
therapeutic potential and toxicity. The drug is te ted in-vitro laboratory tudie ' follov. ed by 
animal studies and reviews of related drug along \\ ith te tlllg of chemical ",tability f th 
drug. 
2. IND: Investigational New Drug Application 
IND is an investigational new drug application file by firms to conduct test of a drug on 
human volunteers to test safety, efficacy and effectiveness. 
B. Development stage: Candidate drugs are subjected to a senes of increasingly 
demanding screening steps that seek to demonstrate that the drugs is an improvement over 
current therapies and to collect evidence necessary to convince regulators and clinical users 
of its safety and efficacy. 
1. Clinical stages 
The clinical trial becomes successively more complex and demanding, beginning with 
small trials aimed at studying the basic behaviour of the drugs in human beings and often 
ending in large-scale trials in an international population of patients. 
Phase I: In Phase I clinical trials safety is determined by testing of the developed drug on 
healthy human volunteers. This attempt to establish how human body handles the new drug 
and what toxic effects, if any are experienced. These trials are invariably placebo 
controlled and involved small number of healthy volunteers. These trials are conducted 
within the hospitals and volunteers are often young people, traditionally medical students. 
Phase II: In phase II clinical trials efficacy at different dosage strengths is evaluated by 
testing the drug on patients for the first time. Once again this trial will usually conducted in 
hospitals but will possibly involve a few hundred patients. 
Phase III: In phase III clinical trial overall efficacy (compared with existing treatments or 
placebo) is tested in large patients sample. This is most expensive phase of the all clinical 
trials. This process is conducted under careful regulatory guidelines, covering everything 
from scientific and ethical standards to record keeping. 
NDA: New Drug Application 
NDA is an application for approval of marketing the drug from drug regularity agencies. 
The FDA can accept or reject the application or alternatively require that the new medicine 
undergo further clinical test to assess more carefully its safety and effectiveness. 
Post marketing studies 
Once drug is approved for nlarketing it is kept under surveillance by the firms and the 
FDA. The wide spread usage may reveal the information that \\as not found in the clinical 
trials. In case of unanticipated side effects. FDA forces companies to add warnings on the 
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package. If the level of side - effects or toxicity is severe then the, FDA can even withdraw 
the product. 
The entire drug development cycle can take anywhere from 8 to 12 years from the time a 
compound is discovered until it is approved for sale. The drop out rates goes on decreasing 
from pre clinical to phase III trials. Starting with as high as 99% in pre clinical to 70% in 
phase I, 20% in phase II and 5-8% in phase III. The average time from initial synthesis to 
NDA approval is approximately 100 months where pre-clinical takes on average 18 
months, clinical phase takes on an average 5 years while NDA review takes up on an 
average 2 years 
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Appendix II 
Glossary of terms 
ANDA: Abbreviated New drug application 
API: Active Pharmaceutical ingredient 
CD RI: Central Drug Research Institute 
CIPR: Commission on Intellectual Property Rights, UK 
CSIR: Council for Scientific and Industrial Research 
DMF: Drug Master File 
DPCO: Drug Price Control Order 
EMR: Exclusive Marketing Rights 
GCP: Good Clinical Practises 
GLP: Good Laboratory Practices 
GMP: Good Manufacturing Practices 
GATT: General Agreement on Trade and Tariffs 
Generic drugs: Off-patent drugs, which have received market approval based on proof of 
bioequivalence to the originator's product. 
IPR: Intellectual Property Rights 
NCE: New Chemical Entity 
NCL: National Chemical Laboratory 
NDDS: New Drug Delivery Systems 
NPIL: Nicholas Piramal India Limited 
TRIPS: Trade Related Intellectual Property Rights Organisation 
W.T.O: World Trade Organisation 
Medical Terms 
AntiuIcerant: Class of drugs against peptic ulcers 
Anti-infective: Something capable of acting against infection, by inhibiting the spread of 
an infectious agent or by killing the infectious agent outright. 
Anti-inflammatory: a drug that reduces inflammation and the redness, heat, swelling, and 
increased blood flow that accompanies it; inflammation can be caused by injuries. 
infections, and many chronic diseases such as rheumatoid arthritis. 
Anti diabetic: Class of drugs that help body to utilise insulin more effectively. 
Anti obesity: class of drugs that increase energy expenditure and weight loss by neural and 
chemical regulation 
Anti oxidants: Nutrients found naturally in the body and in plants such as fruits and 
vegetables 
Anti-psoriasis: Class of drugs used to treat a common chronic. skin disease marked by 
exacerbations and remissions. 
Anti-migraine: class of drugs used to treat a periodic attacks of headache, commonly 
associated with irritability, nausea, vomiting, constipation or diarrhoea. 
Cardiovascular: Branch of medicine concerned with the circulatory system of the heart 
and blood vessels 
Hepatotoxicity: Liver damage caused by medicines and other chemicals 
Pharmacogenomics: The study of how an individual's genetic inheritance affects the 
body's response to drugs 
Respiratory: Branch of medicine concerned with the respiration diseases. 
Rheumatology: Treatment and care of rheumatism and arthritis 
Urology: Branch of medicine concerned with the urinary tract in males and females and 
with the genital tract and reproductive system of males. 
'l ~ '" 
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Appendix III 
List of interviews 
First Phase 
1. Dr. D.Sivaram: Director, National Chemical Laboratory, Pune 
2. Dr. Raj Hirwani: Business Development Manager, National Chemical Laboratory, 
Pune 
3. Dr. Prahudtha Ganguli: Patent Expert, Consultant Vision-IPR group, Legal advisor 
OPPI (Organisation of Pharmaceutical Producers of India) 
4. Mr. Francis P.K.: Editor, Pharmabiz 
5. Mr. Ananth Iyer: Assistant Editor, Express Pharma Pulse 
6. Dr. Gopakumar Nair: IPR consultant, President of IDMA(Indian Drug Manufacturers 
Association) 
7. Dr. Himadri Sen: President, Pharmaceutical Research and Regularity affairs, Lupin 
laboratories ltd 
8. Ms. Sophia Mumtaz: Assistant Director, Intellectual property management group, 
Lupin laboratories ltd 
9. Mr. Dilip Shah: Consultant, Vision-India consulting, Secretary of I.P.A. (Indian 
Pharmaceutical Association) 
10. Dr. M.K. Nair: Consultant 
Second Phase 
List of persons interviewed: 
a. National Chemical Laboratory (Pune) 
1. Dr. M.G. Kulkarni - Head, Polymer Science Engineering and NDDS 
b. Dr.Reddy's Laboratories (Hyderabad) 
2. Dr. Venkatswarlu - Former R&D president and Board Member 
3. Dr. Rajgopalan - President, Discovery Research 
c. Ranbaxy Laboratories ltd (Delhi, Gurgaon) 
4 D J han Khanna- Former R&D director and Board Member . r. ag mo 
5. Dr. Bimal Raizada - Vice - President 
. . dh A . te Dl'rector Microbiologv. New drug discp\,cry research 6. Dr. DlllP Upa yay - SSOCla . . 
7. Dr. Rita Sarin - Group Leader. Intellectual property 
27-l 
8. Mr. Sugata Bhattacharya: Head, Europe Operations 
d. Glenmark (New Mumbai) 
9. Mr. Sameer Paigankar - Director, Strategic Planning 
10. Dr. B. Gopalan - Sr. Vice President (Chemical research) 
e. Nicholas Piramal (Mumbai) 
11. Dr. Swati Piramal - Director, Strategic alliances and communications 
12. Dr. Bansi Lal- Director, Quest institute of life sciences (Nicholas Piramal R&D) 13. 
Dr. Swati Baltembe -General Manager, Medicinal Chemistry and Analytics; 
Head, Patents department 
f. Wockhardt (Mumbai, Aurangabad) 
14. Dr. Noel De Souza - Director, R&D (No recording) 
15. Dr. Mahesh Patel- Director, Anti infective research 
16. Dr. Sahib- Director, Genomics & biotechnology 
17. Dr. Shukla - Director, Informatics Group 
18. Dr. Yati Chugh - Head, Pharmacology division 
19. Mr. V. Rajan - Managin Director, Wallis laboratories (UK Operations) 
g. Lupin Laboratories Ltd (Pune) 
20. Dr. B.N.Roy - Director, R&D 
21. Dr. Himadri Sen - President, Pharma Research and Regulatory affairs. 
22. Dr. Sudershan Arora - President, New Chemical entities Research 
h. Ernst and Young (Hyderabad) 
23. Mr. Amit Dutta - Analyst Biotechnology 
'7-
..;. =' 
Email correspondent 
1. Dr. Mukund Chorghade 
President and Chief Scientific Officer 
Pharmaceutical Sciences Division 
D & 0 Pharmachem, Inc., USA 
2. Dr. Hemant Joshi 
Senior Scientist, 
Barr Laboratories, USA 
3. Mr. Mahdeep Saran 
Clinical Research Officer 
Almebic Laboratories ltd, India 
4. Dr Aakash Ganju, MD 
Medical Advisor, 
Pfizer Global Research and Development 
India 
5. Dr. Pankaj Shah 
Bristol Mayer Squibb 
USA. 
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Appendix IV 
In terview Question Bank 
A. TRIPS and its effects -
1. What is your opinion about changes in patent law and its effect on R&D activities in Indian 
phannaceutical industry? What important trends are emerging in Indian pharmaceutical industry 
and how they are affecting your organisation? 
2. What do you think is the main challenge before Indian finns particularly preparing for 2010 or 
2015 scenarios? 
B. Firm specific: 
3. How would you describe the R&D philosophy of your company? What is the overall role of the 
R&D in your organisation compared to production and marketing? 
4. How much is your organisation focused on product R&D or innovative R&D? 
5. When did your company decide to start work on innovative R&D? 
6. What were the main challenges/ difficulties before company when you started working on 
innovative R&D? What were the major constraints before transformation? 
7. How difficult is it to transform from being cost commodity skill driven player to being 
innovation driven players? Organisation-wise, what have been the challenges for your company? 
8. How has your company overcome these issues? What strategies has your company employed to 
over come those difficulties? 
c. Absorptive capacity 
9. How much knowledge accumulated in process R&D is relevant in product R&D? 
10. The Indian finns are steadily increasing the investments in their R&D over the years. In your 
opinion what is the thinking behind that? 
lOb) In general terms where is this investment going i.e. on infrastructure development or man 
power and specifically is it moving towards innovative R&D? 
I 1. You have chosen some specific fields for new drug discovery research. What was the thinking 
behind choosing those fields? Were those areas decided by the market demand or available 
knowledge in that therapeutic class available within the firm? 
D. Acquisition of capabilities: 
12. The innovative output in terms of NDDS and NDDR from your R&D laboratories is very 
.. d to other Indian firms What are the reasons behind the success of your ImpreSSIve compare . 
company? 
13. How has your company acquired the capabilities in 1\JDDS and NDDR? 
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14. How difficult it is to attract the research talent from abroad? 
15. What changes has the organisation made or needs to make for attracting top talent? 
16. Is this the only solution? Have you tried other ways of acquiring the knowledge in innovathe 
R&D? 
17. In the new drug discovery and development research has become IT intensive and tools like 
bioinformatics, high throughput screening and combinatorial chemistry plays important role. Is 
your company focussing on any of these fields? 
18. If yes then how is your company building infrastructure required for innovative R&D? 
D2. Collaborations and Networking: 
19. In innovative R&D what are the areas generally pursued through alliances? 
20. What are companies really looking to gain through networking? 
21. What were the gains of those collaborations? 
22. What efforts has your company made to promote networking and collaboration between the 
organisations? Is there any individual or department whose primary function is look into the 
opportunities? 
23. If yes, when this activity or department started in the company? 
24. Does nature of work in collaborations with Indian research institutes differ from those of 
overseas institutes? If yes then can you describe how it differs? 
D3. Scanning of Technological information 
25. What sources of information do you used to get latest technological advances or commercial 
opportunities? 
26. Lot of technological advances around the area of new drug discovery are happening around the 
world. So how does the company keeps in touch with those advances? 
Up-gradation of capabilities 
27. What mechanisms company has put to facilitate the knowledge up-gradation of the scientist? 
28. Does formal training programme have any role channelling the knowledge of scientist towards 
the innovative R&D? or it is mostly learned by working on the experiments? 
Integration or combination of knowledge 
29. The areas of NeE and NDDS development require the expertise in various disciplinary areas 
and their effective coordination and integration. How is your company trying to achie\t~ this'? 
Organisational structure: 
d structural changes to its R&D to facilitate working on innovath c 30. Has your company rna e any 
R&D? If yes, what structural changes it made to its R&D? 
27X 
Resource allocation: 
31. How is it detennined who works on which project? How resources are assigned to projects? 
Was it done same way as reverse engineering R&D? 
Cross disciplinary teams: 
32. Does separate multi disciplinary teams works on innovative projects? How do these teams 
come into existence? Are they cross-disciplinary in nature? 
33. Does same team work with project till its final completion? Or different teams work on the 
different phases? 
Review of research 
34. How the project is coordinated and supervised? Does these teams reports to same manager? Is 
same techniques are applied in reverse engineering research projects? 
35. How the review of the project is done? Does it involves measures like peer reviews? 
IPR 
1. According to you what are the key capabilities for the IPR management? 
2. What is the company doing to build capabilities in key IPR functions like infringement analysis, 
patent search and patent claim drafting? 
4. How did you achieve competence m getting regularity approval specifically m developed 
markets? 
5. How would you describe your finn's patenting strategy? 
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Appendix V 
Survey Questionnaire 
lheOpen 
University 
BUSINESS 
SCHOOL 
Survey-
L 
, fQUIS 
() 
....... 
INVESTOR IN 
PEOPLE 
The Open University 
Business School 
Walton Hall 
Milton Keynes 
MK76AA 
Telephone +44 (0) 1908 652884 
Fax +44 (0) 1908 655898 
http://oubs.open.ac.uk 
This survey is aimed at exploring the effect of change in patent law on Indian phannaceutical 
industry focusing on R&D activities within it. In survey the tenn innovative R&D is used for the 
R&D activities involved in research of new drug delivery systems or new chemical entities or 
analogue research. 
Please answer the questions by ticking (-V ) on your choice. 
N = not applicable 
Do you wish to receive the results from the survey? 
VF.S NO 
Name-
1. Effect of change in patent law on 
Indian pharmaceutical industry 
Strongly 
agree 
• The change in patent law will completel! stop reverse ~ngineering 
of patented molecules within R&D of IndIan pharmaceutIcal ftrms... ... 1 
• The change in patent law will restrict but not end the reverse engineering 
within R&D of Indian pharmaceutical firms ................................... 1 
• The change in patent law will have no ef~ect on reverse engineering 
activity within R&D of Indian pharmaceutIcal ftrms .............. , .. , ....... 1 
2. Major constraints 
• Lack of R&D manpower skilled in product research is the constraint 
2 3 4 
2 3 
2 3 
4 
Disagree 
completely 
5 
5 
5 '\ 
2RO 
for pharmaceutical industry in pursuing innovative R&D .................. '" 1 2 3 4 5 ~ 
• Lack of IPR trained manpower like patent attorneys is the constraint 
for pharmaceutical industry in pursuing innovative R&D ............... .... 1 2 3 4 5 ~ 
• Lack of financial resources is the constraint for pharmaceutical 
industry in pursuing innovative R&D ................ , ........................... 1 2 3 4 5 ~ 
• Lack of infrastructure required for innovative R&D is the main constraint 
for pharmaceutical industry in pursuing innovative R&D .................... 1 2 3 4 5 ~ 
• Lack of good research institutes or universities is main constraint 
for pharmaceutical industry in pursuing innovative R&D .................... 1 2 3 4 5 !\ 
3. Relevance of accumulated knowledge through reverse engineering in innovative R&D 
• The accumulated knowledge in reverse engineering will greatly contribute 
in innovative R&D activities ..................................................... 1 2 3 4 5 N 
• The accumulated knowledge in reverse engineering will act only as a base 
and not directly relevant for innovative R&D ................................ 1 2 3 4 5 N 
4. Difference of Knowledge base required in reverse engineering R&D and innovative R&D 
• The activities in reverse engineering R&D requires the 
combination of knowledge from organic, medicinal chemistry 
and pharmacology ............................................. ················ 1 
• The activities in innovative R&D requires the combination of 
knowledge from chemistry, biology as well as formulation 
and toxicology ..................................................................... 1 
5. Reduction of entry barriers: 
• Technological advances like high-throughput screening, 
combinatorial chemistry and bioinformatics have transformed 
the drug discovery and development process .... , ... , ........ , .. , ............ 1 
• Technological advances like high-throughput screening: 
combinatorial chemistry and bioinformatics have demysttfied .. 
the drug discovery and development process offering the opportunItIes 
to pharmaceutical ftrms from emerging countries ................ ··········· 
6. Pharmaceutical R&D 
• In pharmaceutical R&D, scie~tist wi~h experience in process R&f? 
can easily learn knowledge in mnovatlve or product R&D b~ studymg 
the complete set of blue prints .................................................. 1 
I h t· I R&D scientist with experience in process R&D can • n p armaceu Ica , h Ik' 
easily learn knowledge in innovative or product R&D ~ ta . tng 
to experienced R&D personne l. ..................... ·· .......... · ...... · .. · .... 1 
1 
2 
2 
2 
2 
2 
2 
3 4 5 N 
3 4 5 N 
3 4 5 ~ 
3 4 5 1'i 
3 
2xt 
• In pharmaceutical R&D, educating and training R&D personnel 
in innovative R&D is an easy job ............................................. 1 2 3 4 5 ~ 
• For product R&D, knowledge about many different disciplines 
needs to be combined ......................................................... 1 2 3 4 5 N 
• Successful filing of the generic patents in US market indicates high 
level of regulatory competence .............................................. 1 2 3 4 5 N 
7. Capability of research institutes and universities in India 
• The linkages between academia, research institutes and Indian 
pharmaceutical industry are very weak .................................... .1 2 3 4 5 N 
• The Indian pharmaceutical industry and research institutes 
have strong capability in chemistry and other related disciplines .......... 1 2 3 4 5 N 
• The Indian pharmaceutical industry and research institutes have 
weak capability in biology and other related disciplines .................... 1 2 3 4 5 N 
8. Indian firms approaches: 
• Indian ftrms are hiring scientists from overseas RI, universities or 
MNC R&D labs to acquire the knowledge in innovative R&D ............. 1 2 3 4 5 N 
• Indian ftrms are acquiring regulatory competence by ftling patents 
in different countries .......................................................... ·· ... 1 2 3 4 5 N 
• Indian ftrms are acquiring regulatory competence by hiring IPR 
consultants from abroad ........................................................... 1 2 3 4 5 N 
9. Please indicate the degree and direction of change in value / importance of the following 
areas for Indian pharmaceutical industry (between 1995-2003). 
Vcr} strong 
increase 
• The value of reverse engineering projects in over all R&D projects ...... 1 
• The promotion of scientist linked to publications ............................ 1 
• The importance of medicinal chemistry ....................................... 1 
• The importance of genomics .................................................... .1 
• The importance of alliances with other firms to access knowledge of areas 
a. archival libraries ........................................ ' .......................... 1 
b. as other sources of natural compounds ........................................ 1 
c. combinatorial chemistry libraries .......... , ......... ' .... , ......... , ........... 1 
d I d t
· .......................... .1 
. ea genera lon ............ ······························ 
I d 
., t' ............................ 1 
e. ea optlmlsa lon ........... ···························· 
f. screening of the molecules ........... ' ....... , ... ' ............ '.' .................. 1 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
stay 
same 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
"rry strong 
decrease 
4 5 N 
4 5 N 
4 5 N 
4 5 N 
4 :- '\ 
4 5 '\ 
.. 5 N 
4 :- '\ 
.. 5 '\ 
" 
5 '\ 
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h. clinical research ..................................................................... 1 2 3 4 5 
10. Indian firms have in-house capability to do the following processes in innovative R&D 
Strong moderate Lack 
A. Basic genome research 
• Gene expression ................................................................... 1 2 3 4 5 ~ 
• Gene targeting ..................................................................... 1 2 3 4 5 N 
B. Identification of target molecule 
• High throughput screening ...................................................... 1 2 3 4 5 N 
• Combinatorial method ........................................................... 1 2 3 4 5 N 
C. Clinical Scrutiny of leads 
• Toxicology study capabilities ................................................... 1 2 3 4 5 N 
• Phase 1. ............................................................................ 1 2 3 4 5 N 
• Phase 11. ........... '" ........................... '" ............ '" .... , ............ 1 2 3 4 5 N 
• Phase III ............................................................................ 1 2 3 4 5 N 
• Regularity competence to file NDA patents in developed markets ........ 1 2 3 4 5 N 
Any other: 
11. According to you which Indian firms are successful in innovative R&D? 
1. 4. 
2. 5. 
3. 6. 
12. Any comments you want to add: 
